



International
REVIEW OF
Neurobiology

Volume 57
Cumulative Subject Index
Volumes 1-25

EDITED BY

RONALD J. BRADLEY

R. ADRON HARRIS

PETER JENNER

International
REVIEW OF
Neurobiology
Volume 57

International
REVIEW OF
Neurobiology
Volume 57

SERIES EDITORS

RONALD J. BRADLEY

*Department of Psychiatry, School of Medicine
Louisiana State University Medical Center
Shreveport, Louisiana, USA*

R. ADRON HARRIS

*Waggoner Center for Alcohol and Drug Addiction Research
The University of Texas at Austin
Austin, Texas, USA*

PETER JENNER

*Division of Pharmacology and Therapeutics
GKT School of Biomedical Sciences
King's College, London, UK*

EDITORIAL BOARD

PHILIPPE ASCHER

ROSS J. BALDESSARINI

TAMAS BARTFAI

COLIN BLAKEMORE

FLOYD E. BLOOM

DAVID A. BROWN

MATTHEW J. DURING

KJELL FUXE

PAUL GREENGARD

SUSAN D. IVERSEN

KINYA KURIYAMA

BRUCE S. MCEWEN

HERBERT Y. MELTZER

NOBORU MIZUNO

SALVADOR MONCADA

TREVOR W. ROBBINS

SOLOMON H. SNYDER

STEPHEN G. WAXMAN

CHIEN-PING WU

RICHARD J. WYATT

International
REVIEW OF
Neurobiology
Volume 57

EDITED BY

RONALD J. BRADLEY

Department of Psychiatry, School of Medicine
Louisiana State University Medical Center
Shreveport, Louisiana, USA

R. ADRON HARRIS

Waggoner Center for Alcohol and Drug Addiction Research
The University of Texas at Austin
Austin, Texas, USA

PETER JENNER

Division of Pharmacology and Therapeutics
GKT School of Biomedical Sciences
King's College, London, UK



ELSEVIER
ACADEMIC
PRESS

AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier

Elsevier Academic Press
525 B Street, Suite 1900, San Diego, California 92101-4495, USA
84 Theobald's Road, London WC1X 8RR, UK

This book is printed on acid-free paper. ♻

Copyright © 2003, Elsevier Inc. All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (www.copyright.com), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2002 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0074-7742/2003 \$35.00

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.uk. You may also complete your request on-line via the Elsevier homepage (<http://elsevier.com>), by selecting "Customer Support" and then "Obtaining Permissions".

For all information on all Academic Press publications
visit our Web site at www.academicpress.com

ISBN: 0-12-366858-1

PRINTED IN THE UNITED STATES OF AMERICA

03 04 05 06 07 08 9 8 7 6 5 4 3 2 1

Contents

Contents of Volumes 1–25 vii

Subject Index 1

Contributor Index 103

This Page Intentionally Left Blank

Contents of Volumes 1–25

Volume 1

International Review of Neurobiology

Chapter 1 Recent Studies of the Rhinencephalon in Relation to Temporal Lobe Epilepsy and Behavior Disorders

W. R. Adey 1

Chapter 2 Nature of Electro cortical Potentials and Synaptic Organizations in Cerebral and Cerebellar Cortex

Dominick P. Purpura 47

Chapter 3 Chemical Agents of the Nervous System

Catherine O. Hebb 165

Chapter 4 Parasympathetic Neurohumors; Possible Precursors and Effect on Behavior

Carl C. Pfeiffer 195

Chapter 5 Psychophysiology of Vision

G. W. Granger 245

Chapter 6 Physiological and Biochemical Studies in Schizophrenia with Particular Emphasis on Mind-Brain Relationships

Robert G. Heath 299

Chapter 7 Studies on the Role of Ceruloplasmin in Schizophrenia

S. Mårtens, S. Vallbo, and B. Melander 333

Chapter 8 Investigations in Protein Metabolism in Nervous and Mental Diseases with Special Reference to the Metabolism of Amines

F. Georgi, C. G. Honegger, D. Jordan, H. P. Rieder, and M. Rottenberg 343

Volume 2

International Review of Neurobiology

Chapter 1 Regeneration of the Optic Nerve in Amphibia

R. M. Gaze 1

Chapter 2 Experimentally Induced Changes in the Free Selection of Ethanol

Jorge Mardones 41

Chapter 3 The Mechanism of Action of the Hemicholiniums

F. W. Schueler 77

Chapter 4 The Role of Phosphatidic Acid and Phosphoinositide in Transmembrane Transport Elicited by Acetylcholine and Other Humoral Agents

Lowell E. Hokin and Mabel R. Hokin 99

Chapter 5 Brain Neurohormones and Cortical Epinephrine Pressor Responses As Affected by Schizophrenic Serum

Edward J. Walaszek 137

Chapter 6 The Role of Serotonin in Neurobiology

Erminio Costa 175

Chapter 7 Drugs and the Conditioned Avoidance Response

Albert Herz 229

Chapter 8 Metabolic and Neurophysiological Roles of γ -Aminobutyric Acid

Eugene Roberts and Eduardo Eidelberg 279

Chapter 9 Objective Psychological Tests and the Assessment of Drug Effects

H. J. Eysenck 333

Volume 3

International Review of Neurobiology

Chapter 1 Submicroscopic Morphology and Function of Glial Cells

Eduardo De Robertis and H. M. Gerschenfeld 1

Chapter 2 Microelectrode Studies of the Cerebral Cortex

Vahe E. Amassian 67

Chapter 3 Epilepsy

Arthur A. Ward, Jr. 137

Chapter 4 Functional Organization of Somatic Areas of the Cerebral Cortex

Hiroshi Nakahama 187

Chapter 5 Body Fluid Indoles in Mental Illness

R. Rodnight 251

Chapter 6 Some Aspects of Lipid Metabolism in Nervous Tissue

G. R. Webster 293

Chapter 7 Convulsive Effect of Hydrazides: Relationship to Pyridoxine

Harry L. Williams and James A. Bain 319

Chapter 8 The Physiology of the Insect Nervous System

D. M. Vowles 349

Volume 4

International Review of Neurobiology

Chapter 1 The Nature of Spreading Depression in Neural Networks

Sidney Ochs 1

Chapter 2 Organizational Aspects of Some Subcortical Motor Areas

Werner P. Koella 71

Chapter 3 Biochemical and Neurophysiological Development of the Brain in the Neonatal Period

Williamina A. Himwich 117

Chapter 4 Substance P: A Polypeptide of Possible Physiological Significance, Especially Within the Nervous System

F. Lembeck and G. Zelter 159

Chapter 5 Anticholinergic Psychotomimetic Agents*L. G. Abood and J. H. Biel* 217**Chapter 6** Benzoquinolizine Derivatives: A New Class of Monamine Decreasing Drugs with Psychotropic Action*A. Pletscher, A. Brossi, and K. F. Gey* 275**Chapter 7** The Effect of Adrenochrome and Adrenolutin on the Behavior of Animals and the Psychology of Man*A. Hoffer* 307

Volume 5

International Review of Neurobiology

Chapter 1 The Behavior of Adult Mammalian Brain Cells in Culture*Ruth S. Geiger* 1**Chapter 2** The Electrical Activity of a Primary Sensory Cortex: Analysis of Eeg Waves*Walter J. Freeman* 53**Chapter 3** Mechanisms for the Transfer of Information Along the Visual Pathways*Koiti Motokawa* 121**Chapter 4** Ion Fluxes in the Central Nervous System*F. J. Brinley, Jr.* 185**Chapter 5** Interrelationships between the Endocrine System and Neuropsychiatry*Richard P. Michael and James L. Gibbons* 243**Chapter 6** Neurological Factors in the Control of the Appetite*André Soulaïrac* 303**Chapter 7** Some Biosynthetic Activities of Central Nervous Tissue*R. V. Coxon* 347**Chapter 8** Biological Aspects of Electroconvulsive Therapy*Gunnar Holmberg* 389

Volume 6

International Review of Neurobiology

Chapter 1 Protein Metabolism of the Nervous System

Abel Lajtha 1

Chapter 2 Patterns of Muscular Innervation in the Lower Chordates

Quentin Bone 99

Chapter 3 The Neural Organization of the Visual Pathways in the Cat

Thomas H. Meikle, Jr. and James M. Sprague 149

Chapter 4 Properties of Afferent Synapses and Sensory Neurons in the Lateral Geniculate Nucleus

P. O. Bishop 191

Chapter 5 Regeneration in the Vertebrate Central Nervous System

Carmine D. Clemente 257

Chapter 6 Neurobiology of Phencyclidine (Sernyl), a Drug with an Unusual Spectrum of Pharmacological Activity

Edward F. Domino 303

Chapter 7 Free Behavior and Brain Stimulation

José M. R. Delgado 349

Volume 7

International Review of Neurobiology

Chapter 1 Alteration and Pathology of Cerebral Protein Metabolism

Abel Lajtha 1

Chapter 2 Micro-Iontophoretic Studies on Cortical Neurons

K. Krn Jević 41

Chapter 3 Responses from the Visual Cortex of Unanesthetized Monkeys

John R. Hughes 99

Chapter 4 Recent Developments of the Blood–Brain Barrier Concept*Ricardo Edström 153***Chapter 5** Monoamine Oxidase Inhibitors*Gordon R. Pscheidt 191***Chapter 6** The Phenothiazine Tranquilizers: Biochemical and Biophysical Actions*Paul S. Guth and Morris A. Spirtes 231***Chapter 7** Comments on the Selection and Use of Symptom Rating Scales for Research in Pharmacotherapy*J. R. Wittenborn 279***Chapter 8** Multiple Molecular Forms of Brain Hydrolases*Joseph Bernsohn and Kevin D. Barron 297*

Volume 8

International Review of Neurobiology

Chapter 1 A Morphologic Concept of the Limbic Lobe*Lowell E. White, Jr. 1***Chapter 2** The Anatomophysiological Basis of Somatosensory Discrimination*David Bowsher, with the collaboration of Denise Albe-Fessard 35***Chapter 3** Drug Action on the Electrical Activity of the Hippocampus*Ch. Stumpf 77***Chapter 4** Effects of Drugs on Learning and Memory*James L. McGaugh and Lewis F. Petrinovich 139***Chapter 5** Biogenic Amines in Mental Illness*Günter G. Brune 197***Chapter 6** The Evolution of the Butyrophenones, Haloperidol and Trifluoperidol, from Meperidine-Like 4-Phenylpiperidines*Paul A. J. Janssen 221*

Chapter 7 Amplitude Analysis of the Electroencephalogram (Review of the Information Obtained with the Integrative Method)

Leonide Goldstein and Raymond A. Beck 265

Volume 9

International Review of Neurobiology

Chapter 1 Development of "Organotypic" Bioelectric Activities in Central Nervous Tissues during Maturation in Culture

Stanley M. Crain 1

Chapter 2 The Unspecific Intralaminary Modulating System of the Thalamus

P. Krupp and M. Monnier 45

Chapter 3 The Pharmacology of Imipramine and Related Antidepressants

Laszlo Gyermek 95

Chapter 4 Membrane Stabilization by Drugs: Tranquilizers, Steroids, and Anesthetics

Philip M. Seeman 145

Chapter 5 Interrelationships between Phosphates and Calcium in Bioelectric Phenomena

L. G. Abood 223

Chapter 6 The Periventricular Stratum of the Hypothalamus

Jerome Sutin 263

Chapter 7 Neural Mechanisms of Facial Sensation

I. Darian-Smith 301

Volume 10

International Review of Neurobiology

Chapter 1 A Critique of Iontophoretic Studies of Central Nervous System Neurons

G. C. Salmoiraghi and C. N. Stefanis 1

Chapter 2 Extra-Blood–Brain-Barrier Brain Structures*Werner P. Koella and Jerome Sutin* 31**Chapter 3** Cholinesterases of the Central Nervous System with Special Reference to the Cerebellum*Ann Silver* 57**Chapter 4** Nonprimary Sensory Projections on the Cat Neocortex*P. Buser and K. E. Bignall* 111**Chapter 5** Drugs and Retrograde Amnesia*Albert Weissman* 167**Chapter 6** Neurobiological Action of Some Pyrimidine Analogs*Harold Koenig* 199**Chapter 7** A Comparative Histochemical Mapping of the Distribution of Acetylcholinesterase and Nicotinamide Adenine Dinucleotide–Diaphorase Activities in the Human Brain*T. Ishit and R. L. Friede* 231**Chapter 8** Behavioral Studies of Animal Vision and Drug Action*Hugh Brown* 277**Chapter 9** The Biochemistry of Dyskinesias*G. Curzon* 323**Volume 11** _____**International Review of Neurobiology****Chapter 1** Synaptic Transmission in the Central Nervous System and Its Relevance for Drug Action*Philip B. Bradley* 1**Chapter 2** Exopeptidases of the Nervous System*Neville Marks* 57**Chapter 3** Biochemical Responses to Narcotic Drugs in the Nervous System and in Other Tissues*Doris H. Clouet* 99

Chapter 4 Periodic Psychoses in the Light of Biological Rhythm Research*F. A. Jenner* 129**Chapter 5** Endocrine and Neurochemical Aspects of Pineal Function*Béla Mess* 171**Chapter 6** The Biochemical Investigations of Schizophrenia in the USSR*D. V. Lozovsky* 199**Chapter 7** Results and Trends of Conditioning Studies in Schizophrenia*J. Saarna* 227**Chapter 8** Carbohydrate Metabolism in Schizophrenia*Per S. Lingjaerde* 259**Chapter 9** The Study of Autoimmune Processes in a Psychiatric Clinic*S. F. Semenov* 291**Chapter 10** Physiological Foundations of Mental Activity*N. P. Bechtereva and V. B. Gretchin* 329

Volume 12

International Review of Neurobiology

Chapter 1 Drugs and Body Temperature*Peter Lomax* 1**Chapter 2** Pathobiology of Acute Triethyltin Intoxication*R. Torack, J. Gordon, and J. Prokop* 45**Chapter 3** Ascending Control of Thalamic and Cortical Responsiveness*M. Steriade* 87**Chapter 4** Theories of Biological Etiology of Affective Disorders*John M. Davis* 145**Chapter 5** Cerebral Protein Synthesis Inhibitors Block Long-Term Memory*Samuel H. Barondes* 177

Chapter 6 The Mechanism of Action of Hallucinogenic Drugs on a Possible Serotonin Receptor in the Brain*J. R. Smythies, F. Benington, and R. D. Morin* 207**Chapter 7** Simple Peptides in Brain*Isamu Sano* 235**Chapter 8** The Activating Effect of Histamine on the Central Nervous System*M. Monnier, R. Sauer, and A. M. Hatt* 265**Chapter 9** Mode of Action of Psychomotor Stimulant Drugs*Jacques M. van Rossum* 309

Volume 13

International Review of Neurobiology

Chapter 1 Of Pattern and Place in Dendrites*Madge E. Scheibel and Arnold B. Scheibel* 1**Chapter 2** The Fine Structural Localization of Biogenic Monoamines in Nervous Tissue*Floyd E. Bloom* 27**Chapter 3** Brain Lesions and Amine Metabolism*Robert Y. Moore* 67**Chapter 4** Morphological and Functional Aspects of Central Monoamine Neurons*Kjell Fuxe, Tomas Hökfelt, and Urban Ungerstedt* 93**Chapter 5** Uptake and Subcellular Localization of Neurotransmitters in the Brain*Solomon H. Snyder, Michael J. Kuhar, Alan I. Green, Joseph T. Coyle, and Edward G. Shaskan* 127**Chapter 6** Chemical Mechanisms of Transmitter–Receptor Interaction*John T. Garland and Jack Durell* 159**Chapter 7** The Chemical Nature of the Receptor Site: A Study in the Stereochemistry of Synaptic Mechanisms*J. R. Smythies* 181

Chapter 8 Molecular Mechanisms in Information Processing

Georges Ungar 223

Chapter 9 The Effect of Increased Functional Activity on the Protein Metabolism of the Nervous System

B. Jakoubek and B. Semiginovský 255

Chapter 10 Protein Transport in Neurons

Raymond J. Lasek 289

Chapter 11 Neurochemical Correlates of Behavior

M. H. Aprison and J. N. Hingtgen 325

Chapter 12 Some Guidelines from System Science for Studying Neural Information Processing

Donald O. Walter and Martin F. Gardiner 343

Volume 14

International Review of Neurobiology

Chapter 1 The Pharmacology of Thalamic and Geniculate Neurons

J. W. Phillis 1

Chapter 2 The Axon Reaction: A Review of the Principal Features of Perikaryal Responses to Axon Injury

A. R. Lieberman 49

Chapter 3 CO₂ Fixation in the Nervous Tissue

Sze-Chuh Cheng 125

Chapter 4 Reflections on the Role of Receptor Systems for Taste and Smell

John G. Sinclair 159

Chapter 5 Central Cholinergic Mechanism and Behavior

S. N. Pradhan and S. N. Dutta 173

Chapter 6 The Chemical Anatomy of Synaptic Mechanisms: Receptors

J. R. Smythies 233

Volume 15

International Review of Neurobiology

Chapter 1 Projection of Forelimb Group I Muscle Afferents to the Cat Cerebral Cortex

Ingmar Rosén 1

Chapter 2 Physiological Pathways through the Vestibular Nuclei

Victor J. Wilson 27

Chapter 3 Tetrodotoxin, Saxitoxin, and Related Substances: Their Applications in Neurobiology

Martin H. Evans 83

Chapter 4 The Inhibitory Action of γ -Aminobutyric Acid, A Probable Synaptic Transmitter

Kunihiko Obata 167

Chapter 5 Some Aspects of Protein Metabolism of the Neuron

Mei Satake 189

Chapter 6 Chemistry and Biology of Two Proteins, S-100 and 14-3-2, Specific to the Nervous System

Blake W. Moore 215

Chapter 7 The Genesis of the EEG

Rafael Elul 227

Chapter 8 Mathematical Identification of Brain States Applied to Classification of Drugs

E. R. John, P. Walker, D. Cawood, M. Rush, and J. Gehrmann 273

Volume 16

International Review of Neurobiology

Chapter 1 Model of Molecular Mechanism Able to Generate a Depolarization–Hyperpolarization Cycle

Clara Torda 1

Chapter 2 Antiacetylcholine Drugs: Chemistry, Stereochemistry, and Pharmacology*T. D. Inch and R. W. Brimblecombe 67***Chapter 3** Kryptopyrrole and Other Monopyrroles in Molecular Neurobiology*Donald G. Irvine 145***Chapter 4** RNA Metabolism in the Brain*Victor E. Shashoua 183***Chapter 5** A Comparison of Cortical Functions in Man and the Other Primates*R. E. Passingham and G. Ettlinger 233***Chapter 6** Porphyria: Theories of Etiology and Treatment*H. A. Peters, D. J. Cripps, and H. H. Reese 301***Volume 17** _____**International Review of Neurobiology****Chapter 1** Epilepsy and γ -Aminobutyric Acid-Mediated Inhibition*B. S. Meldrum 1***Chapter 2** Peptides and Behavior*Georges Ungar 37***Chapter 3** Biochemical Transfer of Acquired Information*S. R. Mitchell, J. M. Beaton, and R. J. Bradley 61***Chapter 4** Aminotransferase Activity in Brain*M. Benuck and A. Lajtha 85***Chapter 5** The Molecular Structure of Acetylcholine and Adrenergic Receptors: An All-Protein Model*J. R. Smythies 131***Chapter 6** Structural Integration of Neuroprotease Activity*Elena Gabrielescu 189***Chapter 7** On Axoplasmic Flow*Liliana Lubińska 241*

Chapter 8 Schizophrenia: Perchance a Dream?*J. Christian Gillin and Richard J. Wyatt* 297**Volume 18** _____**International Review of Neurobiology****Chapter 1** Integrative Properties and Design Principles of Axons*Stephen G. Waxman* 1**Chapter 2** Biological Transmethylation Involving S-Adenosylmethionine: Development of Assay Methods and Implications for Neuropsychiatry*Ross J. Baldessarini* 41**Chapter 3** Synaptochemistry of Acetylcholine Metabolism in a Cholinergic Neuron*Bertalan Csillik* 69**Chapter 4** Ion and Energy Metabolism of the Brain at the Cellular Level*Leif Hertz and Arne Schousboe* 141**Chapter 5** Aggression and Central Neurotransmitters*S. N. Pradhan* 213**Chapter 6** A Neural Model of Attention, Reinforcement and Discrimination Learning*Stephen Grossberg* 263**Chapter 7** Marihuana, Learning, and Memory*Ernest L. Abel* 329**Chapter 8** Neurochemical and Neuropharmacological Aspects of Depression*B. E. Leonard* 357**Volume 19** _____**International Review of Neurobiology****Chapter 1** Do Hippocampal Lesions Produce Amnesia in Animals?*Susan D. Iversen* 1

Chapter 2 Synaptosomal Transport Processes*Giulio Levi and Maurizio Raiteri* 51**Chapter 3** Glutathione Metabolism and Some Possible Functions of Glutathione in the Nervous System*Marian Orlowski and Abraham Karkowsky* 75**Chapter 4** Neurochemical Consequences of Ethanol on the Nervous System*Arun K. Rawat* 123**Chapter 5** Octopamine and Some Related Noncatecholic Amines in Invertebrate Nervous Systems*H. A. Robertson and A. V. Juorio* 173**Chapter 6** Apomorphine: Chemistry, Pharmacology, Biochemistry*F. C. Colpaert, W. F. M. Van Bever, and J. E. M. F. Leysen* 225**Chapter 7** Thymoleptic and Neuroleptic Drug Plasma Levels in Psychiatry: Current Status*Thomas B. Cooper, George M. Simpson, and J. Hillary Lee* 269**Volume 20** _____**International Review of Neurobiology****Chapter 1** Functional Metabolism of Brain Phospholipids*G. Brain Ansell and Sheila Spanner* 1**Chapter 2** Isolation and Purification of the Nicotine Acetylcholine Receptor and Its Functional Reconstitution into a Membrane Environment*Michael S. Briley and Jean-Pierre Changeux* 31**Chapter 3** Biochemical Aspects of Neurotransmission in the Developing Brain*Joseph T. Coyle* 65**Chapter 4** The Formation, Degradation, and Function of Cyclic Nucleotides in the Nervous System*John W. Daly* 105**Chapter 5** Fluctuation Analysis in Neurobiology*Louis J. DeFelice* 169

Chapter 6 Lipotropin and the Central Nervous System*W. H. Gispen, J. M. van Ree, and D. de Wied* 209**Chapter 7** Tissue Fractionation in Neurobiochemistry: An Analytical Tool or a Source of Artifacts*Pierre Laduron* 251**Chapter 8** Choline Acetyltransferase: A Review with Special References to Its Cellular and Subcellular Localization*Jean Rossier* 283**Volume 21**

International Review of Neurobiology**Chapter 1** Relationship of the Actions of Neuroleptic Drugs to the Pathophysiology of Tardive Dyskinesia*Ross J. Baldessarini and Daniel Tarsy* 1**Chapter 2** Soviet Literature on the Nervous System and Psychobiology of Cetacea*Theodore H. Bullock and Vladimir S. Gurevich* 47**Chapter 3** Binding and Ionophoretic Studies on Centrally Active Amino Acids—A Search for Physiological Receptors*F. V. DeFeudis* 129**Chapter 4** Presynaptic Inhibition: Transmitter and Ionic Mechanisms*R. A. Nicoll and B. E. Alger* 217**Chapter 5** Microquantitation of Neurotransmitters in Specific Areas of the Central Nervous System*Juan M. Saavedra* 259**Chapter 6** Physiology of Glia: Glial–Neuronal Interactions*R. Malcolm Stewart and Roger N. Rosenberg* 275**Chapter 7** Molecular Perspectives of Monovalent Cation Selective Transmembrane Channels*Dan W. Urry* 311**Chapter 8** Neuroleptics and Brain Self-stimulation Behavior*Albert Wauquier* 335

Volume 22

International Review of Neurobiology

Chapter 1 Transport and Metabolism of Glutamate and GABA in Neurons and Glial Cells

Arne Schousboe 1

Chapter 2 Brain Intermediary Metabolism *In Vivo*: Changes with Carbon Dioxide, Development, and Seizures

Alexander L. Miller 47

Chapter 3 *N,N*-Dimethyltryptamine: An Endogenous Hallucinogen

Steven A. Barker, John A. Monti, and Samuel T. Christian 83

Chapter 4 Neurotransmitter Receptors: Neuroanatomical Localization through Autoradiography

L. Charles Murrin 111

Chapter 5 Neurotoxins as Tools in Neurobiology

E. G. McGeer and P. L. McGeer 173

Chapter 6 Mechanisms of Synaptic Modulation

William Shain and David O. Carpenter 205

Chapter 7 Anatomical, Physiological, and Behavioral Aspects of Olfactory Bulbectomy in the Rat

B. E. Leonard and M. Tuite 251

Chapter 8 The Deoxyglucose Method for the Measurement of Local Glucose Utilization and the Mapping of Local Functional Activity in the Central Nervous System

Louis Sokoloff 287

Volume 23

International Review of Neurobiology

Chapter 1 Chemically Induced Ion Channels in Nerve Cell Membranes

David A. Mathers and Jeffery L. Barker 1

Chapter 2 Fluctuation of Na and K Currents in Excitable Membranes*Berthold Neumcke* 35**Chapter 3** Biochemical Studies of the Excitable Membrane Sodium Channel*Robert L. Barchi* 69**Chapter 4** Benzodiazepine Receptors in the Central Nervous System*Phil Skolnick and Steven M. Paul* 103**Chapter 5** Rapid Changes in Phospholipid Metabolism during Secretion and Receptor Activation*F. T. Crews* 141**Chapter 6** Glucocorticoid Effects on Central Nervous Excitability and Synaptic Transmission*Edward D. Hall* 165**Chapter 7** Assessing the Functional Significance of Lesion-Induced Neuronal Plasticity*Oswald Steward* 197**Chapter 8** Dopamine Receptors in the Central Nervous System*Ian Creese, A. Leslie Morrow, Stuart E. Leff, David R. Sibley, and Mark W. Hamblin* 255**Chapter 9** Functional Studies of the Central Catecholamines*T. W. Robbins and B. J. Everitt* 303**Chapter 10** Studies of Human Growth Hormone Secretion in Sleep and Waking*Wallace B. Mendelson* 367**Chapter 11** Sleep Mechanisms: Biology and Control of REM Sleep*Dennis J. McGinty and René R. Drucker-Colin* 391**Volume 24** _____**International Review of Neurobiology****Chapter 1** Antiacetylcholine Receptor Antibodies and Myasthenia Gravis*Bernard W. Fulpus* 1

Chapter 2 Pharmacology of Barbiturates: Electrophysiological and Neurochemical Studies*Max Willow and Graham A. R. Johnston* 15**Chapter 3** Immunodetection of Endorphins and Enkephalins: A Search for Reliability*Alejandro Bayon, William J. Shoemaker, Jacqueline F. McGinty, and Floyd Bloom* 51**Chapter 4** On the Sacred Disease: The Neurochemistry of Epilepsy*O. Carter Snead III* 93**Chapter 5** Biochemical and Electrophysiological Characteristics of Mammalian GABA Receptors*Salvatore J. Enna and Joel P. Gallagher* 181**Chapter 6** Synaptic Mechanisms and Circuitry Involved in Motoneuron Control during Sleep*Michael H. Chase* 213**Chapter 7** Recent Developments in the Structure and Function of the Acetylcholine Receptor*F. J. Barrantes* 259**Chapter 8** Characterization of α_1 - and α_2 -Adrenergic Receptors*David B. Bylund and David C. U'Prichard* 343**Chapter 9** Ontogenesis of the Axolemma and Axoglial Relationships in Myelinated Fibers: Electrophysiological and Freeze-Fracture Correlates of Membrane Plasticity*Stephen G. Waxman, Joel A. Black, and Robert E. Foster* 433**Volume 25** _____**International Review of Neurobiology****Chapter 1** Guanethidine-Induced Destruction of Sympathetic Neurons*Eugene M. Johnson, Jr. and Pamela Toy Manning* 1**Chapter 2** Dental Sensory Receptors*Margaret R. Byers* 39

Chapter 3 Cerebrospinal Fluid Proteins in Neurology

A. Lowenthal, R. Crols, E. De Schutter, J. Gheuens, D. Karcher, M. Noppe, and A. Tasnier 95

Chapter 4 Muscarinic Receptors in the Central Nervous System

Mordechai Sokolovsky 139

Chapter 5 Peptides and Nociception

Daniel Luttinger, Daniel E. Hernandez, Charles B. Nemeroff, and Arthur J. Prange, Jr. 185

Chapter 6 Opioid Actions on Mammalian Spinal Neurons

W. Zieglgänsberger 243

Chapter 7 Psychobiology of Opioids

Alberto Oliverio, Claudio Castellano, and Stefano Puglisi-Allegra 277

Chapter 8 Hippocampal Damage: Effects on Dopaminergic Systems of the Basal Ganglia

Robert L. Isaacson 339

Chapter 9 Neurochemical Genetics

V. Csányi 361

Chapter 10 The Neurobiology of Some Dimensions of Personality

Marvin Zuckerman, James C. Ballenger, and Robert M. Post 391

Subject Index

A

- Ablation studies, **3:167, 3:189, 3:202, 3:206, 3:208, 3:213–215, 3:228, 3:236–240**
- Absence seizures
- acetylcholine role, **24:125**
 - γ -aminobutyric acid in, **24:133–134**
 - serotonergic mechanisms, **24:119**
- Absolute light threshold, **1:247f, 1:253f**
- Abstraction, **3:182**
- Accessory olfactory bulb (AOB), anatomy of, **22:260**
- Acetaldehyde, from ethanol metabolism, oxidation of, **19:127**
- Acetate, **3:300**
- Acetate activating enzyme (AAE), **1:173–174**
- Acetone semicarbazone, **3:323, 3:337**
- Acetophenazine, structure of, **8:253**
- N*-Acetyl amino acids and peptides, in brain, **12:252–257**
- Acetylaspartic acid, in brain, **6:18**
- N*-Acetylaspartic acid (NAA), in brain, **12:252–256**
- N*-Acetyl- α -aspartylglutamic acid (NAAG), in brain, **12:256–257**
- N*-Acetylaspartylglutamic acid nervous system, **17:50**
- Acetylation, **3:338**
- N*-Acetylation, of microamines in invertebrates, **19:192**
- Acetylcarnitine, as contaminant in choline acetyltransferase assay, **20:288–289**
- Acetylcholine (ACh), **1:189, 1:339, 3:51, 3:165**
- antagonists of, in studies of thalamic neuron activity, **14:17–19**
 - binding of
 - in muscarine site, **13:195**
 - in nicotinic site, **13:197**
 - bound, **1:188**
 - in brain, **2:176**
 - decreases related to behavioral excitation, **13:335–338**
 - ethanol effects on, **19:147**
 - CAR, **2:257**
 - cardiovascular effects of, **16:67–68**
 - as central neurotransmitter, criteria for, **14:175–183**
 - as central transmitter, **1:184**
 - central transmitter, **12:229**
 - cerebral formation of, lipid-bound choline role in, **20:17–20**
 - in CNS, **14:175–176, 10:71**
 - in cyclic AMP formation, **20:122–123**
 - in cyclic GMP regulation, **20:141**
 - denervation hypersensitivity to, **3:166**
 - distribution in thalamus
 - cells sensitive to, **14:19–20**
 - and geniculate nucleus, **14:5–8**
 - inhibitory actions of, **14:25–27**
 - drug effects on, **11:117–118**
 - in dyskinesias biochemistry, **10:344–347**
 - effect on body temperature, **12:16–23**
 - effect on brain cell culture, **5:39–40, 5:47**
 - effect on cortical neurons, **7:70–92**
 - effect on enzyme secretion of pancreas, **2:103**
 - effect on equilibrium constants for cholinergic ligands, **24:308**
 - effect on hippocampus, **8:94–95, 8:98, 8:120**
 - effect on intestine of, **5:328**
 - effect of reserpine on content, in various areas of dog brain, **2:208**
 - effects on cerebral RNA metabolism, **16:217–218, 16:220, 16:221**
 - effects on phospholipid metabolism, **2:103–110**
 - effects on postsynaptic membrane, **14:178–182**
 - effect of topical application, **2:138–140**
 - enzymes in ACh stimulated exchange of phosphate in phosphatidic acid, **2:118–119**
 - glucocorticoid effects and, **23:182–184**
 - inhibition of, by HC-3, **2:85–89**
 - as inhibitor, **1:187**
 - mechanism of action of, **2:132**
 - metabolism, in epilepsy, **3:166–168**

- metabolism in cholinergic neuron,
18:69–140
- metabolism of in nerve proteins, **6:75–76**
- muscarinic receptors of, **16:67–68**
- muscarinic v. nicotinic activity, **1:233–238**
- neuronal responses to, **10:16–22**, **14:12–32**
- as neurotransmitter, **13:143**
- interaction with receptor, **13:172–174**
- nicotinic receptors of, **16:3–4**, **16:67–68**
- bioelectric measurements on, **16:17–32**
- as opiate neurochemical correlate,
25:278–281
- as parasympathetic neurohumour,
1:231–233
- receptors, *see* Acetylcholine receptors
- release during neural activity, **14:176–178**
- release from thalamus, **14:9–10**
- role in brain function, **1:197–199**
- role in seizures, **24:122–128**
- in stimulation of P³² incorporation into
phospholipids, **2:103–104**, **2:106**,
2:113–118
- synaptic transmission, **2:85**
- as synaptic transmitter, **11:4–17**, **11:43–51**
- actions on neurons, **11:6–14**, **11:32–34**
- biochemical evidence, **11:4–5**
- histochemical evidence, **11:5–6**
- release of, **11:15–17**
- synthesis of, pleiotropic effect of nerve
impulses on, **20:330–331**
- synthesis and storage, **1:176–180**
- transmission and function, **2:190–193**
- treatment of schizophrenia, **1:199**
- tremorine tremor and, **10:345–347**
- Acetylcholine-operated channels
- B-burst, **24:326–328**
- behavior, **24:313–329**
- as diagnostic tool, **24:328–329**
- in embryonic and denervated muscle,
24:322–323
- multiple grating phenomenon,
24:318–319
- N-burst, **24:319–321**
- open-close switching, **24:323–324**
- rate-limiting steps, **24:321–322**
- silent intervals, **24:324–326**
- Acetylcholine receptors, **24:259–341**
- acetylcholinesterase and, **18:130–133**
- agonist and antagonist activity and,
17:172–174
- α subunit, **24:288–289**
- as archetype, **24:260–261**
- β subunit, **24:288**
- biosynthesis, **24:272–279**
- charge, **24:271**
- δ subunits, **24:286–288**
- disulfide bond in, **17:156–157**
- ganglionic receptor agonist, and,
17:157–161
- gating related to state of ligation,
24:330–331
- general specification of, **17:141–143**
- hydrodynamic properties, **24:261–264**
- hydrogen bonds in, **17:138**
- immunochemical structure, **24:271–272**
- ion-dipole bonds in, **17:139–140**
- ionic bonds in, **17:138–139**
- in membrane
- ion-translocation function, **24:301–329**
- three-dimensional topography,
24:279–290
- molecular analysis of, **17:193–195**
- molecular complexes involved in,
17:137–174
- molecular properties, **24:261–272**
- molecular structure of, **17:131–187**
- molecular weight and size, **24:261–264**
- muscarinic, **17:146–147**, **17:162**
- muscarinic agonists and, **17:162–166**
- muscarinic antagonists and, **17:166–174**
- neuromuscular blocking agents and,
17:151–156
- in neuromuscular junction, **17:143–146**
- nicotinic agonists of, **17:149**
- ν -protein effect on, **24:292–294**
- oligomeric structure, **24:281–283**
- protein
- primary structure, **24:269**
- prosthetic group, **24:267–269**
- secondary structure, **24:270**
- specific activity and polypeptide
composition, **24:266–267**
- structure-activity relationship data for,
17:147–148
- subunit composition, **24:264–269**
- topographic mapping, **24:274–275**
- translational dynamics, **24:295**
- Acetylcholinesterase
- acetylcholine receptor and, **18:130–133**
- in axon, **18:82–84**
- in brain cell culture, **5:41**, **5:49–50**
- in cerebellum, **10:57–92**
- in CNS, **14:182–183**
- onto-genetic considerations, **10:95–100**

- cytochemistry of, **18**:71–72
 distribution in thalamus and geniculate nucleus, **14**:5–8
 drug effects on, **11**:117–118
 histochemical mapping in brain, **10**:231–275
 method for, **10**:237–238
 nomenclature, **10**:59
 in perikaryon, **18**:77–81
 in Renshaw elements, **18**:108–112
 somatofugal transport of, **13**:303
 in spinal motoneuron, **18**:77–112
 in synaptic transmission, **18**:75–77
- Acetyl-CoA, as choline acetyltransferase inhibitor, **20**:308
- Acetyl-CoA carboxylase, as CO₂ fixation enzyme in nervous tissue, **14**:134–135
- N*-Acetylglutamic acid (NAG), in brain, **12**:256
- Acetyl-LSD, **1**:339
- N*-Acetylserotonin, assays of, **18**:57–59, **21**:260–263
- Acetylthiocholine, effect on brain culture, **5**:7
- Acetyltryptophan, **3**:263
- Acidosis
 and alkalosis, **1**:255f, **1**:286f
 intracellular, GABA content, **2**:301–305
- Acid phosphates in cytoplasm
 in ganglion neurons after axon injury, **14**:100–102
 increases in axotomized neurons, **14**:92–93
- Acoustic sense organs, cetacean, physiology, **21**:88–89
- Acoustic signals
 cetacean, **21**:74–84
 production mechanism, **21**:74–75
- Acoustic stimulation, effect on brain RNA and proteins, **13**:274–275
- Acquisition of behavior, marijuana effects on, **18**:338–342
- Acrania, muscle innervation in, **6**:108–110
- ACTH 4-10
 binding to cell membranes, **20**:222–223
 blood flow and, **20**:220–221
 brain uptake of, **20**:221–222
 electrophysiological correlates of, **20**:218–220
 in induction of excessive grooming, **20**:217–218
 learned behavior and, **20**:211–217
 in humans, **20**:214–215
 in hypophysectomized rats, **20**:211–212
 site of action, **20**:216
 structure-activity studies, **20**:215–216
 morphine and, **20**:229–230
 neurochemical response to, **20**:222–229
 in neurotransmitter activity, **20**:227–229
 in protein phosphorylation, **20**:223–224
 in protein synthesis, **20**:225–227
- ACTH, *see* Adrenocorticotrophic hormone
- Actinomycin D
 effect on learning, **8**:166
 retrograde amnesia from, **10**:182–183
- Action potentials, *see* Spikes
- Active transport, ethanol effects on, **19**:140–143
- Acute dystonia, clinical features, **21**:9
- Acute intermittent porphyria (AIP), **16**:149ff, **16**:305
 symptoms and incidence of, **16**:304–308
- Acyases, molecular analysis of, **17**:198
- Addison's disease, psychiatric aspects of, **5**:272–275
- Addition, neurotransmitter role in, **19**:155
- Adenohypophysis, emotion and, **5**:245–282
- Adenoma, hepatic, porphyria from, **16**:305, **16**:306, **16**:308, **16**:318
- Adenosine
 in cyclic AMP formation, **20**:121–122
 in cyclic GMP regulation, **20**:141
- Adenosine monophosphate
 cyclic (cAMP), transmitter effects on, **13**:166–168
 in porphyria therapy, **16**:334–335
- Adenosinetriphosphatase
 assay of, **12**:65–69
 in bioelectric phenomena, **9**:228–229
 effect on brain cell culture, **5**:41
- Adenosine triphosphate, **3**:300
 in bioelectric phenomena, **9**:223–225
see also ATP (Adenosine triphosphate)
- S*-Adenosylmethionine
 assay of, **18**:44–46
 biological transmethylation by, **18**:41–67
 clinical aspects of, **18**:61–63
 levels of, substrate effects on, **18**:47–51
 methionine loading effects on, **18**:51–55
 tissue concentration of, **18**:47
 turnover of, **18**:46–47
- Adenylate cyclases
 apomorphine activation of, **19**:248–249

- in brain, ethanol effects on, **19:139**
- localization of, in nervous system, **20:109–113**
- regulation of, **20:113–127**
- Adenylate kinase, in CSF, clinical significance, **25:128**
- Adenyl cyclase, transmitter effects on, **13:166–168**
- Adipocytes
 - α_1 -adrenergic receptor binding by, **24:364–365**
 - α_2 -adrenergic receptor binding in, **24:402–403**
- Adrenal cortex
 - disorders of, psychiatric aspects of, **5:265–279**
 - periodic psychoses and, **11:154–156**
 - psychological states and, **5:256–282**
- Adrenal cortex hypertrophy, **3:341**
- Adrenalectomy
 - brain GABA levels, **2:285**
 - pressor response in adrenalectomized animals, **2:142**
 - salt intake in rats, **2:42, 2:67**
- Adrenal gland, catecholamines in, drug effects on, **11:116–117**
- Adrenalin, **1:180, 1:265, 1:288, 1:334, 1:339**
- oxidation of, **1:302–303, 1:334**
- Adrenaline
 - determination of, **19:180**
 - presence and action in CNS, **11:17–25**
 - in schizophrenia, **8:205**
 - structure of, **19:175**
- Adrenal medulla, as test tissues for
 - localization of biogenic monoamines, **13:35–38**
- Adrenergic agents
 - effects on EEG's, **8:300–303**
 - effects on hippocampus, **8:99–100**
- Adrenergic blocking agents, effect on cerebral glucose utilization, **22:323**
- Adrenergic receptors, **17:174–185**
- activation of, **22:227–228**
- α -agonists of, **17:182–183**
- α -blockers of, **17:183–185**
- α -receptor for, **17:181–182**
- autoradiography of, **22:155–158**
- β -agonists for, **17:176–180**
- β -blocker for, **17:181**
- β -receptor, **17:174–175**
- chemical nature of, **13:160–161**
- isolation of, **13:164–165**
- molecular structure of, **17:131–187**
- muscarinic receptors compared to, **17:185**
- transmitter-receptor interaction in, **13:174–176**
- Adrenergic transmission, studies on, **10:23–27**
- Adrenochrome
 - action of
 - on cells, **4:314, 4:315**
 - modes of, **4:361–365**
 - potentiation of, **4:359**
 - biochemistry of, **4:311–314**
 - effect on brain cell culture, **5:39**
 - effects of
 - on electrograms, **4:335–337**
 - on fish, **4:315**
 - on humans
 - prolonged reactions, **4:348–352**
 - reported by other laboratories, **4:353–357**
 - on mammals
 - cats, **4:325–333**
 - dogs, **4:333, 4:334**
 - mice, **4:320**
 - monkeys, **4:334, 4:335**
 - rabbits, **4:324, 4:325**
 - rats, **4:320–324**
 - on pigeons, **4:316–320**
 - on spiders, **4:316**
 - sublingually given, **4:357–359**
- d*-Adrenochrome, potentiates CEPR, **2:149**
- Adrenocortical function, pineal gland effects on, **11:181–183**
- Adrenocorticotrophic hormone (ACTH)
 - characterization of, **5:245**
 - determination of activity of, **5:245–247**
 - emotion and, **5:245–282**
 - epileptic seizures and, **24:148–150**
 - nociception and, **25:213–214**
 - peptide sequence of, **25:187**
 - psychological effects of, **5:270–272**
- Adrenoglomerulotropin, **11:181**
- Adrenolutin, **1:304–305, 1:314, 1:338–340**
- effects on humans
 - double blind experiments, **4:337–348**
 - prolonged reactions, **4:352, 4:353**
- Adrenolytic drugs, retrograde amnesic testing of, **10:185**
- Affective disorders
 - antidepressant effects on, **12:149–152**
 - biogenic amines effects on, **18:360–367**
 - biogenic amines in, **12:145–148**

- experimental drugs and, **12:160–161**
- catecholamine metabolism in, **12:157–159**
- characteristics of, **18:359–360**
- cyclic AMP effects on, **18:367–368**
- drug therapy of, **18:368–381**
- electro convulsive shock therapy of, **12:154**
- electrolyte effects on, **12:161–163**
- indole metabolism in, **12:159**
- lithium effects on, **12:154–156**
- theories of biological etiology of, **12:145–175**
- Afferents, of forelimb muscle, to cerebral cortex, **15:1–25**
- Affinity chromatography, of choline acetyltransferase, **20:300–303**
- After-discharge, **1:120**
- After-image latency, **1:251–252**
- After-potentials, **1:51**
- Afterpotentials axonal, **3:92**
- Aggression, **18:213–262**
 - apomorphine effects on, **19:241**
 - by cerebral chemostimulation, **18:232–237**
 - cholinergic mechanism and, **14:202**
 - cholinergic stimulation of, **18:232–237**
 - factors influencing, **18:216–219**
 - isolation-induced, **18:229–231**, **18:237–241**, **18:249**, **18:251**
 - neuroanatomical correlates of, **18:217–219**
 - neurochemical correlation of, **18:220–231**
 - neuropharmacological stimulation of, **18:237–253**
 - neurotransmitters and, **18:213–262**
 - shock-induced, **18:231**, **18:241**, **18:249**, **18:251–252**
 - types of, **18:214–216**
- Aggressive behavior, opiates and, **25:318–319**
- Aggressiveness, inhibition of, **6:428–430**
- Aggressivity, peptides and, **17:41–42**
- Aging, cerebral glucose utilization decrease in, **22:327–328**
- Agnatha, muscle innervation in, **6:110–116**
- Akathisia, clinical features, **21:9**
- Alamethicin channel
 - properties, **21:318**
 - transport models and, **21:312–313**
- Alanine: α -ketoglutarate aminotransferase
 - activity of, **17:88**
 - amino acid composition of, **17:89**
 - in brain, **17:95**
 - factors effecting, **17:111**
 - isozymes of, **17:95**
 - in neural metabolism, **17:86**
 - in neural tissue, **17:95–96**
 - physical properties of, **17:94–95**
 - substrate specificity of, **17:91**
 - in transamination, **17:85**
- Alanine, tricarboxylic acid cycle, **2:285–288**
- β -Alanine, **3:327**, **21:300**
 - activity of spinal neurons, **2:322**
 - effect in vertebrate nervous systems, **2:281**
- Alanylglycine dipeptidase, molecular analysis of, **17:198**
- Albumin, in cerebrospinal fluid, **25:99–100**
- α -Albumin, in CSF, **25:123–125**
- Alcohol, *see* Alcohols; Ethanol
- Alcohol dehydrogenase (ADH)
 - ethanol metabolism by
 - in brain, **19:125–126**
 - in liver, **19:128–129**
- Alcoholic mothers, offspring abnormalities in, **19:156–160**
- Alcoholism
 - amnesia in, **16:273–274**
 - human
 - theories of etiology, **2:71–74**
 - withdrawal symptoms, **2:72**
 - porphyria with, **16:177**, **16:314–315**
 - trace metal diuresis in, **16:344–346**
 - tryptophan metabolism in, **8:214**
 - urinary excretion in, **16:342**
- Alcohols, membrane stabilization by, **9:149–151**, **9:166**
- Aldehyde dehydrogenase, in acetaldehyde oxidation, **19:127**
- Aldehyde fixatives, for biogenic monoamines, **13:32–34**
- Aldehyde reduces, in acetaldehyde oxidation, **19:128**
- Aldolases, in CSF, clinical significance, **25:128**
- Algesic peptides, nociception and, **25:188–195**
- Aliesterase, **3:310**, **3:313**
- Alimentary inhibition, study of, **6:424–428**
- Alkaline phosphatase, in intestinal absorption, **5:321**
- Alkaline phosphate, brain, **7:316–318**
- Alkaloids
 - opiate, effect on spinal neurons, **25:244**

- psychomotor stimulant type, structures, **12:310**
- Alkalosis, GABA content, **2:301–305**
- Allergic encephalitis, sera, effect on normal brain cells, **5:42**
- Allergy, epilepsy and, **11:319–321**
- All-or-none response, **1:51, 1:98**
- Allylglycine, as glutamic acid decarboxylase inhibitor, **17:11**
- α -Adrenergic receptors
- biochemical responses mediated by, **24:347**
 - pharmacological subdivision, **24:345–349**
 - radioligand binding studies, **24:349–354**
- α_1 -Adrenergic receptors, **24:343–431**
- agonist affinity ratio studies, **24:350**
 - antagonist affinity ratio studies, **24:352**
 - biochemical responses mediated by, **24:347**
 - characterization by radioligand binding, **24:354–364**
 - agonist radioligands, **24:364**
 - antagonist radioligands, **24:354–364**
 - multiple affinity states, **24:363–364**
 - effector systems coupled to, **24:364–368**
 - adipocytes, **24:364–365**
 - central nervous system, **24:367–368**
 - salivary glands, **24:365–367**
 - regulation, **24:368–376**
 - circadian rhythm, **24:374–375**
 - down-regulation, **24:371–372**
 - pathological, **24:375–376**
 - physiological, **24:372–375**
 - up-regulation, **24:369–371**
 - solubilization of, **24:376**
- α_2 -Adrenergic receptors, **24:343–431**
- agonist affinity ratio studies, **24:350**
 - antagonist affinity ratio studies, **24:353**
 - biochemical responses mediated by, **24:347**
 - characterization by radioligand binding, **24:377–398**
 - agonist radioligands, **24:387–398**
 - antagonist radioligands, **24:377–387**
 - comparison, **24:404–410**
 - intact-cell binding, **24:387**
 - effector systems coupled to, **24:398–404**
 - adipocytes, **24:402–403**
 - human platelets, **24:401–402**
 - NG 108-15 cells, **24:403–404**
 - localization, **24:417–419**
 - regulation, **24:410–417**
 - down-regulation, **24:412–415**
 - heterologous, **24:415–416**
 - pathological, **24:416–417**
 - physiological, **24:416**
 - up-regulation, **24:410–411**
 - solubilization of, **24:419–420**
- α motoneuron, *see* Motoneuron
- Alpha rhythm, **3:220**
- Alternation behavior, in simple T-maze, **2:376–379**
- Alumina cream, **3:139–149, 3:155, 3:157, 3:166–167**
- Aluminum hydroxide, topical application to cerebral cortex, **8:163**
- Amanita mappa*, **3:257**
- Amanita muscaria*, psychomimetic agents of, **16:158**
- Amanitin, effects on receptors, **14:318–321**
- Amantadine, effect on aggression, **18:248**
- Ameletin, learning, memory and, **17:47–48, 17:74–75**
- Amine metabolism, in schizophrenia, **1:312–313, 1:349–359**
- Amine precursors, retrograde amnesic effects, **10:185**
- Amines
- biogenic
 - assay, **21:259–260**
 - distribution in brain areas, **21:270**
 - in mental illness, **8:197–220**
 - see also* Biogenic amines
 - in brain, distribution of, **10:327–331**
 - brain, MAO inhibitor effect on, **7:211–212**
 - brain lesions and metabolism of, **13:67–91**
 - drug effects on, **11:115–118**
 - in dyskinesias, **10:326–343**
 - effect on cortical neurons, **7:64–70**
 - heart, MAO inhibitor effects on, **7:212**
 - metabolism, in schizophrenia, **8:202–212**
- Amino acid neurotransmitters, **21:129–204**
- glucocorticoids and, **23:184**
 - transport into glial cells, **21:297–303**
 - see also* γ -Aminobutyric acid; Aspartate; Glutamate; Glycine; Taurine
- Amino acid receptors, tissue culture cells and, **21:198–202**
- Amino acids
- in blood-brain exchange, **7:168–172**
 - in brain, **18:170–172**
 - half-life of, **6:5**
 - transport of, **6:5–10**

- in cyclic AMP formation, **20**:124–125
- in cyclic GMP regulation, **20**:142
- effect on alcohol metabolism, **19**:166–167
- effect on neurons, **7**:48–63
- effects on thalamic and geniculate nuclei, **14**:40–42
 - in thalamus, **14**:11–12
- epileptic seizures and, **24**:140–142
- excitatory
 - in degenerative disease etiology, **22**:200–201
 - structures, **22**:185
- excretion of, in porphyria, **16**:325
- metabolism, in brain during excitation, **13**:256–258
- pool, in brain, **6**:3–19
- as synaptic transmitters, **11**:25–29
 - actions on neurons, **11**:26–28
 - biochemical evidence, **11**:25–26
 - release of, **11**:28–29
- as transmitters, receptor sites for, **13**:207–210
- uptake and subcellular localization in brain, **13**:143–146
- ω -Amino acids, **1**:145, **1**:150–151
 - action on apical dendrites, **1**:91–97
- Aminoaciduria, renal, **3**:266–267
- Aminoacidurias, **7**:24–26
- 4-Aminobutyrate 2-oxoglutarate aminotransferase, ethanol effects on, **19**:150
- β -Amino-*n*-butyric acid, **21**:198
- γ -Aminobutyric acid (GABA), **1**:120, **1**:123, **1**:144, **1**:150, **1**:316, **3**:155, **3**:168–169, **3**:324, **3**:343
 - action on dendrites, **1**:92–97, **1**:100
 - action on synaptic processes, **3**:326–329
 - analogs of, **17**:22, **17**:24–27
 - antagonists of, **21**:133–136, **21**:151, **21**:165
 - anticonvulsant drugs and functional role of, **17**:27–29
 - binding studies, **21**:154–177, **21**:191–192
 - biochemical studies with invertebrate preparations, **21**:191–192
 - with vertebrate preparations, **21**:154–177
 - biochemistry, **3**:330–333
 - in brain, **6**:18
 - derivatives, effect on cortical neurons, **7**:62–63
 - drug effects on, **11**:117
 - effect on cortical neurons, **7**:57–62
 - effect on EEG waves, **5**:72–73
 - effect on nerve membrane permeability, **5**:232
 - epilepsy and, **17**:1–36
 - as inhibitor, **1**:187–188
 - in inhibitory synaptic transmission, **15**:167–187
 - antagonism by convulsants, **15**:178–181
 - chemistry, **15**:181–183
 - drug administration and, **15**:171–173
 - electrical changes in neuronal membranes and, **15**:173–178
 - inhibitory transmission in CNS and, **17**:2–4
 - functional systems, **17**:4
 - postsynaptic, **17**:3
 - presynaptic, **17**:3–4
 - ionic mechanism of PAD action, **21**:244–246
 - α -ketoglutarate aminotransferase
 - in brain, **17**:87, **17**:98–99
 - inhibitors of, **17**:97–98
 - isozymes of, **17**:98
 - physical and chemical properties of, **17**:96–97
 - substrate specificity of, **17**:97
 - α -ketoglutarate transaminase
 - distribution in monkey nervous system, **2**:288–294
 - pH activity relationships of cerebral GAD and GABA-T, **2**:301–305
 - pyridoxal phosphate as a coenzyme for, **2**:309
 - metabolic and neurophysiological roles, **2**:280–332
 - metabolism of, **1**:40, **17**:20–24
 - neuronal response to, **10**:22–23
 - as neurotransmitter in brain, **13**:143–156
 - as opiate neurochemical correlate, **25**:286–289
 - physiologic-pharmacologic studies in
 - invertebrates, **21**:150–151
 - in vertebrates, **21**:133–144
 - presynaptic inhibition and, **21**:142–144
 - as presynaptic transmitter, **21**:227–228
 - as primary afferent depolarization transmitter, **21**:240–248
 - receptor blockade for, **17**:15–18
 - convulsive activity and, **17**:18
 - in rhinencephalic seizures, **1**:40
 - structural formula, **21**:134

- structure/activity studies, **21**:136–139,
21:246–247
- synaptosomes storing, **13**:149–156
- synthesis of, **17**:5–15
- GABA shunt and glutamic acid
decarboxylase, **17**:5–7
- tissue localization, **21**:131
- transport in glial cells, **21**:299
- uptake of, **17**:18–20
- see also* GABA
- γ -Aminobutyric acid-ergic synapses,
activators of, **21**:139–142
- γ -Aminobutyric acid-glutamic acid
system, neuroleptic drug effects and,
8:256–260
- γ -Aminobutyric acid receptors, **21**:154–177
- bicuculline sensitivity, **21**:156–163
- distribution of, **21**:247–248
- environment and, **21**:177
- enzymatic degradation, **21**:157
- maturation and, **21**:174–177
- pre- and postsynaptic, differences in,
21:229–231
- regional distribution of, **21**:164–172
- substrate specificity, **21**:158, **21**:163–164
- in sympathetic ganglia, **21**:172
- γ -Aminobutyric transaminase, inhibitors of,
17:20–24
- γ -Aminobutyryl and β -alanyl peptides
in brain, **12**:245–252
- biosynthesis and degradation,
12:249–251
- clinical aspects, **12**:252
- occurrence and distribution,
12:246–248
- physiological aspects, **12**:251–252
- γ -Aminobutyrylcholine, presynaptic
inhibition and, **21**:143–144
- ϵ -Aminocaproic acid, **1**:146–147, **1**:150
- effect on cortical neurons, **7**:56
- ω -Aminocaprylic acid, effect on cortical
neurons, **7**:56
- p*-Aminoclonidone, as α_2 -adrenergic
agonist, **24**:393–398
- trans*-4-Aminocrotonic acid, **21**:137, **21**:139
- 3-Aminocyclopentane-1-carboxylic acid,
21:137
- Aminoethanol, **1**:205–214
- γ -Amino- β -hydroxybutyric acid, as
neuronal blocking agent, **17**:26
- δ -Aminolevulinic acid, in porphyrin
pathway, **16**:319
- δ -Aminolevulinic acid synthetase,
overactivity of, in porphyria,
16:319–320, **16**:323, **16**:333
- D-Amino oxidase, in brain, subcellular
localization of, **20**:266–269
- Aminopentamide, as antiacetylcholine drug,
16:75
- Aminopeptidase(s), **11**:59–60
- in brain, **11**:65
- histological detection, **11**:69
- molecular analysis of, **17**:197
- in nervous system, **11**:66
- α -Aminopeptide amino acid hydrolases
classification of, **11**:59
- of nervous system, **11**:61–64
- aminotripeptidase, **11**:63–64
- leucine aminopeptidase, **11**:61–63
- p*-Aminosalicylic acid, **3**:340
- 4-Aminotetrolic acid, **21**:137
- Aminotransferases
- altered levels of, in tissues, **17**:110–113
- in brain, **17**:85–128
- developmental changes, **17**:119–120
- stability, **17**:113–114
- chemical and physical properties of,
17:87–109
- compartmentation in nervous tissue
related to activity, **17**:114–115
- developmental changes in, **17**:117–121
- in neurotransmitter metabolism,
17:115–117
- regulation of, **17**:109–117
- 2-Aminotricyanopropene, effect on brain
cell culture, **5**:5, **5**:29–30
- Aminotripeptidase
- classification of, **11**:59
- molecular analysis of, **17**:197
- in nervous system, **11**:63–64
- Aminoxyacetic acid, as GABA-
transaminase inhibitor, **17**:21
- Amitriptyline
- as antidepressant drug, **9**:133–134
- as antidepressive drug, **5**:405
- formula of, **9**:109
- Ammonia, increase in brain during
excitation, **13**:260–261
- Amnesia
- frontal lobe type, **19**:11–14
- hippocampal lesions and, **19**:1–49
- retrograde, *see* Retrograde amnesia
- temporal lobe type, **19**:10–11
- use to study memory, **16**:273–276

- Amobarbital in approach-avoidance conflict, **2:251**
- AMP, cyclic, *see* Cyclic AMP (cAMP)
- cAMP, *see* Cyclic AMP (cAMP)
- Amphetamine (Dexedrine) (D-A)
- action of chlorpromazine, **2:237**
 - bulbocapnine catalepsy, **2:254**
 - effect of, an ethanol intake, **2:68–69**
 - learning under amphetamine, **2:346, 2:350–351**
 - results of
 - eyeblink conditioning, **2:349–350**
 - kinesthetic figural after-effects, **2:355**
 - nonsense syllable, **2:346**
 - pursuit rotor, **2:352–353**
 - rotating spiral after-image, **2:361–362**
 - suppression of primary visual stimulus, **2:363–364**
 - vigilance, **2:365**
- d*-Amphetamine, sulfate, retrograde amnesic effects, **10:186–187**
- Amphetamines, **1:265, 1:291**
- addiction to, **12:324–325**
 - psychosis from, **12:325–326**
 - in affective disorder therapy, **18:374–375**
 - analogs, structures and activities of, **12:316**
 - antagonism of action of, **12:347–356**
 - anticataleptic action, **9:138**
 - effect on aggression, **18:247**
 - effect on cerebral glucose utilization, **22:322–323**
 - effect on EEG, **8:284–285, 8:308**
 - effect on food intake, **5:334**
 - effect on learning, **8:148–149**
 - beneficial, **8:171–172**
 - effects on CNS, **11:36–38**
 - effects on
 - affective disorders, **12:156**
 - brain catecholamines, **12:356–357**
 - interaction with other drugs, **12:347–356**
 - kinetics of metabolism of, **12:337–347**
 - mechanism of action of, **12:361–373**
 - meth-, effect on learning, **8:172**
 - physicochemical properties of, **12:337–339**
 - as psychomotor stimulant, **12:308, 12:309**
 - therapeutic use of, **12:323–324**
 - toxic effects of, **12:324**
- Amphibians, CNS regeneration in, **6:268–275**
- Amygdala
- AChe and NAO-d activity of, **10:260**
 - aggression sites in, **18:223**
 - connections with corpus striatum, **1:15–20**
 - effects on brain stem, **1:17–20**
- Amyl alcohol, membrane stabilization by, **9:148–149**
- Amylobarbitone, structure and activity, **24:16**
- Amytal (A)
- alternation behavior in simple T-maze, **2:377–379**
 - results of
 - eyeblink conditioning, **2:348–350**
 - kinesthetic figural after-effects, **2:355**
 - nonsense syllable learning, **2:346, 2:350–351**
 - pursuit rotor learning, **2:352–353**
 - rotating spiral after, **2:361–362**
 - suppression of primary visual stimulus, **2:363–364**
 - sedation threshold, **2:367–368**
 - vigilance, **2:365**
- Analgesia
- effect of drugs and CAR, **2:269–270**
 - opiate-induced, genetic aspects of, **25:290–293**
 - stress-induced, **25:319–320**
- Androgens
- animal behavior and, **11:142–144**
 - human behavior and, **11:144–148**
- Anesthesia
- barbiturate, **3:70–72**
 - chloralose, **3:70–72, 3:120, 3:179**
 - erythrocyte membrane stabilization and, **9:166–168**
 - membrane stabilization and, **9:204–208, 9:212–214**
 - and neuronal activity, **3:70–73, 3:114**
- Anesthetic drugs, retrograde amnesia from, **10:177–180, 10:185**
- Anesthetics
- effect on body temperature, **12:30–32**
 - effect on hippocampus, **8:104–110**
 - effect on nerve membrane permeability, **5:230–232**
 - effects on brain phospholipids, **20:16–17**
 - ethyl ether and pressor response, **2:151**
 - local, complexes of, **9:202–204**
 - membrane stabilization by, **9:149–151, 9:160–161**

- physicochemical properties of, **9**:182–190
 distribution coefficients, **9**:182
 interfacial properties, **9**:184–187
 molar polarizability, **9**:189–190
 penetration into liquid monolayers, **9**:187–189
- Anion vs. cation transport selectivity, **21**:324–327
- Anisospinol, structure of, **8**:253
- Annelids, octopamine function in, **19**:210–211
- Anorectic agents with central stimulant properties
 structures of, **12**:313–314
 survey of, **12**:310–312
- Anorexia nervosa, **5**:341
 endocrine role in, **5**:265
- Anoxia, **1**:247–252, **1**:283–286
- Anserinas, in brain, **11**:66–67
- Antamanide, effects on receptors, **14**:318–321
- Antennae, **3**:351, **3**:353–355, **3**:366
- Antennal nerves, **3**:351, **3**:354
- Anterior pituitary gland
 central nervous system and, **5**:249–256
 control by hypothalamic neurohumoral agents, **5**:253
- Antiacetylcholine drugs, **16**:67–144
 behavioral studies on, **16**:116–125
 chemical evolution of, **16**:71–77
 conformation features related to activity of, **16**:97–100
 crystallographic studies on, **16**:100
 derived from acetylcholine-like drugs, **16**:73
 factors influencing activity of, **16**:105–111
 metabolism of, **16**:133–137
 peripheral effects of, **16**:68
 pharmacological methods used in studies of, **16**:137–139
 potencies of, in CNS and PNS, **16**:111–116
 structure-activity relationship in, **16**:76–77
 quantitative studies, **16**:101–105
 stereochemical aspects, **16**:77–100
 use of, **16**:69
- Antiacetylcholine receptor antibodies
 antigenic determinants in, **24**:12–13
 assays for, **24**:5–7
 by immunoprecipitation, **24**:6
 by inhibition, **24**:6–7
- in cerebrospinal fluid, **24**:10–12
 of human skeletal muscle, **24**:13
 myasthenia gravis and, **24**:1–14
 in various disease forms, **24**:7–10
 pathogenicity of, **24**:2–5, **24**:11–12
 complexed antibodies, **24**:4–5
 free antibodies, **24**:3–4
 of torpedo fish, **24**:12–13
- Antibiotics, stereochemical relations to membrane-active drugs, **13**:215–217
- Antibody specificity, cerebrospinal fluid proteins and, **25**:115
- Antibrain antibodies
 dynamics of, **11**:321–325
 in epilepsy, **11**:319–331
- Anticholinergic chemicals, self-stimulation inhibition, **21**:380–384
- Anticholinergic drugs
 effect on, hippocampus, **8**:102–104
 learning, **8**:159–160
 retrograde amnesic effects, **10**:185
- Anticholinergic psychotomimetic agents
 chemical nature, **4**:221
 effects
 drug action, factors affecting
 acid group, strength of, **4**:238
 cationic charge, **4**:238
 with phospholipids, **4**:238–241
 spatial-geometric, **4**:232, **4**:233
 steric hindrance, **4**:233–238
 on humans
 behavioral, **4**:245–247
 psychological studies, **4**:248–249
 psychotomimetic potency, **4**:224–226
 on rats
 behavioral, **4**:244, **4**:245
 central nervous system (CNS), **4**:224
- Anticholinesterase agents, Hemicholiniums as, **2**:78, **2**:93
- Anticholinesterases, **3**:167
 poisoning by, antiacetylcholine drug treatment of, **16**:70, **16**:125–133
 in studies, of ACh activity in thalamus, **14**:15–17
- Anticonvulsant drugs
 GABA functional role and, **17**:27–29
 retrograde amnesia from, **10**:180–183
- Anticonvulsants
 effect on
 acetylcholine, **24**:126–127
 serotonin, **24**:120–121

- kryptopyrrole as, **16:167**
- porphyria induced by, **16:314**
- reaction with catecholamines, **24:114–115**
- Antidepressant drugs
 - chemically related to imipramine, **9:131–135**
 - classification of, **9:96–107**
- Antidepressants
 - effect on affective disorders, **12:149–152**
 - effect on olfactory bulbectomy syndrome, **22:280–283**
 - tricyclic types, *see* Tricyclic antidepressants
- Antiparkinsonian drugs, **21:383–384**
 - effect on brain catecholamine uptake, **13:137–139**
- Antipsychotic drugs
 - action, **21:3–8**
 - general characteristics, **21:2–3**
 - see also* Neuroleptic drugs
- Antipyretics, effect on, body temperature, **12:26–27**
- Anurans, CNS regeneration in, **6:270–271, 6:275**
- Anxiety, endocrine role in, **5:261–262**
- Apoenzyme relationships between
 - apoenzyme and coenzyme of vitamin B₆ requiring enzyme systems, **2:305–314**
- Apomorphine, **19:225–268**
 - adenylate cyclase activation by, **19:248–249**
 - biochemistry of, **19:244–252**
 - chemistry of, **19:226–231**
 - clinical data of, **19:226**
 - as CNS stimulant, structure of, **12:318, 12:319**
 - effect on aggression, **18:247–248**
 - effects on
 - aggression, **19:241**
 - blood pressure, **19:233**
 - convulsion, **19:234**
 - dopamine turnover and receptors, **19:244–248**
 - EEG, **19:234**
 - hormone release, **19:233–234**
 - locomotor activity, **19:240–241**
 - metabolism, **19:234**
 - neurotransmitter release, **19:250–252**
 - sexual behavior, **19:242**
 - as emetic, **19:231–232**
 - hyperthermic response to, **19:232–233**
 - in vitro* binding to brain dopamine receptors, **19:249–250**
 - mechanism of action of, **19:254**
 - modification of, **19:227–231**
 - narcotic analgesics and, **19:252–256**
 - neuropsychopharmacology of, **19:235–244**
 - in perception of noxious stimuli, **19:253**
 - pharmacology of, **19:231–234**
 - self-administration of, **19:254**
 - stereotyped behavior from, **19:235–240**
- Apparent movement in assessment of drug effects, **2:355–356**
- Appetite
 - control, neurological factors in, **5:303–346**
 - glucostatic theory of, **5:316, 5:322–326**
 - hypothalamus effect on, **5:304–308**
 - intestinal control of, **5:318–322, 5:327–332**
 - lipid deposits and, **5:317**
 - nervous mechanisms controlling, **5:314–341**
 - rhinencephalon and, **5:308–311**
 - sensory role in control of, **5:336–339**
 - thermoregulation of, **5:326–327**
- Area extrema
 - as extra blood-brain barrier, **10:32–36**
 - physiological function, **10:48–52**
- Area postrema, **3:44**
- Arecoline, **1:201–202**
 - CAR, **2:257–259**
 - effect on CEPR, **2:147–149**
 - effect on learning, **8:173**
- (Arg⁸)-vasopressin, peptide sequence of, **25:187**
- Arginino-succinic-aciduria, **7:24–25**
- Aromatic aminotransferases
 - activity of, **17:88**
 - in brain, **17:105–106**
 - localization of, **17:106–107**
 - purification of, **17:103**
- Arousal and arousability, neurobiology of, **25:398–403**
- Arousal reaction, **3:215**
- Arthropods, octopamine function in, **19:205–207**
- Arylamidase A, in brain, **11:70–71**
- Arylamidase B, in brain, **11:71–72**
- Arylamidase N, in brain, **11:72–73**
- Arylamidases
 - in brain, **11:65**

- molecular analysis of, **17:198–199**
 - in nervous system, **11:66**
 - in pituitary, **11:78–79**
- Arylamide amino acid hydrolases, **11:60**
 - in nervous system, **11:69–73**
 - in pituitary, **11:78–79**
- Ascending and descending tracts, AChE
 - activity in, **10:268–269**
- Ascending reticular activating system (ARAS), **9:45, 9:46**
- Ascorbic acid, **1:304, 1:334**
- Asparagine
 - alcohol intake of rats, **2:58**
 - role in cortical depression, **5:222**
 - transamination of, **17:101–103**
- L-Asparagine, effect on cortical neurons, **7:56**
- Aspartate
 - antagonists of, **21:148–150**
 - biochemical studies with invertebrate preparations, **21:192–193**
 - with vertebrate preparations, **21:187–191**
 - α -ketoglutarate aminotransferase
 - activity of, **17:88, 17:93**
 - amino acid composition of, **17:89**
 - in brain, **17:86, 17:87, 17:92**
 - factors affecting, **17:111**
 - physical properties of, **17:87–90**
 - subcellular distribution of, **17:92, 17:94**
 - substrate specificity of, **17:90, 17:91, 17:93**
 - in transamination, **17:85**
 - physiologic-pharmacologic studies in invertebrates, **21:152–154**
 - in vertebrates, **21:147–150**
 - tissue localization, **21:132–133**
- Aspartic acid, **3:327–328**
 - effect in rabbit cortex and cat spinal neurons, **2:281**
 - tricarboxylic acid cycle, **2:285–288**
 - role in cortical depression, **5:222**
- L-Aspartic acid, seizures and, **24:141–142**
- Association cortex, evolution of, **16:244–250**
- Astrocytes
 - in brain cell culture, **5:14, 5:48**
 - contraction of, **3:48**
 - morphological characteristics of, **3:6–18, 3:59**
 - movement of, **5:19**
 - permeability of, **3:49**
- relation to
 - blood-brain barrier, **3:39–44**
 - capillaries in CNS, **3:44–47**
 - cerebrospinal fluid, **3:34–35**
 - extracellular space, **3:28–32**
 - water-electrolyte metabolism of brain, **3:33–34**
- RNA synthesis in, **16:191**
- role in edema of CNS, **3:37–39**
- summary of functional significance, **3:60–61**
- see also* Astroglia; Neuroglia
- Astroglia
 - localization, **21:276**
 - ontogeny, **21:276**
 - see also* Astrocytes; Glial cell
- Astroprotein, in CSF, **25:123–125**
- ATCh, learned behavior and, **17:43–44**
- Atonia, control of, **23:413**
- ATP (Adenosine triphosphate)
 - chemical combination between serotonin and ATP, **2:204**
 - effects of ACh on incorporation of P^{32} from α -Glycerophosphate P^{32} and ATP into phosphatidic acid, **2:116–119**
 - as energy source for osmosis, **2:126–128**
 - metabolism, in brain during excitation, **13:256–258**
 - L-methionine adenosyltransferase, assay of, **18:59**
 - turnover of phosphatidic acid and ATP specific activity, **2:111**
 - see also* Adenosine triphosphate
- Atropine, **1:266, 1:339**
 - abolition of central effects of eserine, pilocarpine, and arecoline, **2:258**
 - abolition of effect of ACh, **2:104**
 - cholinergic agents on enzyme secretion in pancreas, **2:103**
- action of
 - chlorpromazine, **2:237**
 - reserpine, **2:245**
- analogs as hallucinogens, **1:229**
- in anticholinesterase poisoning, **16:126, 16:130**
- as antagonist to HC-3, **2:94**
- atropine arecoline antagonist, **2:258–259**
- behavioral studies on, **16:117–119**
- binding in muscarinic site, **13:200**
- blocking pressor response, **2:147**

- blood pressure lowering effect of GABA, **2:325**
- CAR, **2:257, 2:260**
- drugs derived from, **16:72**
- effect on appetite, **5:334**
- effect on cortical neurons, **7:69**
- effect on EEG, **8:286–287, 8:293**
- effect of GABA, **2:325**
- effect on hippocampus, **8:102–103**
- effect on learning, **8:159–160, 8:173**
- metabolism of, **16:134–135**
- methyl-, effect on learning, **8:160**
- as muscarinic antagonist, **17:166–167**
- pharmacology of, **16:71, 16:92**
- stimulating effect of, on phospholipid turnover, **2:104–105**
- stress-induced behavior in rats, **2:247**
- structure of, **16:72**
- use in mental disease tests, **5:403**
- Atropine sulfate, retrograde amnesia from, **10:183–184, 10:185**
- Attention, neural model of, **18:263–327**
- Auditory area
 - histology, **3:232**
 - unit responses in, **3:119–120**
- Auditory cortex, of cetacea, **21:62–64**
- Auditory deprivation, effects on cerebral glucose utilization, **22:305–307**
- Auditory system, of cetacea, **21:58–64**
- Augmenting response, **3:221–223**
- Autoimmune processes
 - in neurosyphilis, **11:310**
 - in schizophrenia, **11:297–306**
 - studies of, **11:291–328**
- Autointoxication, intestinal as cause of mental illness, **3:252–253, 3:284–285**
- Autointoxication syndrome, in schizophrenia, **11:205–207**
- Autoradiography
 - biochemical pharmacological aspects, **22:118–119**
 - diffusible substances, **22:116–118**
 - in vivo*, **22:119–121**
 - method development, **22:115–116**
 - of neurotransmitter receptors, **22:111–204**
- Avoidance behavior, from β -lipotropin, **20:16–91, 20:235–236**
- Avoidance learning, in olfactory bulbectomy syndrome, **22:274–276**
- Axoglial relationships to axolemma, **24:433–484**
 - aberrant, **24:473–474**
- Axolemma
 - axoglial relationship to, **24:433–484**
 - aberrant, **24:473–474**
 - changes of with glial ensheathment, **24:465–470**
 - myelinated, **24:470–473**
 - premyelinated, **24:463–465**
 - of retinal ganglion cells, freeze-fracture, **24:452–461**
- Axon(al)
 - conduction, barbiturate effect on, **24:21–22**
 - membrane
 - differentiation in myelin absence, **24:475–479**
 - summary of developmental changes in, **24:474**
 - myelinated, freeze-fracture, **24:451–452**
 - optic nerve, **24:474**
 - freeze-fracture studies of myelination in, **24:461–474**
- Axon collaterals, **3:160–161, 3:176**
- Axons, **3:126**
 - acetylcholinesterase in, **18:82–84**
 - in terminals, **18:84–108**
 - of brain, phospholipid composition of, **20:5**
 - choline acetyltransferase transport by, **20:312–314**
 - as delay lines, **18:4–6**
 - demyelination of, **18:33–34**
 - diagram of, **13:318**
 - diameter spectra of, **18:26–28**
 - dorsal column, **3:92**
 - electrotonic coupling in pathways of, **18:19–20**
 - external effects on, **18:18–19**
 - as filtering systems, **18:6–18**
 - functions of, **18:32–33**
 - injury to, perikaryal responses to, **14:49–124**
 - myelination in, critical diameter of, **18:29–32**
 - nodes and internode spacing in, **18:20–26**
 - nonterminal, monoamine cell bodies and, **13:59–61**
 - potassium in, **5:208**
 - properties and design principles of, **18:1–40**
 - protein metabolism in, **15:200–201**
 - proteins in, synthesis in soma, **13:295–296**
 - protein synthesis in, **13:292–296**

protein transport in, **13**:296–313
 pyramidal, **3**:91, **3**:94, **3**:123
 collaterals of, **3**:108
 RNA in, **16**:191–192
 transport, **16**:192–193
 RNA and proteins in, stimulation effects
 on, **13**:277–279
 structure-function relations for,
 18:20–32
 synthesis of, exogenous proteins and,
 17:252–253
 as transmission line, **18**:2–3
 Axons (dental), **25**:40–49
 cytochemical diversity of, **25**:47–49
 intradental arborisation of, **25**:46–47
 size of
 at root apex, **25**:44–45
 at root foramen, **25**:43–46
 types of, **25**:40–49
 Axoplasmic flow, **17**:241–296
 axonal pathway interruption and,
 17:253–261
 factors affecting, **17**:273–278
 fast, **17**:280–285
 general description of, **17**:278–287
 growth and regeneration effects on,
 17:276–277
 in intact nerves, **17**:250–253
 metabolism effects on, **17**:273–274
 nerve activity effects, **17**:277–278
 peripheral and central effects of nerve
 section in, **17**:261–273
 revelation of, **17**:242–273
 slow, **17**:285–287
 temperature effects on, **17**:274–275
 tracer studies on, **17**:245–253
 Axoplasmic organelles, somatofugal
 transport of, **13**:303
 Azacyclonol (Frenquel)
 CAR, **2**:248
 potentiating effect on CEPR, **2**:145
 voluntary alcohol intake in man, **2**:68–69
 8-Azaguanine
 effect on learning, **8**:165–166
 retrograde-amnesic facilitating effects,
 10:193–194
 Azaperone, self-stimulation behavior and,
 21:355, **21**:360, **21**:366
 Azapyrimidines
 metabolic effects, **10**:222–225
 concentration of pyrimidine
 nucleotides, **10**:224

 incorporation of pyrimidine
 pre-cursors, **10**:222–224
 metabolism of, **10**:220–222
 neurobiology of, **10**:219–225
 physiological effects of, **10**:220
 Azaserine, effect of, on free choice of
 alcohol by rats, **2**:70
 6-Azauracil, neurobiology of, **10**:200,
 10:220, **10**:223
 6-Azauridine, neurobiology of, **10**:200,
 10:220–223
 Azido-*N*-methyl-4-piperidyl benzoate,
 structure of, **25**:173

B

BAB, formula and action of, **12**:219
 BABA, *see* β -Amino-*n*-butyric acid
 Baclofen, as possible glutamate-release
 inhibitor, **22**:201
 Balcofen, *see* Lioresal
 Bantu porphyria, **16**:305
 symptoms of, **16**:308
 Barbitals
 pole-jump CAR, **2**:250–251
 see also Sodium barbitals
 Barbitone, structure and activity, **24**:16
 Barbiturates
 as anticonvulsants, **17**:27
 biochemical and neurochemical studies,
 24:34–44
 CAR, **2**:250–251
 convulsant, neuropharmacology,
 24:33–34
 effect on, hippocampus, **8**:105–107
 effect on optic nerve, **5**:136
 effects on axonal conduction, **24**:21–22
 effects on CNS, **11**:34–35
 effects on mitochondrial respiration,
 24:34–35
 effects on neuronal membranes, **24**:32–33
 effects on neurotransmitter release and
 uptake, **24**:35–44
 effects on synaptic transmission, **24**:16–21
 effects on transmitter action, **24**:25–32
 effect on vision, **1**:262–263, **1**:270, **1**:288
 general structures and activities, **24**:16
 learning, **8**:146–148
 neuropharmacological studies on,
 24:16–21
 pharmacology, **24**:15–49
 porphyria induced by, **16**:313

- postsynaptic effects of, **21**:139–140
- presynaptic action, **24**:22–24
- presynaptic inhibition and, **21**:143
- retrograde amnesia from, **10**:179–180
- use with ECT, **5**:401
- Barbiturate spindles, **3**:91
- Barium ion, **3**:304
- Bartel's compounds, **17**:151
- BAS, *see* 1-Benzyl-2,5-dimethylserotonin
- Basal ganglia, hippocampal formation and, **25**:342–346
- Basal ganglia disease
 - amine metabolism in, **10**:331–336
 - altered physical effects, **10**:336–338, **10**:341–343
 - brain metabolism, **10**:333–336
 - urinary excretion, **10**:331–333
 - biochemistry of, **10**:323–370
 - metal metabolism in, **10**:348–352
- Basement membrane, **3**:41, **3**:60
- Bat
 - auditory and visual nuclei, **21**:60
 - echolocation, **21**:86
- Batrachotoxin
 - effects on receptors, **14**:317–318
 - neurobiology of, **16**:149, **16**:172
 - structure of, **16**:171
- B-burst, in acetylcholine-operated channels, **24**:326–328
- BE-2254 (compound), as α_1 -adrenergic antagonist, **24**:362
- Behavior
 - body temperature and, **12**:4–5
 - categories of, **6**:364–367
 - central pharmacology, cyclic nucleotides and, **20**:152
 - central serotonin neuron rule in, **13**:120
 - cerebral RNA effects on, **16**:208–210
 - of cetacea, **21**:97–98
 - classification of, **6**:363–374
 - conditioning studies, **3**:236–240
 - cortical function and, in primates, **16**:260–289
 - definition of, **6**:363–374
 - drug effects on, **15**:284–288
 - evoked
 - flexibility of, **6**:378–379
 - study of, **6**:374–385
 - types of, **6**:385–430
 - free, *see* Free behavior
 - hippocampal lesion effects on, **25**:340–343
 - inhibition of, **6**:413–430
 - insect
 - chemical control of, **3**:370–371
 - control by local brain stimulation, **3**:365–371
 - methodology used in study of, **6**:356–362
 - nerodrenaline neuron role in, **13**:110–114, **13**:120
 - neurochemical correlates of, **13**:325–341
 - acetylcholine changes, **13**:335–338
 - methodological problems, **13**:338–339
 - serotonin changes, **13**:327–335
 - offensive-defensive reaction in, **6**:395–413
 - olfaction effects on, **22**:260–277
 - opiates and, **25**:306–319
 - organization of, **6**:430
 - peptides and, **17**:37–60
 - code in nervous system, **17**:50–56
 - innate behavior, **17**:39–43
 - learned behavior, **17**:43–50
 - methodology for, **17**:48–50
 - in studies of brain anatomy, **16**:237–238
 - units of measurement of, **6**:367–369
 - variability of, **6**:372–374
 - Behavioral assays, in memory studies, **12**:183–185
 - Behavioral chemoreception, of cetacean, **21**:57–58
 - Behavioral role, of locus ceruleus noradrenergic system, **23**:346–353
 - Behavior and cholinergic mechanism, **14**:173–231
 - ACh as central neurotransmitter, **14**:175–183
 - basis for central mechanism, **14**:183–184
 - food and water intake effects, **14**:197–199
 - learning, memory and, **14**:207–217
 - methodological problems in, **14**:217–219
 - motor activity and, **14**:189–197
 - multitransmitter control of central functions, **14**:184–185
 - self-stimulation, punished behavior and, **14**:203–207
 - state of consciousness and, **14**:185–189
 - Behavior disorders, in children, **1**:224–225
 - Behaviors, transferred, types of, **17**:68–70
 - Belladonna, toxic psychosis from, **16**:68
 - Bemegride, use in psychotherapy, **5**:390
 - Benactyzine, **1**:239
 - in animals, **2**:246–248, **2**:259–260
 - effect on EEG, **8**:291
 - in man, **2**:246

- Benapryrazine, as antiacetylcholine drug, **16:114–115**
- Benperidol
 self-stimulation behavior and, **21:356, 21:360, 21:366**
 structure of, **8:254**
- Benzetimide
 as antiacetylcholine drug, **16:74, 16:83**
 metabolism of, **16:136, 16:137**
- Benzhexol, as antiacetylcholine, drug, **16:73**
- Benzodiazepine receptors, autoradiography of, **22:153–155**
- Benzodiazepines
 as anticonvulsants, **17:27**
 neurobiology of, **16:158**
 pharmacological actions of, **23:106–108**
 as phosphodiesterase inhibitors, **20:130–131**
 postsynaptic effects of, **21:140–142**
 presynaptic inhibition and, **21:143**
 receptors in central nervous system
 characterization of, **23:108–113**
 endogenous ligands, **23:116–122**
 heterogeneity, **23:113–116**
 regulation, **23:122–133**
- Benzoquinolizine derivatives
 actions
 clinical, **4:300**
 metabolites, urinary, **4:288**
 on monamine metabolism
 central nervous system, **4:282–286**
 mechanism, **4:288–291**
 organs, peripheral, **4:287, 4:288**
 pharmacological, effects on monamine metabolism and, **4:300–302**
 chemistry
 carbinols, secondary and tertiary, **4:278–280**
 ketones, **4:278**
 metabolism, **4:281**
 tissue distribution and excretion, **4:281**
 pharmacology
 cardiovascular system, **4:296, 4:297**
 gastrointestinal tract, **4:297, 4:298**
 nervous system, **4:291–296**
 toxicity, **4:299**
- Benzoquinolizines, imipramine antagonism to, **9:110**
- 1-Benzyl-2,5-dimethylserotonin, effect on hippocampus, **8:93**
- Benzylpenicillin, antagonist, of GABA, **21:135**
- Betaine, **1:205–208**
 effect on schizophrenia, **8:211**
- Betz cells, **3:70, 3:118, 3:209**
 spikes from, **3:78, 3:80–84, 3:87, 3:94–95, 3:123–124, 3:141–142, 3:146**
 spontaneous discharge from, **3:94**
- BIC, *see* Bicuculline
- Bicuculline
 antagonist, of GABA, **21:134, 21:135, 21:138, 21:151, 21:163, 21:165**
 as antagonist of inhibitory transmission, **15:180–181**
 as GABA receptor blocker, **17:15–17**
- Bicuculline-insensitive GABA receptors, drugs affecting, **21:139**
- Bicuculline methochloride, **21:136, 21:137, 21:138**
- Biochemical transfer
 of acquired information, **17:61–83**
 factors affecting, **17:65–68**
 specificity and, **17:75–78**
 synaptic models, **17:78–80**
- Bioelectric activities, in CNS tissue cultures, **9:1–42**
- Bioelectric phenomena, calcium and phosphates in, **9:223–261**
- Biogenic amines
 affective disorders and, **18:360–367**
 drug effects on, **12:147**
 effect on affective disorders, **12:145–148**
 effects on brain RNA, **16:217–219**
 ethanol effects on urinary excretion of, **19:151–152**
 levels in human brain, **12:159–160**
 synthesis and metabolism of, **12:148–149**
see also Microamines
- Biological receptors, drug activity and, **16:78**
- Biotin, deficiency and free choice of ethanol, **2:58**
- Bird migration, peptides in, **17:43**
- Birds, CNS regeneration in, **6:277–281**
- Bisonium compounds, as blocking agents, **17:158–159**
- Bispyridinium oximes, structure of, **25:153**
- Blockade, dopaminergic, **23:291–293**
- α -Blockers, of adrenergic receptors, **17:183–185**
- Blood-brain barrier, **3:30, 3:36, 3:51, 3:60, 3:299**
 as active transport mechanism, **3:46–47**

- cerebral glucose effects on opening of, **22:325**
- pyrrole determination in, **16:160**
- relation to astrocytes, **3:34, 3:39–44, 3:60–61**
- in schizophrenia, **1:313–314**
- where absent, **3:44, 3:60**
- see also* Extra-blood-brain-barrier brain structures
- Blood-brain barrier concept, **7:153–189**
 - anoxia and death effects on, **7:177–178**
 - blood compartment of, **7:172–173**
 - CO₂ effects on, **7:178–179**
 - CSF compartment of, **7:174–175**
 - definition of, **7:154**
 - hypothermia effects on, **7:178**
 - metabolic tissue compartment, **7:173–174**
 - psychiatric interest in, **7:179–182**
 - “pure barrier lesions” and, **7:175–176**
 - urea effect on, **7:179**
- Blood-brain exchange, **7:168–172**
 - amino acids in, **7:169–170**
 - brain vessels in, **7:171–172**
 - glucose in, **7:170–171**
- Blood-cerebrospinal fluid exchange, **7:155–162**
 - active transport in, **7:156–159**
 - choroid plexus in, **7:161–162**
 - passive transport in, **7:159–160**
 - pial vessels in, **7:160–161**
 - ventricular perfusion techniques and, **7:155–156**
- Blood flow, ACTH 4-10 effects on, **20:220–221**
- Blood pressure, apomorphine effects on, **19:233**
- Blood pyrrole determination in, **16:159–160**
- Body temperature
 - drugs and, **12:1–43**
 - chemical mediators, **12:11–37**
 - methods of investigation, **12:8–10**
 - sites of action of, **12:7–8**
 - measurement of, **12:10**
 - regulation of, **12:2–7**
 - central mechanisms, **12:2–4**
 - peripheral mechanisms, **12:4–7**
- Bombesin
 - nociception and, **25:225**
 - peptide sequence of, **25:187**
- Botulinum toxin, effects on motor neurons, **14:79–81**
- Boutons terminaux, **1:80–82, 1:107–108**
- Brady, effects on receptors, **14:321**
- Bradykinin
 - nociception and, **25:188–190**
 - peptide sequences of, **25:187**
- Brain
 - acetylcholine and serotonin levels related to behavior, **13:325–341**
 - AChe mapping in, **10:231–275**
 - brain stem and diencephalon, **10:241–261**
 - significance, **10:269–273**
 - acidic compounds found in, summary, **12:240–241**
 - ACTH 4-10 uptake of, **20:221–222**
 - amino acid(s), **6:3–19**
 - metabolism in, **6:10–12**
 - pool, **6:3–19**
 - transport, **6:5–10**
 - amino acids in, **12:236, 18:170–172**
 - D-amino oxidase in, subcellular localization of, **20:266–269**
 - aminotransferases in, **17:85–129**
 - anatomy of, **16:237–260**
 - antibrain antibodies in schizophrenia, **11:297–306**
 - effects on brain, **11:303–306**
 - asymmetry of function of, **16:278–280**
 - biogenic amine levels in, **12:159–160**
 - catecholamines in, drug effects on, **11:115–116**
 - cell types in, **18:142–144**
 - metabolic studies, **18:145–147**
 - cellular membrane potentials in, **18:186–191**
 - compartmentation in, **18:150–151**
 - complexity of, **18:142–151**
 - convulsions, causes of, **6:16–17**
 - deep structures of, emotional and mental effects of, **11:335–336**
 - developing, neurotransmission in, **20:65–103**
 - developing glucose utilization in, deoxyglucose metabolite levels in, **22:68–70**
 - dopamine in, **10:330**
 - energy metabolism related to amino acid metabolism, **13:256–261**
 - enzymes in, **6:25–26, 18:174–176**
 - ethanol effects on, **19:130–136**
 - carbon dioxide metabolism, **19:132–133**
 - energy metabolism, **19:136–139**

oxidative metabolism, **19**:130–132
 oxygen metabolism, **19**:131–132
 redox changes, **19**:135–136
 TCA cycle in, **19**:134–135
 ethanol metabolism in, **19**:124–130
 evolution of, **16**:239–240
 excitability, glucocorticoids and, **23**:167
 exopeptidase distribution in, **11**:64, **11**:65
 extra-blood-brain-barrier structure,
10:31–55
 extracellular space of, **5**:61, **5**:198–202
 fatty acid synthesis in, **5**:356–363
 of fetus, *see* Fetal brain
 functional subdivision of, **5**:54–59
 GABA metabolism in, **22**:26–31
 glucose utilization in, deoxyglucose
 method for, **22**:296–301
 glutamate metabolism in, **22**:10
 pathways, **22**:186
 glycogen turnover in, **5**:371–379
 glycolysis in, **18**:173–174
 gray matter, cellular enzyme distribution
 in, **10**:240–241, **10**:262–267,
10:271–273
 hallucinogen effects on serotonin receptor
 in brain, **12**:207–233
 high-energy phosphates in, **18**:160–166
 histamine metabolism in, **12**:266–270
 information exchange between
 hemispheres of, **16**:280–281
 information processing in, **13**:370–371
 molecular mechanisms in, *see*
 Molecular mechanisms in
 information processing
 information storage in, theoretical model,
16:222–228
 intermediary metabolism in, **18**:166–176,
22:47–110
 carbon dioxide effects on, **22**:58–65
 methods for study, **22**:49–58
 stopping rate of, **22**:49–53
 interstitial space of, **18**:144–145
 ion concentrations in, **18**:147–148
 ion and energy metabolism of,
18:141–211
 ionic composition of, **5**:202–207
 malate dehydrogenase mapping in,
10:234–235
 mental activity studies on, **11**:335–344
 metabolic compartmentation in,
18:169–170
 metabolic rate of, **22**:53–58

metabolism of
 during seizures, **22**:71–78
 in schizophrenia, **11**:265–266
 metals in, distribution, **10**:348
 microdissection techniques, **21**:265–270
 NAD-d mapping in, **10**:231–275
 brain stem and diencephalon,
10:241–261
 neurons, neurotoxins specific for,
22:175–179
 noradrenaline in, **10**:330
 ontogenetic and phylogenetic
 development of, **18**:148–150
 opiate receptors in, ACTH 4-10 effects
 on, **20**:229–230
 organic affections, psychic trauma, and
 autoimmunity, **11**:310–325
 oxygen consumption in, **18**:151–160
 peptides in, **12**:235–263
 phospholipids of functional metabolism
 of, **20**:1–29
 potassium in, **5**:209–211
 of primates, cell density, **16**:250–251
 proteins, *see* Brain proteins
 protein synthesis in, **5**:363–371
 protein synthesis inhibitors of, *see*
 Cerebral protein synthesis inhibitors
 RNA metabolism in, **16**:183–231
 self-stimulation behavior, **21**:335–395
 size evolution of, **16**:239–240, **16**:243,
16:247–248
 slices
 GABA transport in, **22**:16–17
 glutamate transport in, **22**:3
 stimulation, *see* Brain stimulation
 subcellular fractions, enzymes in,
11:68–69
 synaptosomes in, *see* Synaptosomes
 tissue fractionation of, **20**:253–269
 vascular diseases of, autoimmune
 processes in, **11**:306–310
 water metabolism in, **18**:176–191
 wave activity in
 models of, **15**:230–232
see also EEG
 white matter, cellular enzyme
 distribution, **10**:238–240, **10**:267–269
see also Central nervous tissue; Cortex
 Brain-behavior relations, cellular
 perspectives, **23**:198–202
 Brain cell culture, **5**:1–52
 brain extract effect on, **5**:40

- capillaries in, **5:29**
- enzyme activity of, **5:40–41**
- narcotics effect on, **5:30–31**
- neuron interaction in, **5:14**
- in neuropathology, **5:41–46**
- stimulant effect on, **5:31**
- Brain-gut peptides, epileptic seizures and, **24:147–148**
- Brain hydrolases
 - alkaline phosphatase, **7:316–318**
 - in tumors, **7:337–338**
 - cholinesterases, **7:311–313, 7:336**
 - in demyelinating disease, **7:333–335**
 - esterases, **7:303–311**
 - assay of, **7:305–307**
 - inhibition and activation of, **7:307–311**
 - isozyme patterns of, **7:319–329**
 - in tumors, **7:337**
 - isolation techniques for, **7:299–303**
 - isozymes of, **7:319–340**
 - in pathological states, **7:333–340**
 - multiple molecular forms of, **7:297–344**
 - 5'-nucleotidases, **7:318–319**
 - phosphatases, **7:313–315**
 - isozymes of, **7:329–330**
 - proteases, **7:318**
 - in sphingolipidosis, **7:338–340**
 - thioesterase, **7:315–316**
 - in tumors, **7:337–338**
- Brain lesions and amine metabolism, **13:67–91**
 - amine changes after central lesions, **13:73–74**
 - anatomical considerations, **13:76–78**
 - direct denervation vs. transsynaptic effects in, **13:83–88**
 - fluorescent histochemical studies on, **13:78–83**
 - interpretation of, **13:72–88**
 - central nervous system, **13:73–88**
 - peripheral model, **13:72–73**
 - subcortical lesions, **13:69–72**
 - in medial forebrain bundle, **13:69–71**
 - in midbrain tegmentum, **13:71–72**
- Brain in the neonatal period behaviour,
 - genesis of
 - chemical constituents, accumulation of, **4:129–137**
 - electroencephalogram (EEG),
 - spontaneous, **4:143–145**
 - enzymatic activity, development of, **4:138–140**
 - evoked potentials, **4:145–147**
 - hematoencephalic exchange, **4:141, 4:142**
 - neuroanatomical development, **4:125–129**
 - neurophysiological development, **4:142, 4:147**
- Brain opioid peptide distribution in, **25:295–297**
- Brain proteins, **6:19–28**
 - amino acid content of, **6:26–28**
 - catabolism of, **6:60–72**
 - cerebral proteinases in, **6:61–66**
 - mechanism of, **6:66–68**
 - relation to formation, **6:69–72**
 - in development, **6:31–35**
 - dynamic state of, **6:28–29**
 - formation of, **6:45–60**
 - amino acid incorporation systems of, **6:50–52**
 - mechanism of, **6:52–60**
 - precursors in, **6:47–50**
 - problems in, **6:45–47**
 - half-life of, **6:29–31**
 - of individual cerebral areas, **6:23–26**
 - metabolism of
 - localization in, **6:42–45**
 - of various regions, **6:35–38**
 - purified, **6:20–23**
 - turnover of, **6:28–45**
 - heterogeneity in, **6:38–42**
- Brain slices, protein autophosphorylation in, **20:137–138**
- Brain stem, of cetacean, **21:56–57**
- Brainstem motoneurons
 - hyperpolarization during sleep, **24:233–235**
 - membrane potential during sleep and wakefulness, **24:218–225**
- Brainstem reticular core, neurons of, **13:13–14**
- Brain stimulation
 - in cetacea, **21:94–95**
 - fatigue in, **6:379–380**
 - free behavior and, **6:349–449**
 - remote control of, **6:362–363**
 - variability of, **6:383–385**
- Brain tumor, glial cell types and, **21:291**
- Brain waves
 - Bremer's "Auto-rhythmicity" theory, **1:77**
 - Eccles' theory, **1:78**
 - independence from spikes, **1:62–64, 1:101f**
 - origin of, **1:53f, 1:154**

- population characteristics and, **8:269–270**
 role of axons, **1:53–58**
 role of dendrites, **1:64f**
 role of *p.s.p.s.*, **1:61f**
 role of somatic potentials, **1:58–61**
see also Electroencephalogram;
 Electroencephalogram amplitude
 analysis; Spontaneous activity
- Branched-chain amino acid
 aminotransferase
 activity of, **17:88**
 in brain, **17:87, 17:100**
 inhibitors of, **17:99–100**
 isozymes of, **17:101**
 localization of, **17:100–101**
 physical and chemical properties
 of, **17:99**
 substrate specificity of, **17:91, 17:93,**
 17:99–100
- Breech birth, frequency of, in alcoholic
 women, **19:159**
- “Bromide test”, **7:180**
- Bromperidol, self-stimulation behavior and,
 21:353, 21:360, 21:366
- Bufotenidin, **3:257**
- Bufotenin
 as central serotonin antagonist, **12:219**
 effect on EEG, **8:291**
 hallucinogenic properties of, **8:210**
 in schizophrenia, **8:204**
- Bufotenine, **3:253, 3:257, 3:279**
 CAR, **2:264**
 potentiates CEPR, **2:149**
- Bulbocapnine, effect in animals, **2:254**
- Bumble bee, **3:364**
- Burst, definition, **24:315**
- Butabarbital, pole-jump CAR, **2:250**
- Butaclamol, self-stimulation behavior and,
 21:357, 21:360, 21:366
- Butaperazine, clinical response and plasma
 levels of, **19:297–298**
- Butobarbitone, structure and activity,
 24:16
- γ -Butyrobetaine, **1:186**
- Butyrolactone
 effect on EEG, **8:296**
 neuroactivity of, **17:27**
- γ -Butyrolactone, effects on cerebral
 glucose utilization, **22:320**
- Butyrophenones
 aromatic substitutions of, **8:225**
 with morphine-like potency, **8:221–263**
- Butyrylcholine, **1:185**
- Butyrylperazine, structure of, **8:253**
- Butyrylthiocholine, effect on brain cell
 culture, **5:7, 5:11**
- C**
- C¹⁴, **3:295–300**
- 3-C¹⁴-serine, **3:298**
- Caffèine, **1:264, 1:291**
 action of Chloropromazine, **2:237**
 beneficial effect on memory, **8:186**
 effect on EEG, **8:288, 8:308**
 retrograde amnesic effects, **10:186–187**
- Cahoba, **3:257**
- Calcitonin
 nociception and, **25:224–225**
 peptide sequence of, **25:187**
- Calcium
 in bioelectric phenomena, **9:223–261**
 coordination complexes with phosphates,
 9:253–258
 in cortical depression, **5:220–221**
 effect on learning, **8:174–175**
 mitochondrial accumulation, **9:251–253**
 in serum, evoked potential (EP) and,
 25:428
- Calcium channels, neurotransmitter effects
 on, **22:212–214**
- Calcium drug effects on, **11:120–121**
- Calcium flux, phospholipid methylation
 and, **23:147–152**
- Calcium ions, **3:304, 3:306**
 in cyclic AMP formation, **20:126–127**
- Calcium transport ethanol effects on,
 19:141–142
- Calliphora, **3:351, 3:357**
- cAMP, *see* Cyclic AMP (cAMP)
- Campaniform sensillae, **3:351**
- Camphor, use in psychotherapy, **5:389**
- Cancer, tropical monopyrrole role in,
 16:174
- Cannabinol, formula of, **12:222**
- Cannibalism, in olfactory bulbectomy
 syndrome, **22:269–270**
- Canonical variate analysis, **2:370–375**
- Capillaries
 of CNS
 filtration coefficient, **3:45–46**
 morphological classification, **3:40–41**
 permeability, **3:45–47**
 submicroscopic analysis, **3:40–44, 3:69**

- Caramiphen
 in anticholinesterase poisoning, **16:126**,
16:127, **16:130**
 CAR, **2:259–260**
 structure of, **16:127**
- Carbachol
 as antiacetylcholine drug, **16:112**
 effect on hippocampus, **8:120**
- Carbamylcholine
 effect on enzyme secretion of pancreas,
2:103
 effects on cerebral RNA, **16:221**
- Carbamyl phosphate, synthesis of,
14:135–137
- Carbohydrate, metabolism, in
 schizophrenia, **11:259–290**
- Carbon dioxide
 analysis of expired, **3:72**
 brain metabolites, **22:60–62**
 cerebral glucose utilization, **22:320**
 effects on, brain intermediary
 metabolism, **22:58–65**
- Carbon dioxide anesthesia, retrograde
 amnesia from, **10:179**
- Carbon dioxide fixation in nervous tissue,
14:125–157
 enzymes for, **14:125–137**
 properties, **14:126–127**
 functional aspects of, **14:142–145**
 metabolic compartmentation in,
14:141–142
 metabolic fate of CO₂, **14:137–140**
- Carbon tetrachloride, cirrhosis induced by,
2:69
- Carboxypeptidase A
 classification of, **11:59**
 in CNS, **11:74–76**
 mechanism of action, **11:75–76**
- Carboxypeptidase B
 classification of, **11:59**
 in CNS, **11:76**
- Carboxypeptidases, **11:59–60**
 in brain, **11:65**
 molecular analysis of, **17:198**
 in nervous system, **11:66**
- α -Carboxypeptide amino acid hydrolases
 classification of, **11:59**
 in nervous system, **11:73–77**
 carboxypeptidase A, **11:74–76**
 carboxypeptidase B, **11:76–77**
- Cardiac muscle, tetrodotoxin and saxitoxin
 effects on, **15:125–128**
- Carnosinase
 in brain, **11:66–67**
 classification of, **11:59**
- Carnosine, in brain, **12:248**
- Cat
 forelimb muscle afferents to cortex of,
15:1–25
 hindlimb muscle afferents to cortex of,
15:18–19
 lateral geniculate nucleus of, **6:171–172**
 mesencephalic projections of, **6:165–172**
 neocortical projections of, **6:177–182**
 optic chiasm of, **6:155**
 optic nerve of, **6:153–155**
 optic tract of, **6:156–158**
 accessory, **6:163–164**
 possible color vision in, **5:162**
 pretectum of, **6:162**, **6:165–166**
 primary optic termination of, **6:152–165**
 reticular formation in, **6:169–172**
 retina of, **6:170–171**
 retinohypothalamic tract of, **6:155–156**
 superior colliculus of, **6:163**, **6:166–169**
 supraoptic commissures of, **6:156**
 thalamic projections of, **6:173–177**
 thalamus of, **6:158–162**
 visual cortex of, **6:172**
 visual pathways of, **6:149–189**
- Catalase, **3:338**
 ethanol metabolism by
 in brain, **19:126–127**
 in liver, **19:129**
- Catalepsy-producing drugs, **8:228–229**,
8:247
- Catecholamine
 assay, **21:260**, **21:263–265**, **21:266**
 hypertension and stress and, **21:271–273**
 interaction with serotonin, in brain,
21:270–271
- Catecholamine hypothesis of self-
 stimulation behavior, **21:336**
- Catecholamine receptor, **14:300–309**
- Catecholaminergic neurons
 in fetal brain, **20:68**
 prenatal development of, **20:67–82**
 thymidine autoradiography of, **20:69–71**
- Catecholaminergic projections, in CNS,
 table of, **24:108**
- Catecholamines (CA), **1:180–181**, **1:313**
 action on neurons, **11:19–22**
 anticonvulsant reaction with, **24:114–115**
 apomorphine effect on release of, **19:250**

- in brain, amphetamine effects on, **12:356–357**
- content in hypothalamus and CEPR, **2:166–169**
- decrease of, after reserpine, **2:181–182, 2:208**
- drug effects on, **11:115–117**
- drugs affecting, **24:115–116**
- effect on EEG, **8:283, 8:300–302**
- imipramine potentiation of, **9:110–118**
- in mental illness, **8:197–220**
- metabolism of in depressed and manic patients, **12:157–159**
- as opiate neurochemical correlates, **25:281–284**
- in periodic psychoses, **11:156–157**
- in phenylketonuria, **3:270**
- presence and action in CNS, **11:17–35**
- role in seizures, **24:107–116**
- specifications for receptors, of, **13:201–202**
- storage synaptosomes for in different brain regions, **13:146–149**
- test tissues for, **13:35**
- uptake in brain
 - antiparkinsonian drug action, **13:137–139**
 - kinetics of, **13:128–134**
 - stereospecificity, **13:134–136**
 - urinary, in stress, **8:216**
 - see also* individual compounds
- Catechol-*O*-methyltransferase
 - ethanol effects on, **19:151**
 - in microamine assay, **19:180**
- Cathepsin A, molecular analysis of, **17:194–195**
- Cathepsin C, molecular analysis of, **17:195**
- Cathepsin D
 - molecular analysis of, **17:194**
 - in stress, **17:225–226**
- Cathepsins, role in brain protein catabolism, **6:60–72**
- Cations
 - effect on learning, **8:174–175**
 - monovalent, membrane transport models, **21:311–332**
 - monovalent vs. divalent selectivity, **21:327–329**
- Caudate-putamen complex, apomorphine activity and, **19:243–244**
- Cell density, in primate brains, **16:250–251**
- Cell membranes, ACTH 4-10 binding to, **20:222–223**
- Cellular immunity, cerebrospinal fluid proteins and, **25:116–117**
- Cellular perspectives, brain-behavior relations and, **23:198–202**
- Central body, **3:365, 3:368**
- Central commissure, **3:365**
- Central depressant drugs, mode of action, **11:34–36**
- Central depressants, cyclic nucleotide activity and, **20:154–155**
- Central monoamine neurons
 - electron microscopy of, **13:102–104**
 - function of, **13:104–119**
 - monoamine pathways, methods of mapping out, **13:94–96**
 - morphological and functional aspects of, **13:93–126**
- Central nerve terminals, **13:53–59**
- Central nervous system (CNS)
 - ACTH 4-10 effects on, **20:218–220**
 - α_1 -adrenergic receptor binding in, **24:367–368**
 - antiacetylcholine drug effects on, **16:111–116**
 - benzodiazepine receptors in
 - characterization of, **23:108–113**
 - endogenous ligands, **23:116–122**
 - heterogeneity, **23:113–116**
 - regulation, **23:122–133**
 - breakdown and synthesis of proteins in, **13:261–265**
 - catecholaminergic projections, **24:108**
 - chemical mediators in, **12:11–37**
 - cholinergic pathways, **24:122**
 - cholinesterases of, **10:57, 10:109**
 - correlation with ACh and ChAc analyses, **10:64–66**
 - correlation with iontophoretic studies, **10:66–68**
 - electron microscopy in, **10:68–70**
 - methods, **10:60–63**
 - phylogenetic and ontogenetic aspects, **10:92–100**
- cyclic nucleotides in function of, **20:144–156**
- drugs influencing learning and, **8:188–189**
- ethanol effects on, **19:123–172**
- GABA and inhibitory transmission in, **17:2–4**
- glutathione turnover in, **19:96–97**

- histamine-activating effect on, **12:265–305**
- intrinsic neurons of, changes following axon injury, **14:102–104**
- lipotropin and, **20:209–250**
- muscarinic acceptors in, **25:139–183**
- neurons, iontophoretic studies, **10:1–30**
- regeneration
 - amphibia, **2:1**
 - mammals, **2:1**
- serotonergic projections, **24:116**
- space-time transformations in, **18:6–7**
- stimulants
 - after ECS, **10:189–190**
 - retrograde amnesic effects, **10:185**
- stimuli effects on, **13:262**
- synaptic transmission in
 - and drug action, **11:1–56**
 - acetylcholine, **11:4–17**
 - amino acids, **11:25–29**
 - monoamines, **11:17–25**
- trauma and stroke, role of glucocorticoids, **23:190–191**
- vertebrate
 - regeneration in, **6:257–301**
 - in fishes, **6:264–268**
- see also* Brain
- Central nervous system networks, computer studies of, **9:23–24**
- Central nervous system tissue
 - cerebral edema and, **7:164**
 - extracellular space of, **7:162**
- Central nervous system tissue cultures
 - bioelectric properties of, **9:1–42**
 - cerebral cortex, **9:17–27**
 - cytological properties and, **9:33–37**
 - embryonic neuromucular tissue, **9:27–30**
 - embryonic rat spinal cord-ganglia, **9:5–16**
 - methods in, **9:3–5**
 - mixed explants, **9:30**
 - cord-brain stem, **9:33**
 - cord-cord, **9:30–31**
 - “organotypic” bioelectric activities in, **9:1–42**
 - spinal cord, **9:5–16**
- Central nervous tissue
 - biosynthetic activities of., **5:347–387**
 - control of anterior pituitary by, **5:249–256**
 - drug effects on membrane permeability of, **5:229–238**
 - exchangeable and nonexchangeable, ions in, **5:207–211**
 - ion flux in, **5:183–242**
 - tracer experiments on, **5:185–198**
- Central neurons, cyclic AMP in, **20:149–150**
- Central receptors, depression and, **12:156–157**
- Central stimulant drugs, effects on CNS, **11:36–38**
- Central stimulants, cyclic nucleotide activity and, **20:154**
- Centrifugation, differential, **1:170–171**
- Cephalin, **3:303, 3:305**
- Cephalopods, octopamine function in, **19:210**
- Cerebellar excitatory substance, **1:186**
- Cerebellar peduncles, AChE activity in, **10:268**
- Cerebellum
 - AChE activity in, **10:265**
 - of cetacean, **21:56–57**
 - cholinesterase of, **10:70–92, 10:103**
 - biochemical analyses, **10:74–77**
 - histochemical studies, **10:77–78**
 - Purkinje neuron of, **13:9–10**
 - role of glia in, **21:279–281**
 - structure of, **10:71–74**
 - vestibular nuclei and, **15:40–42**
- Cerebellum (including various anatomical subdivisions), **3:226–230, 3:237**
- Cerebral cord tissue culture
 - bioelectric properties, **9:17–27**
 - oscillatory afterdischarges, **9:20–24**
 - primary evoked potentials, **9:25–27**
- Cerebral cortex
 - AChE and NAD-d activity in, **10:267**
 - of cetacea, **21:64–70, 21:89–94**
 - cholinergic innervation of, **7:85–92**
 - electrical stimulation, mental effects of, **11:335**
 - forelimb muscle afferents to
 - in cat, **15:1–25**
 - comparative aspects, **15:18–20**
 - convergence of excitation from other afferents and, **15:12–14**
 - cortical neurons of, **15:4–6**
 - cortical projection areas and, **15:6–8**
 - course and relay nuclei of pathway, **15:2–4**
 - diagram of, **15:3**
 - functional aspects of, **15:20–21**
 - inhibition of, **15:14–15**

- receptor identification, **15:8–9**
- spatial patterns of convergence at different levels of pathway, **15:10–12**
- synaptic properties, **15:9–10**
- transmission control, **15:15–18**
- pyramids of, **13:19–21**
- role of glia in, **21:278–279**
- see also* Cortex, cerebral
- Cerebral hemispheres, AChE and NAD-d activity in, **10:265–267**
- Cerebral protein metabolism, **7:1–40**
 - alterations in, **7:2–17**
 - convulsant and stimulant action on, **7:11**
 - drug effects on, **7:12–13**
 - electrical stimulation effects on, **7:8–11**
 - exercise effects on, **7:7–8**
 - hormone effects on, **7:7–8**
 - ion effects on, **7:14**
 - narcosis effect on, **7:11–12**
 - pathological, **7:17–32**
 - protein utilization in, **7:4–6**
 - transglutaminase effect on, **7:16–17**
- Cerebral protein synthesis inhibitors
 - long-term memory blockage by, **12:177–205**
 - behavioral assays, **12:183–185**
 - consolidation and redundancy, **12:185–186**
 - inhibition studies on, **12:186–195**
 - RNA synthesis inhibitors and, **12:180–183**
- Cerebral pulsations, control of, **3:69–70**
- Cerebral spinal fluid, exopeptidases in, **11:81–82**
- Cerebrosidase, **3:303**
- Cerebrosides, **3:313**
 - metabolism in brain, **3:297–299**
- Cerebrospinal fluid (CSF), **3:34**
 - antiacetylcholine receptor antibodies in, **24:10–12**
 - cross-reactivity with brain antibodies, **24:11**
 - organ, **24:10–11**
 - antibody specificity and, **25:115–116**
 - brain exchanges, **7:165–168**
 - CSF-glia relation in, **7:165–166**
 - dye and indicator studies on, **7:167–168**
 - radiotracer studies in, **7:166**
 - cellular immunity and, **25:116–119**
 - crossimmuno-electrophoresis of, **25:108–109**
 - CSF lymphocyte stimulation and, **25:118**
 - electrophoresis of, **25:100–104**
 - abnormal proteins, **25:103–104**
 - normal, **25:102–103**
 - enzyme determination in, **25:127–129**
 - α -globulins, **25:103**
 - γ -globulins, **25:103–104**
 - in humoral immunity, **25:112–115**
 - immunofixation of, **25:108**
 - in immunological problem, **25:110–119**
 - imprint electroimmunofixation of, **25:109**
 - isoelectric focusing of, **25:107–108**
 - isotachopheresis of, **25:109–110**
 - methods for study of, **25:96**
 - nervous-tissue specific, **25:119–127**
 - α -albumin, **25:123–125**
 - enolase, **25:125–127**
 - α_2 -glycoprotein, **25:127**
 - myelin basic protein (MBP), **25:121–123**
 - S-100 protein, **25:119–121**
 - neurotransmitters in, seizure studies, **24:115**
 - in nonconcentrated CSF, **25:105–107**
 - pathological protein changes in, **7:26–27**
 - proteins of, **25:95–138**
 - pyrrole determination in, **16:160**
 - qualitative studies on, **25:100–119**
 - quantitative determination of, **25:97–100**
 - individual proteins, **25:97–98**
 - nervous tissue specific, **25:98**
 - total proteins, **25:97**
 - tumor proteins, **25:98**
 - serotonin in, seizures and, **24:121**
 - T lymphocytes and, **25:117–118**
 - transfer electrophoresis of, **25:109**
- Ceruloplasmin, **1:302f, 1:333f**
 - in Wilson's disease, **7:24**
- Cerveau isolé, **3:73**
- Cetacea
 - acoustic signals, **21:74–84**
 - auditory system, **21:58–64**
 - behavior, **21:97–98**
 - behavioral audition, **21:74–84**
 - behavioral chemoreception, **21:57–58**
 - brain stem, **21:56–57**
 - brain stimulation, **21:94–95**
 - cerebellum, **21:56–57**
 - cerebral cortex, **21:64–70, 21:89–94**
 - chemoreceptor, **21:57–58**
 - cognition, **21:98–103**
 - communication, **21:77–81, 21:98–103**

- echolocation, **21:74–75**, **21:84–88**
 learning, **21:98–103**
 neural ontogeny, **21:52–53**
 neuroanatomy, **21:52–70**
 neurophysiology, **21:70–103**
 peripheral nervous system, **21:53–56**
 physiology of acoustic sense organs and
 brain centers, **21:88–89**
 psychobiology, **21:47–107**
 reflex control of air movement, **21:73–74**
 sleep and wakefulness, **21:95–97**
 sound perception, **21:81–84**
 sound production mechanism, **21:74–75**
 sounds of, **21:75**
 Soviet research on, **21:49–52**, **21:103–106**
 spinal cord, **21:56–57**
 visual system, **21:64**
CHEB (barbiturate), structure and activity,
 24:16
 Chelating agents, in porphyria therapy,
 16:309
 Chelation therapy, of porphyria,
 16:327–335
 Chemical codes, for neural coding,
 13:230–231
 Chemoreceptors
 in blow fly, **3:351**
 of cetacean, **21:57–58**
 Chemoreceptor systems, **14:159–160**
 Chemospecific pathways, in hypothesis of
 information processing, **13:244–248**
 Chiari's syndrome, monopyrrole role in,
 16:173
 Chick, CNS regeneration in, **6:277–279**
 Chimeras, neurochemical genetics of,
 25:384–385
 Chimpanzee
 communication ability in, **16:284–287**
 memory in, **19:19–20**
 Chlorthalixol, structure of, **8:253**
 Chloralose anesthesia, nonprimary
 responses in, **10:117–125**
 Chlordiazepoxide
 effect on EEG, **8:292**, **8:308**
 effect on learning, **8:152**
 beneficial, **8:174**
 Chloretoxybutamoxane, effect on CAR,
 2:256
 Chlorisondamine, as blocking agent,
 17:159–160
 Chlormethiazole
 psychoactivity of, **16:149**
 structure of, **16:150**
p-Chlorophenylalanine, effects on cerebral
 RNA, **16:221**
 Chlorpromazine, **1:19**, **1:37**, **1:39**, **1:200**,
 1:345
 2-Chloropromethazine, 50block of pole-
 jump with, **2:239**
 Chloroquine, in porphyria therapy,
 16:336–338
 Chlorperazine
 central depressive activity of, **2:242**
 influence on CAR, **2:239**
 Chlorpromazine (CPZ), **3:282**
 activity spectra of, **8:234**, **8:243**
 activity spectrum, **9:114**
 antagonistic effect of CNS stimulants on
 CPZ, **2:237**
 binding of, **7:250–253**
 biophysical action of, **7:259–264**
 catalepsy scores of, **8:228**, **8:246**, **8:249**,
 8:259
 clinical and laboratory differentiation of
 imipramine and CPZ, **2:215–219**
 clinical response and plasma levels of,
 19:295–297, **19:300**
 CNS activity of, in animals, **2:235–237**,
 2:240, **2:242**, **2:243**
 compared to methylene blue, **7:264–266**
 compared to phenicyclidine, **6:311–313**
 effect on body temperature, **12:33–35**
 effect on CEPR, **2:144**, **2:151**
 effect on EEG, **8:297–298**
 effect on hippocampus, **8:101**, **8:110–112**,
 8:114
 effect on learning, **8:157**, **8:171**
 beneficial, **8:170–171**
 effect on memory, **8:163**
 effect on plasma corticosteroids, **5:256**
 effects on cerebral protein metabolism,
 7:12
 effect on schizophrenia, **2:234**
 effects on CNS, **11:38–41**
 effects on EEG, **15:290**, **15:297–298**,
 15:302
 effects on glycolytic enzymes, **7:238**
 effects on lipid synthesis, **7:240–242**
 effects on membrane permeability,
 7:243–250
 effects on oxidative phosphorylation,
 7:233–234
 formula of, **9:109**
 high-low dose reversals, **7:266–269**

- interaction with flavins, **7:235–238**
 localization and action of, **7:253–259**
 other phenothiazine derivatives,
2:238–239, 2:241
 piperazinyl derivatives of phenothiazine,
2:239–241
 reserpine compared to, **7:269–271**
 retrograde amnesia from, **10:183**
 in schizophrenia therapy, effects on
 HNA, **11:239–240, 11:244–245,**
11:247
 screening data on, **8:227, 8:247, 8:248**
 self-stimulation behavior and, **21:352,**
21:360, 21:366, 21:381, 21:382,
21:389
 serotonin effects, **2:182**
 voluntary alcohol intake, **2:68–69**
 Wilson's disease and, **7:264**
- Chlorprothixene
 activity spectrum, **9:114**
 antidepressant action, **9:133–134**
 formula of, **9:109**
- Chlorprothixene (Fruxal), CAR, **2:240**
- Cholecystokinin
 nociception and, **25:214–215**
 peptide sequence of, **25:187**
- Cholesterol
 metabolism in brain, **3:295–297, 3:313**
 two types in brain, **3:297**
- Cholestyramine, in porphyria therapy,
16:338
- Cholinacetylase, in hippocampus, **8:97–98**
- Choline, **1:207–220, 3:300–301, 3:305, 3:307,**
3:313
 active transport mechanism of, **2:87**
 antidote for HC-3 poisoning, **2:86–87,**
2:94
 as choline acetyltransferase substrate,
20:306–308
 deficiency and free choice of ethanol, **2:56**
 effect on EEG, **8:283, 8:299–300**
 effect on enzyme secretion of pancreas,
2:103
 lipid-bound, relationship to cerebral
 acetylcholine formation, **20:17–20**
 not an antidote for HC-3, **2:88–89**
 substances similar to, as antidote for HC-
 3, **2:87**
 transport of, choline acetyltransferase in,
20:327–329
- Choline acetylase, **1:176–180, 1:184**
 in brain structures, **2:176**
- Choline acetylase of CNS, **10:71**
 phylogenetic considerations, **10:92–93**
- Choline acetylase oxidative enzymes,
 somatofugal transport of, **13:303**
- Choline acetylase, occurrence, **5:379**
- Choline acetyltransferase, **20:283–337**
 active site of, **20:305–306**
 affinity chromatography of, **20:300–303**
 antigenicity of, **20:315**
 assays of, **20:287–291**
 acetylcarnitine contamination,
20:288–289
 comparison among, **20:287–288**
 pitfalls in, **20:289–291**
 in single cells, **20:322–323**
 axonal transport of, **20:312–314**
 biophysical studies on, **20:303–304**
 chloride ion effect on, **20:310–312,**
20:329–330
 in cholinergic pathways, **20:320–321**
 in choline transport, **20:327–329**
 cross-reactivity of, **20:315–318**
 histochemistry of, **20:319–322**
 future prospects, **20:323–324**
 history of, **20:284–287**
 hydrophobic-affinity chromatography of,
20:302
 immunoabsorbent for, **20:298–300**
 immunohistochemical localization of,
20:318
 immunology of, **20:314–318**
 inhibitors of, **20:307, 20:308–309**
 isoelectric points of, **20:326**
 localization of, at cellular level,
20:318–324
 mechanism of action of, **20:304–312**
 kinetics of, **20:304–305**
 in neuronal tissue, **20:204–303**
 in nonneuronal tissue, **20:291–294**
 purification of, **20:296–303**
 regulation of, **20:310**
 stability of, **20:297**
 styrylpyridine inhibitors of, **20:302**
 subcellular localization of, **20:324–326**
 substrate specificity of, **20:306–308**
 sulfhydryl reagent for, **20:300–302**
- Choline esterase, **1:183–184**
- Choline ethers, as ganglion-blocking agents,
17:160
- Cholinergic agents, effect on hippocampus,
8:94–99, 8:120–121
- Cholinergic antagonists, **13:198–200**

- Cholinergic cells, **10:60**
- Cholinergic drugs, retrograde amnesic effects, **10:185**
- Cholinergic ligands, equilibrium dissociation constants, **24:308–311**
- Cholinergic mechanisms
behavior and, **14:173–231**
REM control and, **23:414–416**
- Cholinergic muscarinic receptors, autoradiographic studies on, **22:132–137**
- Cholinergic neuron
acetylcholine metabolism, in, **18:69–140**
indirect studies on, **18:112–119**
transmitter release of, **18:119–133**
- Cholinergic nicotinic receptors, autoradiographic studies on, **22:122–132**
- Cholinergic pathways, in central nervous system, **24:122**
- Cholinergic receptors
chemical nature of, **13:161–162**
inactivation-reactivation of, **13:163**
isolation of, **13:165**
specification of, **13:192–200**
transmitter-receptor interaction in, **13:176–177**
- Cholinergic transmission
effect on, by hemicholiniums, **2:77**
studies on, **10:23–27**
- Cholinesterase
in acetylcholine metabolism, **18:69–77**
changes in axotomized neurons, **14:70–71**
- Cholinesterase activity, development of, in optic lobe, **2:31**
- Cholinesterases, **3:310–313**
brain, **7:311–313**
of the CNS, **10:57–109**
nomenclature, **10:59–60**
ontogenetic considerations, **10:93–100**
phenothiazines effects on, **7:239–240**
phylogenetic considerations, **10:93**
- Cholinolytic drugs, amphetamine interaction with, **12:335–356**
- Cholinomimetics
effect on body temperature, **12:16–23**
effect on thalamic nuclei, **14:12–15**
- Chordates, lower, muscular innervation of, **6:99–147**
- Choroid plexus, cerebrospinal fluid from, **7:161–162**
- Chromatin
of astrocytes, **3:6**
of oligodendrocytes, **3:18–19**
- Chronometers, electric, **3:74–75**
- Cinemanalysis, of behavior, **6:357–360**
- Cingulate cortex, ablation of, **1:29–30**
- Cingulate seizures, **1:23**
- Cingulumotomy, **1:34–35**
- Circadian rhythms, **11:138–139**
in α_1 -adrenergic receptor binding, **24:374–375**
cellular aspects of, **11:139**
mathematical considerations, **11:139–140**
survival value, **11:140–141**
- Circuits, heterologous and homologous, post-lesion plasticity and, **23:206–207**
- Cirrhosis
free choice of ethanol, **2:69–70**
induced in rats with carbon tetrachloride, **2:69**
Jamaican, monopyrrole role in, **16:174**
- Citrinin
effects on receptors, **14:321–324**
stereochemical relations to membrane-active drugs, **13:217**
- Citrulline-uria, **7:24**
- Classification, in learning process, **16:266–269**
- Clonidine, as α_2 -adrenergic agonist, **24:393–398**
- Clopirozide, self-stimulation behavior and, **21:354, 21:360, 21:366**
- Clothiapine, self-stimulation behavior and, **21:352, 21:360, 21:366**
- Clozapine, self-stimulation behavior and, **21:352, 21:360, 21:366**
- Cobalamins, neurobiology of, **16:149**
- Cobalt ion, **3:306**
- Cobra neurotoxin, **22:180**
as neuromuscular blocking agent, **17:156**
- Cocaine
action of CPZ, **2:237**
addiction to, **12:324–325**
bulbocapnine catalepsy, **2:254**
- Codeine, CAR, **2:253**
- Codes, in neural coding, **13:227–231**
- Coding
in information processing, **13:347**
neural, peptides in, **17:55–56**
- Coenzyme, glutathione as, **19:98–101**
- Coenzyme A (CoA), structure of, **20:286**

- Coenzyme relationships between
 apoenzyme and coenzyme of vitamin
 B₆ requiring enzyme systems,
2:305–314
- Coffee, pyrroles in, **16:175**
- Cognition, in cetacea, **21:98–103**
- Colchicine, effect on axonal transport,
13:315–316
- Collagen diseases, monopyrrole role in,
16:173–175
- Collagenlike protein, in brain, **6:23**
- Color, in vision analysis, **10:286–287**
- Color vision, **5:158–166**
 acotopic blue shift in, **5:161**
- Communication, in cetacea, **21:77–81**,
21:98–103
- Computer
 in analysis of EEG data, **15:268–270**
 use with deoxyglucose method,
22:328–329
- Conditioned avoidance response (CAR),
1:199f
- Conditioned avoidance-response (CAR)
 drugs, **2:229–272**
- Conditioned reflexes, free behavior and,
6:351–353
- Conditioned stimulus (CS), **2:230–231**
 secondary CS, **2:232**
- Conductance fluctuations, in fluctuation
 analysis, **20:176–180**
- Conduction, intermittent, in vertebrates and
 invertebrates, **18:7–13**
- Connectivity changes
 analyzing behavioral consequences of,
23:226
 neurological sequelae strategy,
23:223–249
 sensory-motor system strategy,
23:227–233
 analyzing physiological consequence of
 analysis of processing through
 lesion-induced circuits,
23:220–226
 evaluation of synaptic operation,
23:212–219
 lesion-induced
 anticipating functional consequences of
 nonspecific contributions,
23:207–208
 specific contributions, **23:208–212**
 nature of postlesion plasticity and,
23:202–205
- Consciousness
 cholinergic mechanism and, **14:185–189**
 three states of, **17:298–299**
- Contingent negative variation (CNV),
 mental state and, **11:334–335**
- Contraceptive agents, in porphyria therapy,
16:340
- Contractility, of smooth muscle,
 neurotransmitter modulation of,
22:238–240
- Convulsant drugs, retrograde amnesia from,
10:174–176
- Convulsants, as antagonists of inhibitory
 transmission, **15:178–181**
- Convulsants (chemical)
 barbiturates, neuropharmacology,
24:33–34
 seizures from, **24:101**, **24:103**
- Convulsions
 apomorphine effects on, **19:234**
 brain, amino acids in, **6:16**
- Copper
 abnormal metabolism in Wilson's disease,
8:202
 blood levels, **1:302f**, **1:333f**
 in porphyria etiology, **16:323**,
16:340–348
- Copper ion, **3:306**
- Copper protein, in brain, **6:21**
- Coproporphyrin
 hereditary, **16:305**, **16:306**
 symptoms and incidence of, **16:307**,
16:321
- Corneal epithelium, choline
 acetyltransferase in, **20:292–293**
- Corpora cardiaca, **3:370**
- Corpora pedunculata, **3:365**, **3:367–368**,
3:370
- Corpora quadrigemina, **3:331**
- Corpus callosum, **3:103–105**, **3:125**,
3:179–180, **3:230–232**, **3:238–239**
- Corpus striatum, **1:15–20**, **1:37–39**
- Cortex
 anatomy of, **16:237–260**
 areas of, *see under* Visual area; Auditory
 area; etc.
 association area of, **16:244–250**
 cerebral
 "isolated slab" preparation, **3:124**,
3:166–167, **3:326**
 layers of, **3:98–99**, **3:232**, **3:233**
 relation to cerebellum, **3:225–230**

- topographically organized, role in discrimination, **3:130**
 - see also* Cerebral cortex
- electrical activity of, **5:53–119**
 - behavior and, **5:96–102**
 - distribution of, **5:66**
 - evoked and spontaneous potentials of, **5:79–96**
 - input-output relationships of, **5:102–111**
 - signal of, **5:76–79**
- epileptic
 - lactic acid in, **3:176**
 - oxygen tension of, **3:176**
 - pH of, **3:167**
 - unit recordings from, **3:95, 3:137–183**
- higher functions in, *see* Spreading Depression
- learning trace, transfer of, **4:61**
- prepyriform, anatomy of, **5:55–56**
- and subcortical relations, **4:63**
- unit responses in, *see* Neurons, cortical, unit responses
- visual, *see* Visual cortex
- see also* Cortical evoked response
- Cortical depression, **5:211–229**
 - compounds effecting, **5:223**
 - postmortem potassium fluxes in, **5:217**
 - potassium released in, **5:216–217, 5:224, 5:228**
 - prevention by divalent ions, **5:219–221**
 - recovery processes in, **5:225–229**
 - sodium and chloride movements in, **5:217, 5:219**
 - “trigger substance” in, **5:221–224**
- Cortical evoked response
 - in auditory cortex, **3:102, 3:126**
 - effect of thiosemicarbazone on, **3:328**
 - from specific thalamocortical volley, **3:97–103, 3:126**
 - interactions of, **3:125–126**
 - intercortical, **3:156, 3:233–235**
 - in somatosensory areas, **3:71, 3:97–103, 3:117, 3:202, 3:220, 3:235**
 - to antidromic stimulation of pyramidal tract, **3:107–109**
 - to local cortical stimulation, **3:105–107, 3:181**
 - transcallosal, **3:103–105, 3:125**
 - in visual cortex, **3:102–103, 3:125, 3:128**
- Cortical functions, in primates, **16:233–299**
 - anatomical aspects, **16:233–260**
 - behavior, **16:260–289**
 - cross-modal abilities and, **16:253**
 - lateralization of, **16:252–253**
- Cortical layers, upper, and, release of lower, **4:47–56**
- Cortical nerve cells
 - EEG and, **15:241–245**
 - experimental analysis, **15:255–264**
- Cortical neurons
 - acetylcholine effects on, **7:70–92**
 - amino acid effects on, **7:48–63**
 - amino effects on, **7:64–70**
 - cholinoceptive, **7:71–78**
 - characteristics of, **7:80–85**
 - distribution of, **7:78–79**
 - pharmacology of, **7:71–78**
 - micro-iontophoretic studies on, **7:41–98**
 - see also* Neurons, cortical
- Cortical response, direct differential effect on, **4:47–52**
- Corticosteroids
 - drug effects on, **11:118–119**
 - in induction of pyrroloxygenase, **16:178**
 - plasma, environmental stress and, **5:255–256**
- Cortisol, **3:341–342**
 - evoked potential (EP) and, **25:428**
- Cortisone
 - effect on brain cell culture, **5:5, 5:11**
 - psychological effects of, **5:270–272**
- Cranial nerve nuclei, AChE and NAD-d activity in, **10:263–264**
- Cranial and spinal nerves, AChE activity in, **10:267–268**
- Creatinine phosphokinases, in CSF clinical significance, **25:128**
- CRF, characterization of, **5:253**
- Crickets, **3:366–368**
- Critical flicker frequency (CFF), **1:251, 1:257–258, 1:261, 1:264, 1:269, 1:281, 1:286, 1:288**
- Cruetone, *see* Porphyrin
- Curare
 - effect on EEG, **8:304**
 - effect on learning, **8:149–151**
 - effects on nicotinic effects of ACh, **16:28–29, 16:30**
 - use in ECT, **5:391**
- Curare alkaloids, as neuromuscular blocking agents, **17:151–153**
- Cushing’s syndrome, psychiatric aspects of, **5:265–270**

- Cutaneous hepatic porphyria, types of, **16:305**
- Cyanocobalamine (Vitamin B-12), free choice of ethanol, **2:56**
- Cyclic AMP (cAMP)
 adaptation of systems of, **20:146–148**
 affective disorders and, **18:367–368**
 in autophosphorylation of proteins, **20:135–138**
 biochemistry of, **20:145–148**
 central neurons and, **20:149–150**
 effects on cerebral RNA, **16:219**
 ethanol effects on, **19:137–139**
 in ganglia, **20:150**
 in membrane hyperpolarization, **16:32, 16:55**
 in nervous system, **20:109–138**
 neurophysiology of, **20:148–152**
 in neurotransmitter metabolism, **20:146**
 protein kinases dependent on, **20:133–134**
 regulation of, **22:219**
 transmitter release and, **20:151–152**
see also cAMP
- Cyclic GMP
 in ganglia, **20:151**
 in nervous system, **20:138–144**
 protein kinases dependent on, **20:143–144**
- Cyclic GMP phosphodiesterases, activity of, **20:142–143**
- Cyclicality, of sleep, **23:405–407**
- Cyclic nucleotides
 ACTH 4-10 effects on activity of, **20:223–224**
 analogs of, activity, **20:153–154**
 central pharmacology, behavior, and, **20:152–156**
 cyclic AMP, **20:109–138**
 cyclic GMP, **20:138–144**
 epileptic seizures and, **24:142–143**
 events regulated by, **22:215**
 in function of central and peripheral nervous system, **20:144–156**
 glial cell receptors and, **21:301–303**
 β -lipotropin 61-91 role in activity of, **20:237–238**
 metabolism of, **22:216**
 in nervous system, **20:105–168**
 neurotransmitter regulation of, **22:215–221**
 in peripheral nucleotides, **20:151**
 protein phosphorylation and, **22:237–238**
- Cyclohexamine derivatives, effect on hippocampus, **8:121**
- Cycloheximide and analogs, effects on memory, **12:202**
- Cycloserine
 as GABA-transaminase inhibitor, **17:21, 17:25**
 psychosis from, **8:213**
- Cypropheptadine, formula of, **9:109**
- Cystathione enzymes, **3:338**
- Cystathionine, in brain, **6:18**
- Cystathionine-uria, **7:24**
- Cysteic acid, **3:327–328**
- Cysteinyglycine dipeptidase
 in γ -glutamyl cycle, **19:102**
 in glutathione degradation, **19:89–90**
- Cysteinyglycine dipeptidases
 in brain, **11:66–67**
 hydrolases, **11:73–77**
 in peripheral nerve, **11:83–85**
 in pineal gland, **11:81**
 in pituitary, **11:77–79**
 protein turnover and, **11:88–90**
 in spinal cord, **11:82–83**
 transport processes and, **11:86–88**
- Cytochrome, in porphyria therapy, **16:335**
- Cytochrome oxidase, in brain cell culture, **5:40–41**
- Cytoplasm, of astrocytes, **3:6**
- Cytoplasmic basophilia, changes in following axon injury, **14:61–73, 14:107–109**

D

- DABA, *see* L-2,4-Diaminobutyric acid
- Dansyl derivatives of microamines, **19:188**
- Dark adaption, **1:248f, 1:255f, 1:277–278**
 of insect eye, **3:356–357**
- Data, automatic handling of experimental, **3:74–76**
- Deafferentation, **3:223**
- Deanol (2-dimethylaminoethanol), **1:198, 1:203f**
 adjunct to therapy, **1:226–229**
 CAR, **2:258**
 effect on alcohol intake, **2:68–69**
 effect on EEG, **8:285–286, 8:297, 8:308**
 not an antidote to HC-3, **2:87**
 thio analog of, and CAR, **2:258**
- Debrisoquin, structure-activity effects of, **25:12**

- Decamethonium
 as neuromuscular blocking agent,
 17:153–154
 as nicotinic agonist, 17:149–151
- Decamethonium effect on equilibrium
 constants for cholinergic ligands,
 24:309
- Decarboxylases, 3:255, 3:259–260, 3:263,
 3:270, 3:330, 3:331, 3:333, 3:335, 3:337,
 3:339
- De Duve hypothesis, of neuroprotease
 binding, 17:205–206
- Degenerative neurological diseases, role of
 glucocorticoids in treatment,
 23:191–192
- Dehydrochlorination reactions, glutathione
 in, 19:100
- Dehydrogenation reactions, glutathione in,
 19:97–98
- Deiters' cells, RNA in, 16:190
- Deiters' nucleus, vestibular pathways and,
 15:32
- Delayed response (DR) and delayed
 alternation (DA), in memory testing,
 19:22–23
- Delirium tremens, fructose effects on,
 19:167–168
- Dementia praecox, as endocrine disorder,
 5:243
- Demethylimipramine
 activity spectrum, 9:114
 antidepressant action, 9:132
 formula of, 9:109
 as imipramine metabolite, 9:100–107
 pharmacological actions of, 9:101
- Demethylpromazine, activity spectrum,
 9:114
- Demyelination, 3:295, 3:312
 of axons, 18:33–34
 and isoniazid, 3:340
- Dendrites, 1:64f, 1:86–87, 3:32, 3:81,
 3:87, 3:101–103, 3:105, 3:108–109,
 3:127
 epileptic activity, 3:151–156, 3:163–164,
 3:176–177
 as monoreceptive elements, 13:13–16
 normal activity, 3:147–149
 pattern and place in, 13:1–26
 as polyreceptive elements, 13:16–21
 potential fluctuations in, 15:243–245
 properties of, 1:67–72, 1:153
 role in spreading depression, 3:178–179
 specificity of synaptic position of,
 13:12–23
 specific patterning in, 13:4–12
 convoluted field-specific types, 13:7–11
 straight, unbranched types, 13:5–7
 synaptic position in complex cortical
 systems, 13:21–23
 synchronization, 3:160–165
- Dendritic gemmules, 1:80–82
- Denervation, dopaminergic, 23:291–293
- Denervation supersensitivity, *see* Disuse
 supersensitivity
- Density gradient centrifugation, of brain
 fractions, 20:262–266
- Dental sensory receptors, 25:39–94
 axonal transport mapping techniques for,
 25:51–53
 axons, 25:40–49
 in continuously erupting teeth, 25:65–68
 contralateral innervation, 25:57–59
 in dentin, 25:53–57
 in developing teeth, 25:61–64
 electron microscopy of, 25:51
 location of, 25:4–68
 in mature teeth, 25:49–51
 in reinnervated teeth, 25:59–61
 relationship to other cells, 25:74–80
 axo-axonic contacts, 25:79–80
 odontoblasts, 25:75–79
 schwann cells and fibroblasts, 25:74–75
 ultrastructure of, 25:68–74
- Dentin
 innervation of, 25:53–57
 sensory transduction in, 25:81–84
 hydrodynamic mechanisms, 25:81–84
- Deoxyglucose method
 applications of, 22:315–328
 neurophysiological, 22:316–319
 pathophysiological, 22:323–328
 pharmacological, 22:319–323
 autoradiography in, 22:300–301
 computer use with, 22:328–329
 experimental protocol for, 22:299–300
 fluorodeoxyglucose technique use in man,
 22:329
 for glucose-utilization assay, 22:287–333
 microscopic resolution in, 22:329
 theory of, 22:290–296
- Deoxypridoxine, 3:324, 3:329, 3:335–337,
 3:341
 effect on tryptophan metabolism, 8:214
- 3-Deoxypridoxine, 3:336

- 4-Deoxypyridoxine, **3:337**
 5-Deoxypyridoxine, **3:337**
 Dephenylhydantoin, **1:24, 1:40, 1:263**
 Depolarization
 by amino acids, **3:327–329**
 by mechanical stimuli role in
 epileptogenesis, **3:152–156, 3:157, 3:164**
 Depolarization-hyperpolarization cycle
 acetylcholine and receptors in, **16:3–32**
 current concepts of, **16:50–53**
 effect of various agents on, **16:30, 16:48–49**
 hyperpolarization phase, **16:32–49**
 cause of, **16:55–58**
 membrane depolarization in, **16:5–6**
 membrane hyperpolarization in, **16:32**
 proposed model for, **16:2**
 Depolarizing agents, use in unit recordings, **3:72**
 Depressant drugs
 alternation behavior in simple T-maze, **2:376–379**
 in an application of canonical variate analysis, **2:371–374**
 apparent movement, **2:355–356**
 definition and theory, **2:344–345, 2:368–369**
 eyeblink conditioning, **2:350**
 flicker perimetry, **2:358–359**
 influence on cortical inhibition and excitation, **2:344**
 kinesthetic figural after-effects, **2:355**
 nonsense syllable learning, **2:351–352**
 reaction time, **2:354**
 rotating spiral after-image, **2:361–362**
 “sedation threshold”, **2:368**
 suppression of primary visual stimulus, **2:363–364**
 vigilance, **2:365–366**
 visual after-image, **2:360–361**
 visual-filed effects, **2:356–358**
 Depressants
 effect of lateral geniculate nucleus, **6:245–246**
 effect on memory, **8:161–163**
 Depression
 biogenic amine effects on, **12:149**
 central receptors in, **12:156–157**
 characteristics of, **18:359–360**
 deanol in, **1:225–226**
 drug effects on, **12:147**
 drug therapy of, **18:368–381**
 ECT of, **5:395**
 electrolyte effects on, **12:161–163**
 endocrine role in, **5:262**
 indole metabolism in, **12:159**
 neurochemistry of, **18:357–387**
 reserpine-induced, **12:152–154**
 steroid effects on, **12:163–165**
 Depression (behavioral)
 central serotonin neuron role in, **13:120**
 decrease in brain serotonin and, **13:333–335**
 increase in brain serotonin and, **13:327–333**
 Depression states, blood-brain, barrier in, **7:181**
 Depth reversal, of cortical evoked responses, **3:90–91, 3:95–105, 3:127**
 (Des; Tyr¹)- γ -endorphin
 nociception and, **25:212–213**
 peptide sequence of, **25:187**
 Desai hypothesis, of neuroprotease binding, **17:206**
 Desferrioxime, in porphyria therapy, **16:335**
 Desmethylimipramine, effect on, body temperature, **12:35**
 Detergents, membrane stabilization by, **9:159–160**
 Development, sleep states and state transitions in, **23:410–411**
 Dexamphetamine, absolute configurations in relation to those of ephedrine and noradrenaline, **12:320**
 Dexbenzpetimide, as muscarinic antagonist, **17:169**
 Dextran blue
 as choline acetyltransferase inhibitor, **20:302, 20:308–309**
 use in choline acetyltransferase purification, **20:302**
 DFP, **1:198**
 Diabetes, porphyria with, **16:314**
 Dialkoxymethyl-2-imidazolidines, as phosphodiesterase inhibitors, **20:132**
 Dialkoxyphenyl-2-pyrrolidones, as phosphodiesterase inhibitors, **20:132–133**
 L-2,4-Diaminobutyric acid, **21:300**
 as neurotoxic convulsant, **17:27**
 Diazepam, kryptopyrrole compared to, **16:167**

- Dibenamine, as muscarine antagonist, **17:172**
- Dibutyl adenosine cyclic AMP, effects on cerebral RNA, **16:221, 16:222**
- Dicarboxylic aminoacids, **1:94**
- Dichloroisoproterenol, effect on EEG, **8:284**
- Diencephalon
 AChE and NAD-d activity in, **10:241–261, 10:265–267**
 aggression sites in, **18:226–227**
 analog in insects (corpora pedunculata), **3:370**
- Diethazine, effect of and vertical rope climbing, **2:234**
- Diethylaminoethanol, **1:239**
- Diethylaminomethyl-3-benzodioxane, effects on CAR, **2:255–256**
- Diethyl *p*-nitrophenyl phosphate, effect on learning, **8:173**
- Diethylstilbestrol, alcohol intake in gonadectomized rats, **2:67**
- Diethyltryptamine (DET), as central serotonin antagonist, **12:219**
- Differential centrifugation, in brain fractionation, **20:257–262**
- Diffuorophosphate, retrograde amnesia from, **10:183**
- Diffusible substances, autoradiography of, **22:116–118**
- Dihydroergocryptine
 as α_1 -adrenergic antagonist, **24:362–363**
 as α_2 -adrenergic antagonist, **24:377–380**
- Dihydro- β -erythroidine, as acetylcholine antagonist, **10:24–25**
- Diisopropylfluorophosphate, effect on hippocampus, **8:94–95**
- Diisopropylfluorophosphonate, **3:307**
- Dikryptopyrrol ether, in kryptopyrrole chromatography, **16:155–156**
- Dimercaptopropanol, in porphyria therapy, **16:327–332**
- 2,5-Dimethoxy-4-methylamphetamine (DOM), as central serotonin antagonist, **12:218–219**
- Dimethoxyreserpine, CAR, **2:245**
- Dimethylamine, **1:355–362**
- (4-Dimethylamino- α -methylphenyl) hydrazine, structure of, **7:195**
- Dimethyltryptamine, formula of, **12:208**
- N,N*-Dimethyltryptamine (DMT), **22:83–110**
 at the synapse, **22:104–106**
 biosynthesis of, **22:85–91**
in vivo, **22:91**
 dopamine and, **22:103–104**
 as endogenous hallucinogen, **22:83–110**
 5-hydroxytryptamine and, **22:101–103**
 metabolism of, **22:91–101**
in vitro, **22:92–100**
in vivo, **22:100–101**
 tolerance to, **22:101**
- 2,4-Dinitrophenol, effect on spreading cortical depression, **5:224, 5:234–238**
- Dioxolane, as muscarinic agonist, **17:164**
- Dipeptide hydrolases
 classification of, **11:59**
 molecular analysis of, **17:197–198**
 in nervous system, **11:64–69**
 anserinase, **11:66–67**
 carnosinase, **11:66–67**
 cysteinyl-glycine dipeptidases, **11:66–67**
 glycyl-glycine dipeptidase, **11:65–66**
 imido- and iminodipeptidase, **11:67–68**
 ϵ -peptidases, **11:68**
- Diphenhydramine (Benadryl)
 CAR, **2:259**
 effect on EEG, **8:292–293**
 effect on vertical rope climbing, **2:234**
- Diphenyldiazadamantanol
 beneficial effect on, learning, **8:178–179**
 memory, **8:182–184, 8:189**
- Diphenylhydantoin (Dilantin)
 after topical application of ACh, **2:139**
 retrograde amnesic blocking action, **10:190–191**
- Diphosphoinositide (DPI), **3:299**
 from triphosphoinositide dephosphorylation, **16:58–59**
- Diphosphoinositide kinase
 as cAMP receptor, **16:32–49**
 assay of, **16:35–36**
 preparation of, **16:33–35**
- Dipoles, **3:90, 3:101**
- Di-*n*-propylacetate, as GABA-transaminase inhibitor, **17:21**
- Dipropyltryptamine (DPT), as central serotonin antagonist, **12:219**
- Diptera, **3:355**
- Dipyridamole, as phosphodiesterase inhibitor, **20:132**
- Discrimination
 in learning process, **16:265–266**
 somatosensory, **3:236–238**

- visual, **3:238–239**
- Discrimination learning
 - expectation mechanism of, **18:313–316**
 - generalization gradients in, **18:301–305**
 - neural model of, **18:263–327**
- Dissociation effect, in drug influences, **8:151–153**
- Distance estimation, in insects, **3:363**
- Disulfide bond
 - in acetylcholine receptor, **17:156–157**
 - in receptor site, **13:210–211**
- Disulfiram (tetraethylthiuram disulfide, antabuse)
 - effect of drugs related to, **2:69**
 - effect on free choice of alcohol in rats, **2:69**
 - use in treatment of alcoholism, **2:69**
- Disuse supersensitivity, **21:12, 21:16–27**
 - behavioral evidence for, **21:16–19**
 - contradictory evidence, **21:19–22**
 - evaluation of, in humans, **21:24–27**
 - neurophysiological and biochemical evidence, **21:22–24**
- Ditran
 - as antiacetylcholine drug, **16:119**
 - in anticholinesterase poisoning, **16:128, 16:130**
 - compared to phencyclidine, **6:307**
- DNA
 - in brain, material ethanol intake effects on, **19:158–159**
 - in neurobiology of pyrroles, **16:151**
- DNA synthesis, drug effects on, **11:112–114**
- DOCA, in therapy of Addison's disease, **5:273**
- Dog, self-stimulation behavior, **21:368–372**
- DOPA, in aggression mechanism, **18:242–247**
- L-dopa, effect of on CEPR, **2:167**
- Dopa aminotransferase, substrate specificity of, **17:91**
- Dopa decarboxylase, brain lesions and brain level of, **13:87**
- Dopamine (DA)
 - action on neurons, **11:19–22**
 - assay, **21:260, 21:263–265**
 - in brain, **10:330**
 - determination of, **19:178–189**
 - ethanol effects on, **19:146–147**
 - lesions and, **13:81**
 - phylogenetic distribution of, **19:196–199**
 - structure of, **19:175**
 - in cyclic AMP formation, **20:116–118**
 - in cyclic GMP regulation, **20:141**
 - dimethyltryptamine and, **22:103–104**
 - effect on dyskinesias, **10:341–342, 10:359–360**
 - effects on geniculate nuclei, **14:36–37**
 - evoked potential (EP) and, **25:427**
 - fine structural localization in nervous tissue, **13:27–66**
 - glucocorticoids and, **23:182**
 - metabolism in brain, **21:7**
 - modulation of muscle by, **22:240**
 - neurons
 - autonomic functions of, **13:109–110**
 - mental functions of, **13:107–109, 13:119**
 - motor functions of, **13:104–107, 13:119**
 - nigro-neostriatal type, **13:104–110, 13:119**
 - in thermoregulation, **13:109**
 - tubero-infundibular type, **13:110, 13:119**
 - pathways of, **13:96–98**
 - presence and action in CNS, **11:17–25**
 - protein transport in, **13:302**
 - role in etiology of tardive dyskinesia, **21:15–30**
 - thalamus, **14:32–36**
 - uptake in brain, **13:128–139**
- Dopamine- β -hydroxylase (DBH)
 - in CSF, clinical significance, **25:128**
 - evoked potential (EP) and, **25:427**
 - inhibition effects, **21:272**
 - in microramine assay, **19:180**
 - somatofugal transport of, **13:302**
- Dopamine neurons
 - effect of neuroleptic drugs on, **21:6**
 - in mammalian brain, **21:5**
- Dopamine receptors
 - autoradiography of, **22:142–150**
 - direct characterization, **23:262–263**
 - irreversible modification by phenoxybenzamine and heat, **23:276–282**
 - pituitary D-2 receptor, **23:264–270**
 - radioligand binding technique, **23:263–264**
 - striatal receptors, **23:270–276**
- functional implications of regulation, **23:290–291**
 - chronic receptor stimulation, **23:293–294**

- dopaminergic denervation and blockade, **23**:291–293
 - radioreceptor assays, **23**:294–295
 - neuroanatomical localization of, **23**:283–385
 - neostriatum, **23**:285–288
 - retina, **23**:289–290
 - substantia nigra, **23**:288–289
 - pharmacological characterization of
 - D-1 receptors, **23**:258–260
 - D-2 receptors, **23**:260–261
 - dopamine autoreceptors, **23**:261–262
 - solubilization and isolation of, **23**:256–258
 - Dopaminergic agents, actions of, **23**:256–258
 - Dopaminergic drugs, aggressive behavior from, **18**:242–249
 - Dopaminergic systems
 - effect on behavior, **25**:414–416
 - effects on cerebral glucose utilization, **22**:321–323
 - Dopamine system
 - mesencephalic, dopamine-dependent functions of nucleus accumbens septi, **23**:314–336
 - neuroanatomy, **23**:313–314
 - Dorsal cochlear nucleus, **21**:59, **21**:60
 - Dorsal horn, spinal neurons of, **13**:15–16
 - Dorsal root potential, **21**:235
 - potassium and, **21**:238–240
 - Dreaming
 - hallucinations and, **17**:300–301
 - REM sleep and, **17**:299–300
 - schizophrenia and, **17**:297–342
 - Drinking behavior, peptides and, **17**:41
 - Droperidol
 - self-stimulation behavior and, **21**:356, **21**:360, **21**:366
 - structure of, **8**:254
 - DRP, *see* Dorsal root potential
 - Drug potency, equation for, **16**:101
 - Drug receptor site, **4**:219–221
 - Drugs
 - affecting CNS, mode of action, **11**:31–43
 - behavioral effects of, **15**:284–288
 - body temperature and, **12**:1–43
 - brain states in evaluation of, **15**:273–347
 - methods, **15**:276–284
 - results, **15**:284–339
 - effect on fetal brain catecholamines, **20**:74–76
 - effect on learning and memory, **8**:139–196, **13**:236–239
 - narcotic type, *see* Narcotic drugs
 - noise-induced, in fluctuation analysis, **20**:191–200
 - psychomotor stimulating type, *see* Psychomotor stimulator drugs
 - psychotropic, effect on schizophrenia, **8**:206–210
 - retrograde amnesia and, **10**:167–198
 - topical application of, effects, **8**:163–164
 - Dynorphin
 - nociception and, **25**:211–212
 - peptide sequence of, **25**:187
 - Dyskinesias
 - amines in, **10**:326–343
 - biochemistry of, **10**:323–370
 - relationship of CNS lesions, **10**:339, **10**:341
 - see also* Neuroleptic dyskinesia; Tardive dyskinesia
 - Dzhalangarsk encephalitis, monopyrrole in, **16**:173–175
- ## E
- Eating, nervous, attentional deficits and, **18**:321–323
 - Echolocation, in cetacea, **21**:74–75, **21**:84–88
 - ECT, *see* Electroconvulsive therapy
 - Edathamil, in porphyria therapy, **16**:327–332
 - Edema
 - of brain, **3**:37–39, **3**:60
 - cerebral, **7**:164–165
 - in triethyltin intoxication, **12**:52–83
 - Edrophonium effect on hemicholiniums, **2**:78, **2**:80
 - EEG, **1**:23, **1**:155, **1**:284
 - apomorphine effects on, **19**:234
 - biophysical factors in, **15**:245–252
 - computer analysis of data on, **15**:268–270
 - correlation with psychotic behavior, **1**:39
 - cortical nerve cells and, **15**:241–245
 - experimental analysis, **15**:255–264
 - effect of deanol, **1**:318–319
 - effect of reserpine, **1**:36
 - genesis of, **15**:227–272
 - tentative model of, **15**:263–264
 - gross activity of, evaluation, **15**:267–268
 - models of, **15**:230–232

- in perception, **15:266–267**
- spikes and waves in, differences in, **15:250–252**
- in studies on drug effects, **15:288–300**
- subcortical control of, **15:264–267**
 - pacemaker, **15:264–266**
- synaptic functional units and, **15:241–243**
- in temporal lobe epilepsy, **1:25–27**
- unitary sources of, **15:230–241**
 - cellular potentials, **15:237–239**
 - intracellular wave activity, **15:235–237**
 - microelectrode studies, **15:232–235**
 - theoretical analysis, **15:252–254**
- EEG waves
 - alpha, **5:65**
 - analysis of, **5:53–119**
 - cortex, behavior and, **5:97–102**
 - origin of, **5:59**
 - slow, in sleep, **5:65**
- Efferents, *see* Projection
- Elasmobranchs, muscle innervation in, **6:116–126**
- Electrical activity in neural coding, **13:228–229**
- Electrical field, primary afferent
 - depolarization and, **21:236**
- Electrical stimulation, effect on brain RNA and proteins, **13:275–276**
- Electrical stimulation of seizures, **24:103**
 - by kindling, **24:104–105**
- Electrical summation, by neurotransmitters, **22:207–211**
- Electric shock, effect on memory, **16:276–277**
- Electroconvulsive shock
 - in affective disorder therapy, **18:376**
 - retrograde amnesia from, **10:173, 10:175, 10:186, 10:187**
 - seizures from, **24:101**
 - treatments claimed to block, **10:187–192**
 - treatments claimed to facilitate, **10:193–194**
- Electroconvulsive shock therapy of affective disorders, biogenic amines and, **12:154**
- Electroconvulsive therapy
 - biochemical changes in, **5:393–395**
 - biological aspects of, **5:389–412**
 - clinical effects of, **5:395–397**
 - effect on brain serotonin, **5:405**
 - endocrine changes in, **5:393–395**
 - fatalities from, **5:400–402**
 - mode of action, **5:403–406**
 - neuropathology of, **5:399–400**
 - physiological effects of, **5:391–393**
 - physiopathology of, **5:399–400**
 - prognostic tests and, **5:402–403**
 - psychological effects of, **5:397–399**
- Electroencephalogram (EEG), **3:171–181**
 - cross-spectral analysis of, **13:345–346**
 - effect of HC-3 upon, **2:84**
 - in epilepsy, **3:149–152**
 - and hydrazides, **3:325–326**
 - rabbit, after 5-HTP, **2:184**
 - “sedation threshold”, **2:367–369**
- Electroencephalogram amplitude analysis, **8:265–312**
 - after flicker stimulation, **8:280**
 - after hyperventilation, **8:280**
 - after sound stimulation, **8:280–281**
 - after visual filed stimulation, **8:281**
 - antianxiety drug effect on, **8:291–294**
 - antidepressant drug effect on, **8:282–289**
 - blood circulation and, **8:281–282**
 - blood pressure and, **8:281**
 - in brain disorders, **8:279–280**
 - CNS stimulants’ effects on, **8:282–289**
 - electronic integrator for, **8:272–275**
 - hallucinogenic drug effect on, **8:289–291**
 - methodological basis for, **8:267–270**
 - placebo effects on, **8:305**
 - planimetric method for, **8:271–272**
 - of resting EEG, **8:275–279**
 - under modified physiological conditions, **8:280–282**
 - see also* individual drugs
- Electroencephalography (EEG)
 - in conditioning and mental tests, **11:330–334**
 - of deep brain structures during mental tasks, **11:337–339**
- Electrogenesis
 - at synapses, **1:73–77**
 - catalog of varieties, **1:51–53**
 - conductile vs. synaptic, **2:175–177, 2:190**
 - major determinants, **1:153**
- Electrolytes
 - effects on affective disorders, **12:161–163**
 - role in porphyria, **16:324–325**
- Electron microscope, **3:3–28 pass., 3:36, 3:41, 3:50, 3:52, 3:162–163**
 - advantages of, **3:2–4**
 - on brain slices, **3:31–32**
 - on insect eye, **3:355**

- Electron microscopy
of central monoamine neurons,
13:102–104
in cholinesterase studies in CNS,
10:68–70
of monoamines, **13:29–34**
- Electroretinogram, **1:280f**
in insects, **3:355–357**
- Electroshock therapy, brain serotonin,
content, **2:182**
- Electroshock treatment, **3:280–281**
- Electrotonic coupling, in axonal pathways,
18:19–20
- Emetic, apomorphine as, **19:231–232**
- Emetine, as α -blocker, **17:185**
- Emmetropic
frogs, **2:2, 2:4**
newts, **2:2**
- Emotion
endocrine glands and, **5:245–282**
noradrenaline neuron role in, **13:120**
- Encephale isolee, **3:70, 3:73, 3:202**
- Encephalomyelitis, collagenlike protein in,
6:23
- Encephalopathy
cerebral, from fluropyrimidines, **10:209**
hepatic, **3:253**
- Endocrines
influence of, on free choice of alcohol
adrenals, **2:67**
gonads, **2:66–67**
pancreas, **2:65–66**
thyroid, **2:64–65**
- Endocrine systems
effects of sleep on, **23:394–395**
neuropsychiatry in, **5:243–302**
pineal gland effects on, **11:174–183**
- Endopeptidases, **11:58**
molecular analysis of, **17:193–196**
- Endoplasmic reticulum
in axotomized neurons, **14:65**
enzyme markers for, **20:273**
site of phospholipid turnover in salt
gland, **2:120–121**
- β -endorphin
in brain, **25:296–297**
nociception and, **25:203–211**
peptide sequence of, **25:187**
- Endorphins
evoked potential (EP) and, **25:427**
role in neurobiology of personality,
25:425–426
- Endorphins and enkephalins
identification and localization, **24:62–87**
immunoassay versus radioimmunoassay
of, **24:74–87**
immunodetection, **24:51–92**
reliability, **24:87–88**
sensitivity, **24:62–74**
tissue extraction, **24:57–62**
tissue processing and handling,
24:53–57
- Energy, in brain, during seizures, **22:74–75**
- Energy metabolism
in brain, ethanol effects on, **19:136–139**
effect on cerebral glucose metabolism,
22:304–314
local functional activity and,
22:314–315
- Energy metabolism of brain, **18:141–211**
- Energy-rich phosphate, in brain, ethanol
effects on, **19:136–137**
- Engram, **13:227**
- Enkephalins
in brain, **25:295–296**
in cyclic AMP formation, **20:125**
in cyclic GMP regulation, **20:142**
nociception and, **25:195–203**
- Enolase
clinical significance, **25:128**
in CSF, **25:125–127**
- Entorhinal area, **1:8–13, 1:33**
- Enzymes
in brain, **6:25–26, 18:174–176**
in brain cell cultures, **5:40–41, 5:49**
in cerebrospinal fluid, **25:127–129**
clinical significance, **25:128**
for CO₂ fixation in nervous tissue,
14:125–137
drug-metabolizing, in liver, **11:104–106**
as markers, in brain fractionation, **20:273**
in microamine assays, **19:178–182**
role in schizophrenia, **11:266–267**
- Ependymal cell
localization, **21:277**
ontogeny, **21:276**
see also Glial cell
- Ephaptic interaction, **3:161–163**
- Ephedrine, action of CPZ, **2:237**
- Epilepsy, **3:95, 3:137–183**
 β -aminobutyric acid and, **17:1–36**
autoimmune processes in, **11:319–325**
brain amino acid changes in, **6:16–17**
developmental aspects, **24:150–152**

- diversity of disorders in, **24:94–95**
- Epileptic focus, neuroanatomical features of, **3:140–141, 3:160–161**
- experimental method of study, **3:139–140**
- experimental models, **24:99–106**
- glucocorticoids and, **23:190**
- Jacksonian, **3:177–178**
- neurochemistry, **3:167–169, 24:93–180**
- pyridoxine deficiency and, **17:11–12**
- reflex or sensory type, **17:13–14**
- relation of experimental to natural, **3:138–140**
- temporal lobe, **1:20–27, 1:310**
- deanol in, **1:225**
- effect of age, **1:26**
- psychological factors in, **1:25–26**
- sleep, **1:26–27**
- surgery in, **1:29**
- thalamus and, **9:65–67**
- see also* Seizures, epileptic
- Epileptics, EEG analysis of, **8:279**
- Epileptic seizure
- mechanism of origin, **3:169–177, 3:181**
- mechanism of propagation, **3:177–181**
- role of environmental stress, **3:181**
- see also* Seizures, epileptic
- Epileptogenic foci, cerebral cortex shows decreased glutamic acid levels, **2:301**
- Epinephrine
- as α_2 -adrenergic agonist, **24:387–393**
- analogies with serotonin, **2:203–204**
- as appetite inhibitor, **5:331**
- assay, **21:260, 21:263–265**
- CAR, **2:255**
- cortical epinephrine pressor response (CEPR), **2:138–171**
- effect on body temperature, **12:11**
- effect on brain cell culture, **5:7, 5:38–39, 5:40, 5:47**
- effect on EEG, **8:283**
- fine structural localization in nervous tissue, **13:27–66**
- hippocampus, **8:99**
- in hypothalamus, **2:158–163**
- mental disease test using, **5:401–403**
- receptors for, **24:344–345**
- reserpine, **2:245**
- Ergotamine, as α -blocker, **17:183–184**
- Ergothioneine, as possible synaptic transmitter, **11:30**
- Erythrocytes, phenothiazine effect on, **7:246–247**
- β -Erythroidine, as neuromuscular blocking agent, **17:154–155**
- Erythropoietic porphyria, **16:305, 16:306**
- symptoms and incidence of, **16:307**
- Erythropoietic protoporphyria, **16:305, 16:306**
- symptoms and incidence of, **16:306**
- Eserine, **3:307**
- action of reserpine, **2:245**
- CAR, **2:257–258**
- effect on brain cell culture, **5:39–40, 5:47**
- effect on hippocampus, **8:94–98, 8:120**
- P³² incorporation into phospholipids, **2:104**
- see also* Physostigmine
- Esterases
- brain, **7:303–311**
- in CSF, clinical significance, **25:128**
- Esters, of phosphoric acid in brain, **3:305–308, 3:313**
- Estradiol benzoate, alcohol consumption in deer mice, **2:67**
- Estral clock, **11:141–142**
- Estrogens, **1:305–306**
- animal behavior and, **11:142–144**
- effect on glutamic acid dehydrogenase activity, **17:12–13**
- human behavior and, **11:144–148**
- Ethanol
- animal differences in intake, **2:44–45**
- CAR, **2:252**
- diet and free choice of ethanol, **2:50–58**
- effect on EEG, **8:293, 8:303**
- effects on cerebral metabolism, **19:130–136**
- effects on nervous system, **19:123–172**
- effects on neurotransmitters, **19:143–152**
- forced administration of, **2:62–64**
- free choice by rats, **2:42ff**
- heavy consumption of, in pregnancy, fetal abnormalities and, **19:156–160**
- heredity and ethanol preference in rats, **2:45–49**
- induced changes in free selection, **2:42–73**
- metabolism of
- in brain, **19:124–130**
- factors affecting, **19:160–168**
- hormone effects on, **19:162–163**
- rate-limiting steps, **19:161–162**

- 3rd choice and free choice of ethanol, **2:59–61**
- tolerance to, physical dependence and, **19:152–156**
- withdrawal from, factors affecting, **19:167–168**
- Ethanolamine, **1:355–362, 3:300–301, 3:305, 3:307**
- Ethanolamine-*O*-sulfate, as GABA-transaminase inhibitor, **17:21**
- Etheno-coenzyme A, structure of, **20:323**
- Ether, retrograde amnesia from, **10:178–179**
- Ethidium, formula of, **12:224**
- Ethoxybutamoxane, effects on CAR, **2:256**
- Ethyl alcohol, **1:259–262, 1:270, 1:287**
- Ethylamine, **1:355–362**
- Ethyl carbamate, effect on EEG, **8:297**
- Ethylenediamine compounds, effect on EEG, **8:288**
- Ethyl ether, effect on hippocampus, **8:109–110**
- 5-Ethyl-5-phenyl-2-pyrrolidone, as GABA-transaminase inhibitor, **17:21, 17:22–23**
- 4-Ethylpyrazole
structure of, **16:150**
as tranquilizer, **16:149**
- Ethyl urethan, effect on hippocampus, **8:107–109**
- Eryptamine
as MAO inhibitor, **7:215**
structure of, **7:195**
toxicity of, **7:221**
- Evoked potential (EP), biochemistry of the augmenting- reducing of, **25:426–428**
- Evoked response, *see* Cortical evoked response
- Excitable membrane, RNA role in, **13:184–189**
- Excitants, effect on lateral geniculate nucleus, **6:246–248**
- Excitation, cortical, **2:339–340, 2:343, 2:344**
- Excitation (behavioral), decreases in brain acetylcholine and, **13:335–338**
- Excitation-inhibition balance, **2:343–347**
- Exocytosis
phospholipid methylation and, **23:147–152**
in synaptic vesicle discharge, **18:125–128**
- Exopeptidases
in cerebral spinal fluid, **11:81–82**
- classification of, **11:58–61**
hormone activity and, **11:85**
in hypothalamus, **11:79–81**
inborn metabolic errors and, **11:85–86**
molecular analysis of, **17:197–199**
of nervous system, **11:57–97**
 α -aminopeptide amino acid hydrolases, **11:69–73**
 α -carboxypeptide amino acid hydrolases, **11:69–73**
dipeptide hydrolases, **11:64–69**
- Experimental allergic myasthenia gravis (EAMS), neurotoxin studies on, **22:181–182**
- Experimental conditions
animal vs. human experimentation, **2:375–379**
appropriate, **2:335–342**
errors in, **2:334–335**
scheme of appropriate experimental conditions, **2:342–347, 2:366–369**
- Experimental tests in assessment of drug effects
alteration behavior in simple T-maze, **2:376–379**
apparent movement, **2:355–356**
eyeblink conditioning, **2:341–342, 2:348–350**
flicker perimetry, **2:358–359**
kinesthetic figural after-effects, **2:355**
nonsense syllable learning, **2:346, 2:350–352, 2:371–375**
pursuit rotor learning, **2:335–342, 2:352–353**
reaction times, **2:354, 2:371–375**
rotating spiral after-image, **2:361–362**
suppression of primary visual stimulus, **2:362–364**
vigilance, **2:364–366**
visual after-image, **2:359–361**
visual-field effects, **2:356–358**
- Extinction, **3:192**
- Extra-blood-brain-barrier brain structures, **10:31–55**
amine content, drug effects on, **10:43–44**
anatomical data, **10:32–37**
area extrema as, **10:32–36**
biochemical and histochemical data, **10:37–41**
chemical uptake by, **10:41–43**
physiological function of, **10:44–52**
subcommissural organ as, **10:36–57**

physiological function, **10:46–48**
 subformal organ as, **10:36, 10:44–46**

Extracellular
 lack of, **3:16–18, 3:35–36, 3:46, 3:49–50**
 relation to “ground substance” of CNS,
3:35–36
 space determination by physiological
 methods, **3:29–31**

Extracellular patch clamp, ion channels in
 nerve cell membranes and, **23:8–10**

Extracellular space
 of brain, **5:198–202**
 definition of, **5:199**
 determination of, **5:199–201**

Extrajunctional Ach receptor, channel
 properties, **21:318**

Extrajunctional receptors, fluctuation
 analysis of, **20:196–198**

Extralemniscal reticular system, sensory
 discrimination in, **8:53–63**

Extraocular motoneurons, projections of
 vestibular nuclei to, **15:66–76**

Extraversion, as personality trait,
25:395–398

Extraversion-introversion
 apparent movement, **2:355–356**
 definition and theory, **2:343–347,**
2:366–369
 kinesthetic figural after-effects, **2:355**
 pursuit rotor learning, **2:353**
 visual after-image, **2:360–361**

Eye
 amphibia
 autograft, **2:12, 2:26**
 color vision, **2:3**
 homograft, **2:12, 2:13, 2:24**
 magnification factor, **2:5**
 orientation, **2:4**
 polarity, **2:33**
 rod-cone rates, **2:4**
 rotation, **2:16ff**
 and reimplantation, **2:33**
 shape differentiation, **2:3**
 visual elements, **2:5**
 kryptopyrrole effects on, **16:166–167**

Eyeblink conditioning
 in assessment of drug effects, **2:348–350**
 Doriden, **2:341–342**

Eye movement, lambda wave and, **7:100,**
7:125–130, 7:144–148

Eye vesicle, transplanted to position of ear
 vesicle, **2:25**

F

Facial sensation, neural mechanisms,
9:301–394
 bulbar neurons and, **9:321–346**
 functional characteristics, **9:331–343**
 morphology, **9:321–331**
 trigeminal nuclear complex, **9:321–331**

cortical influence on synaptic
 transmission in sensory pathway,
9:367–382

cutaneous nerve terminations, **9:304**

cutaneous receptors, **9:305–309**
 in hairy and glabrous skin, **9:303–309**
 mechanoreceptors, **9:306–307**
 primary afferent neurons with facial
 cutaneous receptors, **9:303–321**
 thermoreceptors, **9:307–309**

somatic projections to cerebral cortex in,
9:360–367

thalamic nuclear regions and, **9:346–360**
 ventrobasal complex, **9:347–356**

trigeminal primary afferents
 conduction in different segments, of,
9:316
 topographical organization, **9:309–316**
 trigeminal semilunar ganglion,
9:311–314
 trigeminal skin folds, **9:309–311**
 trigeminal spinal tract, **9:314–316,**
9:318

Facilitation, **3:114, 3:128, 3:212, 3:224–225,**
3:228–230, 3:234–235, 3:239

Factor 1, **21:150**

Factor N, free choice of ethanol, **2:43, 2:53,**
2:54

Factor N1, free choice of ethanol, **2:43,**
2:54, 2:55, 2:62, 2:70

Fanconi syndrome, **7:24**

Fastigial nucleus, projections of, **15:42**

Fasting, porphyria induction by, **16:315**

Fatigue, therapy by deanol, **1:223–224**

Fatty acid activate enzyme (FAAE),
1:172–173

Fatty acids, oxidation by brain, **1:172–175**

Fear
 cholinergic mechanism and, **14:202–203**
 Pavlovian extinction of, vs. learned
 avoidance, **18:297**
 rebound to relief of, **18:276–282**
 “Feed-back”, **3:166, 3:210, 3:218, 3:240–241**

Feeding behavior

- of *Hydra*, glutathione and, **17:39–40**
- peptides and, **17:41**
- “Feeding center”, **5:305–306**, **5:307**, **5:326**, **5:333**
- Fetal alcohol syndrome, neurochemical aspects of, **19:156–160**
- Fetal brain
 - catecholaminergic innervation in, **20:77–81**
 - catecholaminergic neurons of, **20:67–82**
 - regional innervation, **20:72–74**
 - synatogenesis on, **20:76–77**
 - catecholamines in, drug effects on, **20:74–76**
 - octopamine and β -phenylethanolamine in, **20:71–72**
- Fibers, *see* Projection
- Fibrils, glial, **3:15**, **3:59**, **3:140**
- Field effects
 - role in
 - epileptogenic focus, **3:157–160**
 - interaction of neurons, **3:161–165**
 - spread of epileptic seizure, **3:178**
- First Central synapse, sensory discrimination in, **8:40–44**
- Fishes
 - CNS regeneration of, **6:264–268**
 - dual motor system in, **6:134–135**
 - muscle innervation in, **6:105–106**
 - proprioception in, **6:139–140**
 - swimming muscles of, **6:105–106**
- Five-fraction procedure, for brain fractionation, **20:257–262**
- Flagellum, **3:353–354**
- Flaxedil, **3:72**
- Flicker fusion frequency, **3:357**
- Flicker perimetry, in assessment of drug effects, **2:358–359**
- Fluanisone
 - self-stimulation behavior and, **21:355**, **21:360**, **21:366**
 - structure of, **8:253**
- Fluctuation analysis
 - ion channels in nerve cell membranes and, **23:2–6**
 - of K channels, **23:58**
 - blockage of, **23:62–64**
 - conductance and number of, **23:59–60**
 - gating of, **23:60–62**
 - of Na channels
 - blockage of, **23:55–56**
 - conductance and number of, **23:51–53**
 - gating of, **23:53–55**
 - modification of, **23:56–58**
 - principles of
 - difference procedures for recording fluctuations from different channels, **23:39–40**
 - stationary and nonstationary random processes, **23:36–39**
 - types of spectral density functions, **23:40–44**
- Fluctuation analysis in neurobiology, **20:169–208**
 - conductance fluctuations, **20:176–180**
 - of drug-induced noise, **20:191–200**
 - general relationships in, **20:181–183**
 - of mechanoreceptors, **20:203–204**
 - methods for, **20:175–183**
 - of photoreceptors, **20:201–203**
 - results of, **20:183–205**
 - of sensory systems, **20:200–205**
- Fluorodeoxyglucose method, use to study cerebral glucose in man, **22:329**
- Fluorimetry, of microamines, **19:179**, **19:188–189**
- Fluoropyrimidines
 - metabolic effects of, **10:216–218**
 - biosynthesis of free pyrimidine nucleotides, **10:216–217**
 - biosynthesis of RNA, **10:217**
 - nucleotide coenzyme function, **10:218**
 - protein synthesis, **10:218**
 - metabolism of, **10:209–216**
 - anabolic conversions, **10:210–213**
 - incorporation into RNA, **10:213–216**
 - neurobiology of, **10:200**, **10:201–219**
 - physiological and pathological effects, **10:201–209**
 - cerebral encephalopathy, **10:209**
 - myelopathy, **10:202–206**
 - rhombencephalopathy, **10:207–209**
- Fluphenazine
 - activity spectra of, **8:231**, **8:240**
 - catalepsy scores of, **8:228**, **8:246**, **8:249**, **8:250**
 - screening data on, **8:227**, **8:247**, **8:248**
 - structure of, **8:255**
- Fluspiperone, self-stimulation behavior and, **21:356**, **21:360**, **21:361**, **21:366**
- Formaldehyde, as stain for biogenic monoamines, **13:30**, **13:32–33**
- Formica rufa*, **3:363–364**
- Fornicate gyrus, of limbic lobe, **8:6–7**

Fornix acids, connections of, **1:3–8**
 Free behavior
 brain stimulation and, **6:349–449**
 cinemanalysis of, **6:357–360**
 conditioned reflexes and, **6:351–352**
 telemetry in study of, **6:360–362**
 Freeze-fracture
 of axolemma, **24:452–461**
 of myelinated axons, **24:451–452**
 of myelin development in optic nerve axons, **24:461–474**
 technique, **24:449–451**
 Frogs, muscular innervation in, **6:100–105**
 Frontal cortex
 afferent and efferent connections in, **19:39–41**
 amnesia involving, **19:11–14**
 function of, electrophysiological correlates of, **19:41–44**
 neural properties, memory and, **19:30–44**
 Fructose
 effects on
 alcohol metabolism, **19:164–166**
 alcohol withdrawal, **19:167–168**
 metabolic pathways of, in liver, **19:166**
 use in appetite studies, **5:337**
 Frustration, in discrimination learning, **18:297–300**
 Funkenstein test, **1:307**

G

G-31,406, as antidepressant drug, **9:132**
 G-33,040, as antidepressant drug, **9:132–133**
 G3063, in anticholinesterase poisoning, **16:130**
 GABA, **22:1–45**
 analogs of, effect on GABA uptake, **22:25**
 in brain, ethanol effects on, **19:146**
 importance as neurotransmitter, **24:181–182**
 markers, in monkey brain, **24:129**
 metabolism of, **22:26–33**
 in brain, **22:26–31**
 in glial cells, **22:32–33**
 in neurons, **22:31–32**
 seizures and, **24:128–140**
 drug interaction and, **24:135–140**
 in synaptosomal transport processes, **19:54–59**
 transport of, **22:16–26**
 in brain slice, **22:16–17**
 in glial cells, **22:19–23**
 in neurons, **22:17–19**
 substrate specificity, **22:23–26**
 see also γ -Aminobutyric acid
 GABA receptors, **24:181–212**
 autoradiography of, **22:150–153**
 binding, **24:193–196**
 drug effects, **24:197–199**
 hormone effects, **24:197–199**
 regulation, **24:196–201**
 biochemical aspects, **24:192–204**
 classification, **24:201–203**
 electrophysiological studies, **24:182–192**
 inhibition, **24:182–188**
 in vitro models, **24:184–188**
 postsynaptic, **24:183**
 presynaptic, **24:183–184**
 pharmacological aspects, **24:189–192**
 solubilization, **24:203–204**
 types, **24:188–189**
 GABA-transaminase
 activity of, in neurons and glial cells, **22:31**
 ethanol effects on, **19:150**
 Galactose, **3:298**
 Galactosemia, **7:24**
 γ neurons, in vestibular pathways, **15:53**
 Ganglia
 cyclic AMP in, **20:150**
 cyclic GMP in, **20:151**
 Ganglion, acetylcholine receptor in, **17:146**
 Ganglion cells, RNA in, **16:189**
 Gardiner's differential processing experiment, **13:366–369**
 Gas chromatography, of microamines, **19:179, 19:187–188**
 Gastropods, octopamine function in, **19:208–209**
 Gates, electronic, **3:75–76**
 Gaucher's disease sera, effect on brain cell culture, **5:45–46**
 Gemistocytes, in brain cell culture, **5:14**
 Genetic analysis potentials and limitations of, **25:362–364**
 Genetic models of seizures, **24:102, 24:103, 24:106**
 Genetics
 neurochemical, **25:361–389**
 of opiate mechanisms of action, **25:290–294**
 Genetotropic disease, alcoholism as a, **2:43**

- Geniculate neurons, pharmacology of, **14:1–48**
- Genital apparatus, pineal gland effects on, **11:175–178**
- GF, *see* Glial factor
- Giant squid axon, fluctuation analysis of, **20:189–190**
- Gjessing's studies on periodic psychoses, **11:152–154**
- Glanzmann's thrombasthenia, glutathione peroxidase in, **19:111–112**
- Glia, of brain, phospholipid composition of, **20:4**
- Glia cells, cerebral, energy metabolism in, **18:155–157**
- Glial cell receptors, cyclic nucleotide responses and, **21:301–303**
- Glial cells
- amino acid neurotransmitters and, **21:297–303**
 - amino acid release, **21:300–301**
 - amino acid transport, **21:297–300**
 - in brain cell culture, **5:14–15, 5:49**
 - brain tumor types arising from, **21:291**
 - classification, **21:276–278**
 - depolarization, **21:294–295**
 - extracellular potential shifts, **21:294–295**
 - function of, potassium and, **21:290–297**
 - GABA metabolism in, **22:32–33**
 - GABA transport in, **22:19–23**
 - glutamate metabolism in, **22:13–16**
 - glutamate transport in, **22:5–8**
 - membrane potential, **21:290–292**
 - neuronal migration and connectivity and, **21:278**
 - ontogeny, **21:276**
 - physiology of, **21:275–304**
 - protein and nucleic acid metabolism in during increased activity, **13:261–266**
 - regulation of extracellular potassium and, **21:293–294**
 - role in CNS development, **21:278–290**
 - seizure activity and, **21:296**
 - spreading cortical depression and, **21:296–297**
- Glial factor, **21:286–287**
- Glial-neural growth factors, **21:285–288**
- Glial-neuronal differentiation, **21:283–290**
- Glial-neuronal interaction, **21:193–198, 21:275–304**
- Glomerulotropin, *see* Adrenoglomerulotropin
- Glucagon
- as appetite inhibitor, **5:332**
 - effects on alcohol metabolism, **19:163**
- Glucocerebrosides, in brain, **3:298**
- Glucocorticoids
- effects on specific neurotransmitters
 - acetylcholine, **23:182–184**
 - amino acids, **23:184**
 - dopamine, **23:182**
 - norepinephrine, **23:181–182**
 - serotonin, **23:178–181** - effects on whole brain excitability, **23:167**
 - epilepsy and, **23:190**
 - mechanism of action, **23:184–185**
 - ionic conductance actions, **23:187–188**
 - metabolic actions, **23:188–189**
 - receptor-mediated versus membrane mediated actions, **23:185–186** - multiple unit evoked response and, **23:167–168**
 - excitatory function studies, **23:168–172**
 - inhibitory function studies, **23:172–173** - role in psychiatric disease, **23:189–190**
 - role in treatment of central nervous system trauma and stroke, **23:190–191**
 - role in treatment of degenerative neurological diseases, **23:191–192**
 - single unit responses and extracellular unit recording, **23:173–174**
 - intracellular unit recording, **23:174–178**
- Glucocorticosteroids, **3:342**
- Gluconeogenesis, **3:341–342**
- Glucose
- in blood-brain exchange, **7:170–171**
 - in brain
 - carbon dioxide effects on, **22:58–65**
 - during seizures, **22:74–75** - in brain amino acid metabolism, **6:10–11**
 - cerebral utilization of
 - in anesthetized brains, **22:301–304**
 - deoxyglucose method for, **22:296–301**
 - energy effects on, **22:304–314**
 - in normal conscious state, **22:301, 22:302** - effects on alcohol metabolism, **19:164**
 - incorporation in brain lipids, **3:298, 3:300**
 - metabolism
 - in brain during excitation, **13:256–258**
 - in developing brain, **22:65–71**

- metabolism of, aminotransferases in, **17:109–110**
- in porphyria therapy, **16:177**
- use in appetite studies, **5:337**
- Glucose tolerance tests, in schizophrenia, **11:261–262**
- Glutamate, **22:1–45**
 - antagonists of, **21:148–150**
 - biochemical studies with invertebrate preparations, **21:192–193**
 - with vertebrate preparations, **21:187–191**
 - metabolism of, **22:10–16**
 - in brain, **22:10**
 - in glial cells, **22:13–16**
 - in neurons, **22:10–13**
 - pathways for, in CNS, **22:186**
 - physiologic-pharmacologic studies in invertebrates, **21:152–154**
 - in vertebrates, **21:147–150**
 - receptor site for, **13:207**
 - somatofugal transport of, **13:302**
 - tissue localization, **21:132–133**
 - toxicity of, **22:200**
 - as transmitter, **12:229**
 - transport into glial cells, **21:298–299**
 - transport of, **22:3–10**
 - in brain slices, **22:3**
 - in glial cells, **22:5–8**
 - in neurons, **22:3–5**
 - substrate specificity, **22:8–10**
- D-Glutamate, effect on cortical neurons, **7:54–56**
- L-Glutamate
 - effect on cortical neurons, **7:48–54**
 - neuronal response to, **10:22–23**
- γ -Glutamate amino acids, enzymology of, **19:80–96**
- L-Glutamate l-carboxylase, ethanol effects on, **19:150**
- Glutamate and GABA receptor, **14:283–287**
- Glutamate receptors
 - channel properties, **21:318**
 - fluctuation analysis of, **20:198–200**
- Glutamic acid, **1:175, 3:167, 3:327–328, 3:330, 3:340**
 - alcohol intake of rats, **2:58**
 - in brain, **6:18**
 - distribution in animal tissues, **2:283**
 - effect on learning, **8:144–146**
 - effect in rabbit cortex and cat spinal neurons, **2:281**
 - role in cortical depression, **5:222**
 - tricarboxylic acid cycle, **2:285–288**
- L-Glutamic acid, **3:324**
 - seizures and, **24:141–142**
- Glutamic acid cycle, **3:330**
- Glutamic acid decarboxylase
 - GABA shunt and, **17:5–7**
 - inhibitors of, **17:7–11**
 - epilepsy and, **17:14–15**
- L-Glutamic acid decarboxylase (GAD)
 - in cerebrospinal fluid, **2:282**
 - changes with animal age, **2:295–299**
 - distribution in monkey and rabbit, **2:288–294**
 - inhibition by hydrazides, **2:310**
 - pH activity relationships of cerebral GAD and GABA-T, **2:301–305**
 - pyridoxal phosphate as a coenzyme for, **2:308–309**
 - as rate-limiting reaction of GABA sequence, **2:300–301**
- Glutamic-aspartic transaminase, **3:337**
- Glutamic-oxaloacetic transaminase, **3:311–313, 3:330, 3:331**
- Glutamine
 - alcohol intake of rats, **2:57**
 - in brain, **6:14**
 - distribution in animal tissues, **2:283**
 - effect of antagonists of free choice of ethanol by rats, **2:70**
 - role in cortical depression, **5:222**
 - transamination of, **17:101–103**
 - tricarboxylic acid cycle, **2:285–288**
- Glutamine aminotransferase
 - in brain, **17:102–103**
 - properties of, **17:101–102**
- Glutamine-glutamate neuronal-glial cycle, **21:301, 21:302**
- γ -Glutamyl cycle, glutathione in, **19:102–107**
- γ -Glutamyl cyclotransferase
 - in γ -glutamyl cycle, **19:102**
 - in glutathione biosynthesis, **19:80–82**
 - inborn deficiency of, **19:109–110**
- Glutamyl peptides, in nervous system, **17:50**
- γ -Glutamyl peptides
 - in brain, **12:237–244**
 - metabolism of, **12:244**
 - metabolism of, **11:71**
 - occurrence of, **19:79**
- γ -Glutamyl transpeptidase
 - in γ -glutamyl cycle, **19:102, 19:103**

- in glutathione degradation, **19:84–88**
- metal ion activation of, **19:86**
- serum deficiency of, **19:110–111**
- Glutaraldehyde, as stain for biogenic monoamines, **13:30**, **13:33–34**
- Glutathione, **1:302**
 - analogs of, **19:79**
 - biochemistry of, **19:76**
 - biosynthesis of, **19:80–84**
 - in brain, **12:237**, **19:77–79**
 - chemical properties of, **19:77**
 - coenzyme functions of, **19:98–101**
 - degradation of, **19:84–90**
 - in dehydrochlorination reactions, **19:100**
 - in dehydrogenation reactions, **19:97–98**
 - detoxification of, **19:97–98**
 - enzymology of, **19:80–96**
 - functions proposed for, **19:97–107**
 - in γ -glutamyl cycle, **19:102–107**
 - history of, **19:76**
 - Hydra* feeding behavior and, **17:39–40**
 - in hydration reactions, **19:99**
 - in isomerization reactions, **19:100–101**
 - in maintenance of cellular thiol groups, **19:101–102**
 - metabolism of, **19:75–121**
 - inherited disorders, **19:107–112**
 - in nervous system, **19:77–79**
 - turnover of, **19:96–97**, **19:112**
 - sulfhydryl group of, enzymic reactions involving, **19:90–96**
- Glutathione peroxidase
 - in glutathione metabolism., **19:91–92**
 - inborn deficiency of, **19:111–112**
- Glutathione reductase
 - in glutathione metabolism, **19:92–94**
 - inborn deficiency of, **19:111**
- Glutathione synthetase
 - in γ -glutamyl cycle, **19:102**
 - in glutathione synthesis, **19:82–84**
 - in “pyroglutamic aciduria”, **19:107–109**
- Glutethimide (Doriden)
 - in an application of canonical variate analysis, **2:371–374**
- CAR, **2:252**
 - effects on
 - eyeblink conditioning, **2:341–342**
 - flicker perimetry, **2:358**
 - nonsense syllable learning, **2:351**
 - pursuit rotor test, **2:354**
 - reaction times, **2:354**
 - suppression of primary visual stimulus, **2:363**
 - vigilance, **2:365**
 - visual field, **2:357**
- Glycerol, **3:300–302**
- α -Glycerophosphate dehydrogenase, effect on brain cell culture, **5:41**
- Glycerylphosphorylcholine, **3:301**, **3:304**, **3:306–307**, **3:313**
- Glycerylphosphorylethanolamine, **3:301**, **3:306–307**
- Glycine, **1:346–348**, **3:300**
 - alcohol intake of rats, **2:58**
 - antagonists of, **21:144–147**
 - binding studies, **21:183–187**
 - biochemical studies with vertebrate preparations, **21:177–187**
 - epileptic seizures and, **24:140**
 - α -ketoglutarate aminotransferase, properties and occurrence in brain, **17:108**
 - metabolism in brain, **6:14–15**
 - physiologic-pharmacologic studies in invertebrates, **21:151**
 - in vertebrates, **21:144–147**
 - receptor site for, **13:207–210**
 - somatofugal transport of, **13:300**
 - tissue localization, **21:131–132**
 - as transmitter, **12:229**
 - as transmitter for inhibitory synapses, **15:170**
 - uptake in glial cells, **21:300**
- Glycine receptor, **14:287–289**
- Glycolate esters, *see* Piperidyl glycolates
- Glycolic acid esters, as muscarinic antagonists, **17:168**
- Glycolysis, **3:338**
 - in brain, **18:173–174**
- β -Glucuronidases, in CSF, clinical significance, **25:128**
- Glycylglycine dipeptidase
 - classification of, **11:59**
 - molecular analysis of, **17:197–198**
 - in nervous system, **11:65–66**
- Golgi complex
 - of astrocytes, **3:7–8**
 - of oligodendrocytes, **3:19**
- Golgi-Cox stain, **3:141**, **3:232**
- Gonadal hormones, in neurobiology of personality, **25:403–406**
- Gonadectomy, alcohol consumption in rats, **2:66–67**

- Gonads, sex difference and alcohol intake, **2:66**
- “Gosh-type” agent, HC-3 as antagonist, **2:93**
- Gramicidin A, transport selectivity models and, **21:324–329**
- Gramicidin A channel
properties, **21:319**, **21:320**
structure, **21:314–317**
- Granular vesicles (large) (LGV),
localization of monoamines in, **13:51–53**
- Granular vesicles (small) (SGV),
localization of, monoamines in, **13:41–51**
- Gray matter, central, AChE and NAD-d activity in, **10:264–265**
- Grooming
dopaminergic effects on excessive, **25:352–355**
excessive, ACTH 4-10 in induction of, **20:218–220**
- Ground substance (*intercellulares grau*), **3:36**, **3:60**
as blood-brain barrier, **3:40**
- Growth hormone administration
acute, effect on sleep, **23:382–385**
repeated, effect on growth hormone secretion, **23:385–386**
- Growth hormone secretion
effect of alterations in neurotransmitter function on
data, **23:371–375**
discussion, **23:375–382**
effect of repeated administration of growth hormone on, **23:385–386**
- GTP, in cyclic AMP formation, **20:127**
- γ -Guanidinobutyric acid, **1:93**
- Guanacline, structure-activity effects of, **25:11**
- Guanethidine
chemical structure of, **25:2**
oxidative phosphorylation inhibition by, **25:13–15**
pharmacology of, **25:2–4**
structure-activity effects of, **25:9–13**
sympathetic neuron destruction by, **25:1–37**
degree and specificity, **25:5–7**, **25:23–33**
discovery, **25:4–5**
immune-mediated mechanism, **25:16–20**
mechanism, **25:13–20**
morphologic effects, **25:5–7**
species-specificity, **25:7–8**
strain specificity, **25:20–23**
in vitro, **25:8–9**
- Guanfacine, as α_2 -adrenergic agonist, **24:398**
- γ -Guanidinobutyric acid, **3:329**
GABA precursor for, effect of, **2:295**
- Guanoxan, structure-activity effects of, **25:12**
- Guanylate cyclases
localization of, **20:138–139**
regulation of, **20:139–142**
- Guvacine, structural formula of, **22:25**
- Gymnarchus niloticus*, **3:158**
- Gyrus
anterior sigmoid, **3:95**
postcentral, **3:111**, **3:117**, **3:189**
- ## H
- Habenular lesions, **1:30**
- Habits, drives, rewards, motivation and, **18:274–276**
- Habituation, hippocampus and, **18:305–306**
- Hair cell mechanoreceptor, channel
properties, **21:318**
- Hair plates, **3:352**
- Hallucinations, dreaming and, **17:300–301**
- Hallucinogenic compound(s)
dimethyltryptamine as, **22:83–110**
mechanisms of action of, **22:101–102**, **22:106–107**
- Hallucinogenic drugs
as central serotonin antagonists, **12:215–223**
characteristics of, **12:207–210**
formulas of, **12:208**
mechanism of action on brain serotonin receptor, **12:207–233**
hypothesis generalization, **12:224–225**
RNA role in, **12:225–239**
testing hypothesis, **12:230–231**
type B0, in central serotonin antagonist, **12:223–225**
- Hallucinogens
effect on brain cell culture, **5:39**
retrograde amnesic effects, **10:185**

- Haloperidide, structure of, **8:253**
- Haloperidol, **8:221–263**
 activity spectra of, **8:229, 8:238**
 catalepsy scores of, **8:228, 8:246, 8:249, 8:250**
 clinical results on, **8:250–252**
 effects of, **6:309**
 neuroleptic potency of, **8:225, 8:247, 8:248**
 in schizophrenia therapy, effects on HNA, **11:240–241, 11:244–245, 11:247**
 screening data on, **8:227**
 self-stimulation behavior and, **21:353, 21:360, 21:363, 21:366, 21:387**
 structure of, **8:253**
- Halothane, retrograde amnesia from, **10:179**
- Hamster incisor, sensory receptors in, **25:67**
- Hansch equation, **16:102**
- Harmine, **16:176**
 structure of, **7:195**
- Hartnup disease, **3:255, 3:261, 3:265–269, 7:24, 7:25, 8:200–201, 8:213, 8:214**
- Heat, dopamine receptors and, **23:276–282**
- Helurine, **17:170**
- Hematin, in porphyria therapy, **16:333**
- Hematoporphyrin
 neurobiology of, **16:149**
 toxicity of, **16:322**
- Hemicholiniums, **2:77ff**
 autoradiography of, **18:112–117**
 central state of action, **2:84–90**
 postsynaptic, **2:87–90**
 presynaptic, **2:84–87**
 distribution and excretion studies on, **2:93**
 other actions, **2:92–94**
 possible inhibitor of polio virus, **2:94**
 rate of onset of action, **2:89–90, 2:93**
- Hepatolenticular degeneration (Wilson's disease), **8:201–202, 7:23–24, 7:26**
 copper proteins in, **6:21**
 phenothiazine action and comparison of, **7:263–264**
see also Wilson's disease
- Hexachlorobenzene, porphyria induction by, **16:308, 16:315**
- Hexafluorodiethyl ether, therapeutic convulsions by, **5:390, 5:404**
- Hexamethonium, effect on equilibrium constants for cholinergic ligands, **24:310**
- Hexamid, effect on CNS, **2:240**
- Hexobarbital
 effect on hippocampus, **8:101, 8:102**
 effect on pressor response, **2:150**
- Higher nervous activity (HNA), studies
 alterations in schizophrenia, **11:232–235, 11:241–248**
 special features of, **11:235–238**
 under treatment, **11:238–241, 11:244**
 use to assess improvement, **11:244–246**
 methodological problems in, **11:229–232**
- Hippocampal damage
 effects on dopaminergic systems of basal ganglia, **25:339–359**
 interaction effects, **25:355–357**
 neuropeptide action and, **25:351–352**
- Hippocampal pyramid, organization of, **13:17–19**
- Hippocampal sclerosis, **1:26**
- Hippocampal seizures
 induced by BAS, **1:36**
 neuropharmacology of, **1:23, 1:34**
 spread of, **1:21–24**
- Hippocampus, **3:68, 3:339**
 AChE and NAD-d activity of, **10:260–262**
 afferent and efferent connections of, **19:32–35**
 connections of, **1:6–9, 1:14, 1:33**
 dendritic potentials of, **1:86–87**
 drug action on, **8:77–138**
 electrical activity of, **8:78–92**
 fast type, **8:89–92**
 theta rhythm, **8:78–89**
 electrical responses, **1:7**
 feedback from, conditioning and, **18:319–321**
 fine structure of, **19:31–32**
 function of
 neurophysiological theories of, **19:37–39**
 neuropsychological theories of, **19:35–37**
 habituation and, **18:305–306**
 lesions of, amnesia and, **19:1–49**
 limbic lobe and, **8:6**
 neural properties of, **19:30–44**
 potentials from, influence of iproniazid on serotonin content, MO inhibitors on, **2:5**
 role in memory, **1:29, 1:41**
 seizure-inducing drugs for, **8:113–121**
 septum and, **8:85–89**
 stimulation of, **1:30**

- susceptibility to damage, **1:22–23**
 theta rhythm from, **3:94**
 theta rhythm of, **8:78–89**
 drug effects on, **8:92–113**
 uptake of methionine by, **1:35**
 His-Held (pericapillary) space, **3:41, 3:44, 3:60**
 Histamine, **1:324–325, 1:327, 1:339, 1:360–362**
 assays of, **18:57–59**
 CNS-activating effect of, **12:265–305**
 compared to amphetamine and chlorpromazine, **12:282–286**
 in direct intracerebral administration, **12:293–294**
 in intravascular administration, **12:288–292**
 in cyclic AMP formation, **20:120–121**
 effect on EEG, **8:283**
 effect of
 estimation of, in hypothalamus, **2:165–166**
 systemic application on pressor response, **2:151**
 topical application on systemic blood pressure, **2:140**
 metabolism of in brain, **12:266–270**
 as possible synaptic transmitter, **11:29**
 release of in hemodialysate of aroused animals, **12:294–298**
 Histamine receptors, autoradiography of, **22:158–159**
 Histidine, in porphyria therapy, **16:332–333**
 “Histotropic” growth, in tissue culture, **9:1–2**
 Hominids
 cranial capacities of, **16:257**
 fossil type, encephalometric indexes for, **16:248**
 Homoanserine, in brain, **12:247–248**
 Homocarnosine, in brain, **6:18, 11:67, 12:246, 12:247**
 Homocysteine, **3:339**
 Honey bee, **3:369–370**
 Hoover sign, in porphyria, **16:309**
 Horizontal canal-abducens reflex arcs, **15:72–74**
 Hormones
 activity of, exopeptidases and, **11:85**
 drug effects on, **11:118–119**
 effect on body temperature, **12:36–37**
 effect on brain protein metabolism, **13:266–268**
 effect on GABA receptor binding, **24:197–199**
 effect on personality, **25:403–406**
 effects on alcohol metabolism, **19:162–163**
 effects on sleep, **23:418–419**
 porphyria induced by, **16:312–313, 16:315–316**
 release of, apomorphine effects on, **19:233–234**
 Horn cells, RNA in, **16:190**
 5-HT, **21:29**
 see also 5-Hydroxytryptamine; Serotonin
 HTP, **2:191**
 reduction of hippocampal potentials by serotonin, **2:204**
 5-HTP decarboxylase
 activity of, in homogenates of brain and kidney injected with reserpine, **2:208–209**
 not inhibited in reserpinized animals, **2:208**
 specificity of, **2:185–189**
 Hull-Lepley hypothesis, **2:346–347**
 Human, auditory and visual nuclei, **21:61**
 Human skeletal muscle, antiacetylcholine receptor antibodies of, **24:13**
 Hunger
 control in insects, **3:370**
 see also Appetite
 Huntington’s chorea, **10:323, 10:325, 10:326, 10:358**
 glutamic acid dehydrogenase and, **17:13**
 metals and, **10:350–351**
 Huntington’s disease
 kainic acid studies on, **22:194–200**
 therapy of, **22:201**
 Hydantoins, as anticonvulsants, **17:27**
Hydra, glutathione and feeding behavior of, **17:39–40**
 Hydration reactions, glutathione in, **19:99**
 Hydrazides, **3:319–348**
 biochemistry of, **3:329–339**
 hydrazide induced seizures and B₆, **2:309–310**
 as inhibitors of glutamic acid decarboxylase, **17:7–8**
 neuropathology, **3:339–340**
 neurophysiology of, **3:325–329**
 pharmacodynamic effects of, **3:324–325**

- potentiation of other convulsant compounds by, **3:323**
- reversal of convulsant effects by depressants, **3:322–325**
- pyridoxine congeners, **3:323–325**
- use in psychotherapy, **5:390**
- Hydrazine, **3:320**
- Hydrazinopropionic acid, as GABA-transaminase inhibitor, **17:21, 17:27**
- Hydrazones, **3:332–338, 3:342**
- Hydrocortisone, effects on cerebral RNA, **16:221**
- Hydrolases, brain, *see* Brain hydrolases
- Hydrolytic enzymes, changes in axotomized neurons, **14:91–95**
- Hydrophobic-affinity chromatography, of choline acetyltransferase, **20:302**
- γ -Hydroxybutyrate, effect on EEG, **8:296**
- 4-Hydroxybutyric acid, neuroactivity of, **17:27**
- 6-Hydroxydopamine
 - effect on aggression, **18:246–247**
 - structure compared to neurotransmitters, **22:176**
- Hydroxydopamines
 - fine structural localization in nervous tissue, **13:27–66**
 - use to map out monoamine neurons, **13:95**
- 5-Hydroxyindoleacetic acid, in schizophrenia, **8:203**
- Hydroxyindole-*O*-methyltransferase, in microamine assay, **19:180**
- 5-Hydroxyindolylacetic acid, **3:255, 3:258, 3:262, 3:263, 3:270, 3:281–284, 3:286**
- 6-Hydroxyindolylacetic acid, **3:286**
- Hydroxylamine
 - GABA levels, **2:311–314**
 - as GABA-transaminase inhibitor, **17:21**
- Hydroxylases, **3:269, 3:270**
- 6-Hydroxy-*N*-dimethyltryptamine, **3:286**
- 3,4-Hydroxyphenylethylamine, *see* Dopamine
- 6-Hydroxyskatole, **3:272**
- 5-Hydroxytryptamine (5-HT), **3:253, 21:138**
 - action on neurons, **11:22–25, 11:32–34**
 - determination of, **19:178–189**
 - dimethyltryptamine and, **22:101–103**
 - effect on body temperature, **12:11–16**
 - effect on cortical neurons, **7:66–68**
 - effect on hippocampus, **8:125–127**
 - effects on geniculate nuclei, **14:37–38**
 - phylogenetic distribution of, **19:196–199**
 - potentiation of, **9:115–118**
 - presence and action in CNS, **11:17–25**
 - receptor site in brain, hallucinogens and, **12:207–233**
 - structure of, **19:175**
 - thalamus, **14:39–40**
 - see also* Serotonin
- 5-Hydroxytryptophan (5-HTP), **3:271, 3:286**
 - behavioral changes in animals after, **2:180–181**
 - brain serotonin concentration after I.V. 5-HTP, **2:184**
 - decarboxylation of, in sympathetic ganglia, pheochromocytomata, **2:186**
 - depressed cortical potentials after, **2:184, 2:208**
 - effect on hippocampus, **8:125–127**
 - effect on schizophrenia, **8:208**
 - inhibition of hippocampal potentials in cats given, **2:204**
 - rate of metabolism of, in brain homogenates, **2:186–187**
 - somatofugal transport of, **13:302**
- 5-Hydroxytryptophan decarboxylase, in pineal gland, **11:185**
- Hydroxyzine (Atarax)
 - in animals, **2:248**
 - in man, **2:248**
- Hymenoptera, **3:355**
- Hyoscyne
 - as antiacetylcholine drug, **16:79, 16:92**
 - behavioral studies, **16:118–124**
 - stereochemistry, **16:96**
 - in antiacetylcholinesterase therapy, **16:130**
 - metabolism of, **16:136**
- Hyoscyamine
 - as antiacetylcholine drug, **16:78, 16:79**
 - behavioral studies, **16:117–118**
 - stereochemistry, **16:95–96**
- Hypercapnia, metabolic changes during, **22:62–64**
- Hyperglycemia, **7:24**
- Hypermetropic frogs, **2:2**
- newts, **2:2**
- Hyperprolinemia, monopyrrole role in, **16:173–175**
- Hypertension, α_1 -adrenergic receptor binding and, **24:375–376**

Hyperthyroidism, psychiatric changes in, **5:289–291**

Hypoenergetic syndrome, in schizophrenia, **11:204–205**

Hypoglossal cells, RNA in, **16:190**

Hypoid syndrome, in schizophrenia, **11:201–202, 11:242**

Hypophysectomy
 brain GABA levels, **2:285**
 pressor response in hypophysectomized animals, **2:142**

Hypothalamic hyperphagia, **5:304**

Hypothalamic-releasing factor, exopeptidases and, **11:80–81**

Hypothalamus, **3:203**
 AChE and NAD-d activity of, **10:256**
 CEPR, **2:142**
 connection with hippocampus, **1:14, 1:21–22**
 effects on feeding behaviour, **5:304–308**
 exopeptidases of, **11:79–81**
 neurohumoral substances in extracts of rabbit hypothalamus, **2:157–166**
 neurovegetative divisions of, **2:176**
 primary amine content of, **2:187**
 secretory nuclei in, **1:181**

Hypothalamus periventricular stratum, **9:263–300**
 anatomical studies, **9:266–276**
 ascending fiber in, **9:274–276**
 descending fiber in, **9:274–276**
 experimental anatomical studies, **9:271–276**
 functional activities, **9:265–266**
 methods in, **9:266–268**
 morphology, **9:263–265**
 neurophysiological studies, **9:277–297**
 methods, **9:277–278**
 normal, **9:268–276**
 stimulation studies, **9:278–296**

Hypothermic drugs, retrograde amnesic effects, **10:185**

Hypothesis
 Autrum's, **3:357**
 Chang's three-component of callosal response, **3:231–232**
 Cragg and Temperley's, **3:161**

Hypothyroidism, psychiatric changes in, **5:275–279, 5:286–289**

Hypoxemia, cerebral glucose utilization in, **22:325, 22:327**

Hysterics, porphyrics as, **16:177**

I

Ibogaine, **16:176**
 effect on EEG, **8:288–289**

Ibotenic acid, structural formula of, **22:184**

IMA, *see* Imidazoleacetic acid

Imidazoleacetic acid, **21:137, 21:138**

Imidazole derivatives, effect on cortical neurons, **7:68–69**

Imidazolines, effect on body temperature, **12:32–33**

Imidodipeptidase
 in brain, **11:67–68**
 classification of, **11:59**
 molecular analysis of, **17:198**

Iminodipeptidase
 in brain, **11:67–68**
 classification of, **11:59**

Imipramine (Tofranil)
 as antidepressive drug, **5:404**
 CAR, **2:240**
 clinical and laboratory differentiation of CPZ, **2:215–219**
 effect on learning, **8:157**
 as muscarinic antagonist, **17:172**

Imipramine and imipramine-like drugs
 activity spectrum, **9:114**
 anticataleptic actions, **9:138**
 antidepressants chemically related to, **9:131–135**
 antiserpine actions, **9:107–110**
 benzoquinolizine antagonism, **9:110**
 catecholamine potentiation, **9:110–115**
 cholinolytic action, **9:121–122**
 clinical studies on, **9:135**
 effect on
 brain monoamines, **9:118–120**
 EEG and brain potentials, **9:124–127**
 various biochemical systems, **9:122–124**
 formula of, **9:109**
 general formulas of, **9:136–137**
 5-hydroxytryptamine potentiation, **9:115–118**
 metabolism of, **9:100**
 neurophysiological and behavioral explorations on, **9:124–131**
 pharmacology, **9:95–143**
 toxicity, **9:98**

Immunoabsorbent, for choline acetyltransferase, **20:298–300**

Immunoglobulin G, in cerebrospinal fluid, **25:99–100**

- Inborn errors of metabolism, **8**:197–202
of glutathione, **19**:107–112
- Inborn metabolic disorders, exopeptidase and, **11**:85–86
- Indican, **3**:258, **3**:260–261, **3**:266, **3**:267, **3**:271
- Indicanuria, **3**:252, **3**:266–268, **3**:275
- Indigo, **3**:262
- Indirubin, **3**:262
- Indoklan, retrograde amnesia from, **10**:176
- Indole-3-acetic acid, in schizophrenia, **8**:203
- Indoleacetylcholine, **1**:185
- Indolealkylamine, test tissues for, **13**:35–38
- Indoleamines, in mental illness, **8**:197–220
- Indole metabolism, in depression, **12**:159
- Indole-*N*-methyltransferase (INMT)
occurrence of, **22**:86–87
regulation and inhibition of, **22**:87–89
role in DMT biosynthesis, **22**:85–86
- Indoles, **3**:258
abnormal metabolism of, **8**:199–200
abnormal tissue, **3**:253, **3**:285–286
excretion, in schizophrenia, **8**:203–206
metabolism in phenylketonuria, **3**:269–271
normal blood, **3**:263–265
normal urinary, **3**:260–263
as pyrroles, **16**:171, **16**:175–176
role in mental illness, **3**:251–288
- Indolethylamines, structure of, **19**:175
- Indolylacetic acid, **3**:255, **3**:258, **3**:259–260, **3**:262, **3**:263, **3**:264, **3**:266, **3**:267, **3**:269, **3**:276, **3**:281–283, **3**:286
- Indolylacetylglucuronide, **3**:262, **3**:265
- Indolylacrylic acid, **3**:262
- Indolylformic acid, **3**:262, **3**:277
- Indolylformylglucuronide, **3**:277
- Indolylglycolic acid, **3**:262
- Indolylactic acid, **3**:258, **3**:260, **3**:262, **3**:263, **3**:269, **3**:277
- Indolylpropionic acid, **3**:260
- Indolylpyruvic acid, **3**:258, **3**:262
- Indoxyl, **3**:258, **3**:261
- Inferior colliculus, **21**:62
- Inferior olive, neurons of, **13**:8
- Information
acquired, biochemical transfer of, **17**:61–83
definition and properties of, **13**:348–354
transmission of, **13**:352–353
- Information processing
definition of, **13**:354–356
explicit system models, **13**:369–371
molecular mechanisms in, *see* Molecular mechanisms in information processing
system models for representing weak evoked responses, **13**:356–361
system science for study of, **13**:343–374
basic concepts of, **13**:343–356
systems concepts for, **13**:343–347
- Information storage, in brain, theoretical model of, **16**:222–228
- Inhibition, **1**:52f, **3**:114–116, **3**:119, **3**:122, **3**:123, **3**:165–166, **3**:176–177, **3**:192, **3**:196, **3**:224–225, **3**:229–230
chemical, **1**:186–189
cortical, **2**:339–340, **2**:343, **2**:344
in retina, **1**:279–280
- Inhibitory synapses, with glycine or GABA as transmitter, **15**:170
- Inhibitory synaptic transmission
by γ -aminobutyric acid, **15**:167–187
chemistry of, **15**:181–183
- Inositol monophosphate, **3**:304
- Inositol phosphate, **3**:304
- Institute of Psychiatry (USSR), schizophrenia studies at, **11**:216–222
- Insulin
effect on brain amino acid, **6**:16, **6**:18
effect on food intake, **5**:334
effect of, on alcohol intake, **2**:66
effects on alcohol metabolism, **19**:162
in schizophrenia therapy, effects of HNA, **11**:238–239, **11**:244–245, **11**:247
tolerance tests, in schizophrenia, **11**:262–263
- Insulin coma, 5-HTP carboxylase, **2**:182
- Insulin hypoglycemia, **1**:253–255, **1**:283
- Insulin receptors, autoradiography of, **22**:159–161
- Integrated ion-current studies, on microamines, **19**:185–186
- Integration, sensorimotor, **3**:223–225, **3**:241
- Intensity, in vision analyses, **10**:284–286
- Interactions, noradrenergic-dopaminergic, **23**:353–360
- Intermale aggression in olfactory bulbectomy syndrome, **22**:270–271
- Intermediary metabolism
in brain, *in vivo*, **22**:47–110
drug effects on, **11**:108–110
- Intestine, appetite control by, **5**:318–321

- Intracellular cleft, **3:18, 3:29, 3:49–50**
- Intrinsic brain stem nuclei, AChE and NAD-d activity in, **10:265**
- Invertebrate muscle, tetrodotoxin and saxitoxin effects on, **15:131–133**
- Invertebrate nervous systems, octopamine and other amines, in, **19:173–224**
- Invertebrate neurons, ion channels in, **23:10–18**
- Ion channels in nerve cell membranes chemically induced methods
extracellular patch clamp, **23:8–10**
fluctuation analysis, **23:2–6**
voltage jump relaxation, **23:6–8**
results
invertebrate neurons, **23:10–18**
vertebrate autonomic ganglion neurons, **23:28–31**
vertebrate central neurons, **23:18–28**
- Ion-exchange chromatography, of sodium channel proteins, **23:84–86**
- Ion fluxes
in the central nervous system, **5:183–242**
permeability coefficient and, **5:190–191**
theoretical aspects in study of, **5:187–198**
- Ionic channels, neurotransmitter regulation of, **22:211–214**
- Ion conductance, action of glucocorticoids and, **23:187–188**
- Ionic conductance mechanism, **21:228–229**
- Ionic conduction, glucocorticoids and, **23:187–188**
- Ionic exchanges
of brain capillaries, **3:45–46**
effect on pyridoxine, **3:342–343**
of glia, **3:33–35, 3:61**
on intracellular cleft, **3:49–52**
of neurons, **3:165**
- Ion metabolism, of brain, **18:141–211**
- Iontophoresis
micro-, quantitative aspects of, **7:44–48**
use to study cortical neurons, **7:41–98**
- Iontophoretic studies
of cholinesterase, **10:66–68**
of CNS neurons, **10:1–30**
drug administration in, **10:9–15**
microelectrophoresis in, **10:4–7**
neuronal responses to suspected transmitters, **10:15–27**
technical considerations, **10:3–9**
- Ion translocation
by membrane-bound acetylcholine receptor, **24:301–329**
channel activation, **24:304–305**
desensitization and binding equilibria, **24:305–312**
- Ion transport, selectivity theories, **21:324–329**
- Iproniazid, **1:315–316**
action of reserpine, **2:245**
CAR, **2:261**
CEPR, **2:145–146**
depression by 5-HTP of cortical potentials, **2:184**
effect on anesthesia, **7:216–217**
effect on cardiovascular system, **7:217–218**
effect of chronic iproniazid on serotonin in rats, dogs, rabbits, **2:194–195**
effect on food intake, **5:335**
excitation in animals given reserpine pretreated with iproniazid, **2:208, 2:211**
metabolites of, **7:207**
as monoamine oxidase inhibitor, **7:191, 7:194, 7:215**
monoamine oxidase inhibitor action of, **2:198**
structure of, **7:195**
- Irritability, in olfactory bulbectomy syndrome, **22:267–268**
- Iso-amylamine, **1:355f**
- Isocarboxazid
metabolism of, **7:207–208**
structure of, **7:195**
- Isocitrate dehydrogenase, as CO₂ fixation enzyme in nervous tissue, **14:132–133**
- Isoguvacine, structural formula of, **22:25**
- Isomerization reactions glutathione in, **19:100–101**
- Isoniazid, **3:320, 3:324–325, 3:331, 3:342–343**
and neuropathy, **3:339–340**
psychotropic effects of, **8:213–214**
- Isoprenaline, β -receptor binding of, **17:175**
- Isoproterenol
effect on EEG, **8:284**
effect of topical application on systemic BP, **2:140**
- Isoquinolines, as ganglion-blocking agents, **17:161**

Isospirilene, structure of, **8:254**
 Isoxazolidines, as ganglion-blocking agents,
17:160

J

JB-156 (Catron), fast acting cerebral MO
 inhibitors, **2:198**
 "J.B.516", **1:316**
 "Jelly roll" theory of myelogenesis, **3:52**
 Johnston's organ, **3:353–355**

K

"Kabi 888", **1:314, 1:339**
 Kainate, structural formula, **21:190**
 Kainic acid
 as neurobiological tool, **22:182–201**
 lesions from, **22:189–193**
 structural formula of, **22:184**
 in studies of Huntington's disease,
 22:194–200
 thalamic injections of, myocardial
 necrosis and, **22:198–200**
 Kamin effect, odor dependence of,
22:265–266
 KAO-264, as antiacetylcholine drug, **16:115**
 Kava, psychoactive components of, **16:158**
 K channel, *see* Potassium channel
 Kernicterus, bile pigments of, **16:149**
 Ketobemidone, CAR, **2:253**
 α -Ketoglutarate, **3:323**
 Kidney, **3:342**
 γ -glutamyl peptide uptake by, **19:106**
 metabolism of amines by, **3:263, 3:286**
 Kindly of seizures, **24:104–105**
 Kinesthetic figural after-effects, in
 assessment of drug effects, **2:355**
 Kinins, **11:76–77**
 Klüver-Bucy syndrome
 anatomical basis, **1:13**
 components of, **1:27–30**
 in human, **1:27**
 Klüver syndrome, **5:309**
 Koenig hypothesis, of neuroprotease
 binding, **17:206–209**
 Korsakoff syndrome, memory in, **19:28–29**
 Kryptopyrrole
 analytical techniques for, **16:158–159**
 anticonvulsant action of, **16:167**
 behavioral pharmacology of, **16:168–170**
 discriminated avoidance studies, **16:170**

 food reinforcement studies, **16:169**
 biochemistry of, **16:158–165**
 in blood, **16:159–160**
 chromatography of, **16:151–153**
 anomalies in, **16:153–156**
 excreted, biological sources of,
 16:163–165
 eye effects of, **16:166–167**
 lactams of propentdyopents compared to,
 16:156–157
 molecular neurobiology of, **16:145–182**
 neuroelectrical effects of, **16:167–168**
 oxidation products of, **16:153**
 biological activity, **16:157–158**
 pharmacology of, **16:165–168**
 in porphyria, **16:160–162**
 in psychiatric disorders, **16:178**
 pyrrolooxxygenases and, **16:162–163,**
 16:178
 structure-activity studies on, **16:147–151**
 toxicity of, **16:165–166**
 Kuru, **1:31–32**
 Kynurenic acid, **3:267**
 Kynurenine, **3:254, 3:267**
 Kynurenine metabolism, psychotic behavior
 and, **8:212–213**
 Kyotorphin
 nociception and, **25:212**
 peptide sequence of, **25:187**

L

Labyrinth, input of, into vestibular nuclei,
15:28–40
 Lactate dehydrogenases, in CSF, clinical
 significance, **25:128**
 Lactate/pyruvate ratio, in schizophrenia,
11:217–221, 11:264–265, 11:281–283
 Lactic acid, **3:176**
 Lactoflavin phosphate, use in appetite
 study, **5:319–320**
 Lambda wave, eye movement and, **7:100,**
7:125–130, 7:144–148
 Language
 brain structure and, **16:251–252**
 areas for, **16:254**
 size factors, **16:254–257**
 importance of, **16:290–291**
 in nonhuman primates, **16:284–287**
 Latency, **3:111, 3:117–119, 3:122, 3:123,**
3:125, 3:129, 3:365
 postsynaptic, **3:79**

- presynaptic, **3:79**
- Lateral geniculate body, **5:138–145**
 - anatomy of, **5:138–139**
 - binocular interaction in, **5:144–145**
 - electrical activity of, **5:139–142**
 - neurons, excitability of, **5:142–143**
 - spikes from, **3:79, 3:83**
- Lateral geniculate nucleus, **6:194–196**
 - afferent synapses of, **6:191–255**
 - dendrites of, **6:233–236**
 - neurons
 - pharmacology of, **6:242–248**
 - refractory, **6:236–241**
 - pharmacology of, **6:242–248**
 - repetitive firing in, **6:212–223**
 - responses, waveforms of, **6:196–209**
 - sensory neurons of, **6:191–255**
 - spontaneous activity of, **6:209–212**
- Lateralization, of hemispheric function, **16:277–281**
- Lateral lemniscus, **21:62**
- Lateral neuropil, **3:367**
- Lateral suprasylvian gyrus, nonprimary responders of, **10:125–129**
- Lateral tegmentum
 - noradrenergic system
 - behavioral and neuroendocrinological role, **23:337–344**
 - neuroanatomy, **23:336–337**
- Laudexium, as neuromuscular blocking agent, **17:156**
- “Leao’s spreading depression”, retrograde amnesia from, **10:180**
- Learned behavior, ACTH 4-10 and, **20:211–217**
- Learning
 - associative, **16:271–272**
 - biochemistry of, **17:62–80**
 - cerebral RNA and, **16:210–217**
 - in cetacea, **21:98–103**
 - cholinergic mechanism and, **14:207–217**
 - conditioned, **3:217–218, 3:230, 3:236–240**
 - definition of, **13:226–227**
 - drug effects on, **13:236–239**
 - evolution of, **16:242–251**
 - marihuana effects on, **18:329–356**
 - neocorticalization and, **16:264–272**
 - classification, **16:266–269**
 - discrimination performance, **16:265–266**
 - lateralization, **16:277–281**
 - opiate effects on, **25:311–314**
 - peptides in, **17:44–50**
- Lecithin, **3:299–305**
- Lectin affinity chromatography, of sodium channel proteins, **23:86–88**
- Leminiscus, medial, **3:193**
- Lemniscal system
 - of dorsal column, **8:44–47**
 - sensory discrimination in, **8:44–52**
 - of spine, **8:47–52**
- Lenticular nucleus, AChE and NAO-d activity in, **10:254–255**
- Lesion-induced changes in connectivity, anticipating functional consequences
 - nonspecific contributions of changes, **23:207–208**
 - specific contributions of changes, **23:208–212**
- Lesion-induced circuits, analysis of processing through, **23:220–226**
- Lesions, in brain, *see* Brain lesions
- Leucine, in nicotinic acid deficiency, **8:213**
- Leucine aminopeptidase (LAP)
 - classification of, **11:59**
 - molecular analysis of, **17:197**
 - in nervous system, **11:61–63**
 - properties of, **11:62**
- Leucine aminotransferase
 - activity of, **17:88, 17:100**
 - factors affecting, **17:111**
- Leucotomy, use in depression therapy, **5:405**
- Leu-enkephalin, peptide sequence of, **25:187**
- Leukergy, in allergic reactions, **11:322, 11:323**
- Leukotomy, effect on personality, **2:343**
- Ligands, for neurotransmitter receptors, **22:120**
- Light
 - effects on pineal activity, **11:187–191**
 - menstrual cycle and, **11:148–149**
 - “Light-compass reaction”, **3:363**
- Light stimulation, effect on brain RNA and proteins, **13:274**
- Limbic lobe
 - commissures of, **8:11–13**
 - cortex of, **8:17–19**
 - components of, **8:20–23**
 - descriptive anatomy of, **8:19–28**
 - fasciculi of, **8:23–25**
 - fiber tracts of, **8:29**
 - fornix of, **8:13**

- insula of, **8:13**
 - morphologic concept of, **8:1–34**
 - oatogenetic development of, **8:14–19**
 - phylogenetic development of, **8:9–14**
 - projection tracts of, **8:25–28**
 - rhinencephalon and, **8:3–4**
 - terminology of, **8:3–9**
- Limbic system, anatomical relationships of, **19:27–30**
- Limb motoneurons, in vestibular pathways, **15:52**
- Limulus ommatidia* eye, border contrast effect in, **5:168–171**
- Lioresal, presynaptic inhibition and, **21:144**
- Lipid metabolism
 - drug effects on, **11:115**
 - in porphyria, **16:325–326**
- Lipids
 - breakdown in brain, **3:303–308**
 - effects on transmitters, **13:168–170**
 - synthesis in brain, **3:294–303**
- Lipofuscin granules, changes in axotomized neurons, **14:91**
- Lipoproteins role of biosynthesis in myelinogenesis, **3:58**
- Lipotropin
 - ACTH 4-10, **20:211–230**
 - amino acid sequence of, **20:210**
 - central nervous system and, **20:209–250**
 - β -lipotropin, **20:61–91**, **20:232–239**
 - β -MSH, **20:230–232**
 - β -Lipotropin 47-53, *see* ACTH 4-10
 - β -Lipotropin 61-91
 - avoidance behavior from, **20:235–236**
 - biological significance of, **20:238–239**
 - cyclic nucleotide role in activity of, **20:237–238**
 - effects on central nervous system, **20:232–239**
 - electrophysiology of, **20:236–237**
 - excess grooming activity from, **20:234–235**
 - morphinelike activity of, **20:233–234**
- Lisuride, as α_2 -adrenergic antagonist, **24:386**
- Lithium
 - in affective disorder therapy, **18:375–376**
 - dosage requirements
 - individual differences, **19:272–274**
 - intracellular studies, **19:274–278**
 - methodology, **19:271–272**
 - effect on manic-depressive illness, **7:181**
 - effects on affective disorders and biogenic amines, **12:154–156**
 - in periodic psychoses, **11:158–160**
 - use in psychiatry, **19:271–278**
- Liver
 - alcohol metabolism in, **19:128–130**
 - acetaldehyde from, **19:130**
 - drug-metabolizing enzymes of, **11:104–106**
- Lobotomy, **1:12–13**
- Locomotion, insect, control by local brain stimulation, **3:365–366**
- Locomotor activity, in olfactory bulbectomy syndrome, **22:273–274**
- Locus ceruleus
 - noradrenergic system
 - behavioral role, **23:346–353**
 - neuroanatomy, **23:344–345**
 - REM control and, **23:412–413**
- Locus coeruleus, dorsal epinephrine system in, **25:410–414**
- Locust, **3:363**
- Longitudinal fiber tracts, of limber lobe, **8:8–9**
- Long-term memory, blockage by cerebral protein synthesis inhibitors, **12:177–205**
- LSD
 - binding to PG-RNA complex, **13:203–205**, **13:207**
 - neurobiology of, **16:149**
 - in studies of kryptopyrrole pharmacology, **16:159**
- LSD-25 (D-lysergic acid diethylamide)
 - action with
 - chlorpromazine, **2:237**
 - morphine, **2:253**
 - reserpine, **2:244–245**
 - CAR, **2:262–263**
 - compared to phencyclidine, **6:304ff**
 - effect on brain cell culture, **5:28**, **5:39–40**
 - effect on food intake, **5:335**
 - effect of, on alcohol intake, **2:69**
 - effects on body temperature, **6:338–339**
 - effects on CNS, **11:42–43**
 - effects on photic driving responses, **6:327**
 - effect on vision, **10:293–294**
 - potentiates CEPR, **2:149**
 - psychotomimetic effect of, not strictly correlated to its antiserotonin activity, **2:213–215**

- Lysergic acid
 effect on cerebral protein metabolism,
 7:12, 7:15
 effect on cortical neurons, 7:68
 use in study of stress, 5:259
- Lysergic acid diethylamide (LSD), 3:253,
 3:285
 as central serotonin antagonist,
 12:220–221
 characteristics of, 12:207–209
 EEG, 8:289–291, 8:308
 effect on body temperature, 12:35–36
 effect on, cerebral protein metabolism,
 8:12, 8:15
 formula of, 12:208
 hippocampus, 8:93, 8:121–125, 8:129,
 8:131
see also LSD; LSD-25
- D-Lysergic acid diethylamide (LSD), effects
 on cerebral glucose utilization, 22:320
- Lysergic acid diethylamine (LSD), 1:35–36,
 1:39, 1:200, 1:305, 1:314, 1:339
- Lysolecithin, 3:305
 action on brain, 3:308–313
- Lysophosphatides, 3:308
- Lysosomal lability test, for neuroproteases,
 17:228–230
- Lysosomes
 in axotomized neurons, enlargement,
 14:93–94
 enzyme markers for, 20:273
 neuroproteases in, 17:200–201
 proliferation in, 14:91–92
 significance of, 14:94–95
- Lysosomal enzymes, in CSF, clinical
 significance, 25:128
- Lysyl peptides, in nervous system, 17:50
- M**
- 3M2B (barbiturate), structure and activity,
 24:16
- Macroamylasemia, in porphyria,
 16:326–327
- Macromolecular factors, in cyclic AMP
 formation, 20:125–126
- Magnesium ion, 3:304, 3:306
- Magnesium transport, ethanol effects on,
 19:141–142
- Main olfactory bulbs (MOB), anatomy of,
 22:256–260
- Malabsorption syndrome, 3:272, 3:276
- Malate dehydrogenase, in brain,
 10:234–235
- Malic dehydrogenase, in brain cell culture,
 5:41
- Malic enzyme, as CO₂ fixation enzyme in
 nervous tissue, 14:132
- Malvaria hypothesis, in pyrrole metabolism,
 16:150–151
- Mammals, CNS regeneration in, 6:281–293
- Mammillary nucleus, AChE and NAD-d
 activity of, 10:256
- Man
 cortical functions in, 16:233–299
 evolution of ancestors of, 16:234
- Mandelyltropine, structure of, 16:72
- Manganese ion, 3:306
- Manganese poisoning, extrapyramidal
 symptoms, 10:351–352
- Mania, endocrine role in, 5:262–263
- Manic-depression, REM sleep in,
 17:332–333
- Mantid, 3:363
- MAO inhibitors, effect on aggression,
 18:244–246
- Maple syrup disease, 7:24, 8:201
- Marihuana
 learning, memory
 and, 18:329–356
 animal studies, 18:330–345
 human studies, 18:345–353
- Mass spectrometry, of microamines, 19:179,
 19:182–187
- Mauthner cell, RNA in, 16:189, 16:190,
 16:192
- “Mauve factor”
 identification of, 16:152
 in psychiatric disorders, 16:148, 16:151
- Meanings, learned, persistence of,
 18:291–294
- Mecamylamine, prevents effect of arecoline
 and nicotine on CEPR, 2:148
- Mechanoreceptors, fluctuation analysis of,
 20:203–205
- Medial forebrain bundle, amine levels and
 lesions of, 13:69–71
- Medial nucleus, 21:61
- Medial pontine reticular formation, REM
 control and, 23:412
- Medial vestibulospinal tract (MVST)
 inputs to neurons of origin, 15:59–62
 origin and course of, 15:58–59
 spinal action of, 15:62–66

- Medulla, motoneuron control and, **24:245**
- Medulla oblongata, AChE and NAD-d activity in, **10:245–247**
- Medullary reticular neurons, control studies on, **24:250–251**
- Megaphen, use in psychotherapy, **5:390**
- Megimide, and action of CPZ, **2:237**
- Melanins, in basal ganglia disease, **10:353–354**
- Melanocyte, stimulating hormone, behavior and, **17:44**
- α -Melanocyte-stimulating hormone nociception and, **25:227**
peptide sequence of, **25:187**
- Melanocyte-stimulating hormone inhibitory factor
nociception and, **25:226–227**
peptide sequence of, **25:187**
- Melatonin
biosynthesis and metabolism of, **11:183–187**
biorhythm of, **11:191–193**
pathways of, **11:186**
effects on reproductive function, **11:175–176**
- Membrane
cell, **3:342**
neuronal, as electrically inexcitable, **3:83, 3:147, 3:162–163**
- Membrane-active drugs, stereochemical relations to antibiotics, **13:215–217**
- Membrane channel
electric-field-dependent formation theory, **21:317–324**
models, **21:312–314**
monovalent cation selective, **21:311–332**
- Membrane channel-forming peptides,
polymorphism of, **21:329–332**
- Membrane current, **3:83–84, 3:153–155**
- Membrane lipids, ethanol effects on, **19:142–143**
- Membrane potential, **3:80, 3:152–156, 3:161**
fluctuations of, role in epileptogenesis, **3:165**
glial, **3:164–165**
- Membranes
action of glucocorticoids and, **23:185–186**
asymmetry and structure, **23:142–143**
ethanol effects on, **19:142–143**
neuronal, electrical changes in, **15:173–178**
see also Nerve cell membranes
- Membrane stabilization, **9:145–224**
anesthesia and, **9:166–168, 9:212–214**
mechanism, **9:204–208**
biphasic action in, **9:148–160**
by alcohols, **9:149–151, 9:166**
by detergents, **9:159–610**
adsorption in, **9:160–161**
by local anesthetics, **9:148–151**
adsorption in, **9:160–161**
by phenothiazines, **9:154–158**
adsorption in, **9:161–164**
electrochemical aspects, **9:180–182**
by reserpine, **9:154–158**
adsorption in, **9:164**
by sedatives, **9:149–151**
effects on passive permeability, **9:190–199**
ionic strength and, **9:178**
local anesthesia by phenothiazine in, **9:146–148**
mechanical strength and, **9:199–200**
mechanisms, **9:199–211**
membrane expansion and, **9:208–209**
molecular configurations and, **9:209–211**
pH and, **9:168–178**
in erythrocytes, **9:174–177**
extracellular variation, **9:169–172**
intracellular variations, **9:172–174**
subcellular organelles and, **9:177–178**
physicochemical factors in, **9:168–172**
prolysis and, **9:198–199**
reversibility of, **9:200–201**
stabilizer adsorption in, **9:160–166**
by steroids, **9:158–159, 9:166–168**
by vitamin A, **9:151–154**
membranal area and, **9:164–166**
- Memory
anatomical substrates of, **19:27–30**
in animals
amnesia studies on, **19:14–15**
normal, **19:15–20**
brain information storage and, **16:222–228**
brain protein metabolism and, **15:189**
brain studies and, **11:340–342**
charts of reproductibility dynamics in studies on, **11:340–342**
cholinergic mechanism and, **14:207–217**
cycloheximide effects on, **12:202–203**
definition of, **13:227**
drug effects on, **8:139–196, 13:236–239**
methodological problems in study of, **8:151–157**

- drug facilitation of, **8:179–188**
- drug impairment of, **8:160–169**
- EEG studies and, **11:339**
- evolution of, **16:251–252**, **16:273–277**
 - electrical stimulation studies, **16:276–277**
 - lesion studies, **16:273–276**
- in humans, **19:1–15**
 - lesion effects on, **19:4–14**
- information transfer and, **17:61–83**
- long-term type, *see* Long-term memory
- marihuana effects on, **18:329–356**
- in monkeys, **19:19**, **19:21–26**, **19:44–45**
- opiate effects on, **25:311–314**
- peptides in, **17:44–50**
- reinforcement acquisition effect on, **18:300–301**
- short-term
 - activity normalization and, **18:282–289**
 - protein synthesis inhibitors in, **12:198–201**
 - storage, mechanisms of, **8:189–191**
- Menstrual clock, **11:141–142**
- Menstrual cycle, light and, **11:148–149**
- Mental activity
 - brain studies on, **11:335–344**
 - contingent negative variation and, **11:334–335**
 - physiological foundations of, **11:329–352**
 - steady potential, neuron population activity and oxygen in brain in mental tasks, **11:339–342**
 - structural-functional basis of, **11:344–346**
- Mental depression, symptomatic relief with Imipramine, **2:215–219**
- Mental disease
 - blood-CNS transfer in, **7:179–182**
 - metabolic changes in, **7:18**
- Mental disorder, endocrine role in, **5:261–265**
- Mental functions
 - of dopamine neurons, **13:107–109**, **13:119**
 - of serotonin neurons, **13:115–118**
- Mental illness
 - biogenic amines in, **8:197–220**
 - brain opiates and, **25:322–324**
- Mepazine
 - central depressive activity, **2:242**
 - effect on CAR (pole-jump), **2:239**
- Meperidine, stress-induced behavior in rats, **2:253**
- Meperidine-like 4-phenylpiperidines, **8:221–263**
- Mephesisin, CAR, **2:250**
- Meprobamate, effect on EEG, **8:291**, **8:292**, **8:308**
- Meprobamate (Miltown, Equanil) (M)
 - action in animals, **2:249–250**
 - in an application of canonical variate analysis, **2:371–374**
 - effects on
 - apparent movement, **2:356**
 - flicker perimetry, **2:358**
 - nonsense syllable learning, **2:351–352**
 - reaction times, **2:354**
 - rotating spiral after-image, **2:362**
 - vigilance, **2:365**
 - visual after-image, **2:360–361**
 - visual-field effects, **2:357**
 - voluntary alcohol intake, **2:68–69**
 - no effect on CEPR, **2:145**
- Meprobromate, retrograde-amnesic blocking action of, **10:191–192**
- Meratran, alteration behavior in simple T-maze, **2:377–379**
- Mescaline, **1:339**, **1:340**
 - analogs, as central serotonin antagonists, **12:215–219**
 - CAR, **2:263**
 - effect on brain protein metabolism, **7:15**
 - effect on CEPR of pretreatment with mescaline, **2:149–150**
 - effect on EEG, **8:291**
 - effects on CNS, **11:42–43**
 - effects on photic driving responses, **6:330**
 - formula of, **12:208**
 - structural formula of, **22:84**
- Mesencephalon
 - AChe and NAD-d activity in, **10:251–254**
 - aggression sites in, **18:227–228**
 - dopamine system, dopamine-dependent functions of nucleus accumbens septi, **23:314–336**
 - motoneuron control and, **24:241–243**
 - neuroanatomy, **23:313–314**
- Mesodiencephalic junction, motoneuron control and, **24:241–243**
- Metabolic actions, glucocorticoids and, **23:188–189**
- Metabolism
 - brain(sc) in epilepsy, **3:167–169**, **3:181**
 - drug effects on, **11:108–115**

- inborn errors of, *see* Inborn errors of metabolism
- indoles, **3**:251–291
- lipids in brain, **3**:293–317
- sleep and, **23**:399–405
- water-electrolyte of brain, **3**:33–34
- Metacircuits, in nervous system, **17**:53–55
- Metals, in dyskinesias biochemistry, **10**:347–352
- Metamphetamine
 - action with
 - chlorpromazine, **2**:237
 - reserpine, **2**:245
 - effects on EEG, **15**:294, **15**:299–300, **15**:302–305
- Metanephrine, **21**:264–265
- Metaraminol, fine structural localization in nervous tissue, **13**:27–66
- Met-enkephalin, peptide sequence of, **25**:187
- Meter, “Berkeley Universal”, **3**:75
- Methacholine
 - CAR, **2**:257
 - classification of mental diseases by, **5**:402
 - effect on CEPR, **2**:147
- Methadone, stress-induced behavior in rats, **2**:253
- Methionine
 - assay of, **18**:59–61
 - in brain protein metabolism, **7**:10–12
 - effect on renal metabolism of glutathione, **19**:107
 - effects on *S*-adenosylmethionine levels, **18**:51–55
 - effect on schizophrenia, **8**:210
 - role in schizophrenia, **18**:61–63
 - use in study of protein synthesis, **5**:363–364
- Methionine sulfoximine, alcohol
 - consumption in rats, **2**:70
- Methohexitone, structure and activity, **24**:16
- Methoxypyridoxine, **3**:339
- Methoxytryptamine, **21**:264
- 2-Methyl-3-piperidinopyrazin, effect on EEG, **8**:289
- N*-Methyl-3-piperidylbenzilate, effect on brain cell culture, **5**:39
- Methyl acceptors, assays of, **18**:57–61
- Methylamine, **1**:355–362
- α -Methylamines, as MAO inhibitors, **7**:190
- N*-Methyl-D-aspartate, structural formula, **21**:190
- O*-Methylated amines, in experimental dyskinesias, **10**:338–339
- Methyl atropine, CAR, **2**:259
- Methylcholine derivatives, as antiacetylcholine drugs, **16**:88
- Methyl-1,3-dioxolans, derivatives of, as antiacetylcholine drugs, **16**:73–74, **16**:85
- Methyl donor, *S*-adenosylmethionine as, **18**:41–67
- α -Methyl dopa, effect on Parkinsonian symptoms, **10**:343
- Methylene blue, phenothiazines compared to, **7**:264–266
- Methylethylmaleimide
 - as kryptopyrrole oxidation product, **16**:153
 - structure of, **16**:154
- Methyl norepinephrine, fine structural localization in nervous tissue, **13**:27–66
- Methylparafynol, CAR, **2**:252
- Methylperidide, structure of, **8**:253
- Methylperidol
 - neuroleptic potency of, **8**:225
 - structure of, **8**:253
- Methylphenidate (Ritalin)
 - action of chlorpromazine, **2**:237
 - antagonizes CAR inhibition, **2**:237
 - effect of, on ethanol intake, **2**:68–69
- Methylpiperidin-3-01, as antiacetylcholine drug, **16**:99
- ω -Methylpyridoxine, **3**:337
- Methyl-scopolamine, CAR, **2**:259
- 5-Methylterahydrofolate, as methyl donor, **22**:89–91
- Methyl tetrahydrofolate, in transmethylation, **18**:55–57
- Methylxanthines, as phosphodiesterase inhibitors, **20**:130
- Metoclopramide, self-stimulation behavior and, **21**:357, **21**:360, **21**:366
- Metrazol
 - action of CPZ, **2**:237
 - effect on hippocampus, **8**:114
 - effect on optic nerve, **5**:136
 - use in psychotherapy, **5**:389, **5**:404
- Michaelis content, **3**:307
- Microamines
 - analytical chemistry of, **19**:178–189
 - biosynthesis of, **19**:189–191
 - catabolism of, **19**:191–194
 - dansyl derivates of, **19**:188

- fluorimetric assay of, **19:179**,
19:188–189
 gas chromatography of, **19:179**,
19:187–188
 in invertebrate nervous system,
19:173–224
 mass spectrometry of, **19:179**, **19:182–187**
 metabolism of, **19:189–194**
 pharmacological activity of, **19:174**
 phylogenetic distribution of, **19:177**
 radiochemical-enzymic assays of,
19:178–182
 structure of, **19:175**
 thin-layer chromatography of,
19:182–187
- Microelectrode**, **3:51**, **3:67–121 pass.**,
3:141–172 pass., **3:327**
 analysis of pyramidal activity, **3:225**
 analysis of recruiting response, **3:220**
 determination of position of tip of, **3:74**
 glass, **3:73–74**
 Hubel's tungsten, **3:73**
 metal, **3:73–74**
 position of tip of, **3:48–49**, **3:61**, **3:83–84**,
3:141
 size of tip of, **3:78–79**, **3:98**, **3:141**, **3:355**
- Microelectrophoresis**
 of central neuron study, **10:4–7**
 drug administration in, **10:9–15**
 axon terminals vs. effector cell,
10:10–12
 neuronal vs. nonneuronal sites, **10:9**
 postsynaptic membrane, **10:12–15**
 interpretation of results, **10:7–9**
- Microglia**
 characteristics of, **3:28**
 localization, **21:277–278**
 ontogeny, **21:276**
 RNA synthesis in, **16:191**
see also Glial cell
- Microiontophoresis of opioids into spinal
 neurons**, **25:250–251**
- Micropipettes, for iontophoresis**, **7:43–44**
- Microsomal fractions, enzymes in**, **11:87**
- Microsomes**, **1:169**, **3:58**, **3:297**, **3:312**
 chemistry of, **1:172–175**
- Microtubules, protein autophosphorylation
 in**, **20:136–137**
- Midbrain tegmentum, amine metabolism
 and lesions of**, **13:71–72**
- Mind, nature of**, **1:41**
“Mirror” focus, **3:180**
- Mitochondria**, **3:32**, **3:295**, **3:300**, **3:309**,
3:312, **3:335**
 of astrocytes, **3:7**
 in axotomized neurons, **14:88–91**
 of brain cells, protein metabolism in,
15:197–198
 enzyme markers for, **20:273**
 enzymes in, **11:66**
 of microglia, **3:28**
MO in, **2:191**
 neuroproteases in, **17:200–202**
 of oligodendrocytes, **3:18–19**
 somatofugal transport of, **13:303–304**
- Mitochondria chemistry**, **1:172**
 fine structure, **1:168–170**
- Mitochondrial respiration, barbiturate
 effect on**, **24:34–35**
- Mitomycin**
 activated, formula of, **12:211**
 in central serotonin antagonism, **12:223**
 stereochemical relations to membrane-
 active drugs, **13:215–216**
- MJ 9022, effects on EEG**, **15:291**, **15:298**,
15:302
- MO**
 importance, **2:193–203**
 location, **2:191**
 physiological substrates of, **2:194**
 specificity, **2:194**
see also Monoamine oxidase
- Modafinil, structure of**, **7:195**
- Models, role in scientific procedure**, **3:182**
- Modulation, definition of**, **22:205–206**
- MO inhibitors**
 iproniazid as, **2:198**, **2:211–212**
 JB-516 (Catron), **2:198**
 pretreatment with, and electrical
 potentials in hippocampus, **2:191**
 SKF, **2:198–202**, **2:385**
see also Monoamine oxidase inhibitors
- Molecular mechanisms in information
 processing**, **13:223–253**
 evidence for, **13:231–242**
 bioassay methods, **13:239–242**
 chemical correlates, **13:232–236**
 critical factors, **13:235**
 location of chemical changes, **13:234**
 RNA and protein changes, **13:232–233**
 learning and memory, **13:226–227**
 molecular hypotheses of, **13:242–248**
 based on chemospecific pathways,
13:244–248

- nonspecific, **13:242–243**
- neural coding in, **13:227–231**
 - chemical code, **13:230–231**
 - electrical activity, **13:229–230**
 - structural code, **13:229–230**
- neural information processing, **13:224–226**
- Molindone
 - as antipsychotic agent, **16:149**
 - structure of, **16:150**
- Mollusks, octopamine function in, **19:207–210**
- Monkeys
 - group I projection in, **15:19–20**
 - memory in, **19:19, 19:44–45**
 - bilateral frontal lesion and, **19:26**
 - temporal-lobe lesion effect, on, **19:21–25**
 - visual deprivation in, effects on cerebral glucose utilization, **22:307–313**
- Monoamine decreasing drugs, *see* Benzoquinolizine derivatives
- Monoamine oxidase, **3:255, 3:281, 3:284, 3:311, 3:313**
 - activity tests for, **7:201–206**
 - ethanol effects on, **19:151**
 - evoked potential (EP) and, **25:426**
 - in microamine catabolism, in invertebrates, **19:192**
 - personality dimensions and, **25:406–409**
 - human studies on, **25:418–425**
 - substrate and inhibitor interaction with, **7:199–201**
 - see also* MO
- Monoamine oxidase inhibitors, **7:191–229**
 - in affective disorder therapy, **18:372–373**
 - anticonvulsant activity of, **7:220–221**
 - as anti-depressant, **5:404**
 - biochemical effects of, **7:208–215**
 - on blood lactic and pyruvic acids, **7:213–214**
 - on blood platelets, **7:212–213**
 - on brain amines, **7:208–212**
 - on heart amines, **7:212**
 - organ specificity in, **7:214**
 - on urinary constituents, **7:213**
 - chemical considerations of, **7:192–208**
 - distribution and metabolism of, **7:207–208**
 - effects on affective disorders, **12:149–152**
 - effects on behavior, **7:219**
 - effects on electrical activity of brain, **7:219**
 - effects on fertility and capillary permeability, **7:221–222**
 - effects on ganglionic transmission, **7:218–219**
 - function of, **7:199**
 - interaction with amphetamines, **12:353–354**
 - medical applications of, **7:222**
 - nomenclature of, **7:193–194**
 - pharmacological effects of, **7:215–222**
 - potency tests for, **7:201–206**
 - structure-activity relationships of, **7:192–199**
 - toxic effects of, **7:221**
 - see also* MO inhibitors
- Monoamines
 - actions on neurons, **11:19–25**
 - autoradiography of, constraints in use, **13:38–39**
 - binding to cellular organelles, **13:39–41**
 - to tissue components, **13:40–41**
 - biochemical evidence, **11:17–18**
 - brain, imipramine effect on, **9:118–120**
 - central neurons for, *see* Central monoamine neurons
 - cytochemical localization of, **13:28–29**
 - effect on body temperature, **12:11–16**
 - electron microscopy of, reactivity with stains, **13:29–34**
 - fine structural localization of in nervous tissue, **13:27–66**
 - central nerve terminals, **13:53–59**
 - nonterminal axons, **13:59–61**
 - peripheral sympathetic nerve terminals, **13:41–53**
 - histochemical evidence, **11:18–19**
 - model tissue experiments and “ideal localizing paradigm”, **13:28–39**
 - oxidation to insoluble pigments, **13:34**
 - pathways of, methods of mapping out, **13:94–96**
 - release of, **11:25**
 - as synaptic transmitters, **11:17–25**
 - in thalamus, **14:10–11**
 - effects on, **14:32–36, 14:39–40**
 - see also* Amines; Microamines
- Monopyrroles in clinical psychiatry, **16:176–178**
 - neurobiology of, **16:147**
 - structure effects, **16:147–151**

- Monosodium glutamate
 alcohol intake of rats, **2:58**
 effect on learning, **8:145**
- Monosynaptic reflexes, enhancement of,
 with thiosemicarbazide, **2:323**
- Monro-Kellie doctrine, **3:45**
- Mood, central serotonin neuron role in,
 13:120
- Moperone, self-stimulation behavior and,
 21:353, 21:360, 21:366
- Morphia, withdrawal syndrome, **1:34–35**
- Morphine
 ACTH 4-10 effects on activity of,
 20:229–230
 alteration of action of, **2:253–254**
 CAR, **2:252–253**
 compounds potentiating, **8:300**
 distribution and levels in nervous system,
 11:101–102
 effect on body temperature, **12:27–30**
 effect on CEPR, **2:151**
 effect on EEG, **8:298–299**
 effects on cerebral glucose utilization,
 22:321
 free choice by rats, **2:42**
 -like drugs, synthesis and testing of,
 8:221–263
 β -lipotropin 61-91 similarity to,
 20:233–234
 uptake and transport in nervous system,
 11:102–104
 withdrawal from, aggression from, **18:248**
- Motivation, generalization and, **18:309–310**
- Motoneurons
 control during sleep, **24:213–258**
 central control mechanisms,
 24:240–251
 effect of GABA on, **3:327–328**
 extracellular reflect studies on,
 24:240–245
 medulla, **24:245**
 mesencephalon, **24:241–243**
 pons, **24:243**
 hyperpolarization, synaptic mechanisms
 for, **24:232–240**
 intercellular studies, **24:246–251**
 medullary reticular, control studies on,
 24:250–251
 membrane potential during sleep and
 wakefulness, **24:218–225**
 in brainstem, **24:218–225**
 in spinal cord, **24:225–231**
 trigeminal, control studies on, **24:245–250**
- Motor activity, effect on brain RNA and
 proteins, **13:273–274**
- Motor functions
 of dopamine neurons, **13:119**
 evolution of, **16:241–242**
 neocorticalization and, **16:262–264**
- Motor-sensory area, **3:191–241 pass.**
 activation of, **3:224–225**
- Motor systems, effects of sleep on,
 23:393–394
- Mountcastle and Werner's sensory
 transmission experiment, **13:364–366**
- Mouse incisors, sensory receptors in, **25:67**
- Movement perception
 in insects, **3:358–364**
 theoretical mechanism for,
 3:360–362
- β -MSH effects on central nervous system,
 20:230–232
- Mucopolysaccharides, in oligodendrocytes,
 5:14, 5:19
- Multineuronal synapses, inhibition of
 spinal, with meprobamate, **2:249**
- Multiple sclerosis, **1:359–362**
 brain esterases in, **7:26, 7:333–335**
- Multiple unit evoked responses
 excitatory function studies, **23:168–172**
 glucocorticoid effects, **23:167–168**
 inhibitory function studies, **23:172–173**
- Multisynaptic pathways, reduced threshold
 of, after increased brain serotonin,
 2:184
- Muramidase, in CSF, clinical significance,
 25:128
- Muricidal behavior, in olfactory
 bulbectomy syndrome, **22:268–269**
- Muricide, aggression inducement and,
 18:231, 18:241–242, 18:249–250, 18:252
- Muscarine
 action on receptor, **12:229**
 as muscarinic agonist, **17:163–164**
 receptor site for, **13:192–195**
- Muscarinic acetylcholine receptors,
 14:262–268
 activation of, **22:227–228**
- Muscarinic agonists, **17:162–166**
 binding of, **25:156–161**
 structure of, **25:140**
- Muscarinic antagonists, **17:166–174**
 binding of, **25:147–155**
 structure of, **25:141**

- Muscarinic ligands, irreversible, structure of, **25:173**
- Muscarinic receptors
for acetylcholine, **17:146–147**, **17:162**
 β -adrenergic receptors compared to, **17:185**
binding of, **25:147–155**
 cooperative and site interactions, **25:152–155**
 kinetic and equilibrium measurements, **25:147–152**
in central nervous system, **25:139–183**
ligand binding in proposed scheme for, **25:176**
localization of, **25:167–171**
 ontogenesis, **25:169–171**
 post-and presynaptic types, **25:168–169**
 regional distribution, **25:167–168**
radioligand-binding studies on, **25:143–147**
receptor-receptor interactions, **25:161–166**
structure-function relationships of, **25:174–177**
- Muscarinic stimulation of brain, **2:258–260**
- Muscarone, as muscarinic agonist, **17:164**
- Muscimol, **21:137**
- Muscle
 acetylcholine-operated channels in, **24:322–323**
 tetrodotoxin and saxitoxin effects on, **15:108–122**
- Muscle innervation
 in frogs, **6:100–105**
 in lower chordates, **6:99–147**
 in mammals, **6:100–105**
- Mushroom bodies, **3:365**, **3:367–368**, **3:370**
- Myanesin, in optic nerve study, **5:136**
- Myasthenia gravis
 antiacetylcholine receptor antibodies and, **24:1–14**
 central nervous system involvement, **24:11–12**
 neurotoxin therapy of, **22:180–181**
 result of presynaptic biochemical defect, **2:90**
- Myelin basic protein (MBP), in CSF, **25:121–123**
- Mydriacyl, as antiacetylcholine drug, **16:75**
- Myelin
 of brain, phospholipid composition of, **20:5**
 destruction by lysolecithin, **3:309**
 disposal of, **3:58–59**
 enzyme markers for, **20:273**
 enzymes in, **11:66**
 neuroproteases in, **17:201–202**
- Myelinated fibre, axolemma and axoglial relationships in, **24:433–484**
- Myelination
 in axons, critical diameter of, **18:29–32**
 lipid metabolism in, **3:296f**
 role of biosynthesis of lipoproteins in, **3:58**
 role of glia, **3:52–59**, **3:61**
 specificity in, **24:437–440**
- Myelopathy, from fluoropyrimidines, **10:202–206**
- Myocardium, necrosis of, after thalamic kainic acid injections, **22:198–200**
- Myoclonic models of seizures, **24:104**
- Myoclonic seizures
 acetylcholine role, **24:125**
 γ -aminobutyric acid and, **24:134**
 catecholamines and, **24:112**
- Myotomes, muscle fibers of, **6:106–108**
- Mytilotoxin, *see* Tetrodotoxin
- Myxine*, muscle innervation in, **6:111–115**
- N**
- Na-86 1-Piperidinomethyltetralon
 Myasthenia gravis
 inhibits CAR, **2:258**
 synergistic with reserpine, **2:245**
- Na channel, *see* Sodium channel
- $\text{Na}^+ \text{-K}^+ \text{-ATPase}$, in brain, **18:161–163**
- Nalorphine
 effect on EEG, **8:298–299**
 reversal of morphine-induced inhibition of the CAR, **2:253**
- Naloxone, effect on opioid effects on spinal neurons, **25:261–262**
- Naphazoline (Privine), effect on pressor response, **2:140**
- Naphthazoline, as α -agonist, **17:183**
- β -Naphthylamine, in detection of aminopeptidases, **11:69**
- Narcolepsy, **1:34**
- Narcotic analgesics
 apomorphine and, **19:252–256**
 comparison to neuroleptic effects, **21:380–383**

- Narcotic drugs
 biochemical responses to, **11:99–128**
 biotransformations of, **11:104–108**
 by liver drug-metabolizing enzymes, **11:104–106**
 effects of chronic drug administration on, **11:106–108**
 distribution and transport in nervous system, **11:101–104**
 distribution and levels, **11:101–102**
 uptake and transport, **11:102–104**
 effects on
 amines, **11:115–118**
 calcium, **11:120–121**
 general metabolic systems, **11:108–115**
 hormones, **11:118–120**
 intermediary metabolism, **11:108–110**
 lipid metabolism, **11:115**
 nucleic acid metabolism, **11:112–115**
 Protein metabolism, **11:110–112**
 metabolic disposition of, **11:101–108**
 serum and brain factors, **11:121**
 Nauta-Gygax method, **3:202f**, **3:231–233**
 N-burst, in acetylcholine-operated channels, **24:319–321**
N-diethyltryptamine, **3:253**
N-dimethyltryptamine, **3:253**, **3:279**, **3:286**
 NE, *see* Norepinephrine
 Neocortex
 cat, nonprimary sensory projections, **10:111–165**
 evolution of, **16:243**
 immature catecholaminergic innervation in, **20:77–81**
 Neostigmine
 CAR, **2:257**
 effect on
 CEPR, **2:147**
 EEG, **8:299–300**
 hemicholinium, **2:78**, **2:80**
 hippocampus, **8:94**
 sensitization with, after topical application of acetylcholine, **2:139**
 Neostriatum, dopamine receptors in, **23:285–288**
 Norepinephrine
 as appetite inhibitor, **5:331**
 effect on brain cell culture, **5:40**
 in mental disease tests, **5:403**
 Nerve axon, fluctuation analysis of, **20:183–190**
 Nerve cell membranes
 chemically induced ion channels in, methods
 extracellular patch clamp, **23:8–10**
 fluctuation analysis, **23:2–6**
 voltage jump relaxation, **23:6–8**
 results
 invertebrate neurons, **23:10–18**
 vertebrate autonomic ganglion neurons, **23:28–31**
 vertebrate central neurons, **23:18–28**
 see also Membranes
 Nerve degeneration, **3:59**
 Nerve endings
 of brain, phospholipid composition of, **20:5**
 enzyme markers for, **20:273**
 enzymes in, **11:66**
 neuroproteases in, **17:201–202**
 Nerve growth factor (NGF), **6:80–82**, **21:286–287**
 in cyclic AMP formation, **20:125**
 guanethidine inhibition of transport of, **25:15**
 Nerve proteins
 exoplasmic flow of, **6:74–78**
 incorporation of, **6:73–74**
 metabolism of, **6:72–82**
 nerve growth factor and, **6:80–82**
 peripheral, **6:72–73**
 Nerves
 growth of, **6:261–264**
 orientation of, **6:261–264**
 peripheral, proteinases of, **6:65–66**
 tetrodotoxin and saxitoxin effects on, **15:108–122**
 tracers in, **17:245–253**
 Wallerian degeneration of, **6:78–80**
 Nerve terminal potential
 effect of inhibitory transmitter on, **21:222–224**
 excitatory, **21:219–222**
 Nerve terminals
 central type, *see* Central nerve terminals
 peripheral type, *see* Peripheral sympathetic nerve terminals
 Nerve tissue
 choline acetyltransferase in, **20:294–303**
 ionic composition of, **5:203**
 potassium in, **5:208–211**
 Nerve tumors, diagnosis by tissue culture, **5:46**

- Nervous system
 cyclic nucleotides in, **20**:105–168
 electrical fields of, **5**:69
 ethanol effects on, **19**:123–172
 exopeptidases of, **11**:59–97
 glutathione in, **19**:77–79
 in invertebrates, amines in, **19**:173–224
 narcotic drug effects on, **11**:99–128
 peptide code in, **17**:50–56
 protein metabolism in, *see* Protein metabolism of nervous system
 protein metabolism of, **6**:1–98
- Nervous system proteins, **15**:215–225
 developmental studies on, **15**:221
 distribution and localization of, **15**:219–220
 immunological assays of, **15**:217
 preparation of, **15**:217, **15**:218
 species distribution of, **15**:219
- Nervous tissue
 carbon dioxide fixation in, **14**:125–157
 CSF proteins specific for, **25**:119
 fine structural localization of biogenic amines in, **13**:27–66
- Nervous-tissue specific proteins, in cerebrospinal fluid, **25**:98
- Nervus terminalis, anatomy of, **22**:255–256
- Neural coding, peptides in, **17**:55–56
- Neural coding of information, **13**:227–231
- Neural information processing, **13**:224–226
 Gardiner's differential processing experiment, **13**:366–369
 Mountcastle and Werner's sensory transmission experiment, **13**:364–366
 Strak's experiment on, **13**:361–364
- Neural networks, spreading depression in, *see* Spreading depression
- Neural ontogeny, of cetaceans, **21**:52–53
- Neural proteinases, role in brain protein catabolism, **6**:64–65
- Neural tissue, aminotransferase activity of, **17**:109
- Neuroanatomy
 of cetaceans, **21**:52–70
 of lateral tegmental noradrenergic system, **23**:336–337
 of locus ceruleus noradrenergic system, **23**:344–345
 of mesencephalic dopamine system, **23**:313–314
- Neurobiochemistry, tissue fraction in, **20**:251–281
- Neurobiology, fluctuation analysis in, **20**:169–208
- Neurobiology of personality, **25**:391–436
 arousal and arousability, **25**:398
 biochemical studies, **25**:403–428
 dopaminergic system, **25**:414–416
 endorphin role, **25**:425–426
 evoked potential (EP) studies on, **25**:426–428
 monoamine oxidase and, **25**:406–409, **25**:418–425
 norepinephrine system, **25**:412–413
 serotinergetic system, **25**:416–418
- Neurochemical genetics, **25**:361–389
 of chimerae, **25**:384–385
 of heterogeneous polylineal populations, **25**:367–368
 of homogeneous populations, **25**:369–382
 bilineal strains, **25**:374–380
 quadrilineal strains, **25**:369–374
 unilineal strains, **25**:380–382
 of natural and experimental populations, **25**:364–367
 regulated heterogenicity and, **25**:382–385
 in heterozygous isogenic populations, **25**:382–384
- Neurochemistry of epilepsy, **24**:93–180
- Neuroendocrine function
 of noradrenaline neurons, **13**:114, **13**:120
 of serotonin neurons, **13**:118–119, **13**:120
- Neurofibrils, **1**:168
- Neurofibrils, neurofilaments, and neurotubules, changes in, following nerve injury, **14**:60–61
- Neuroglia
 contraction of, **3**:164–165
 electrical responses of, **3**:164–165
 membrane potentials of, **3**:88
 pathology in epileptic focus, **3**:169
 relation to neuronal activity, **3**:47–52
see also Glial cell
- Neurohumoral substances, difficulty in estimation of, **2**:157, **2**:159
- Neurohypothesis, **3**:44
- Neurokeratins, brain, **6**:22
- Neuroleptic-anticholinergic interaction
 differential antagonism, **21**:384–388
 literature review, **21**:379–380
- Neuroleptic drugs
 action, **21**:3–8
 basic structure of, **8**:252

- brain self-stimulation behavior and, **21:335–395**
- chemical analysis of, **19:292–293**
- classification, **21:373–377**
- clinical studies on, **19:293–302**
- control base-line, **21:359–362**
- dose-effect relationship, **21:358, 21:383**
- effect on dopamine neurons, **21:6**
- evaluation of, **8:224–228**
- future research on, **8:252–260**
- impairment of self-stimulation, **21:391–395**
- neurologic side effects, **21:8–12**
- plasma levels of, in psychiatry, **19:269–309**
- potency, **21:358–359, 21:373–375**
- spectral map analysis, **21:375–378**
- see also* Antipsychotic drugs
- Neuroleptic dyskinesia, experimental, **21:35–36**
- Neuroleptic receptors, autoradiography of, **22:142–150**
- Neuroleptics, amphetamine antagonism with, **12:348–351**
- Neurological sequelae, connectivity changes and, **23:233–249**
- Neuromuscular blocking agents, hemicholinium as, **2:78, 2:80, 2:84–85, 2:89**
- Neuromuscular junction, acetylcholine receptor in, **17:143–146**
- Neuromuscular junction Ach channel, channel properties, **21:318**
- Neuromuscular tissue, embryonic, bioelectric activity, **9:27–30**
- Neuronal-glia genetic regulation, **21:288–290**
- Neuronal membranes
 - barbiturate effects on, **24:32–33**
 - effect of GABA, β -alanine and taurine on, of cat spinal cord, **2:322–323**
- Neuronal perikarya, RNA in, **16:189**
- Neuronal specificity
 - Sperry's hypothesis, **2:26**
 - advantages, **2:30**
 - obstacles, **2:26–29**
- Neuronography, evoked potential
 - method, **3:196–202, 3:216–218, 3:230, 3:233–234**
- Neurons
 - axotomized, changes in size and shape of, **14:52–55**
 - of brain, phospholipid composition of, **20:4**
 - central monoamine type, *see* Central monoamine neurons
 - cerebral, energy metabolism in, **18:155**
 - of cerebral cortex, forelimb muscle afferents and, **15:4–6**
 - chromatolysis of, **14:107–112**
 - recovery, **14:71–73**
- CNS
 - diagram of, **10:2**
 - iontophoretic studies, **10:1–30**
- comparison of two or more
 - simultaneously, **3:77, 3:94–95, 3:112, 3:116, 3:130**
- cortical
 - effect of anesthesia, **3:72**
 - field effects of, **3:157–160, 3:161–165**
 - input-output function of, **3:113, 3:130, 3:241**
 - sensitive to joint rotation, **3:198–199**
 - topographical patterns of, **3:199**
 - types of spontaneous discharge of, **3:93–95, 3:141–146**
 - unit responses
 - in auditory area, **3:119–120**
 - in motor areas, **3:117–119**
 - patterns of, **3:93–95, 3:112f, 3:123–126**
 - in somatosensory areas, **3:110–117, 3:129, 3:197–202**
 - to corticocortical volleys, **3:124–125**
 - to direct cortical stimulation, **3:123–124**
 - in visual area, **3:120–122, 3:129**
 - see also* Cortical neurons
- effects on synaptic transmitters on, **11:31–34**
- “end-blade”, **3:339**
- epileptic, **3:152–157**
- function of, glial cells and, **42:193–198**
- GABA metabolism in, **22:32–33**
- GABA transport in, **22:17–19**
- geniculate, **3:102**
- glutamate metabolism in, **22:10–13**
- glutamate transport in, **22:3–5**
- Golgi type II, **3:92, 3:101, 3:103, 3:124, 3:128**
- microscopy of, **17:242–245**
- migration and connectivity of, **21:278–281**

- motor, metabolic changes following injection of botulinum toxin, **14:79–81**
- myelination, **21:281–283**
- neurotransmitter modulation of electrical responses in, **22:241–244**
- number of in cerebral cortex, **5:383**
- protein metabolism of, **15:189–213**
- protein and nucleic acid metabolism in during increased activity, **13:268–279**
- protein specific to, **15:203–205**
 - metabolism related to brain function, **15:205–207**
- protein synthesis in, **13:290–296**
 - in soma, **13:290–292**
- protein transport in, **13:289–324**
- pyramidal, **3:127**
- pyramidal tract projection, **3:70–71, 3:77, 3:97, 3:107–109, 3:118, 3:123, 3:125, 3:128**
- reaction with glial cells, **5:22**
- RNA synthesis in, **16:191**
- sensory, events leading to the firing of, **2:320**
- sodium in, **5:206**
- thalamic and geniculate, *see* Thalamic and geniculate neuron pharmacology
- wave activity originating in, **15:239–240**
- Neuropathy and isoniazid, **3:339–340**
- Neuropeptides, hippocampal lesion effect on activity of, **25:351–352**
- Neurophysiological studies, on effects of sleep, **23:397–399**
- Neurophysiology
 - of cetacea, **21:70–103**
 - of epileptic seizures, **24:95–99**
 - methodology, in cetacean studies, **21:70–73**
- Neuroproteases, **17:189–239**
 - energy potential and cofactors for, **17:211–212**
 - function of, **17:230–232**
 - histochemistry of, **17:217–230**
 - methodology, **17:218**
 - history and present data on, **17:191–193**
 - inhibitor relationships of, **17:216–217**
 - lysosomal lability test for, **17:228–230**
 - in lysosomes, **17:200–201**
 - in micromedium, **17:209–212**
 - in microsomes, **17:202–203**
 - in mitochondria, **17:200–202**
 - molecular analysis of, **17:193–199**
 - in nerve endings, synaptosomes, and myelin, **17:201–202**
 - in nuclear fraction, **17:204**
 - in plasma membranes, **17:204**
 - in stress, **17:221–230**
 - structural binding of, **17:205–209**
 - De Duve hypothesis, **17:205–206**
 - Desai hypothesis, **17:206**
 - Koenig hypothesis, **17:206–209**
 - in subcellular compartments
 - functional aspects, **17:209–217**
 - structural integration, **17:199–204**
 - substrate relationships of, **17:212–216**
 - topochemistry of, **17:218–220**
- Neuropsychiatry
 - endocrine system and, **5:243–302**
 - transmethylation studies relating to, **18:41–67**
- Neurosecretion, **1:181–183**
- Neurosecretory granules, somatofugal transport of, **13:303–304**
- Neurosecretory peptides, in invertebrates, **17:40–41**
- Neurosyphilis, autoimmune processes in, **11:310**
- Neurotensin
 - nociception and, **25:216–222**
 - peptide sequence of, **25:187**
- Neurotensin receptors, autoradiography of, **22:159–161**
- Neuroticism, as personality trait, **25:395–398**
- Neurotoxins, **22:173–204**
 - as labels for sodium channels, **23:71–74**
 - modified, as probes of sodium channel, **23:74–78**
 - as neurobiological tools, **22:173–204**
 - as receptor agonists, **22:182–201**
 - as receptor antagonist, **22:179–182**
 - with receptor specificity, **22:179–201**
 - with specificity for CNS neurons, **22:175–179**
- Neurotransmission, in developing brain, **20:65–103**
- Neurotransmitter receptors, **22:111–171**
 - adrenergic type, **22:155–158**
 - anatomical studies of, **22:114–121**
 - antagonists of, neurotoxins as, **22:179–182**
 - autoradiography of, **22:115–121**
 - for benzodiazepine, **22:153–155**
 - changes in efficacy of, **22:221–226**

- cholinergic muscarinic type, **22**:132–137
 cholinergic nicotinic type, **22**:122–132
 definition and description of, **22**:113–114
 dopamine and neuroleptic type,
 22:142–150
 for GABA, **22**:150–153
 for histamine, **22**:158–159
 ligands for, **22**:120
 neurotoxins specific for, **22**:179–201
 agonists, **22**:182–201
 antagonists, **22**:179–182
 for opiates, **22**:137–142
 release of, **22**:228–238
 electrical aspects, **22**:228–231
 presynaptic membrane potential and,
 22:230
 variation in, **22**:232–236
 for serotonin, neurotensin, and insulin,
 22:159–161
- Neurotransmitters**
 ACTH 4-10 effects on, **20**:227–229
 amino acids as, *see* Amino acid
 neurotransmitters
 apomorphine effects on, **19**:250
 autoradiographic studies, **21**:199–200
 barbiturate effects on, **24**:24–32
 binding properties, **24**:41–44
 in brain
 amino acid uptake and, **13**:143–146
 catecholamine-storing synaptosomes in
 different brain regions, **13**:146–149
 catecholamine uptake and, **13**:128–139
 serotonin uptake and, **13**:139–143
 uptake and subcellular localization of,
 13:127–158
 cyclic AMP in metabolism of, **20**:146
 cyclic nucleotides, behavior, and,
 20:152–156
 definition of, **22**:112–113
 effect of alteration of function on growth
 hormone secretion
 data, **23**:371–375
 discussion, **23**:375–382
 effects on brain phospholipids, **20**:20–26
 effects on postsynaptic membranes,
 22:238–244
 ethanol effect on, **19**:143–152
 enzymes, **19**:150–151
 turnover, **19**:147–151
 false, role in addiction, **19**:155–156
 fetal and neonatal, maternal ethanol
 consumption and, **19**:159
 glucocorticoid effects on
 acetylcholine, **23**:182–184
 amino acids, **23**:184
 dopamine, **23**:182
 norepinephrine, **23**:181–182
 serotonin, **23**:178–181
 localized, microquantitation, **21**:259–274
 mechanisms of action of, **2**:190–193,
 22:206
 cyclic nucleotides, **22**:215–221
 electrical summation, **22**:207–211
 ionic-channel regulation, **22**:211–214
 metabolism of, aminotransferase
 metabolism in, **17**:115–117
 nature of changes brought about by, in
 postsynaptic membrane, **2**:190
 neurotoxin structure compared to, **22**:176
 opioid interaction with, **25**:298–299
 opioids as possible, **25**:249
 presynaptic, **21**:227–228
 primary afferent depolarization and,
 21:236–238
 receptors for, *see* Neurotransmitter
 receptors
 release of, **19**:65–70
 spontaneous, **19**:65–66
 stimulus-coupled, **19**:66–70
 research summary, **21**:202–204
 role in addiction, **19**:155
 role in seizures, **24**:105–150
 specific membrane receptors for specific,
 2:190
 tardive dyskinesia and, **21**:30–35
- Neurulae**, tissue culture, bioelectric activity,
 9:30
- Neutral proteinases**, molecular analysis of,
 17:195–196
- NG 108-15 cells**, α_2 -adrenergic binding in,
 24:403–404
- NGF**, *see* Nerve growth factor
- Nialamide**, structure of, **7**:195
- Nicotinamide**, **3**:254–255, **3**:266–268
- Nicotinamide adenine dinucleotide**
 diaphorase
 histochemical mapping in brain,
 10:231–275
 method for, **10**:238
- Nicotine**, **1**:59, **1**:266, **1**:291, **1**:355–362
 action on receptor, **12**:229
 beneficial effect on learning and
 performance, **8**:172–174
 CEPR, **2**:148

- effect on EEG, **8**:287–288
- effect on equilibrium constants for cholinergic ligands, **24**:311
- effect on hippocampus, **8**:117–120
 - as nicotinic agonist, **17**:149
 - receptor site for, **13**:193–198
- Nicotinic acetylcholine receptors
 - amino acid composition of, **20**:45
 - chemical and structural properties of, **20**:44–49
 - identification of, **20**:32–34
 - isolation and purification of, **20**:31–63
 - reconstitution of, **20**:49–58
 - measured by bilayer membrane conductance, **20**:52–54
 - measured by Na⁺ flux, **20**:49–52
 - reduction myasthenia gravis, **24**:1
 - size and subunit structure of, **20**:46–49
 - solubilization of, **20**:39–40
 - purification following, **20**:40–44
- Nicotinic agonists, for acetylcholine, **17**:149–151
- Nigro-neostriatal dopamine neurons,
 - function of, **13**:104–110, **13**:119
- Nigrostriatal circuit
 - postnatal development of, **20**:82–97
 - dopaminergic innervation to striatum, **20**:83–87
 - ontogenesis of function of, **20**:93–97
 - striatal cholinergic neurons, **20**:88–91
 - striatal GABAergic neurons, **20**:91–93
- Nipeptic acid, structural form of, **22**:25
- Nissl granules, stains for, **5**:7
- Nissl bodies, **1**:167–168
- Nitrophenols, effect on oxidative phosphorylation, **9**:238
- Nitroserotonin
 - neurobiology of, **16**:149
 - structure of, **16**:150
- N*-Methylaminoethanol, **1**:205–214
- NMN (N-methylnicotinamide), HC-3 as inhibitor of NMN uptake, **2**:86
- N,N*-Dimethyl-*p*-phenylenediamine, **1**:303–304, **1**:334
- Nociception, peptides and, **25**:185–241
- Node of Ranvier
 - channel properties, **21**:318
 - fluctuation analysis of, **20**:183–189
- Nodes, in axons, spacing of, **18**:20–26
- Nonadrenergic drugs, aggressive behavior from, **18**:237–242
- Nonprimary sensory projections, of cat neocortex, **10**:111–165
 - afferent organization and, **10**:125–141
 - behavioral correlates, **10**:147–153
 - complex learning situations, **10**:151–153
 - habituation, **10**:149–151
 - level of general alertness, **10**:149
 - control of, **10**:141–147
 - inhibition from the stratum, **10**:142–144
 - primary sensory areas, **10**:145–147
 - reticular formation, **10**:141–142
 - thalamus, **10**:144–145
 - definitions, **10**:113–114
 - distribution and characteristics, **10**:114–125
 - functional correlates, **10**:156–158
 - general characteristics, **10**:155–156
 - of polysensory areas, **10**:128–141
 - reticulocortical projections, **10**:134–135
 - thalamocortical pathways, **10**:137–141
- Nonsense syllable learning
 - in assessment of drug effects, **2**:350–352
 - results on, with subjects under placebo, amytal and dexedrine conditions, **2**:346
- Noradrenaline
 - action on neurons, **11**:19–22, **11**:32–34
 - in brain, **10**:330
 - determination of, **19**:178–189
 - effect on, EEG, **8**:283
 - effects on, geniculate nuclei, **14**:36–37
 - hippocampus, **8**:99
 - neurons
 - in behavior and wakefulness, **13**:110–114, **13**:119–120
 - functions of, **13**:110–115
 - neuroendocrine function of, **13**:114, **13**:120
 - octopamine ratio, **19**:217
 - pathways of, **13**:98–101, **13**:110–115
 - ascending NA neurons, **13**:98–100, **13**:110–114
 - descending NA neurons, **13**:100, **13**:114–115
 - innervating lower brainstem, **13**:110–111
 - phylogenetic distribution of, **19**:196–199
 - presence and action in CNS, **11**:17–25
 - structure of, **19**:175
 - thalamus, **14**:32–36

- Noradrenaline-dopamine interactions, **23:353–360**
- Noradrenergic system
 lateral tegmental
 behavioral and neuroendocrinological role, **23:337–344**
 neuroanatomy, **23:336–337**
 locus ceruleus
 behavioral role, **23:346–353**
 neuroanatomy, **23:344–345**
- Norepinephrine (NE), **21:138**
 action of reserpine, **2:245**
 as α_2 -adrenergic agonist, **24:387–393**
 assay, **21:260**, **21:263–265**
 binding in major groove site, **13:201**
 in brain
 ethanol effects on, **19:144–146**
 lesions, effect on, **13:71**, **13:75**, **13:76**,
13:86, **13:87**
 brain content depressed by certain
 Rauwolfia alkaloids, **2:181**
 CAR, **2:255**
 in cyclic AMP formation, **20:114–116**
 in cyclic GMP regulation, **20:140–141**
 depletion of peripheral stores by
 reserpine, **2:208**
 effect on body temperature,
12:11–16
 effects on cerebral RNA, **16:219**
 evoked potential (EP) and, **25:427**
 fine structural localization in nervous
 tissue, **13:27–66**
 glucocorticoids and, **23:181–182**
 in hypothalamus, **2:158–163**
 neuronal responses to, **10:16–22**
 pressor response after topical application,
2:140
 receptors for, **24:344–345**
 somatofugal transport of, **13:302**
 storage nerve terminals in intra-axonal
 SGV, **13:61**
 in synaptosomal transport, **19:60–65**,
19:70–71
 synaptosomes storing, **13:149**
 uptake in brain, **13:128–139**
- Norepinephrine system
 in locus coeruleus, **25:410–414**
 function, **25:412–413**
- Normetanephrine, **21:264–265**
- Nortriptyline
 as antidepressant drug, **9:134**
 formula of, **9:109**
- Nuclear fraction, neuroproteases in, **17:204**
- Nuclei
 of brain cells, protein metabolism in,
15:196–197
 cranial nerve, **3:203–206**, **3:207**, **3:215**
 thalamic, **3:193–196**
- Nucleic acid metabolism, drug effects on,
11:112–115
- Nucleic acids
 measurement methods for, **13:269–273**
 metabolism of in neurons and glial cells
 during increased activity, **13:268–279**
- 5'-Nucleotidase, brain, **7:318**
- Nucleus
 caudate, **3:326**, **3:331**
 cuneate, **3:79**
 of microglia, **3:28**
 of nerve cell changes in, following axon
 injury, **14:55–61**
 of oligodendrocytes, **3:18–19**
 solitary, **3:206**
 spinal of fifth nerve, **3:193**
- Nucleus accumbens septi
 dopamine-dependent functions of
 complications, **23:328–330**
 conclusions, **23:334–336**
 coordinated functioning of forebrain
 dopaminergic system, **23:330–334**
 response to amphetamines, **23:314–318**
 role in spontaneous behavior,
23:318–328
- Nucleus tractus spinalis V caudalis,
9:323–327
- Nucleus tractus spinalis V interparalis,
9:327
- Nucleus tractus spinalis V oralis, **9:330**
- ν -proteins, **24:290–301**
 effect on acetylcholine receptors,
24:292–294
 thiol-reaction role, **24:295–296**
 function studies, **24:290–301**
 topographical localization, relationship
 to acetylcholine receptor structure,
24:296–301
- O**
- Octopamines
 determination of, **19:178–189**
 in fetal brain, **20:71–72**
 in invertebrate nervous systems,
19:173–224

- noradrenaline ratio, **19:217**
- phylogenetic distribution of, **19:195–201**
- physiological roles for, **19:205–211**
- subcellular localization of, **19:203–205**
- ODAP, formula and neurobiological activity of, **22:184**
- Odontoblasts, dental sensory receptors' relationship to, **25:75–79**
- Olfaction, evolutionary significance of, **14:167–171**
- Olfactory bulbectomy syndrome, **22:251–286**
 - avoidance learning in, **22:274–276**
 - biochemical aspects of, **22:277–280**
 - cannibalism in, **22:269–270**
 - characteristics of, **22:266–283**
 - drug effects on, **22:280–283**
 - intermale aggression in, **22:270–271**
 - irritability in, **22:267–268**
 - locomotor activity in, **22:273–274**
 - muricidal behavior in, **22:268–269**
 - sexual behavior in, **22:271–273**
 - territorial aggression in, **22:271**
- Olfactory bulbs
 - aggression sites in, **18:223, 18:226**
 - anatomy of, **22:256–260**
- Olfactory mucosa, anatomy of, **22:253–254**
- Olfactory nerve, anatomy of, **22:253–254**
- Olfactory nerve complex, anatomy and ontogeny, **14:163–167**
- Olfactory receptors, **14:161–162**
- Olfactory system
 - anatomy of, **22:252–260**
 - olfactory bulbectomy syndrome effects on, **22:266–277**
 - physiology of, **22:253–260**
 - role in behavior, **22:260–277**
 - simulation of, effects on cerebral glucose utilization, **22:304**
- Oligodendrocytes, **3:41**
 - “acute” swelling of, **3:37**
 - contraction of, **3:48**
 - function of, **3:52–59, 3:61**
 - perineuronal, **3:18**
 - two types, **3:59–60**
 - in white matter, **3:19**
- Oligodendroglia
 - of brain, phospholipid composition of, **20:4**
 - localization, **21:276–277**
 - ontogeny, **21:276**
 - RNA synthesis in, **16:191**
 - role in myelin formation, **21:281–283**
 - see also* Glial cell
- Oligophrenia, **3:269**
- Ommatidium, **3:355, 3:358–364**
- Opiate peptides
 - receptor and ligands, **24:146**
 - role in epileptic seizures, **24:143–146**
- Opiate receptors, autoradiographic studies on, **22:137–142**
- Opiates
 - agonists-antagonists of, **25:293–294**
 - analgesic effects of, **25:301–302**
 - behavior and, **25:306–319**
 - social behavior, **25:315–319**
 - diurnal and circadian rhythm of production of, **25:321**
 - effect on synaptic modulation, **22:226–227**
 - environmental effects of, **25:319–322**
 - genetic characterization of mechanisms of, **25:290–294**
 - learning and memory effects of, **25:311–314**
 - mental illness and, **25:322–324**
 - neurochemical correlates of, **25:278–289**
 - neuroendocrine effects of, **25:299**
 - phylogenetic and genetic studies on, **25:302–305**
 - receptors for, **25:299–301**
 - ontogeny of, **25:305–306**
 - opiate potency and, **25:302**
 - seizures from, **25:307–309**
 - sleep effects of, **25:309**
 - stress-induced production of, **25:319–321**
 - tolerance of, **25:310–311**
 - learning mechanisms, **25:314–315**
- Opioids
 - biosynthesis of, **25:297–298**
 - in brain, **25:295–297**
 - definition of, **25:294**
 - effect on spinal neurons, **25:243–275**
 - microiontophoresis and pressure injection of, **25:250–251**
 - naloxone effects, **25:261–262**
 - opiate alkaloids, **25:244**
 - opioid peptides, **25:244–248**
 - single unit recording, **25:249**
 - site of action, **25:252–261**
 - tolerance to, **25:262–264**
 - interaction with neurotransmitter, **25:298–299**
 - neuroendocrine effects of, **25:299**

- nociception and, **25**:195–213
 as possible neurotransmitter, **25**:249
 psychology, **25**:277–337
- Optic atrophy, **3**:340
- Optic lobe, amphibia
 anatomy, **2**:6
 electrical activity, response to
 stimulation, **2**:8–9
 embryology, **2**:7
 sensorimotor coordinating area,
2:9, **2**:14
- Optic nerve
 antidromic action potentials of,
5:131–133
 axons, myelin development in,
24:461–474
 of cat, **6**:153–155
 centrifugal fibers of, **5**:134
 development, **24**:440–449
 electrophysiological studies,
24:441–449
 fibers, **2**:5, **2**:6, **5**:130–131
 types of, **5**:174
 growth in abnormal direction, **2**:24–25
 impulsive conduction in, **5**:129–134
 neurograms of, **5**:133–134
 operative procedures, **2**:10, **2**:11, **2**:24,
2:26, **2**:33
 regeneration
 amphibia, **2**:1–38
 teleost fishes, **2**:5, **2**:6
 selective restitution of nerve fibers, **2**:22ff
 visual recovery after optic nerve
 regeneration, explanation, **2**:15ff
- Optokinetic response
 frogs, **2**:4
 return of, after section of optic nerve
 amphibia, **2**:11–12
 teleost fish, **2**:12
- Orbital gyrus, nonprimary responses of,
10:129
- “Organotypic” growth, in tissue culture,
9:1–12
- Orientation response (taxis), frogs, **2**:3
- Orienting reactions
 in discrimination learning, **18**:311–313
 regulation of, **18**:316–319
- Ornithine aminotransferase
 activity of, **17**:88
 amino acid composition of, **17**:89
 factors affecting, **17**:111
 properties of, **17**:107–108
- Orotic acid, somatofugal transport of,
13:301
- Orphenadrine, effect on EEG, **8**:293, **8**:308
- Osmium tetroxide, as stain for biogenic
 monoamines, **13**:30, **13**:31–32
- Osmotic stimulation, effect on brain RNA
 and proteins, **13**:275
- Osteichthyes, muscular innervation in,
6:127–128
- Ouabain, effects on cerebral RNA, **16**:220
- Oxalic acid *bis* (2-ethyl) hydrazide, structure
 of, **7**:195
- Oxazolinediones, as anticonvulsants,
17:27
- Oxidase, **3**:311
- Oxidative phosphorylation, inhibition by
 guanethidine, **25**:13–15
- Oxiperomide, self-stimulation behavior and,
21:357, **21**:360, **21**:366
- Oxotremorine
 as antiacetylcholine drug, **16**:112–113
 behavioral studies, **16**:116–118
 as muscarinic agonist, **17**:165–166
- Oxygen
 in brain, during seizures, **22**:74–75
 cerebral consumption of, carbon dioxide
 effects on, **22**:58–65
 cerebral metabolism of, ethanol effects
 on, **19**:131–132
- Oxygen tension, of epileptic cortex, **3**:176
- Oxykryptopyrrole lactams, neurobiology of,
16:149
- Oxytocin
 enzymatic inactivation of, **11**:80
 release of after CEPR, **2**:142
- P**
- P2S, in anticholinesterase poisoning,
16:129–131
- P³², **3**:299–302
- Pacemaker activity, of unspecific thalamus,
9:46
- Pacinian corpuscle, **1**:71–72
- PAD, *see* Primary afferent depolarization
- Pain
 cerebral representation of, **8**:66–69
 fear of, motive for CAR, **2**:70
 opiates and sensitivity to, **25**:318–319
 peptides and perception of, **25**:185–241
- Paints, porphyria induction by, **16**:315–316
- Pallium, of limbic lobe, **8**:4–6

- Pancreas
 effect of antidiabetic sulfa (Nadisan) on alcohol intake, **2:66**
 effect of cholinergic agents on enzyme secretion of, **2:103**
- Pancreatectomy
 alcohol consumption, **2:65**
 carbohydrate consumption in rats, **2:42**
- Pancreozymin, stimulates phospholipid turnover, **2:109**
- Panting, body temperature and, **12:5–6**
- Pantothenate deprivation and free choice of ethanol, **2:56**
- Papaverine, as phosphodiesterase inhibitor, **20:131**
- Papez circuit, **1:2–8**
- Papez's circuit, in memory processing, **19:27–30, 19:32**
- Para peridide, structure of, **8:253**
- Paravertebral sympathetic chain, isolation of, **16:18–19**
- Pargyline
 as MAO inhibitor, **7:198**
 structure of, **7:195**
- Parkinsonism
 clinical features, **21:9**
 glutamic acid dehydrogenase and, **17:13**
- Parkinson's disease, **1:17–20, 1:35, 1:231**
 amine metabolism in, **10:336–337**
 antiacetylcholine drug treatment of, **16:111**
 brain amines in, **10:335**
 definitions in, **10:324**
 pathogenesis of, **16:117**
- Pars intracerebralis, **3:367**
- Pattern and form, in vision analysis, **10:289–291**
- Pattern vision, **5:166–175**
- Patulin
 effects on receptors, **14:321–324**
 stereochemical relations to membrane-active drugs, **13:217**
- pA_x, definition of, **16:69–70**
- Pedicle, **3:353–354**
- Pellagra, **3:265–268, 3:339**
 neuropsychiatric symptoms in, **8:213**
 tryptophan metabolism in, **8:215**
- Penfluridol, self-stimulation behavior and, **21:354, 21:360, 21:366**
- Penicillamine, in porphyria therapy, **16:334**
- Penicillin, as GABA receptor blocker, **17:17**
- Pentobarbital (Nembutal)
 effect on brain cell culture, **5:31, 5:37, 5:40**
 effect on EEG, **8:294–296**
 effect on EEG waves, **5:73**
 effect on pressor response, **2:150**
 hippocampus, **8:105**
 learning, **8:146–147, 8:158–159**
 pole-jump CAR, **2:250–251**
 retrograde amnesia from, **10:179–180**
- Pentobarbitone
 effects on CNS, **11:35–36**
 structure and activity, **24:16**
- Pentylene-tetrazol, **3:326–327, 3:329, 3:330, 3:333, 3:339**
 after ECS, **10:189**
 retrograde amnesia from, **10:174–176**
- Pentylene-tetrazole
 effect on EEG, **8:304–405**
 effect on memory, **8:162, 8:168–169**
 beneficial, **8:185**
- Pentylene-tetrazol, effect on brain protein metabolism, **7:11**
- Peptidases
 in brain, **12:257–259**
 in CSF, clinical significance, **25:128**
 role in brain protein catabolism, **6:63–64**
- ϵ -Peptidases, in nervous system, **11:68**
- Peptide breakdown, pathways of, **11:89–90**
- Peptide code, in nervous system, possibility of, **17:50–56**
- Peptide liberation mechanism, in channel model, **21:328**
- Peptides
 behavior and, **17:37–60**
 in brain, **12:235–263**
N-acetyl amino acids and peptides, **12:252–257**
 γ -aminobutyryl and β -alanyl-types, **12:245–252**
 γ -glutamyl types, **12:237–244**
 proteases, peptidases and, **12:257–259**
 brain-gut type, role in epileptic seizures, **24:147–148**
 in cyclic AMP formation, **20:125**
 in cyclic GMP regulation, **20:142**
 learning, memory and, **17:44–50**
 in neural coding, **17:55–56**
 nociception and, **25:185–241**
 algescic peptides, **25:188–195**
 naloxone-sensitive nonopoid type, **25:213–216**
 naloxone-sensitive type, **25:216–226**

- opioid peptides, **25**:195–213
 - opioid, effect on spinal neurons, **25**:244–248
 - role in epileptic seizures, **24**:143–150
 - sleep and, **17**:42
- Perazine, influence on CAR, **2**:239
- Perception, EEG role in, **15**:266–267
- Perfusion, of brain, **3**:304
- Perhydrazepine-3-carboxylic acid,
 - structural formula of, **22**:25
- Pericruciale (motor) cortex nonprimary
 - responses of, **10**:121–123
- Perikaryal responses to axon injury, **14**:49–124
 - axotomized neurons, changes in size and shape of, **14**:52–55
 - cell death in, **14**:95–97
 - cholinesterase changes in, **14**:70–71
 - chromatolysis in, **14**:107–112
 - contralateral responses, **14**:106–107
 - cytoplasmic basophilic changes, **14**:61–73
 - central chromatolysis, **14**:61–65
 - electron microscopic studies of, **14**:65–70
 - “densa bodies” and hydrolytic enzyme changes, **14**:91–95
 - Golgi apparatus changes, **14**:81–87, **14**:99
 - lysosome changes in, **14**:91–95
 - mitochondrial and respiratory enzyme changes, **14**:88–91
 - neurofibril, neurofilament, and neurotubule changes, **14**:87–88
 - nuclear responses to, **14**:55–61
 - eccentricity of nucleus, **14**:55–58
 - nucleolar changes, **14**:59–60
 - sex chromatin changes, **14**:60–61
 - size and shape changes, **14**:58–59
 - protein and RNA metabolism as, **14**:73–81
 - protein synthesis changes, **14**:109–110
 - retrograde responses in special sites, **14**:97–106
 - intrinsic neurons of CNS, **14**:102–104
 - invertebrate neurons, **14**:104–105
 - retinal ganglion cells, **14**:104
 - sensory ganglion cells, **14**:97–102
- Perikaryon
 - acetylcholinestase in, **18**:77–81
 - of nerve cell protein metabolism in, **15**:190–200
- Periodic illnesses, **11**:133–136
- Periodic psychoses
 - adrenal cortex and, **11**:154–156
 - autonomic concomitants of, **11**:157
 - biological rhythm and, **11**:129–169
 - catecholamines in, **11**:156–157
 - circadian rhythms and, **11**:138–139
 - early work on, **11**:152
 - electroencephalography in, **11**:157
 - evidence for existence of, **11**:130–132
 - Gjessing’s studies on, **11**:152–154
 - lithium and, **11**:158–160
 - menstrual and estral clock in, **11**:142–143
 - nosology and, **11**:132–133
 - Richter’s hypotheses and, **11**:137–138
 - thyroid activity and, **11**:149–151
 - vasopressin and, **11**:151
- Perioral tremor, clinical features, **21**:9
- Peripheral nerve, exopeptidases of, **11**:83–85
- Peripheral nerve system
 - learning-drug effect on, **8**:153
 - sensory discrimination in, **8**:37–40
- Peripheral nervous system
 - ACTH 4-10 effects on, **20**:220
 - antiacetylcholine drug effects on, **16**:111–116
 - breakdown and synthesis of proteins in, **13**:265–266
 - of cetaceans, **21**:53–56
 - cyclic nucleotides in function of, **20**:144–156
- Peripheral sympathetic nerve terminals
 - localization of monoamines in, **13**:41–53
 - in large granular vesicles, **13**:51–53
 - in small granular vesicles, **13**:41–51
- Periplaneta Americana*, **3**:356
- Periventricular stratum, of hypothalamus, **9**:263–300
- Peroxisome, enzyme markers for, **20**:273
- Perphenazine
 - activity spectra of, **8**:232, **8**:241
 - CAR, **2**:240, **2**:242
 - catalepsy scores of, **8**:228, **8**:246, **8**:249, **8**:250
 - central depressive activity of, **2**:242
 - clinical response and plasma levels of, **19**:299
 - effect on EEG, **8**:297–298
 - screening data on, **8**:227, **8**:247–248
 - self-stimulation behavior and, **21**:381, **21**:382
 - structure of, **8**:253

- Personality
abnormalities of, **25**:394–395
dimension of, **25**:392–393
 schematic of, **25**:396
neurobiology of, **25**:391–436
- PGO system, REM control and, **23**:413–414
- Ph 881/7 compound, structure-activity effects of, **25**:11
- Phenacemide, retrograde-amnestic blocking action, **10**:190–191
- Phenaglycodol, CAR and SCR, **2**:250
- Phenamine, effect on brain protein metabolism, **7**:11
- Phencyclidine
cardiovascular action of, **6**:333–337
chemical structure of, **6**:304–305
conditioned reflex and, **6**:310–313
EEG effects of, **6**:315–326
effects of
 on animals, **6**:310
 on blood pressure, **6**:334–337
 on man, **6**:305–310
 on sciatic nerve responses, **6**:331
metabolic actions of, **6**:338–342
neurobiology of, **6**:303–347
respiratory action of, **6**:333–337
sensory and motor reflexes and, **6**:313–315
- Phenelzine, in depression therapy, withdrawal effects on REM sleep, **17**:329–332
- Phenethylamine derivatives, effect on cortical neurons, **7**:64–66
- Pheniprazine, structure of, **7**:195
- Phenobarbital, **1**:24, **1**:40, **1**:110
effect on, EEG, **8**:293–294, **8**:308
effects on EEG, **15**:293, **15**:298–300, **15**:302
hippocampus, **8**:105
learning, **8**:146–148, **8**:154
and pole-jump CAR, **2**:250–251
- Phenobarbital retrograde-amnestic blocking actions, **10**:190–192
- Phenolic acids, in phenylketonuria, **3**:269–271
- Phenothiazines, **3**:282
amines and, **10**:356
extrapyramidal symptoms from, **10**:354–357
local anesthesia by, **9**:146–148
membrane stabilization by, m, **9**:154–158, **9**:160–164
as phosphodiesterase inhibitors, **20**:131
- Phenothiazine tranquilizers, **7**:231–278
binding of, **7**:250–253
biophysical action of, **7**:259–264
effects on
 cholinesterase, **7**:239–240
 enzymes and coenzymes, **7**:233–243
 flavins, **7**:235–238
 glycolytic enzymes, **7**:238–239
 lipid synthesis, **7**:240–242
 membrane permeability, **7**:243–250
 oxidative phosphorylation, **7**:233–235
 high-low dose reversals of, **7**:266–269
 localization and action of, **7**:253–259
 rauwolfia alkaloids and, **7**:269–271
- Phenoxybenzamine
as α -blocker, **17**:183
dopamine receptors and, **23**:276–282
- Phenurone, **1**:24, **1**:40
- Phenylalanine, **3**:269–271
 α -ketoglutarate aminotransferase, in brain, **17**:87
pyruvate aminotransferase, factors affecting, **17**:111
- Phenylalanine hydroxylase, **3**:269
- Phenylephrine, as α -agonist, **17**:183
- Phenylethanolamine
in brain, **19**:174
in invertebrates, **19**:211–212
 β -Phenylethanolamine, in fetal brain, **20**:71–72
- Phenylethanolamine-*N*-methyltransferase, in microamine assay, **19**:180
- β -Phenylethylamine
in brain, **19**:174
determination of, **19**:178–189
structure of, **19**:175
in vertebrates, **19**:211–212
- β -Phenylethyl hydrazine, **3**:337
- β -Phenylisopropylhydrazine, **3**:337
- Phenylketonuria, **3**:269–271, **3**:285, **7**:21–23
blood-CNA exchange in, **7**:180
- Phenylpyruvic oligophrenia, **8**:198–200
- Phenyltrimethylammonium, effect on equilibrium constants for cholinergic ligands, **24**:311
- Pheromones
from rodents, effects on behavior, **22**:264–265
neurobiology of, **16**:149
pyrrolic neurobiology of, **16**:170–172

- Phlebotomy, in porphyria therapy, **16:336**
- Phloridzine, use in appetite study, **5:319, 5:320**
- Phosphatases
alkaline, **3:311**
brain, **7:313–315**
- Phosphates
activation energy, **9:231–233**
in bioelectric phenomena, **9:223–261**
coordination complexes with calcium, **9:253–258**
depolarization, **9:240, 9:258–259**
heat of denaturation and entropy, **9:233–235**
high-energy, in brain, **18:160–166**
methods in, **9:224–229**
potassium entry and, **9:248**
in schizophrenic and normal red blood cells, **11:278**
temperature effects, **9:229–231**
thermodynamics, **9:229–240**
transport across membrane, **9:248–250**
treatments' effect on, **9:235**
- Phosphatides, diacyl glycerols carriers in membranes, **2:99–133**
- Phosphatidylcholine, **3:307**
- Phosphatidylethanolamine, **3:299–300, 3:307**
- Phosphatidylinositol, **23:155–157**
metabolism of, receptor mechanisms and, **20:23**
receptor stimulation and, **23:158–159**
secretion and, **23:157–158**
- Phosphatidylserine, **3:299–301**
- Phosphodiesterases, **3:304–308, 3:310, 3:313**
in brain, ethanol effects on, **19:139**
inhibitors and activators of, **20:130–133**
in central pharmacology, **20:153**
localization of, in brain tissue, **20:127–128**
regulation of, **20:128–130**
- Phosphoenolpyruvate carboxykinase, as CO₂ fixation enzyme in nervous system, **14:130–132**
- 6-Phosphogluconate dehydrogenate, as CO₂ fixation enzyme in nervous tissue, **14:134**
- Phosphoinositide turnover
significance of stimulation of, **2:128–130**
stimulation in pancreas, **2:109**
- Phospholipase C, effect on oxidative phosphorylation, **9:238**
- Phospholipases, **3:304–305, 3:307, 3:309, 3:310, 3:312, 3:313**
- Phospholipid methylation
Ca²⁺ flux and exocytosis, **23:147–152**
enzymes and, **23:143–144**
receptors and, **23:152–155**
- Phospholipid methyltransferases,
asymmetric distribution of, **23:144–147**
- Phospholipids, **3:295f**
of brain
anesthetic effects on, **20:16–17**
de novo synthesis of, **20:7–11**
functional metabolism of, **20:1–29**
naturally occurring modifications of, **20:11–16**
neurotransmitter effects on, **20:20–26**
origin and metabolism of, **20:6–11**
relationship to brain function, **20:11–17**
structure and distribution of, **20:2–5**
in synaptic transmission, **20:17–26**
hydrolysis of, **3:303–308**
metabolism in brain, **3:299–303, 3:313**
in receptors, **17:135–136**
somatofugal transport of, **13:301**
- Phospholipid turnover
concerned with sodium transport, **2:110–112, 2:121–126**
effect of atropine on, **2:104–105**
effect of cholinergic agents on, **2:103**
in endocrine and exocrine gland, **2:109–110**
individual, in cerebral cortex slices, **2:106–107**
in various parts of brain, **2:107–108**
- Phosphomonoesterase, **3:305–308, 3:313**
- Phosphoprotein phosphatases, cyclic AMP and, **20:134–135**
- Phosphoproteins
in brain, **6:22–23, 6:24**
somatofugal transport of, **13:301**
- Phosphorus³², in studies of bioelectric phenomena, **9:226–228, 9:229**
- Phosphorylase, **3:339**
- Phosphorylation
depolarization and, **9:240–244**
inhibitors, **9:242**
of proteins, cyclic nucleotides and, **22:237–238**
see also Phosphates
- Phosphorylcholine, **3:300, 3:305, 3:307–308, 3:313**

- Phosphorylethanolamine, **3:305, 3:307–308, 3:313**
- Phosphorylserine, **3:305, 3:313**
- Phosphoserine: α -ketoglutarate aminotransferase
in brain, **17:87, 17:108–109**
properties of, **17:108–109**
- Photoreceptors
channel properties, **21:318**
fluctuation analysis of, **20:201–203**
- Phototaxis, in insects, **3:363–364**
- Phylogenetics, of microamines, **19:196–199, 19:215–218**
- Physostigmine
antidoting effect of, to HC-3, **2:89, 2:94**
blood pressure lowering effect of GABA, **2:325**
effect on CEPR, **2:147**
effect on, EEG, **8:287**
learning, **8:154, 8:186–187**
stimulates cortical suppressor areas, **2:139**
see also Eserine
- Pial vessels, **7:160–161**
- Pia mater, dimpling by microelectrode, **3:74**
- PIC, *see* Picrotoxin
- Picrotoxin
antagonist, of GABA, **21:133–134, 21:142–143, 21:145, 21:152, 21:165**
as antagonist of inhibitory transmission, **15:179–180**
beneficial effect on memory, **8:184**
effect on brain protein metabolism, **7:11**
as GABA receptor blocker, **17:17**
retrograde amnesia from, **10:175–176**
“Picture memory”, in animals, **19:18**
- Pilocarpine
CAR, **2:257**
effect on CEPR, **2:147**
- Pimozide
aggression and, **18:248**
self-stimulation behavior and, **21:354, 21:360, 21:366, 21:387, 21:389**
- Pincytotic vesicles, somatofugal transport of, **13:304**
- Pineal body, role in schizophrenia, **1:316–317**
- Pineal gland
biorhythms in, **11:191–193**
effects on
adrenocortical function, **11:181–183**
endocrine system, **11:174–183**
genital apparatus, **11:175–178**
thyroid-stimulating hormone, **11:178–181**
exopeptidases in, **11:81**
function of, endocrine and neuro-chemical aspects of, **11:171–198**
light effects on, **11:187–191**
melatonin and serotonin metabolism in, **11:183–187**
metabolism of, **11:171–174**
structure of, **11:171–174**
sympathetic innervation effects on, **11:187–191**
- Pinocytosis, and phospholipid effect, **2:131**
- Pioglial membrane, as blood-brain barrier, **3:39**
- Pipamperone, self-stimulation behavior and, **21:355, 21:360, 21:366, 21:387**
- Piperazine esters of glycolic acid derivatives, structure activity studies with, **4:227–232**
- Piperazinoalkylglycolates, *see* Piperidyl glycolates
- Piperidin-3-01 esters, as antiacetylcholine drugs, **16:98**
- Piperidin-4-01 esters, as antiacetylcholine drugs, **16:98–99**
- Piperidine, **1:355–362**
- Piperidine-4-carboxylic acid, structural formula of, **22:25**
- Piperidinomethylbenzodioxane (933F), effects on CAR, **2:256**
- Piperidyl glycolates
antagonists, **4:254, 4:255**
biochemical and electrophysiological studies
biochemical effects, mechanism, **4:264–266**
biochemical-functional relationships, **4:271**
enzyme systems, effect on, **4:260, 4:261**
frog nerve and muscle, metabolic effects, **4:261–264**
frog sartorius muscle, **4:267**
central mechanism of action
electrophysiological studies, **4:249–250**
hyperactivity, relation to other CNS functions, **4:251**
temperature regulation centers and activity, **4:251–254**
glycolate esters, clinical studies, **4:256–260**

- piperazinoalkylglycolates, clinical studies, **4:259**, **4:260**
 tetrahydroaminoacridine (THA), antagonist to Ditrans, **4:258**, **4:259**
 psychotomimetic, neurological-autonomic effects, **4:247**, **4:248**
 radioactive labeled, **4:241–244**
 structure-activity relationships, **4:226–227**
Pipradrol (Meratran)
 action of chlorpromazine, **2:237**
 antagonizes CAR inhibition, **2:237**
 voluntary alcohol consumption, **2:68–69**
Piptadenis peregrine, **3:257**
Pituitary
 anterior, **1:324–325**
 D-2 dopamine receptors, **23:264–270**
 exopeptidases in, **11:77–79**
 arylamidases, **11:78–79**
 posterior, **1:181–182**
Pituitary disease, psychiatric aspects of, **5:265–279**
Pituitary hormones, drug effects on, **11:119–120**
Pivaloylbenzylhydrazine, structure of, **7:195**
Placenta, choline acetyltransferase in, **20:291–292**
Planaria, memory storage experiments on, **8:166–168**
Plankton poison, *see* Saxitoxin
Plasma membranes
 enzyme markers for, **20:273**
 neuroproteases in, **17:204**
Platelets, α_2 -adrenergic receptor binding in, **24:401–402**
Platyphylline
 as antiacetylcholine drug, **16:75**
 as muscarinic antagonist, **17:169–171**
PMCG, in anticholinesterase poisoning, **16:128**, **16:130**
Polarized light, reaction of insects to, **3:355**, **3:363–364**
Poly-AAG
 channel properties, **21:319**, **21:321–323**
 transport selectivity models and, **21:324–329**
Polyarteritis nodosum
 porphyria and, **16:341**
 urinary excretion in, **16:342**
Polypeptide, *see* Substance P
Polysynaptic reflexes, enhancement of, with thiosemicarbazide, **2:323**
Pond skater, **3:364**
Pons
 AChE and NAD-d activity in, **10:247–251**
 motoneuron control and, **24:243**
Pontomesencephalic junction, motoneuron control and, **24:243**
Porphobilinogen
 in psychiatric disease, **16:178**
 secretion of, in porphyria, **16:148**, **16:151**, **16:172–175**
Porphobilinogen-deaminase, neurobiology of, **16:162–163**
Porphyria cutanea tarda hereditaria, **16:305**, **16:306**
Porphyria cutanea tarda symptomatica, **16:305**
 symptoms and incidence of, **16:307**
Porphyrias, **3:262**, **16:301–355**
 amino acid excretion in, **16:325**
 biochemistry of, **16:318–322**
 cardiorespiratory signs of, **16:310–311**
 clinical symptoms of, **16:308–309**
 dermatological signs of, **16:311**
 drug-induced, **16:313–314**
 electrolyte role in, **16:324–325**
 enzymes in, **16:319–322**
 gastrointestinal signs of, **16:310**
 genitourinary signs of, **16:310**
 growth hormone role in, **16:327**
 history of, **16:302–304**
 hormone-induced, **16:312–313**
 incidence of, **16:304–305**
 lipid metabolism in, **16:325–326**
 macroamylasemia in, **16:326–327**
 neuropathology of, **16:317**
 onset of, **16:308**
 pathogenesis of, **16:322–327**
 pathology of, **16:316–318**
 porphyrin pathways in, **16:319**
 precipitating factors in, **16:311–316**
 in pregnancy, **16:311–312**
 psychiatric symptoms of, **16:309**
 in psychoses, **8:213**
 pyrrole neurobiology and, **16:147**, **16:148**, **16:149–151**, **16:160–162**, **16:172–173**, **16:177–178**
 renal symptoms of, **16:316–317**
 therapy of, **16:327–340**
 by chelation, **16:327–335**
 trace metal role in, **16:323**
 urinary excretion in, **16:343**
 vasculitis in, **16:317–318**

- Porphyria variegata, **16:305, 16:306**
 symptoms and incidence of, **16:307**
- Porphyrin-producing hepatic adenoma,
16:305, 16:306, 16:308, 16:318
- Porphyrins
 disturbed metabolism of, classification,
16:305–308
 excessive excretion of in nonporphyric
 prophyr disease, **16:308**
 role in porphyria, **16:304**
- Postlesion plasticity
 classification schemes for
 heterologous and homologous circuits,
23:206–207
 nature of changes in connectivity,
23:202–205
- Postsynaptic inhibition, **21:139–142**
- Postsynaptic membranes
 changes brought about by the transmitter
 in, **2:190**
 excitatory and inhibitory effects
 transmitted by chemical mediators
 effecting, **2:319–325**
 neurotransmitter modulation of,
22:238–244
- Post-synaptic potential (*p.s.p.*), **1:52f, 1:79f,**
1:98–99, 1:107f, 1:123, 1:153–154
 of apical dendrites, **1:83f**
- Potassium, **3:167**
 dorsal root potential and, **21:238–240**
 effect on learning, **8:174–175**
 in nervous tissue, **5:208–211**
 neuroglial function and, **21:290–297**
 transport in nerve, **5:227–228**
- Potassium channels
 blockage and, **23:62–64**
 conductance and number of, **23:59–60**
 fluctuation analysis of, **23:58**
 gating of, **23:60–62**
 neurotransmitter effects on, **22:211–212**
- Potassium chloride
 beneficial effect on learning, **8:174–175**
 effects on cerebral RNA, **16:220, 16:221**
 retrograde amnesia from, **10:180**
 topical application to cortex, **8:164**
- Potassium permanganate, as stain for
 biogenic monoamines, **13:30, 13:32**
- Potassium transport, ethanol effects on,
19:140–141
- Potentials
 action, *see* Spikes
 membrane, **3:48, 3:88**
 post-synaptic, **3:87, 3:89, 3:91, 3:94, 3:97,**
3:101–105, 3:108, 3:127
 standing in epileptic cortex, **3:157, 3:160,**
3:174–176
 standing in normal cortex, **3:158–159**
- Prazosin, as α_1 -adrenergic antagonist,
24:354, 24:360–362
- Pregnancy, porphyria in, **16:311–312**
- Pressure injection of opioids into spinal
 neurons, **25:250–251**
- Presynaptic activity of barbiturates,
24:22–24
- Presynaptic inhibition, **21:142–144**
 anatomical considerations, **21:226–227**
 effects of PAD on, **21:249–251**
 electrical transmission and, **21:233**
 electrophysiological mechanism of,
21:218–226
 in invertebrates, **21:218–233**
 mechanisms, **21:227**
 pharmacology of, **21:227–233**
 research summary, **21:251–253**
 transmitter and ionic mechanisms,
21:217–253
 in vertebrates, **21:233–251**
- Presynaptic receptors, activity of,
22:231–232
- Preteectum, of cat, **6:162**
- Primary afferent depolarization
 axo-axonic synapses and, **21:248**
 effect on synaptic transmission,
21:249–251
 electrical fields and, **21:236**
 GABA and, **21:240–248**
 neurotransmitters and, **21:236–238**
 origin and nature of, **21:235–240**
 potassium and, **21:238–240**
 presence and location, **21:234–235**
- Primates, cortical functions in, **16:233–299**
- Procaine
 effect on cortical neurons, **7:69–70**
 effect on hippocampus, **8:101**
 effect on nerve membrane permeability,
5:230–232
 effect of systemic application, **2:151**
 effect of topical application on blood
 pressure, **2:138**
- Prochlorperazine
 activity spectra of, **8:233, 8:242**
 catalepsy scores of, **8:228, 8:246, 8:249,**
8:250
 screening data on, **8:227, 8:247, 8:248**

- self-stimulation behavior and, **21:381**
 structure of, **8:253**
- Procyclidine, as anticholinergic drug,
16:82, 16:88
- Proflavine, formula of, **12:224**
- Progesterone, and alcohol intake in deer
 mice, **2:67**
- Projection
 afferent from muscle, **3:198–199**
 cortical to cranial nerve nuclei, **3:203–206**
 cortical to diencephalon, **3:203**
 cortical to dorsal column nuclei,
3:206–208
 corticocerebellar, **3:226–230**
 corticocortical, **3:179**
 corticospinal, **3:208–213**
 frontal corticoreticular, **3:215–218**
 ipsilateral intercortical, **3:232–235**
 of medial lemniscal afferents, **3:193–196**
 of motor cortex, **3:117–119**
 specific thalamocortical, **3:97–103,**
3:109–117
 mode of termination of axons, **3:126**
 of spinothalamic afferents, **3:193–196**
 of splanchnic afferents, **3:200**
 to auditory area, **3:119–120**
 to visual area, **3:120–122**
 transcallosal, **3:103–105, 3:125, 3:230–232**
 unspecific thalamocortical, **3:218–223,**
3:225, 3:241
- Prolactin, neuroleptic effects on plasma
 levels of, **19:300–301**
- Prolidase
 molecular analysis of, **17:198**
see also Imidodipeptidase
- Prolysis, membrane stabilization and,
9:198–199
- Promazine
 50block of pole-jump with, **2:239**
 activity spectra of, **8:235, 8:244,**
9:114
 catalepsy scores of, **8:228, 8:246, 8:249,**
8:250
 formula of, **9:109**
 screening data on, **8:227, 8:247, 8:248**
 vertical rope climbing, **2:234, 2:242**
 voluntary alcohol intake, **2:68–69**
- Promethazine, 50block of pole-jump with,
2:239
- Propentdyopents, kryptopyrrole lactams
 compared to, **16:156–157**
- Propionylcholine, **1:185**
- Proprioception
 in fishes, **6:139–140**
 mechanisms in insects, **3:351–355**
- Propylthiouracil, and alcoholic intake of
 rats, **2:64**
- Prostaglandin receptors, **14:309–314**
- Prostaglandin-ribonucleoprotein complex,
 in receptor site, **13:189–191, 13:221–222**
- Prostaglandins
 in cyclic AMP formation, **20:123–124**
 in cyclic GMP regulation, **20:141**
 mechanism of action, **12:227–228**
 as possible synaptic transmitters,
11:30–31
- Proteases
 brain, **7:318**
 in brain, **12:257–259**
- Protein
 exopeptidases and, **11:88–90**
 metabolism, drug effects on, **11:110–112**
 metabolism in axotomized neurons,
14:73–81
 in receptors, **17:135**
 role in ethanol tolerance, **19:152–155**
 synthesis, sleep and, **23:419–423**
- 14-3-2 Protein, **15:215–225**
 developmental studies on, **15:221**
 distribution and localization of,
15:219–220
 immunological assay of, **15:217**
 preparation of, **15:217, 15:218**
 species distribution of, **15:219**
- 14-3-3 Protein, in CSF, **25:127**
- Protein A, in antibody precipitation, **24:6**
- Proteinases, role in brain protein
 catabolism, **6:60–72**
- Protein kinases
 cyclic AMP-dependent, **20:133–134**
 cyclic GMP-dependent, **20:143–144**
- Protein metabolism
 in axons, **15:200–201**
 in brain mitochondria, **15:197–198**
 in brain nuclei, **15:196–197**
 cerebral, *see* Cerebral protein metabolism
 fetal, maternal ethanol intake effects on,
19:157–158
 inborn errors of, **7:20–26**
 in neuron, **15:189–213**
 catabolism, **15:202–203**
 functional activity and, **15:205–207**
 mechanisms, **15:193–198**
 perikaryon, **15:190–200**

- Protein metabolism of nervous system
 amino acid metabolism during,
13:256–261
 breakdown and synthesis of nervous
 system proteins, **13:261–266**
 hormonal effects, **13:266–268**
 increased functional activity effects on,
13:255–288
 neuroglial relationships in, **13:276–277**
 stimulation effects on, **13:273–276**
 studies performed at tissue level,
13:256–268
- Proteins
 autophosphorylation of, cyclic AMP in,
20:135–138
 brain, *see* Brain proteins
 in brain information processing,
13:232–233
 metabolism, of nervous system, **6:1–98**
 metabolism of
 in glial cells and neurons, **13:268–279**
 in nervous system during increased
 activity, **13:261–266**
 nerve, *see* Nerve protein
 neuro-neuronal and neuro-nonneuronal
 transfer of, **15:203**
 phosphorylation of
 ACTH 4-10 effects on, **20:223–224**
 cyclic nucleotides and, **22:237–238**
 specific to neurons, **15:203–205**
 synthesis of, ACTH 4-10 effects on,
20:225–227
- Protein synthesis
 in brain, drugs effecting, **8:168–169**
 inhibitors of, RNA and, **17:63**
- Protein transport
 in axons, **13:296–313**
 bidirectional transport, **13:310–313**
 components transported in,
13:308–310
 mechanisms for, **13:316–319**
 physiological and pathological changes
 affecting, **13:313–316**
 somatofugal type, **13:296–298**
 velocity of, **13:298–308**
 in neurons, **13:289–324**
- Proteolipids, in brain, **6:24–25**
- Proteolytical enzymes, in CSF, clinical
 significance, **25:128**
- Protocerebral lobe, **3:365–367**
- Protocoproporphyrin, *see* Porphyrin
 cutanea tarda hereditaria
- Protrityline
 as antidepressant, **9:134–135**
 formula of, **9:109**
- Pseudocholinesterase, **1:185–186**
 of the CNS, **10:100–102**
 functions, **10:100–102**
 nomenclature, **10:59–60**
- Psilocin
 as central serotonin antagonist, **12:219**
 psychotropic effects of, **8:209–210**
- Psilocybin
 effect on EEG, **8:291**
 psychotropic effects of, **8:209–210**
- Psilocybine, **3:253, 3:255**
- Psychiatric disease, role of glucocorticoids,
23:189–190
- Psychiatric patients, REM sleep studies on,
17:314–328
- Psychiatric symptoms, how to deal with
 them, difficulties and complexities,
2:380–382
- Psychiatry, thyroid and, **5:282–292**
- Psychological tests, and assessment of drug
 effects, **2:333–383**
- Psychology of opioids, **25:227–337**
- Psychomotor stimulator drugs
 amphetamine psychosis from, **12:325–327**
 effects
 in animals, **12:327–337**
 on brain catecholamines, **12:356–361**
 in man, **12:323–326**
 history of, **12:309–310**
 mechanism of action, **12:361–373**
 mode of action of, **12:307–383**
 structures and configuration of, **12:311**
 activity and, **12:312–322**
 survey of, **12:310–311**
see also Amphetamines
- Psychopharmacology
 definition, **2:333**
 methodological problems, **2:333–383**
- Psychoses, periodic, *see* Periodic
 psychoses
- Psychosis
 body fluid indoles in, **3:271–284**
 in Hartnup's disease, **3:266**
- Psychoticism, as personality trait,
25:395–398
- Psychotic states, abnormal blood-CNS
 exchange in, **7:180–182**
- Psychotomimetic (definition),
4:218, 4:219

- Psychotomimetic agents, *see*
 Anticholinergic psychotomimetic
 agents
- Psychotomimetic drugs, effects on CNS,
 11:42–43
- Psychotropic assay
 positioning of, 21:377–379
 self-stimulation and, 21:372–379
- Psychotropic drugs
 effect on blood-brain exchange, 7:182
 effect on body temperature, 12:33–35
- Puffer fish, tetrodotoxin from, 15:84–85
- Pulp of teeth, sensory transduction in,
 25:84–85
- Purkinje cells, 1:183, 13:16–17
 of cerebellum, 13:9–10
- Puromycin
 effect on learning, 8:168–169
 retrograde amnesia from, 10:181–182
- Pursuit rotor test
 in assessment of drug effects, 2:352–353
 interpretation of results, 2:335, 2:340
 performance under placebo and Doriden
 conditions, 2:340–342
- “Pyramidal” cat, 3:70, 3:73, 3:221
- Pyramidal tract, 3:80
- 1-H-Pyrazole[3,4b]pyridines, as
 phosphodiesterase inhibitors, 20:132
- Pyribenzamine, effect of, and vertical rope
 climbing, 2:234
- Pyridine nucleotides, 3:268
- Pyridoxal (vitamin B-6), 3:323, 3:326–328,
 3:332–338, 3:341
 as a coenzyme, 2:305–314
 convulsive seizures and dietary
 pyridoxine deficiency, 2:316–318
 5-HTP decarboxylase activity,
 2:188–189
 relationships between apoenzyme and
 coenzyme of vitamin B₆ requiring
 enzyme systems, 2:305–314
- Pyridoxal kinase, 3:337
- Pyridoxal phosphate, 3:331–338
- Pyridoxal semicarbazone, 3:332
- Pyridoxamine, 3:321, 3:323, 3:341
- Pyridoxine, 3:321, 3:323–324, 3:327, 3:330,
 3:339–341, 3:343
 biochemistry, 3:332–339
 neuropathology, 3:339–340
 in porphyria therapy, 16:338–339
 seizures produced by diet low in,
 3:340–341
- Pyridoxine analogs, as inhibitors of
 glutamic acid decarboxylase, 17:10
- Pyridoxine deficiency, 1:40
- Pyridoxine deprivation, and free choice of
 ethanol, 2:56
- Pyrimidine analogs, neurobiological action,
 10:199–230
- Pyrogens, effect on body temperature,
 12:23–26
- “Pyroglutamic aciduria”, glutathione
 synthetase deficiency in, 19:107–109
- Pyrrrole-2-carboxylic acid, biological activity
 of, 16:175
- Pyrroles
 indoles as, 16:171, 16:175–176
 neuropharmacology of, 16:146,
 16:170–176
 pharmacology of, 16:165–168
- Pyrrolidine, 1:355–362
- Pyrrolidone carboxylate hydrolase
 in γ -glutamyl cycle, 19:102
 in glutathione metabolism, 19:90
- Pyrrrolizidine alkaloid(s)
 as antiacetylcholine drugs, 16:75
 metabolites, as neurochemical disease
 agents, 16:174
 neurobiology of, 16:149
- Pyrrrolonitrin, as nonindolic monopyrrole,
 16:175
- Pyrrroloxygenases
 neurobiology and isolation of,
 16:162–163
 role in psychiatric disorder, 16:178
- Pyruvate, 3:323
 effect on alcohol metabolism, 19:166–167
- Pyruvate carboxylase, as CO₂ fixation
 enzyme in nervous system, 14:128–130
- ## Q
- Quarternary amines, 1:202–203
- Quick test, 1:346–347
- Quinacrine, stereochemical relations to
 membrane-active drugs, 13:216
- Quinuclidin-3-01, as antiacetylcholine drug,
 16:99
- ## R
- Rabbit syndrome, clinical features, 21:9
- Rabbit teeth, sensory receptors in,
 25:67–68

- Radioligand binding technique, dopamine receptors and, **23**:263–264
- Rage, cholinergic mechanism and, **14**:200–202
- Rapid eye movement sleep, *see* REM sleep
- Rat
- electrode implantation, surgical techniques, **21**:337–338
 - olfactory bulbectomy syndrome in, **22**:251–286
 - visual deprivation in, effects on cerebral glucose utilization, **22**:307
- Rat incisors, sensory receptors in, **25**:65–67
- Rauwolfia alkaloids, phenothiazines and, **7**:269–271
- Rauwolscine, as α_2 -adrenergic antagonist, **24**:380–386
- Reaction times, in assessment of drug effects, **2**:354
- Receptive fields, of somatosensory neurons, **3**:192–193, **3**:196–200
- “Receptor”, two-dimensional map of, **17**:133
- Receptors
- for Acetylcholine, **14**:261–283
 - muscarinic type, **14**:262–268
 - nicotinic type, **14**:268–283
 - action of glucocorticoids and, **23**:185–186
 - adrenergic type, **13**:160–161
 - for benzodiazepines
 - characterization of, **23**:108–113
 - endogenous ligands, **23**:116–122
 - heterogeneity, **23**:113–116
 - regulation, **23**:122–133
 - for catecholamine, **14**:300–309
 - α receptor, **14**:307–309
 - β receptor, **14**:301–307
 - chemical anatomy of, **14**:233–329
 - testing hypothesis of, **14**:325–328
 - chemical nature of, **13**:160–166
 - cholinergic type, **13**:161–162, **13**:163
 - for GABA and glutamate, **14**:283–287
 - for glycine, **14**:287–289
 - inactivation-reactivation of, **13**:163–164
 - isolation of, **13**:164–165
 - molecular complexes involved in, **14**:237–261
 - for neurotransmitters, *see* Neurotransmitter receptors
 - phospholipid methylation and, **23**:152–155
 - physiological, studies on, **21**:129–204
 - for prostaglandins, **14**:309–314
 - reaction with transmitters, *see* Transmitter-receptor interaction
 - serotonergic type, **13**:163–164
 - for serotonin, **14**:290–299
 - stimulation, phosphatidylinositol and, **23**:158–159
 - transmitter structure-activity relationships and, **13**:160–162
- Receptor site
- for catecholamines, **13**:201–202
 - chemical nature of, **13**:181–222
 - disulfide bond in, **13**:210–211
 - prostaglandin-ribonucleoprotein complex and, **13**:189–191
 - reserpine effects on, **13**:213–215
 - RNA and, **13**:182–187
 - in excitable membrane, **13**:184–189
 - stereochemical relations between membrane-active drugs and antibiotics, **13**:215–217
 - tetrodotoxin effects on, **13**:212–213
 - veratridine effects on, **13**:212–213
- Receptor systems, for taste and smell, **14**:159–171
- Red cells
- glycolysis and phosphate metabolism in, **11**:269
 - metabolism in
 - normal, **11**:267–271
 - phosphates, **11**:278
 - in schizophrenia, **11**:271–279
- Redox potentials
- in brain, ethanol-induced, **19**:135–136
 - in epileptic cortex, **3**:167
- Reflex, grasp, **3**:213
- Reflex activity
- central serotonin neuron role in, **13**:120
 - noradrenaline neuron role in, **13**:120
- Reflexes, spinal effect of thiosemicarbazone, **3**:327
- Reinforcement
- neural model of, **18**:263–327
 - novelty and, **18**:308–309
- Relief, rebound from fear to, **18**:276–282
- REM elements, dissociation of, **23**:409–410
- REM sleep, **17**:297–298
- after withdrawal of phenelzine, **17**:329–332
 - dreaming and, **17**:299–300
 - localization of control mechanism, **23**:411–412

- cholinergic mechanisms, **23:414–416**
- control of atonia, **23:413**
- locus ceruleus, **23:412–413**
- media pontine reticular formation, **23:412**
- PGO system, **23:413–414**
- summary, **23:416**
- in manic-depression, **17:332–333**
- model of, **23:423–429**
- physiology of, **17:299**
- rebound in, **17:301–302**
 - individual differences in, **17:302**
 - in schizophrenia, **17:304–305**
- Renshaw cells, **1:76–100**, **3:51**, **3:327–328**
 - bioelectric processes of, **16:25–26**
 - preparation of, **16:19**
- Renshaw elements, acetylcholinesterase in, **18:108–112**
- Reptiles, CNS regeneration in, **6:276–277**
- Rescinnamine
 - CAR, **2:245**
 - in frontal lobe lesioned monkeys, **2:243**, **2:245**
- Reserpine, **1:35**, **1:37–39**, **1:200**, **3:253**, **3:284**, **16:176**
 - action in animals, **2:242–244**, **2:248**
 - action in man, **2:242**
 - activity spectra of, **8:236**
 - in affective disorder therapy, **18:377**
 - altering effects of, **2:244–245**
 - amphetamine effects on action of, **12:351–353**
 - antagonism by iproniazid, **2:145**
 - catalepsy scores of, **8:228**, **8:246**, **8:249**, **8:250**
 - chlorpromazine compared to, **7:269–271**
 - depression induction by, **12:152–154**
 - effect on blood serotonin, **3:280–281**
 - effect on brain amines, **8:207**
 - effect on food intake, **5:335**
 - effect on hippocampus, **8:112–113**
 - effect on norepinephrine and serotonin content of brain, **2:145**, **2:156**
 - effect on plasma corticosteroids, **5:256**
 - effects on receptor sites, **13:212–213**
 - imipramine effects on sedation by, **9:104–105**, **9:107–110**
 - induced Parkinsonism, **10:337–338**
 - membrane stabilization by, **9:154–158**
 - potentiation of CEPR, **2:144**, **2:146**, **2:151**
 - reserpine-like substances, **2:245–246**
 - retrograde amnesic-facilitating effects, **10:194**
 - in schizophrenia therapy, effects on HNA, **11:240**
 - screening data on, **8:227**, **8:247**, **8:248**
 - serotonin metabolism and, **2:207–212**
 - structure of, **8:255**
 - tranquilization by, and brain serotonin content, **2:181–182**, **2:184**
 - voluntary alcohol intake, **2:68–69**
- Respiration
 - of cetacea, **21:73–74**
 - depressant action on of HC-3, **2:80–84**, **2:91–92**
 - insect, control by local brain stimulation, **3:366–367**
- Respiratory control, effects of sleep on, **23:396–397**
- Respiratory enzymes, in axotomized neurons, **14:88–91**
- Response
 - conditioned, patterns of cortical unit activity in, **3:130**
 - corticocerebellar, **3:226–227**
 - recruiting, **3:91**, **3:126**, **3:128**, **3:218–223**
 - recruiting relation to unit recording, **3:95–97**
 - spreading burst, **3:124**, **3:166–167**
 - unit, *see under* Cortex; Neurons; Spikes
- Responses
 - augmenting, **1:120–123**, **1:128–133**, **1:138**
 - evoked
 - in cerebellar cortex, **1:113**
 - in cerebral cortex, **1:112–142**
 - “direct” cortical, **1:87–88**
 - graded, **1:52–53**, **1:61f**
 - relation to single unit activity, **1:103–112**
 - in striate cortex, **1:57**, **1:106–107**
 - recruiting, **1:127–133**, **1:138**
- Reticular formation
 - AChE and NAD-d activity in, **10:264**
 - brain stem, **3:215–218**, **3:224–225**, **3:229**, **3:241**, **3:327**
 - thalamic, **3:218–223**
- Retina
 - dopamine receptors in, **23:289–290**
 - ganglion cells of, **13:10–11**
 - information transfer in, **5:122–134**
 - lateral conduction in, **5:126–129**
 - local sign, **2:14**, **2:15**
 - neuronal layer of, **5:124–126**

- receptor potential of, **5**:122–124
- regeneration (amphibia), **2**:12, **2**:14
- role of glia in, **21**:281
- role in pattern vision, **5**:174–175
- rotation of retinal ganglion cell “field”, **2**:33
- Retinal ganglion cells, changes after axonal injury, **14**:104
- Retinene, **3**:355
- Retrograde amnesia
 - drugs and, **10**:167–198
 - methodology, **10**:168–173
 - screening program for, **10**:184–187
 - treatments claimed to block, **10**:187–192
 - treatments claimed to facilitate, **10**:193–194
 - treatments claimed to produce, **10**:173–187
- Rhabdome, **3**:355
- Rhabdomeres, **3**:355
- Rhinencephalon
 - feeding behavior in, **5**:308–311
 - limbic lobe and, **8**:3–4
- Rhodopsin, use in retina study, **5**:122
- Rhomencephalopathy, from
 - fluoropyrimidines, **10**:207–209
- Rhythms, circadian, *see* Circadian rhythms
- Riboflavin deprivation and free choice
 - ethanol, **2**:56
- Ribonucleic acid
 - drugs influencing, **8**:164–168
 - effect on memory storage, **8**:187
 - “messenger”, **5**:367
 - role in brain protein formation, **6**:53–60
- Ribose nucleic acid
 - of astrocytes, **3**:44
 - of oligodendrocytes, **3**:18–19
- Ribosomes
 - of astrocytes, **3**:7, **3**:44
 - of oligodendrocytes, **3**:18, **3**:60
- Richter’s hypotheses, **11**:137–138
- Ringer’s solution, ionic composition of, **5**:203
- RNA
 - in axon, **13**:292–294
 - in brain, **16**:183–231
 - age factors in, **16**:199–203
 - anatomical and subcellular distribution in, **16**:189
 - base composition, **16**:187–189, **16**:205
 - biogenic amine effects on, **16**:217–219
 - content, **16**:184–189
 - drug effects on, **16**:219–222
 - during development, **16**:199–203
 - function, **16**:206–217
 - hybridization studies, **16**:186–187
 - information storage and, **16**:222–228
 - learning and, **16**:210–217
 - maternal ethanol intake effects on, **19**:158–159
 - metabolism of, **16**:183–231
 - metabolism pools, **16**:206
 - neuronal and glial metabolism, **16**:204
 - nonlearning behavior and, **16**:208–210
 - physiological and electrical stimulation of, **16**:197–199
 - synthesis patterns, **16**:204–205
 - turnover rates, **16**:204
 - types, **16**:204–206
 - in brain information processing, **13**:232–233
 - in excitable membrane, **13**:184–189
 - inhibition of synthesis in brain, memory effects, **12**:180–183, **12**:195–198
 - measurement, methods for, **13**:269–271
 - metabolism, ACTH 4-10 effects on, **20**:224–225
 - metabolism in axotomized neurons, **14**:73–81
 - in nerve cell perikaryon, **15**:194–196
 - in neurobiology of pyrroles, **16**:151
 - in neurons and glial cells
 - concentration and distribution of, **13**:271–273
 - stimulation effects on, **13**:273–276
 - protein controversy, **17**:70–72
 - protein synthesis inhibitors and, **17**:62–63
 - in receptor site, **13**:182–184
 - role in ethanol tolerance, **19**:152–155
 - role in receptor mechanism, **12**:225–229
 - sodium pump mechanism and, **13**:217–220
 - somatofugal transport of, **13**:301
 - synthesis of, drug effects on, **11**:112–115, **13**:238–239
- Root potentials
 - dorsal, **1**:72–76
 - ventral, **1**:75–76
- Rotating spiral after-image in assessment
 - of drug effects, **2**:361–362
- Rotation, effect on brain RNA and proteins, **13**:275

Rudolfo-Masera organ, *see* Septal olfactory organ
 Russia, *see* USSR

S

S³⁵, 3:297

S-100 protein, 15:215–225

chemistry of, 15:222

developmental studies on, 15:221

distribution and localization of, 15:219–220

function of, 15:223–224

immunological assay of, 15:217

as nervous-tissue specific protein in CSF, 25:119–121

preparation of, 15:217, 15:218

species distribution of, 15:219

turnover studies on, 15:221–222

Saccharose, effect on feeding, 5:337

Salicylates, effect on body temperature, 12:26–27

Salivary glands, α_1 -adrenergic receptor binding in, 24:365–367

Salivation, antagonism of, as test for antiacetylcholine drug, 16:113

Salt gland

endoplasmic reticulum as site of phospholipid turnover, 2:120–121
 role of phosphatides in ion transport, 2:110–112

Sarin, 1:266, 1:290–291

“Satiating center”, 5:333

Saxitoxin (STX), 15:83–166

bioassay of, 15:101–105

chemical assay of, 15:106

chemical and physical properties of, 15:92–94

differentiation from tetrodotoxin, 15:106–108

effects on

cardiovascular system, 15:144–147

CNS, 15:147–152

muscle, 15:122–133

nerve, 15:108–122

neuromuscular junctions and synapses, 15:133–137

neuromuscular systems,

15:141–144

receptor organs, 15:137–139

in vivo effects of, 15:141–152

lethal doses of, 15:104–105

sources of, 15:86–89

structure of, 15:93

Scape, 3:353–354

Schaffer collaterals, in hippocampus, 19:31

Schiff bases, 3:338

Schilder's disease, brain esterases in, 7:335

Schizophrenia, 1:290–291, 11:199–306,

17:297–342

abnormal factors in serum, 2:169–170

acute, sleep studies on, 17:311–314

amine metabolism in, 8:202–212

antibrain antibodies in, 11:297–303

autointoxication syndrome in,

11:205–207

biochemical factors, 1:298f

biochemical studies on

at Institute of Psychiatry, 11:216–222

in USSR, 11:199–225

blood/CSF concentration gradients in, 7:180–181

brain metabolism in, 11:265–266

carbohydrate metabolism in, 11:259–290

ceruloplasmin in, 1:320f, 1:335f

citric acid cycle intermediates in,

11:264–265

classification of, 11:214–216

conditioning studies in, 11:227–258

deanol in, 1:225

EEG analysis in, 8:279–280, 8:306–309

in drug therapy, 8:286, 8:290,

8:295–296, 8:297–298

effect of serum from, on CEPR,

2:151–153, 2:167

electroconvulsive therapy of, 5:396

endocrine role in, 5:263–265

enzymes in, 11:266–267

genetic factors in, 1:319

glucose tolerance tests on, 11:261–262

HNA studies on, 11:228–229, 11:241–248

in therapy, 11:238–241

of various stages, 11:235–238

hypnoid syndrome in, 11:201–202, 11:242

hypoenergetic syndrome in, 11:204–205

indoles in, 3:272, 3:276, 3:282–283

insulin tolerance tests in, 11:262–263

lactate/pyruvate ratio in, 11:217, 11:221, 11:264–265, 11:281–283

liver function test in, 1:346–348

liver supportive therapy, 1:348–349

neuroallergic reactions in, 11:302–303

pathogenesis of, 11:204–214

phencyclidine effect on, 6:307

- plasma proteins in, **1**:344–346
 porphyria and, **16**:304, **16**:309
 prognosis, HNA data in, **11**:245–247
 protein metabolism in, **7**:28
 psychology, **1**:317f
 pyrrole metabolism in, **16**:147, **16**:151, **16**:177
 radioiodine uptake in, **5**:283–285
 recovery evaluation, using HNA data, **11**:244–246
 red cell metabolism in, **11**:271–279
 REM sleep deprivation in, **17**:304–305
 “schizophrenic ester” in, **11**:271–272
 sera, effect on normal brain cells, **5**:42–45
 serum factors in, **11**:279–285
 sleep studies on, **17**:302–310
 cross-sectional studies, **17**:302–303
 longitudinal studies, **17**:303–304
 reservations, **17**:305–309
 stress in, **1**:322–325
 theories of, **22**:103
 “toxic” factor in, **11**:280–281
 toxicity of body fluids in, **1**:350–352
 toxicosis of, **11**:202
 toxic proteins in, **7**:28–33
 trace metal metabolism in, **16**:347–348
 transmethylation in, **8**:210–212, **18**:61–63
 tryptophan metabolism in, **8**:204–205, **8**:215
- Schwann cells, **3**:50, **3**:58, **3**:340
 dental sensory receptors’ relationship to, **25**:74–75
- Sciatic nerve, effects on cerebral glucose utilization, **22**:304
- Scopolamine
 CAR, **2**:259–260
 chlorpromazine, **2**:237
 effect on hippocampus, **8**:98–99, **8**:102–104
 effect on learning, **8**:160
 enhances bulbocapine catalepsy, **2**:254
 methyl-, effect on learning, **8**:160
 morphine and CAR, **2**:254
- Scotophobin, learning, memory and, **17**:46–47, **17**:72–75
- Scrotonergic drugs, aggressive behavior from, **18**:251–253
- Seawater, ionic composition of, **5**:203
- Secobarbital
 effect on, memory, **8**:186
 visual discrimination, **8**:162–163
- Secobarbitone, structure and activity, **24**:16
- Secretion, phosphatidylinositol and, **23**:157–158
- “Sedation threshold”, test for, **2**:367–369
- Sedative drugs, effects on CNS, **11**:34–36
- Sedatives
 membrane stabilization by, **9**:149–151
 porphyria induced by, **16**:313
- Seizures
 audiogenic, **3**:321–322, **3**:328
 brain metabolism during, **22**:71–78
 cerebral glucose utilization in, **22**:324
 effects on cerebral glucose utilization, **22**:304–305
- epileptic
 absence models, **24**:102–103
 acetylcholine role, **24**:122–128
 clinical correlates, **24**:127–128
 rug effects, **24**:126–127
 ACTH and, **24**:148–150
 γ -aminobutyric acid and, **24**:128–140
 L-aspartic acid and, **24**:141–142
 catecholamine role, **24**:107–116
 anticonvulsants and, **24**:114–115
 classification, **24**:95
 cyclic nucleotides and, **24**:142–143
 developmental aspects, **24**:150–152
 experimental models, **24**:99–106
 table, **24**:100
 from chemical convulsants, **24**:101, **24**:105–106
 from electrical stimulation, **24**:102
 kindling, **24**:104–105
 genetic models, **24**:102, **24**:106
 L-glutamic acid and, **24**:141
 glycine and, **24**:140
 myoclonic models, **24**:104
 neurophysiology, **24**:95–99
 neurotransmitter role, **24**:106–150
 partial-seizure models, **24**:104–106
 peptide role, **24**:143–150
 serotonin role, **24**:116–122
 anticonvulsant role, **24**:120–121
 CSF studies, **24**:121
 taurine and, **24**:140–141
 from opiates, **25**:307–309
 glial cell and, **21**:296
 hydrazide, **3**:333
 kainic acid studies on brain areas of, **22**:193
 produced by low pyridoxine intake, **3**:340–341

- Self-stimulation behavior, **21**:335–395
 catecholamine hypothesis, **21**:336
 clinical implications, **21**:395–398
 data analysis, **21**:340–349, **21**:361
 experimental methods, **21**:337–339
 impairment of, **21**:391–395
 implantation site, **21**:365–367
 influence of neuroleptics on, **21**:349–365
 psychotropic assays, **21**:372–379
 species differences, **21**:367–372
 spectral map analysis, **21**:375–378
 test procedures, **21**:339–340
- Semicarbazide, **3**:302f *pass.*
 used as a 5-HTP carboxylase inhibitor,
2:209
- Sensation seeking, as personality trait,
25:395–398
- Sense-modalities, information exchange
 between, **16**:282–284
- Sensory functions
 evolution of, **16**:240–241
 neocorticalization and, **16**:260–262
- Sensory ganglion cells, changes after axons
 injury, **14**:97–107
- Sensory hairs, of insects, **3**:351–352
- Sensory-motor areas I and II, **3**:191–241
pass.
- Sensory-motor system, connectivity changes
 and, **23**:227–233
- Sensory receptors, in teeth, **25**:39–94
- Sensory systems, fluctuation analysis of,
20:200–205
- Septal olfactory organ, anatomy of,
22:256
- Septum
 aggression sites in, **18**:226
 connections of, **1**:5–6, **1**:12
 effect of drugs on, **1**:314
 lesions of, **1**:30–31
 role in schizophrenia, **1**:300–301,
1:309–310, **1**:316–317
- Serine, **3**:300, **3**:305, **3**:339
- Sernyl
 effect on hippocampus, **8**:121
see also Phencyclidine
- Serotonergic receptors
 inactivation-reactivation of,
13:163–164
 isolation of, **13**:165
 specification of, **13**:202–207
- Serotonergic system, effect on behavior,
25:416–418
- Serotonin (5-HT), **1**:339, **3**:253–258, **3**:263,
3:264, **3**:270, **3**:271, **3**:280–281,
3:283–284, **3**:286, **3**:339
 assay, **21**:260, **21**:261–263
 bioassay of, **2**:156, **2**:164
 biosynthesis and metabolism of,
11:183–187
 biorhythm of, **11**:191–193
 in brain, **8**:207–208
 ethanol effects on, **19**:144–146
 lesions, effect on, **13**:69, **13**:71, **13**:75,
13:76, **13**:86, **13**:87
 CAR, **2**:260–262
 concentration of, in brain, **2**:156
 content of brain, **1**:36
 in cyclic AMP formation, **20**:118–120
 in cyclic GMP regulation, **20**:141
 decrease of, in behavioral depression,
13:333–335
 drug effects on, **11**:117
 effect on brain cell culture, **5**:28, **5**:37–38,
5:40
 effect on CEPR after pretreatment with
 serotonin, **2**:149
 effect on CNS, **8**:209
 effect on food intake, **5**:335
 effect of
 reserpine on serotonin content of brain,
2:145, **2**:156
 tropical application on systemic blood
 pressure, **2**:140
 effects on brain RNA, **16**:218, **16**:221
 neurobiology of, **16**:149
 in electroconvulsive therapy, **5**:394
 evoked potential (EP) and, **25**:427
 fine structural localization in nervous
 tissue, **13**:27–66
 glucocorticoids and, **23**:178–181
 increase of in behavioral depression,
13:327–333
 interaction with catecholamines, in brain,
21:270–271
 levels in blood, **3**:279–281
 levels in urine, **3**:277–279
 neuronal responses to, **10**:16–22
 neurons
 behavior and, **13**:120
 mental functions of, **13**:115–118, **13**:120
 mood and, **13**:120
 neuroendocrine functions of,
13:118–119, **13**:120
 reflex activity and, **13**:120

- in sexual behavior, **13:118**
 - thought processes and, **13:120**
- as opiate neurochemical correlate, **25:284–286**
- pathways of, **13:101–102**
 - ascending 5-HT neurons, **13:101, 13:115–119**
 - descending bulbospinal 5-HT neurons, **13:102, 13:119**
 - innervating lower brainstem, **13:102**
- in phenylpyruvic aligophrenia, **8:199–200**
- reserpine, **2:245**
- role of in mental processes, **1:36**
- role of in neurobiology, **2:175–227**
- role in seizures, **24:116–122**
- role as transmitter, **1:35–36**
- uptake in brain, **13:139–143**
- see also* 5-HT; 5-Hydroxytryptamine
- Serotonin receptors, **14:290–299**
- autoradiography of, **22:159–161**
- Serratia plymuthica*, **3:306**
- Serum
 - from patients with organic diseases and CEPR, **2:154**
 - from pregnant women and CEPR, **2:153–154**
 - from schizophrenics and CEPR, **2:151–156**
- Sex chromatin, changes in, following nerve injury, **14:60–61**
- Sexual behavior
 - apomorphine effects on, **19:242**
 - in olfactory bulbectomy syndrome, **22:271–273**
 - opiate effects on, **25:319**
 - serotonin neuron role in, **13:118**
- SGV (small granular vesicles), localization of monoamines in, **13:41–51**
- Single unit responses
 - glucocorticoid responses
 - extracellular unit recording, **23:173–174**
 - intracellular unit recording, **23:174–178**
- Skatole, **3:259**
- Skatole derivatives, neurobiology of, **16:149**
- Skatoxysulfate, *see* 6-Sulfatoxy-skatole
- Skeletal muscle, tetrodotoxin and saxitoxin effects on, **15:122–128**
- SKF, **2:385**
 - CAR, **2:261**
 - as a monamine oxidase inhibitor, **2:198–202**
- Skin photosensitivity, in porphyria, **16:302**
- Sleep
 - in cetacea, **21:95–97**
 - cholinergic mechanism and, **14:186–189**
 - effect of acute growth hormone
 - administration on, **23:382–385**
 - induced, study of, **6:413–418**
 - modulating variables
 - cyclicality, **23:405–407**
 - metabolism, **23:399–405**
 - motoneuron control during, **24:213–258**
 - motoneuron membrane potential during, **24:218–232**
 - opiate effect on, **25:309**
 - paradoxical type, **9:71–72**
 - peptides and, **17:42**
 - peptides, polypeptides, and proteins in
 - hormonal effects, **23:418–419**
 - model of REM sleep, **23:423–429**
 - protein synthesis and sleep, **23:419–423**
 - specific sleep factors, **23:416–418**
 - pervasive effects on physiology, **23:392–393**
 - endocrine systems, **23:394–395**
 - motor systems, **23:393–394**
 - neurophysiological studies, **23:397–399**
 - respiratory control, **23:396–397**
 - summary, **23:399**
 - thermoregulation, **23:395**
 - in schizophrenia, **17:302–310**
 - somatic reflex activity during, **24:215–217**
 - states of, **24:214**
 - synchronization and, **9:66–70**
 - thalamus and, **9:67–72**
- Sleep states, **23:407–408**
 - development, sleep states and state transitions, **23:410–411**
 - dissociation of REM elements, **23:409–410**
 - SWS-waking dissociations, **23:408–409**
- Slow waves, **3:81–82**
 - comparison of cortical with spinal, **3:87–88**
 - postsynaptic, **3:92**
 - relation to unit activity, **3:89–109, 3:149–152, 3:160–165, 3:173–176**
 - see also* Electroencephalogram; Spontaneous activity
- Slow-wave sleep, waking dissociations and, **23:408–409**
- Smooth muscle, tetrodotoxin and saxitoxin effects on, **15:128–131**

- Smooth muscle contractility,
neurotransmitter modulation,
22:238–240
- Sodium, effect on synaptosomal transport
processes, **19:59–65, 19:70–71**
- Sodium amobarbital, effect on
hippocampus, **8:105**
- Sodium azide, effect on spreading cortical
depression, **5:224**
- Sodium barbital, effect on brain cell culture,
5:30
- Sodium channel protein
labels for
 modified neurotoxins as probes,
 23:74–78
 neurotoxins, **23:71–74**
physical characteristics of
 Stokes radius, S_{20w} and molecular
 weight, **23:90–94**
 subunit composition, **23:94–96**
purification of
 early attempts, **23:79–80**
 ion-exchange chromatography and,
 23:84–86
 lectin affinity chromatography and,
 23:86–88
 procedures for, **23:88–90**
 stabilization of solubilized channel,
 23:80–84
reconstitution of, **23:96–98**
- Sodium channels
fluctuation analysis of
 blockage and, **23:55–56**
 conductance and number of, **23:51–53**
 gating and, **23:53–55**
 modification of, **23:56–58**
 neurotransmitter effects on, **22:211–212**
- Sodium chloride, **3:30, 3:33, 3:60**
secretion of albatross, **2:110–112,**
2:121–122
- Sodium cyanide, effect on spreading cortical
depression, **5:224**
- Sodium 1,3-dimethylbutylethyl barbiturate,
effect on brain cell culture, **5:31**
- Sodium exchange, in depression states,
7:181
- Sodium ion
equilibration of, **3:45**
equilibration potential of, **3:49**
- Sodium nitrite, and GABA levels, **2:311**
- Sodium pump, phosphatidic acid as a
carrier, **2:121–126, 2:128–130**
- Sodium pump mechanism, RNA and,
13:217–220
- Sodium transport
 ethanol effects on, **19:140–141**
 in nerve, **5:227–228**
- Solvents, porphyria induced by, **16:315–316**
- Soma, protein synthesis in, **13:290–292**
- Somatic cell hybrids, neuronal-glia genetic
regulation and, **21:288–290**
- Somatic reflex activity, during sleep and
wakefulness, **24:215–217**
- Somatofugal axonal transport of proteins,
13:296–313
- Somatosensory areas
 auditory functions, **3:200–201**
 evoked potentials in, **3:97–103**
 functional organization, **3:188–241**
 unit responses in, **3:110–117**
 “vertical columns” in, **3:115–117, 3:200**
- Somatosensory discrimination
 anatomophysiological basis of, **8:35–75**
 of pain, **8:66–69**
- Somatostatin
 nociception and, **25:215–216**
 peptide sequence of, **25:187**
- Sound perception, in cetacea, **21:81–84**
- Spangenglobus, **3:358–360**
- Spatial reversal tests, on monkeys, **19:23**
- Specific inhibition of CAR, definition,
 concepts, **2:265–268**
- Spectral map analysis, **21:375–378**
- Spectral sensitivity, of insect eye, **3:356**
- Spermidine, effects on cerebral RNA,
16:221
- Sphingolipidosis, brain hydrolases in,
7:338–340
- Sphingomyelin, **3:299–303, 3:305**
- Sphingomyelinase, **3:303**
- Spike-and-wave discharges, **3:151**
- Spike (E.E.G.), **3:149–152, 3:160–165,**
3:181
- Spikes
 A-B, **3:82–83**
 analysis of components of, **3:82–85,**
 3:145–146
 antidromic, **3:81**
 extracellular, **3:78, 3:83–87**
 from axons, **3:81–87**
 from Betz cells, **3:78, 3:80–84, 3:87,**
 3:94–95, 3:118–119, 3:123–124,
 3:141–142, 3:146
 from cortical neurons, **3:77f, 3:141f**

- from "epileptic" neurons, **3:142–146**,
3:149–152, **3:156**, **3:163**
- from soma, **3:81–87**, **3:120**, **3:122**,
3:141–147, **3:150**, **3:156**
- initially negative, **3:78**, **3:89**
- initially positive, **3:80**
- of injury discharge, **3:88–89**, **3:143**
- interspike internal, **3:75**, **3:94**, **3:113**
- intracellular, **3:78**, **3:80–84**, **3:97**,
3:123–124, **3:165–166**
- neuronal, **3:221**
 - classification of, **3:76–80**
- positive-negative, **3:79**, **3:84**, **3:88–89**,
3:120
- relation to slow waves, **3:89–95**,
3:149–152, **3:160–165**, **3:173–176**
- Spinal cord
 - AChe and NAD-d activity in,
10:242–243, **10:262–263**
 - of cetaceans, **21:56–57**
 - exopeptidases of, **11:82–83**
 - role of glia in, **21:281**
 - vestibular nuclear projections to,
15:42–66
- Spinal cord motoneurons
 - hyperpolarization during sleep,
24:233–235
 - membrane potential, during sleep and
wakefulness, **24:225–231**
- Spinal cord tissue culture
 - bioelectric properties, **9:5–16**
 - long-term cultures, **9:11–16**
 - two-week cultures, **9:5–10**
- Spinal neurons, opioid effects on,
25:243–275
- Spinal roots and ganglia, exopeptidases of,
11:83
- Spindles, **3:91**, **3:93**, **3:95**, **3:221–222**
- Spiroperone, self-stimulation behavior and,
21:356, **21:360**, **21:361**, **21:366**
- Spiramide, structure of, **8:254**
- Spiroperidol, structure of, **8:254**
- Spontaneous activity, **3:77**
 - automatic analysis of, **3:76**
 - microelectrode analysis of, **3:89–109**
 - see also* Electroencephalogram; Slow
waves
- Spreading convulsion, **4:52–56**
- Spreading cortical depression
 - cerebral glucose utilization in,
22:324–325, **22:326**
 - glial cells and, **21:296–297**
- Spreading depression, **3:178–179**
 - cellular changes during
 - intercellular components, release of,
4:39–41
 - intercellular space and glia, **4:41–44**
 - ions and water, entry into cells, **4:33–39**
 - in chronic preparations, **4:17–19**
 - conditioned responses, effect on, **4:56–61**
 - and cortex, higher functions in, **4:56–63**
 - excitation of
 - modes of, **4:14–17**
 - modification of, **4:19–20**
 - metabolic events connected with, **4:44–47**
 - in nonneocortical tissue, **4:11**, **4:12**
 - phenomenological aspects
 - asphyxial change, **4:12–14**
 - cortical responses, **4:7**
 - EEG changes, **4:3–5**
 - electrical impedance, **4:7**, **4:8**
 - steady potential changes, **4:5–7**
 - subcortical effects, **4:9–11**
 - vascular changes, **4:8**, **4:9**
 - propagation of
 - characteristics of, **4:22**, **4:23**
 - mechanism of spread, **4:23–27**
 - transmission, contiguity theory of,
4:27–33
 - refractoriness and recovery time, **4:20–22**
- Squid giant axon, channel properties,
21:318
- Stains, for biogenic monoamines, **13:30–34**
- Stark's experiment on neural coding in
crayfish, **13:361–364**
- Stereotyped behavior, from apomorphine,
19:235–240
- Steroids
 - in affective disorder therapy, **18:377–380**
 - effects on affective disorders, **12:163–165**
 - as inducers of pyrroloxygenase, **16:178**
 - membrane stabilization by, **9:158–159**,
9:166–167
- Stiel system, **3:368**
- Stimulant drugs
 - in an application of canonical variate
analysis, **2:371–374**
 - apparent movement, **2:355–356**
 - definition and theory, **2:344–345**,
2:366–369
 - eyeblink conditioning, **2:350**
 - flicker perimetry, **2:358–359**
 - influence on cortical inhibition and
cortical excitation, **2:344**

- kinaesthetic figural after-effects, **2:355**
 nonsense syllable learning, **2:351–352**
 reaction time, **2:354**
 rotating spiral after-image, **2:361–362**
 sedation thresholds, **2:368**
 suppression of primary visual stimulus,
 2:363–364
 vigilance, **2:365–366**
 visual after-image, **2:360–361**
 visual-field effects, **2:356–369**
- Streptomycin, stereochemical relations to
 membrane-active drugs, **13:217**
- Stress, neuroprotease activity in, **17:221–230**
- Stretch receptors
 crayfish, **3:332**
 insect, **3:352–353**
- Striatum, dopamine receptors, **23:270–276**
- Stridulation, insect, control by local brain
 stimulation, **3:367–371**
- Stroke, glucocorticoids and, **23:190–191**
- Structural code, for neural coding,
 13:229–230
- Strychnine, **1:117, 1:263, 1:270, 1:291**
 after ECS, **10:189**
 antagonist, of glycine, **21:134, 21:180–183**
 as antagonist of inhibitory transmission,
 15:178–181
 effect on learning, **8:155**
 beneficial, **8:175–178**
 effect on memory, beneficial, **8:180–182,**
 8:189
 free choice by rats, **2:42**
 as glutamate receptor block, **13:208–210**
 in optic nerve study, **5:136**
 retrograde amnesia from, **10:175, 10:176**
- Styrylpyridine inhibitors, of choline
 acetyltransferase, **20:302**
- SU 3118, and brain biogenic amine
 depletion, **2:181**
- SU 5171, and brain biogenic amine
 depletion, **2:181**
- Subcommissural organ
 as extra-blood-brain barrier,
 10:36–37
 physiological function, **10:46–48**
- Subcortex, amine metabolism and lesions
 in, **13:69–72**
- Subcortical motor areas
 midbrain tectum, **4:96–100**
 motor effects
 cerebellum stimulation, **4:86–96**
 diencephalon stimulation, **4:76–86**
 motor organization, **4:71–76**
 tegmental reaction, **4:100, 4:101**
- Suberyldicholine, effect on equilibrium
 constants for cholinergic ligands,
 24:311
- Subesophageal lobe, of insect brain, **3:364f**
 pass.
- Subfornical organ
 as extra-blood-brain barrier, **10:36**
 physiological function, **10:44–46**
- Substance P
 chemistry
 characteristics, **4:167, 4:168**
 differentiation, **4:168–170**
 enzymatic destruction, **4:165–167**
 estimation, **4:162, 4:163**
 extraction, **4:161, 4:162**
 purification, **4:163–165**
 distribution in the organism
 central nervous system, **4:170–181**
 gastrointestinal tract, **4:170**
 peripheral nervous system, **4:181, 4:182**
 estimation of in hypothalamus, **2:165**
 nociception and, **25:190–195**
 organ function and tissue concentration
 degenerating nerve, **4:185, 4:186**
 intestine, **4:183, 4:184**
 nervous system, **4:184, 4:185**
 peptide sequence of, **25:187**
 pharmacological actions
 circulation, **4:194, 4:195**
 intestine, **4:191–194**
 nervous system, **4:195–203**
 tachyphylaxis, **4:203, 4:204**
 pharmacological interactions
 central nervous system, **4:207–209**
 intestine, **4:205–207**
 as possible synaptic transmitter, **11:30**
 and “transmitter substance of sensory
 nerves”, **4:186, 4:191**
- Substantia nigra, dopamine receptors in,
 23:288–289
- Subthalamus, **3:203**
- Subunits, of sodium channel protein,
 23:94–96
- Succinamides, as anticonvulsants, **17:27**
- Succinic dehydrogenase, effect on brain cell
 culture, **5:44**
- Succinic semialdehyde dehydrogenase, in
 α -aminobutyric and metabolism, **17:20**
- Succinoxidase, effect on brain cell culture,
 5:41

- Succinylcholine, **3:72**
- Sulfa drugs
 Na sulfadiazine and alcohol consumption, **2:70**
 porphyria induced by, **16:314**
 sulfasuxidine and alcohol intake, **2:70**
- 6-Sulfatoxyskatole, **3:259, 3:271–276**
- Sulfhydryl group, of glutathione, enzymic reactions involving, **19:90–96**
- Sulfhydryl reagent, for choline acetyltransferase, **20:300–302**
- Sulfonamides, as anticonvulsants, **17:27**
- Superficial cortical response (SCR), **3:105–107**
- Superior cervical ganglion, isolation of, **16:18**
- Superior olivary complex, **21:59–61, 21:62**
- Superior olive, neurons of, **13:8**
- Supernatant fraction, of brain, enzyme markers for, **20:273**
- Supraesophageal lobe, of insect brain, **3:364f pass.**
- Sweating, body temperature and, **12:5–6**
- Sympaholytic drugs, interaction with amphetamines, **12:355**
- Sympathetic ganglia, phospholipid effect in, **2:108–109**
- Sympathetic neurons, guanethidine destruction of, **25:1–37**
- Symptom rating scales, **7:279–295**
 item format in, **7:283–285**
 observational period for, **7:283**
 preparation of, **7:294**
 rater effects on, **7:287–288**
 reliability of, **7:287**
 scoring considerations in, **7:289–292**
 semantic limitations in, **7:288–289**
 summary scores in, **7:285**
 use of, **7:292–294**
 validity of, **7:282–287**
- Symptoms
 as an indication of illness, **7:281**
 episodic nature of, **7:281**
 as a social or behavioral defect, **7:280**
- Synapses
 axosomatic v. axodendritic, **1:97–101, 1:124, 1:147**
 dimethyltryptamine at, **22:104–106**
 excitatory, transfer function of, **21:224–225**
 morphology in cerebral cortex, **1:80–82**
 role of field effects, **3:161–165, 3:176**
- Synaptic cleft, **3:51**
- Synaptic endings, **3:32, 3:127, 3:139, 3:147–149, 3:162–163**
- Synaptic junction and glial processes, **3:50–51, 3:61**
- Synaptic mechanisms, chemical anatomy of, **14:233–329**
- Synaptic microvesicles, **1:176–177**
- Synaptic modulation, **22:205–250**
 definition of, **22:205–206**
- Synaptic noise, **3:79, 3:87**
- Synaptic operation, evaluation of, **23:212–219**
- Synaptic transmission
 barbiturate effects on, **24:16–21**
 brain phospholipid role in, **20:17–26**
 in CNS, **11:1–56**
 drug effects on, **13:236–237**
 effects of PAD on, **21:249–251**
 monosynaptic *versus* polysynaptic, **3:211–213, 3:215**
 and phosphatidic acid cycle, **2:131–132**
 relation to astrocytes, **3:50–52**
 relation to superficial cortical response, **3:105–107**
- Synaptic vesicles
 charging of, **18:121–123**
 discharging of, **18:123–128**
 enzyme markers for, **20:273**
 origin of, **18:119–121**
 in tissue fractionation, **20:276–279**
- Synaptochemistry, of acetylcholine metabolism, **18:69–140**
- Synaptogenesis, on fetal catecholaminergic neurons, **20:76–77**
- Synaptosomal transport processes, **19:51–74**
 methodological aspects of, **19:52–54**
 modulatory mechanisms of transmitter fluxes in, **19:70**
 neurotransmitter release, **19:65–70**
 sodium dependence of, **19:59–65**
 effects on efflux, **19:60–65**
 effects on influx, **19:59–60**
 role, **19:65**
 uptake studies on, **19:54–59**
 at synaptosomal membrane, **19:54–56**
 kinetic aspects, **19:56–59**
- Synaptosomes
 catecholamine-storage type in different brain regions, **13:146–149**
 cyclic AMP effect on protein phosphorylation in, **20:136**

- neuroproteases in, **17:201–202**
 separation storing different transmitters, **13:149–156**
 Synephrine(s), structure of, **19:175**
- T**
- T-35, *see* 4-Ethylpyrazole
 Tape-recorder molecule hypothesis, of information processing, **13:243–244**
 Taraxein, **1:309f**, **1:326–327**, **1:338–340**
 effect on brain cell culture, **5:45**
 in schizophrenia, **7:29–30**
 Tardive dyskinesia, **21:1–37**
 clinical features, **21:9**, **21:10**
 differential pharmacology of, **21:12**, **21:13**
 disuse supersensitivity concept and, **21:12**, **21:16–27**
 etiology, **21:12–36**
 experimental induction of, **21:35–36**
 neuroleptic drugs and, **21:8–12**
 pathophysiology, **21:12–13**
 presynaptic mechanisms for, **21:27–30**
 role of neurotransmitters in, **21:30–35**
 Tarichatoxin, *see* Tetrodotoxin
 Taste, appetite and, **5:337**
 Taste receptors, **14:160–161**
 Taurine
 activity of spinal neurons, **2:322**
 biochemical studies with vertebrate preparations, **21:151–152**
 effect in vertebrate nervous systems, **2:281**
 epileptic seizures and, **24:140–141**
 physiologic-pharmacologic studies in invertebrates, **21:151–152**
 in vertebrates, **21:147**
 tissue localization, **21:132**
 uptake in glial cells, **21:299–300**
 Tay-Sachs disease, brain esterases in, **7:339**
 Technique
 “closed head”, **3:69–70**
 wax chamber, **3:69–70**
 Teeth
 axons of, types, **25:42**
 reinnervated, **25:59–61**
 sensory properties of, **25:80–81**
 sensory receptors in, **25:39–94**
 Telemetry, use in behavior studies, **6:360–362**
 Telencephalic fiber systems, AChE activity, in, **10:269**
 Telencephalon
 aggression sites in, **18:223**
 ontogenetic development of, **8:14–17**
 Telencephalon medium, limbic lobe and, **8:708**
 Teleosts
 muscle innervation in, **6:128–133**
 optic nerve regeneration in, **6:266–268**
 spinal cord regeneration in, **6:264–266**
 Telepathy, **1:41**
 Temperature
 of body, *see* Body temperature
 effects on axoplasmic flow, **17:274–275**
 Temporal lobe
 amnesia involving, **19:10–11**
 lesions of, effects on memory, **19:4–11**
 Territorial aggression, in olfactory bulbectomy syndrome, **22:271**
 Territoriality, peptides and, **17:41–42**
 Testosterone, and alcohol intake in gonadectomized rats, **2:67**
 Tetrabenazine
 augmentation of CEPR, **2:144–145**
 brain norepinephrine content, **2:181**
 CAR, **2:245**
 serotonin content, **2:181**
 Tetraethylammonium chloride (TEA), blocks afferent impulses through autonomic ganglia, **2:264**
 Tetrahydrocannabinol binding to PG-RNA complex, **13:206**, **13:207**
 Δ^9 -Tetrahydrocannabinol (THC)
 as central serotonin antagonist, **12:221–223**
 formula of, **12:222**
 Tetrahydroharmine, formula of, **12:208**
 Tetramethylenedisulfotetramine, antagonist, of GABA, **21:135**
 Tetrodotoxin (TTX), **15:83–166**
 bioassay of, **15:95–101**
 chemical and physical properties of, **15:89–92**
 differentiation from saxitoxin, **15:106–108**
 effects on cardiomuscular system, **15:144–147**
 effects on cerebral RNA, **16:220**, **16:221**
 effects on CNS, **15:147–152**
 effects on muscle, **15:122–133**
 effects on nerve, **15:108–122**
 effects on neuromuscular junctions and synapses, **15:133–137**

- effects on neuromuscular systems, **15:141–144**
- effects on receptor organs, **15:137–139**
- effects on receptors, **14:315–317**
- effects on receptor sites, **13:212–213**
- in vivo* effects of, **15:141–152**
- lethal dose of, **15:96–97**
- sources of, **15:84–86**
- structural formula of, **22:175**
- structure of, **15:91**
- in studies of EEG, **15:261–263, 15:264–265**
- Thalamic and cortical responsiveness
 - ascending control of, **12:87–144**
 - specific and unspecific influences on, **12:97–133**
 - auditory relays, **12:113–116**
 - motor system, **12:119–133**
 - somesthetic relays, **12:116–119**
 - visual relays, **12:97–112**
- testing responses in study of, **12:91–96**
 - motor cortex responses, **12:94–96**
 - sensory systems, **12:91–94**
- Thalamic and geniculate neuron pharmacology, **14:1–48**
- ACh and acetylcholinesterase
 - distribution, **14:5–6**
- amino acids in
 - distribution, **14:11–12**
 - effects of, **14:40–42**
- biochemical and histochemical aspects, **14:5–12**
- cholinergic innervation in, **14:27–32**
- excitatory receptor in, **14:25**
- medial geniculate nucleus, **14:23–25**
- monoamines in
 - actions of, **14:32–40**
 - distribution, **14:10–11**
 - responses to acetylcholine, **14:12–32**
- Thalamic ventrobasal cells, neurons of, **13:7–8**
- Thalamus
 - AChe and NAD-d activity of, **10:256–260**
 - anterior nucleus, **3:219**
 - of cat, **6:158–162**
 - centromedian nucleus, **3:126, 3:203, 3:219, 3:235, 3:241**
 - connections of, **1:14, 1:127**
 - dorsomedial nucleus, **3:203**
 - effect on cortex, **1:106–107**
 - posterior nuclei, **3:193–194, 3:201, 3:219**
 - reticular nucleus, **3:203, 3:219**
 - ventral nuclei, **3:83, 3:97, 3:194–196, 3:199, 3:201, 3:203, 3:222**
- Thalamus unspecific intralaminary modulating system, **9:45–94**
 - action on cortex, **9:58–75**
 - EEG spindles, **9:64–65**
 - EEG synchronization, **9:58–72**
 - anatomy of, **9:47–57**
 - connections of, **9:50–57**
 - afferent, **9:50–53**
 - efferent, **9:53–57**
 - desynchronization and, **9:72–75**
 - epilepsy and, **9:65–67**
 - functions, **9:45–46**
 - as integrating and modulating system, **9:75–84**
 - heterogeneity of function, **9:77–80**
 - integrative function, **9:75–77**
 - modulatory function, **9:80–84**
 - nuclei of, **9:47–50**
 - pacemaker activity, **9:46**
 - sleep and, **9:67–72**
- Thermogenesis, body temperature and, **12:6–7**
- Thermoregulation
 - dopamine neuron role in, **13:109**
 - effects of sleep on, **23:395**
- Theta rhythm, of hippocampus, **8:78–89**
- Thiamine, deprivation and alcohol preference by rats, **2:43, 2:52**
- Thiamine pyrophosphatase, in synapses, **18:117–119**
- Thin-layer chromatography, of microamines, **19:182–187**
- Thioctic acid, and free choice of ethanol by rats, **2:55**
- Thioesterase, brain, **7:316–318**
- Thiol groups, in cells glutathione in maintenance of, **19:101–102**
- Thiol reactions, role in ν protein acetylcholine receptor interaction, **24:295–296**
- Thiopental
 - effect on EEG, **8:296**
 - effect on memory, **8:161–162**
- Thiopentone, structure and activity, **24:16**
- Thioperazine, structure of, **8:253**
- Thiopropazat (Dartal), and CAR, **2:242**
- Thiopropazate, self-stimulation behavior and, **21:381, 21:382**

- Thiopropazine
 interaction with flavins, **7:236**
 self-stimulation behavior and, **21:381**
- Thioridazine
 activity spectra of, **8:237, 8:245**
 catalepsy scores of, **8:228, 8:246, 8:249**
 clinical response and plasma levels of,
19:298–299
 effect on CAR, **2:239, 2:242**
 screening data on, **8:227, 8:247, 8:248**
 self-stimulation response rates and,
21:352, 21:360, 21:361, 21:366,
21:381, 21:382
- Thiosemicarbazide, **1:40, 3:320f pass.**
 GABA production, **2:310**
 intracellular GABA levels, **2:323**
- Thiothixene, clinical response and plasma
 levels of, **19:299**
- Thiphenamil, as antiacetylcholine drug,
16:75
- Third choice (sugar, fat or saccharin
 solution), effect of, on alcohol
 consumption of rats, **2:59–61**
- Thoracic ganglia, **3:364, 3:366, 3:368**
- Thought processes, central serotonin
 neuron role in, **13:120**
- Thymoleptic drugs, plasma levels of, in
 psychiatry, **19:269–309**
- Thymoleptics, interaction with
 amphetamines, **12:354–355**
- Thyroidectomy
 alcoholic intake of rats, **2:65**
 brain GABA levels, **2:285**
- Thyroid activity, periodic psychoses and,
11:149–151
- Thyroid gland, psychiatry and, **5:282–292**
- Thyroid-stimulating hormone, pineal gland
 effects on, **11:178–181**
- Thyrotropin-releasing hormone
 nociception and, **25:226**
 peptide sequence of, **25:187**
- Thyroxine
 alcoholic intake of rats, **2:64**
 effects on alcohol metabolism,
19:162–163
 effect of systemic administration on
 pressor response, **2:151**
- Tissue culture cell, neurotransmitter studies
 in, **21:198–199**
- Tissue fractionation
 of brain, **20:253–269**
 differential centrifugation, **20:257–262**
 homogenization, **20:254–256**
 medium for, **20:256–257**
 scheme, **20:261**
 subfractionation, **20:262–266**
 enzyme and neurotransmitters as markers
 in, **20:272–275**
 interpretation of results of, **20:269–279**
 biochemical criteria, **20:269–275**
 morphological criteria, **20:275–276**
 synaptosomes, **20:276–279**
 in neurobiochemistry, **20:251–281**
- T lymphocytes in cerebrospinal fluids,
25:117–118
- TMB4, in anticholinesterase poisoning,
16:126
- TMDST, *see*
 Tetramethylenedisulfotetramine
- Tobacco, pyrroles in, **16:175**
- Tocopherols, in porphyria therapy,
16:339–340
- Torpedo fish, antiacetylcholine receptor
 antibodies of, **24:12–13**
- Toxiferine, as neuromuscular blocking
 agent, **17:151–152**
- Toxopyrimidine, **3:324, 3:335–336**
- Trace metal, in porphyria etiology, **16:323**
- Tracers, in intact nerves, **17:245–253**
- Tract
 pyramidal, **3:103, 3:107, 3:123–124,**
3:207–213
 electrical responses of, **3:210–211,**
3:214, 3:222–223
 phylogenetic development of,
3:211–213
see also Neurons, pyramidal tract
 projection
 spinothalamic, **3:193**
- Tranquilizer drugs, retrograde amnesic
 testing of, **10:185**
- Tranquilizers
 complexes of, **9:202–204**
 effect on hippocampus, **8:110–113**
 effects on, CNS, **11:38–41**
 phenothiazine, *see* Phenothiazine
 tranquilizers
 physicochemical properties of, **9:182–190**
 distribution coefficients, **9:182–184**
 interfacial properties, **9:184–187**
 molar polarizability, **9:189–190**
 penetration into liquid monolayers,
9:187–189
 porphyria induction by, **16:313**

- Transaminases
in CSF, clinical significance, **25:128**
serum, in ECT, **5:394**
see also Transamination/transaminases
- Transamination, in brain during excitation, **13:258–260**
- Transamination/transaminases, **3:258**,
3:260, **3:262**, **3:311–313**, **3:330**, **3:331**,
3:337, **3:342**
- “Transfer”, transcallosal, **3:238–239**
- Transglutaminase, effect on brain protein
metabolism, **7:16–17**
- Transhydrogenases, in glutathione
metabolism, **19:94–96**
- Transmethylation
assays for, **18:57–63**
biochemical assays of, **18:44–57**
by *S*-adenosylmethionine, **18:41–67**
in schizophrenia, **8:210–212**
- Transmission, by axons, **18:2–4**
- Transmitter-receptor interaction,
13:159–180
biochemical effects of transmitters in,
13:166–171
chemical mechanisms of, **13:159–180**
receptors in, *see* Receptors
theories of, **13:171–178**
interrelationships of, **13:177–178**
models requiring chemical changes,
13:174–177
models requiring only conformational
changes, **13:172–174**
- Transmitters
on adenylyl cyclase, **13:166–168**
biochemical effects of, **13:166–171**
in central neurons, barbiturate effects on,
24:24–32
in CNS, **14:2–4**
see also Neurotransmitters
- Transport, of monovalent cations,
21:311–332
- Transport processes, exopeptidases and,
11:86–88
- Transsulfuration, **3:338**
- Tranlycypamine, effect on EEG,
8:289
- Tranlycypromine, effects on cerebral
RNA, **16:220**
- Tranlycypromine
as MAO inhibitor, **7:197**
structure of, **7:195**
- Trapezoid body, lateral nucleus, **21:61**
- Trasentine, effect in stress-induced behavior
in rats, **2:247**
- Trauma, CNS, glucocorticoids and,
23:190–191
- Tremorine, derivatives of, as
antiacetylcholine drugs, **16:74**
- Tremorine tremor, acetylcholine and,
10:345–357
- Tributyrylase, **3:310**, **3:313**
- Tricarboxylic cycle, in brain, ethanol effects
on, **19:133–135**
- Trichodesma toxicosis, *see* Dzhalangarsk
encephalitis
- Tricyanoaminopropene, retrograde
amnesic blocking action, **10:190**
- 1,1,3-Tricyano-2-amino-1-propene, effect
on learning, **8:187**
- Tricyclamol, as antiacetylcholine drug,
16:75, **16:82**, **16:88**
- Tricyclic antidepressants, **19:278–292**
in affective disorder therapy, **18:368–372**
chemical analysis of, **19:278–279**
effect on affective disorders, **12:150–152**
plasma level determinations on,
19:279–292
drug interactions, **19:287–290**
predictions of, **19:290–291**
problems in, **19:284–287**
side effects, **19:287**
- Tricyclic compounds, as muscarinic
antagonists, **17:172**
- Tridione, **1:24**
- Triethyltin acute intoxication, **12:45–86**
ATPase activity and, **12:65–69**
in development of edema, **12:79–82**
biochemical assay in, **12:50–51**
brain water content in, **12:52–53**
cell membranes in, **12:49**, **12:75–78**
cerebral edema in, **12:52–58**
sequence of events of, **12:70–75**
space compartments in, **12:78**
experimental technique in, **12:49**
materials and methods of study,
12:49–51
space measurement in, **12:50**
sulfate and sucrose uptake in, **12:59–65**
- Trifluoperazine, **1:19**
in schizophrenia therapy, effects on
HNA, **11:241**, **11:244–245**, **11:247**
self-stimulation behavior and, **21:381**,
21:382
structure of, **8:253**

- Trifluoperidol, **8:221–263**
 activity spectra of, **8:230, 8:239**
 catalepsy scores of, **8:228, 8:246, 8:249, 8:250**
 clinical results on, **8:250–252**
 neuroleptic potency of, **8:225, 8:247, 8:248**
 screening data on, **8:227**
 structure of, **8:253**
- Triflupromazine, compared to CPZ, **2:239**
- Trigeminal motoneurons control mechanisms, **24:246–250**
- Trigeminal nerves
 afferent axons in, **25:40–43**
 anatomy of, **22:255**
- Trigeminal system, sensory discrimination in, **8:63–66**
- Trihexyphenidyl, as antiacetylcholine drug, **16:117**
- Trimetaphan, as ganglion-blocking agent, **17:161**
- Trimethadione, **1:40**
- Trimethylamine, **1:355f**
- Trimipramine, as antidepressant drug, **9:132**
- Triorthoocresylphosphate, **3:307**
- Triphosphoinositide phosphomonoesterase
 as Ach nicotinic receptor, **16:4**
 assay of, **16:10–12**
 fractionation into subunits, **16:9–10**
 isolation of, **16:8–9**
- 3-Tropanyl 2,3-diarylacrylates, quantitative studies on activity of, **16:103**
- Tropine derivatives, as neuromuscular blocking agents, **17:155–156**
- Tropines
 effect on EEG, **8:286–287**
see also Atropine; Scopolamine
- Trypsin, use in brain cell culture, **5:4**
- Trypsin-like cathepsins, molecular analysis of, **17:195**
- Tryptamine derivatives
 as central serotonin antagonists, **12:219**
 neurobiology of, **16:149**
- Tryptamines, **3:254–255, 3:259–260, 3:262, 3:263, 3:277–278, 3:281–282, 3:286**
 α -alkylated, as MAO inhibitors, **7:215**
 assay, **21:260–263**
 in brain, **19:174**
 derivatives, effect on cortical neurons, **7:66–68**
 determination of, **19:178–189**
 dimethylated, psychotropic effects of, **8:209**
 effect on CNS, **8:209**
 effect on hippocampus, **8:127–128**
 increased toxicity of, **2:199**
 in invertebrates, **19:212–215**
 phylogenetic distribution of, **19:196**
 in schizophrenia, **8:204**
 serotonin, **2:189**
 structure of, **19:175**
- Tryptase
 histochemistry of, **17:223–224**
 in stress, **17:227**
- Tryptophan, **3:254, 3:266, 3:283–284, 3:336**
 abnormal metabolism of, in porphyria, **16:323–324**
 effect on schizophrenia, **8:210**
 metabolism
 by bacteria, **3:258–263, 3:275–276**
 in Hartnup's disease, **3:267–269**
 metabolism of
 abnormal, **8:200–201, 8:210, 8:212**
 in alcoholism, **8:214**
 normal metabolism, by tissues, **3:255–258, 3:260–261, 3:286**
 in schizophrenia, **8:204–205**
- Tryptophan aminotransferase, factors affecting, **17:111**
- Tryptophanase, **3:258**
- Tryptophanyl peptides, in nervous system, **17:50**
- Tuaminoheptane, as α -agonist, **17:183**
- Tubero-infundibular DA neurons, functions of, **13:110, 13:119**
- Tubocurarine, **3:72**
 as GABA receptor blocker, **17:17–18**
- d*-Tubocurarine, **1:96, 1:143**
 antagonist, of GABA, **21:135**
 effect on dendritic potential, **1:84–85**
 effect on EEG, **8:304**
 effect on equilibrium constants for cholinergic ligands, **24:310–311**
 effects on cerebral RNA, **16:220**
 learning, **8:149–151**
 as neuromuscular blocking agent, **17:152–153**
 post synaptic blockade by, and the effects of HC-3, **2:90**
- Tuftsins
 nociception and, **25:224**
 peptide sequence of, **25:187**

- Tumor growth and brain GABA levels, **2:285**
- Tumor proteins, in cerebrospinal fluid, determination, **25:98**
- Turkish porphyria, **16:305**
causes of, **16:308**
- Two-state channels
gating of ionic channels, **23:46–48**
general properties of, **23:44–45**
kinetics of channel blockage, **23:48–50**
variance of current fluctuations, **23:45–46**
- Tyrosine: α -ketoglutarate aminotransferase amino acid composition of, **17:89**
in brain, **17:87**
factors affecting, **17:111**
localization of, **17:104**
properties of, **17:103**
substrate specificity of, **17:91, 17:93, 17:103**
- Tyrosine hydroxylase, brain lesions and brain level of, **13:87**
- U**
- Ulcers, predictability and, **18:271–272, 18:310–311**
- Unconditioned response (UR), **2:231**
- Unconditioned stimulus (US), **2:231**
- Unit, “cut-off” type, **3:114, 3:116**
- Unit response, *see under* Spikes; Neurons; *and under* specific anatomical area
- Urethane
effect on CAR, **2:251**
effect on hippocampus, **8:101**
- Uridine, role in glycogen synthesis, **5:378**
- Uridine diphosphogalactose, **3:297**
- Urodeles, CNS regeneration in, **6:268–270, 6:273–275**
- Uroporphyrinogen synthetase, in porphyria, **16:320–321**
- USSR, biochemical studies on schizophrenia in, **11:199–225**
- V**
- Vascular diseases of brain, autoimmune processes in, **11:306–310**
- Vasculitis, in porphyria, **16:317–318**
- Vasomotor tone, body temperature and, **12:5**
- Vasopressin
biosynthesis of, **5:379**
CEPR, **2:143**
inactivation of, **11:80**
nociception and, **25:222–224**
in periodic psychoses, **11:151–152**
- Velia currens*, **3:364**
- Venom, cobra, **3:312**
- Venooclusive disease, monopyrrole role in, **16:173–175**
- Ventral cochlear nucleus, **21:59, 21:60**
- Ventral ganglia, **3:364**
- Veratridine
effects on receptors, **14:315–317**
effects on receptor sites, **13:212–213**
- Vertebrate autonomic ganglion neurons, ion channels in, **23:28–31**
- Vertebrate central neurons, ion channels in, **23:18–28**
- “Vertical columns” of neurons, **3:115–117, 3:129, 3:200**
- Vestibular cells, RNA in, **16:190**
- Vestibular nuclei
cells in, labyrinthine influence on, **15:30–40**
cerebellovestibular pathways through, **15:41–42**
cerebellum and, **15:40–42**
electrical stimulation, **15:30–36**
labyrinthine input to, **15:28–40**
natural stimulation, **15:37–40**
physiological pathways through, **15:27–81**
projections to extraocular motoneurons, **15:66–76**
projections to spinal cord, **15:42–66**
lateral vestibulospinal tract, **15:42–58**
medial vestibulospinal tract, **15:58–66**
vestibular nerve fibers within, **15:28–30**
vestibulocerebellar pathways through, **15:40–41**
- Vestibulo-extraocular reflexes, pathways of, **15:69–70**
- Vigilance, in assessment of drug effects, **2:364–366**
- Vinblastine, stereochemical relations to membrane-active drugs, **13:216–217**
- Violacein, stereochemical relations to membrane-active drugs, **13:216**
- Vision
behavioral-neurophysiological correlations, **10:292–295**
behavior-environmental relationships, **10:295–307**

- drug-response interactions, **10:307–313**
 - drug-stimulus interactions, **10:295–307**
 - clinical correlations, **10:313–316**
 - drug action and, **10:277–322**
 - information transfer in, **5:121–181**
 - photochemical theory of, **1:272f**
 - quantum aspects of, **1:279**
 - studies of, **10:278–292**
 - experimental orientation and design, **10:282–284**
 - methodological development, **10:278–282**
 - perceptual analysis, **10:288–292**
 - psychophysical analysis, **10:284–287**
 - Visual acuity, **1:250f**
 - Visual after-image, in assessment of drug effects, **2:359–361**
 - Visual area
 - activation of motor cortex by, **3:224–225**
 - histology of, **3:232**
 - unit responses in, **3:120–122, 3:129**
 - Visual cortex, **5:151–155**
 - responses from, **7:99–152**
 - lambda waves, **7:125–130, 7:144–148**
 - photic driving responses from, **7:114–125**
 - rhythmical oscillatory activity in, **7:101–114, 7:130**
 - role in color vision, **5:162, 5:166**
 - Visual deprivation, effects cerebral glucose utilization, **22:307–313**
 - Visual discrimination, **1:249f, 1:254f**
 - Visual environment, response to, frogs, **2:3**
 - Visual field
 - frogs
 - anterior, **2:7**
 - in motion, **2:2**
 - posterior, **2:7**
 - stationary, **2:2**
 - Visual field effects, in assessment of drug effects, **2:356–358**
 - Visual learning, in monkeys, **19:21–22**
 - Visual mechanisms, in insects, **3:355–357**
 - Visual pathways
 - corticofugal influence on, **5:158**
 - corticopetal influence on, **5:155–157**
 - Visual stimulus, suppression of primary in assessment of drug effects, **2:362–364**
 - Visual system, of cetacea, **21:64**
 - Visual systems pathway, of cat, **6:149–189**
 - Visual transmission, nonspecific afferents and, **5:145–151**
 - Vitamin A
 - deficiency and free choice of ethanol, **2:56**
 - membrane stabilization by, **9:151–154**
 - Vitamin B₄, aminotransferase activity and, **17:116–117**
 - Vitamin B-6
 - as a coenzyme, **2:305–314**
 - convulsive seizures and dietary pyridoxine deficiency, **2:316–318**
 - 5-HTP decarboxylase activity, **2:188–189**
 - relationships between apoenzyme and coenzyme of vitamin B₆-requiring enzyme systems, **2:305–314**
 - Vitamin B complex, deprivation and carbohydrate intake in rats, **2:42**
 - Vitamins
 - multiple vitamin deficiencies and free choice of ethanol, **2:56**
 - single vitamin deficiency and free choice of ethanol, **2:56**
 - Voltage, in fluctuation analysis, **20:180–181**
 - Voltage clamp, **3:83**
 - Voltage jump relaxation, ion channels in nerve cell membranes and, **23:6–8**
 - Vomer nasal organ (VNO), anatomy of, **22:254–255**
- ## W
- Wakefulness
 - ascending noradrenaline neuron role in, **13:110–114**
 - central noradrenaline function in, **13:119–120**
 - central serotonin neuron role in, **13:120**
 - in cetacea, **21:95–97**
 - cholinergic mechanism and, **14:186–189**
 - somatic reflex activity during, **24:215–217**
 - Waldenström's protocoproporphyrin, *see* Porphyrin cutanea tarda hereditaria
 - Wallerian degeneration
 - in nerve trunks, **17:263, 17:270–272**
 - protein metabolism in, **6:78–80**
 - Wasps, **3:364**
 - Water intoxication, **3:155**
 - Water metabolism, in brain, **18:176–191**
 - Waveform generator, Tektronix, **3:75**
 - WB 4101 (compound), as
 - α_1 -adrenergic antagonist, **24:354, 24:360–362**
 - Weber-Fechner law, **3:357**
 - Weber ratio, **3:357**

Wilson's disease, **10:323**, **10:324**, **10:326**
 metal metabolism in, **10:348–350**
 see also Hepatolenticular degeneration
Wisconsin Card Sorting Test, **19:12**
Witt's spider web test, **1:350–352**

X

Xanthenuria, **3:321**
Xanthurenic acid, **3:267**, **3:332**, **3:336**
X-porphyrin, in porphyria variegata,
 16:306, **16:307**
X-rays, action on blood-brain
 barrier, **3:47**

Y

Yeast cell respiration test, **1:350–352**
Yohimbine, **16:176**
 as α_2 -adrenergic antagonist, **24:380–386**
 in mental disease tests, **5:403**

Z

Zieve syndrome, porphyria in, **16:314**
Zinc, in porphyria etiology, **16:323**,
 16:340–348
Zinc ion, **3:306–307**
Zylometazoline, as α -agonist, **17:183**

This Page Intentionally Left Blank

Contributor Index

A

Abel, Ernest L., **18**:329
Abood, L. G., **4**:217;**9**:223
Adey, W. R., **1**:1
Albe-Fessard, Denise, **8**:35
Alger, B. E., **21**:217
Amassian, Vahe E., **3**:67
Aprison, M. H., **13**:325

B

Bain, James A., **3**:319
Baldessarini, Ross J., **18**:41;**21**:1
Ballenger, James C., **25**:391
Barchi, Robert L., **23**:69
Barker, Jeffery L., **23**:1
Barker, Steven A., **22**:83
Barondes, Samuel H., **12**:177
Barrantes, F. J., **24**:259
Barron, Kevin D., **7**:297
Bayon, Alejandro, **24**:51
Beaton, J. M., **17**:61
Bechtereva, N. P., **11**:329
Beck, Raymond A., **8**:265
Benington, F., **12**:207
Benuck, M., **17**:85
Bernsohn, Joseph, **7**:297
Biel, J. H., **4**:217
Bignall, K. E., **10**:111
Bishop, P. O., **6**:191
Black, Joel A., **24**:433
Bloom, Floyd E., **13**:27
Bloom, Floyd, **24**:51
Bone, Quentin, **6**:99
Bowsher, David, **8**:35
Bradley, R. J., **17**:61
Bradley, Philip B., **11**:1
Brian Ansell, G., **20**:1
Briley, Michael S., **20**:31
Brimblecombe, R. W., **16**:67
Brinley, F. J., Jr., **5**:185
Brossi, A., **4**:275
Brown, Hugh, **10**:277
Brune, Günter G., **8**:197

Bullock, Theodore H., **21**:47
Buser, P., **10**:111
Byers, Margaret R., **25**:39
Bylund, David B., **24**:343

C

Carpenter, David O., **22**:205
Castellano, Claudio, **25**:277
Cawood, D., **15**:273
Changeux, Jean-Pierre, **20**:31
Chase, Michael H., **24**:213
Cheng, Sze-Chuh, **14**:125
Christian, Samuel T., **22**:83
Clemente, Carmine D., **6**:257
Clouet, Doris H., **11**:99
Colpaert, F. C., **19**:225
Cooper, Thomas B., **19**:269
Costa, Erminio, **2**:175
Coxon, R. V., **5**:347
Coyle, Joseph T., **13**:127;**20**:65
Crain, Stanley M., **9**:1
Creese, Ian, **23**:255
Crews, F. T., **23**:141
Cripps, D. J., **16**:301
Crols, R., **25**:95
Csányi, V., **25**:361
Csillik, Bertalan, **18**:69
Curzon, G., **10**:323

D

Daly, John W., **20**:105
Darian-Smith, I., **9**:301
Davis, John M., **12**:145
DeFelice, Louis J., **20**:169
DeFeudis, F. V., **21**:129
Delgado, José M. R., **6**:349
De Robertis, Eduardo, **3**:1
De Schutter, E., **25**:95
de Wied, D., **20**:209
Domino, Edward F., **6**:303
Drucker-Colin, René R., **23**:391
Durell, Jack, **13**:159
Dutta, S. N., **14**:173

E

Edström, Ricardo, 7:153
 Eidelberg, Eduardo, 2:279
 Elul, Rafael, 15:227
 Enna, Salvatore J., 24:181
 Ettlinger, G., 16:233
 Evans, Martin H., 15:83
 Everitt, B. J., 23:303
 Eysenck, H. J., 2:333

F

Foster, Robert E., 24:433
 Freeman, Walter J., 5:53
 Friede, R. L., 10:231
 Fulpius, Bernard W., 24:1
 Fuxe, Kjell, 13:93

G

Gabrielescu, Elena, 17:189
 Gallagher, Joel P., 24:181
 Gardiner, Martin F., 13:343
 Garland, John T., 13:159
 Gaze, R. M., 2:1
 Gehrman, J., 15:273
 Geiger, Ruth S., 5:1
 Georgi, F., 1:343
 Gerschenfeld, H. M., 3:1
 Gey, K. F., 4:275
 Gheuens, J., 25:95
 Gibbons, James L., 5:243
 Gillin, J. Christian, 17:297
 Gispén, W. H., 20:209
 Goldstein, Leonide, 8:265
 Gordon, J., 12:45
 Granger, G. W., 1:245
 Green, Alan I., 13:127
 Gretchin, V. B., 11:291
 Grossberg, Stephen, 18:263
 Gurevich, Vladimir S., 21:47
 Guth, Paul S., 7:231
 Gyermek, Laszlo, 9:95

H

Hall, Edward D., 23:165
 Hamblin, Mark W., 23:255
 Hatt, A. M., 12:265
 Heath, Robert G., 1:299
 Hebb, Catherine O., 1:165

Hernandez, Daniel E., 25:185
 Hertz, Leif, 18:141
 Herz, Albert, 2:229
 Himwich, Williamina A., 4:117
 Hingtgen, J. N., 13:325
 Hoffer, A., 4:307
 Hökfelt, Tomas, 13:93
 Hokin, Lowell E., 2:99
 Hokin, Mabel R., 2:99
 Holmberg, Gunnar, 5:389
 Honegger, C. G., 1:343
 Hughes, John R., 7:99

I

Inch, T. D., 16:67
 Irvine, Donald G., 16:145
 Isaacson, Robert L., 25:339
 Ishit, T., 10:231
 Iversen, Susan D., 19:1

J

Jakoubek, B., 13:235
 Janssen, Paul A. J., 8:221
 Jenner, F. A., 11:129
 John, E. R., 15:273
 Johnson, Eugene M., Jr., 25:1
 Johnston, Graham A. R., 24:15
 Jordan, D., 1:343
 Juorio, A. V., 19:173

K

Karcher, D., 25:95
 Karkowsky, Abraham, 19:75
 Koella, Werner P., 4:71;10:31
 Koenig, Harold, 10:199
 Krnjević, K., 7:41
 Krupp, P., 9:45
 Kuhar, Michael J., 13:127

L

Laduron, Pierre, 20:251
 Lajtha, A., 17:85
 Lajtha, Abel, 6:1;7:1
 Lasek, Raymond J., 13:289
 Lee, J. Hillary, 19:269
 Leff, Stuart E., 23:255
 Lembeck, F., 4:159
 Leonard, B. E., 18:357;22:251

Levi, Giulio, **19**:51
 Leysen, J. E. M. F., **19**:225
 Lieberman, A. R., **14**:49
 Lingjaerde, Per S., **11**:259
 Lomax, Peter, **12**:1
 Lowenthal, A., **25**:95
 Lozovsky, D. V., **11**:199
 Lubińska, Liliana, **17**:241
 Luttinger, Daniel, **25**:185

M

Mårtens, S., **1**:333
 Manning, Pamela Toy, **25**:1
 Mardones, Jorge, **2**:41
 Marks, Neville, **11**:57
 Mathers, David A., **23**:1
 McGaugh, James L., **8**:139
 McGeer, E. G., **22**:173
 McGeer, P. L., **22**:173
 McGinty, Dennis J., **23**:391
 McGinty, Jacqueline F., **24**:51
 Meikle, Thomas H., Jr., **6**:149
 Melander, B., **1**:333
 Meldrum, B. S., **17**:1
 Mendelson, Wallace B., **23**:367
 Mess, Béla, **11**:171
 Michael, Richard P., **5**:243
 Miller, Alexander L., **22**:47
 Mitchell, S. R., **17**:61
 Monnier, M., **9**:45;**12**:265
 Monti, John A., **22**:83
 Moore, Blake W., **15**:215
 Moore, Robert Y., **13**:67
 Morin, R. D., **12**:207
 Morrow, A. Leslie, **23**:255
 Motokawa, Koiti, **5**:121
 Murrin, L. Charles, **22**:111

N

Nakahama, Hiroshi, **3**:187
 Nemeroff, Charles B., **25**:185
 Neumcke, Berthold, **23**:35
 Nicoll, R. A., **21**:217
 Noppe, M., **25**:95

O

Obata, Kunihiro, **15**:167
 Ochs, Sidney, **4**:1
 Oliverio, Alberto, **25**:277
 Orłowski, Marian, **19**:75

P

Passingham, R. E., **16**:233
 Paul, Steven M., **23**:103
 Peters, H. A., **16**:301
 Petrínovich, Lewis F., **8**:139
 Pfeiffer, Carl C., **1**:195
 Phillis, J. W., **14**:1
 Pletscher, A., **4**:275
 Post, Robert M., **25**:391
 Pradhan, S. N., **14**:173;**18**:213
 Prange, Arthur J., Jr., **25**:185
 Prokop, J., **12**:45
 Pscheidt, Gordon R., **7**:191
 Puglisi-Allegra, Stefano, **25**:277
 Purpura, Dominick P., **1**:47

R

Raiteri, Maurizio, **19**:51
 Rawat, Arun K., **19**:123
 Reese, H. H., **16**:301
 Rieder, H. P., **1**:343
 Robbins, T. W., **23**:303
 Robertis, Eduardo De, **3**:1
 Roberts, Eugene, **2**:279
 Robertson, H. A., **19**:173
 Rodnight, R., **3**:251
 Rosenberg, Roger N., **21**:275
 Rosén, Ingmar, **15**:1
 Rossier, Jean, **20**:283
 Rottenberg, M., **1**:343
 Rush, M., **15**:273

S

Saarma, J., **11**:227
 Saavedra, Juan M., **21**:259
 Salmoiraghi, D. C., **10**:1
 Sano, Isamu, **12**:235
 Satake, Mei, **15**:189
 Sauer, R., **12**:265
 Scheibel, Arnold B., **13**:1
 Scheibel, Madge E., **13**:1
 Schousboe, Arne, **18**:141;**22**:1
 Schueler, F. W., **2**:77
 Seeman, Philip M., **9**:145
 Semenov, S. F., **11**:291
 Semiginovský, B., **13**:255
 Shain, William, **22**:205
 Shashoua, Victor E., **16**:183
 Shaskan, Edward G., **13**:217

Shoemaker, William J., **24:51**
 Sibley, David R., **23:255**
 Silver, Ann, **10:57**
 Simpson, George M., **19:269**
 Sinclair, John G., **14:159**
 Skolnick, Phil, **23:103**
 Smythies, J. R., **12:207;13:181;14:233;17:131**
 Snead, O. Carter III, **24:93**
 Snyder, Solomon H., **13:127**
 Sokoloff, Louis, **22:251**
 Sokolovsky, Mordechai, **25:139**
 Soulairac, André, **5:303**
 Spanner, Sheila, **20:1**
 Spirtes, Morris A., **7:231**
 Sprague, James M., **6:149**
 Stefanis, C. N., **10:1**
 Steriade, M., **12:87**
 Steward, Oswald, **23:197**
 Stewart, R. Malcolm, **21:275**
 Stumpf, Ch., **8:77**
 Sutin, Jerome, **9:263;10:31**

T

Tarsy, Daniel, **21:1**
 Tasnier, A., **25:95**
 Torack, R., **12:45**
 Torda, Clara, **16:1**
 Tuite, M., **22:287**

U

Ungar, Georges, **13:223**
 Ungar, Georoës, **17:37**

Ungerstedt, Urban, **13:93**
 U'Prichard, David C., **24:343**
 Urry, Dan W., **21:311**

V

Vallbo, S., **1:333**
 Van Bever, W. F. M., **19:225**
 van Ree, J. M., **20:209**
 van Rossum, Jacques M., **12:307**
 Vowles, D. M., **3:349**

W

Walaszek, Edward J., **2:137**
 Walker, P., **15:273**
 Walter, Donald O., **13:343**
 Ward, Arthur A., Jr., **3:137**
 Wauquier, Albert, **21:335**
 Waxman, Stephen G., **18:1;24:433**
 Webster, G. R., **3:293**
 Weissman, Albert, **10:167**
 White, Lowell E., Jr., **8:1**
 Williams, Harry L., **3:319**
 Willow, Max, **24:15**
 Wilson, Victor J., **15:27**
 Wittenborn, J. R., **7:279**
 Wyatt, Richard J., **17:297**

Z

Zelter, G., **4:159**
 Zieglgänsberger, W., **25:243**
 Zuckerman, Marvin, **25:391**